BlackRock Health Sciences Trust Form N-CSRS September 04, 2018

## UNITED STATES

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM N-CSR

### CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES

Investment Company Act file number: 811-21702

Name of Fund: BlackRock Health Sciences Trust (BME)

Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809

Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Health Sciences Trust, 55 East 52<sup>nd</sup> Street, New York, NY 10055

Registrant s telephone number, including area code: (800) 882-0052, Option 4

Date of fiscal year end: 12/31/2018

Date of reporting period: 06/30/2018

Item 1 Report to Stockholders

#### JUNE 30, 2018

### SEMI-ANNUAL REPORT (UNAUDITED)

BlackRock Energy and Resources Trust (BGR) BlackRock Enhanced Capital and Income Fund, Inc. (CII) BlackRock Enhanced Equity Dividend Trust (BDJ) BlackRock Enhanced Global Dividend Trust (BOE) BlackRock Enhanced International Dividend Trust (BGY) BlackRock Health Sciences Trust (BME) BlackRock Resources & Commodities Strategy Trust (BCX) BlackRock Science and Technology Trust (BST) BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

Not FDIC Insured May Lose Value No Bank Guarantee The Markets in Review

Dear Shareholder,

In the 12 months ended June 30, 2018, the strongest corporate profits in seven years drove the equity market higher, while rising interest rates constrained bond returns. Though the market s appetite for risk remained healthy, risk taking was tempered somewhat, as shorter-term, higher-quality securities led the bond market, and U.S. equities outperformed most international stock markets.

Strong equity performance worldwide was driven by synchronized economic growth across the most influential economies. However, volatility in emerging market stocks rose, as U.S.-China trade relations and debt concerns weighed heavily on the Chinese stock market.

Short-term U.S. Treasury interest rates rose the fastest, while longer-term rates slightly increased, leading to a substantial flattening of the yield curve. The annual return for the three-month U.S. Treasury bill surpassed 1.0%, but remained well below the annual headline inflation rate of 2.9%. In contrast, the ten-year U.S. Treasury a bellwether of the bond market posted a negative return, as rising inflation expectations drove yields higher. Although the fundamentals in credit markets remained relatively solid, investment-grade bonds declined slightly, and high-yield bonds posted modest returns.

In response to rising growth and inflation, the U.S. Federal Reserve (the Fed ) increased short-term interest rates three times during the reporting period. The Fed also announced plans to reduce its \$4.4 trillion balance sheet by \$420 billion in 2018, which began the process of gradually reversing its unprecedented stimulus measures after the financial crisis. Meanwhile, the European Central Bank announced that its bond-purchasing program would conclude at the end of the year, while also expressing an open-ended commitment to low interest rates. In contrast, the Bank of Japan continued to expand its balance sheet through bond purchasing while lowering its expectations for inflation.

The U.S. economy continued to gain momentum despite the Fed s modest reduction of economic stimulus; unemployment declined to 4.0%, wages increased, and the number of job openings reached a record high. Strong economic performance may justify a more rapid pace of rate hikes in 2018, as the headline inflation rate and investors expectations for inflation have already surpassed the Fed s target of 2.0%.

While U.S. monetary policy is seeking to restrain economic growth and inflation, fiscal policy has produced new sources of growth that could nourish the economy for the next few years. Corporate tax cuts and repatriation of capital held abroad could encourage a virtuous cycle of business spending. Lower individual tax rates coupled with the robust job market may refresh consumer spending. Proposed infrastructure spending would deliver growth from the government sector, generate demand, and improve economic activity in other sectors.

We continue to believe the primary risks to economic expansion are trade protectionism, rapidly rising interest rates, and geopolitical tension. Given the deflationary forces of technology and globalization, a substantial increase in inflation is unlikely to materialize as long as the unemployment rate remains above 3.0%. However, we are closely monitoring trade protectionism and the rise of populism in Western nations. In particular, the outcome of trade negotiations between the United States and China is likely to influence the global growth trajectory and set the tone for free trade in many other nations.

In this environment, investors need to think globally, extend their scope across a broad array of asset classes, and be nimble as market conditions change. We encourage you to talk with your financial advisor and visit **blackrock.com** for further insight about investing in today s markets.

Sincerely,

## Rob Kapito

President, BlackRock Advisors, LLC

Rob Kapito

President, BlackRock Advisors, LLC

### Total Returns as of June 30, 2018

	6-month	12-month
U.S. large cap equities	2.65%	14.37%
(S&P 500 <sup>®</sup> Index)		
U.S. small cap equities	7.66	17.57
(Russell 2000 <sup>®</sup> Index)		
International equities	(2.75)	6.84
(MSCI Europe, Australasia,		
Far East Index)		
Emerging market equities	(6.66)	8.20
(MSCI Emerging Markets Index)		
3-month Treasury bills	0.81	1.36
(ICE BofAML 3-Month U.S. Treasury Bill Index)		
U.S. Treasury securities	(2.68)	(2.69)
(ICE BofAML 10-Year U.S. Treasury Index)		
U.S. investment grade bonds	(1.62)	(0.40)
(Bloomberg Barclays U.S.		
Aggregate Bond Index)		
Tax-exempt municipal bonds	(0.02)	1.61
(S&P Municipal Bond Index)		
U.S. high yield bonds	0.16	2.62
(Bloomberg Barclays U.S. Corporate High Yield 2% Issuer		
Capped Index)		
Capped Index)		

Past performance is no guarantee of future results. Index performance is shown for illustrative purposes only. You cannot invest directly in an index.

THIS PAGE IS NOT PART OF YOUR FUND REPORT

Supplemental Information (unaudited)

#### Section 19(a) Notices

BlackRock Energy and Resources Trust s (BGR), BlackRock Enhanced Capital and Income Fund, Inc. s (CII), BlackRock Enhanced Equity Dividend Trust s (BDJ), BlackRock Enhanced Global Dividend Trust s (BOE), BlackRock Enhanced International Dividend Trust s (BGY), BlackRock Health Sciences Trust s (BME), BlackRock Resources & Commodities Strategy Trust s (BCX), BlackRock Science and Technology Trust s (BST) and BlackRock Utilities, Infrastructure & Power Opportunities Trust s (BUI) (each, a Trust and collectively, the Trusts ), amounts and sources of distributions reported are estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources for tax reporting purposes will depend upon each Trust s investment experience during the fiscal year and may be subject to changes based on tax regulations. Each Trust will provide a Form 1099-DIV each calendar year that will tell you how to report these distributions for U.S. federal income tax purposes.

#### June 30, 2018

					% Breakdown of the Total				1		
	Total Cumulative Distributions			Cumulative							
		for	the Fiscal Per	riod		Dist	ributions	for the	e Fis	cal Pe	eriod
	Net	Net Realized	Net Realized			Net	Net Red	alized			
					Total Per l	Net Red	alized				
	InvestmenC	apital Gain <b>C</b>	apital Gains		Investi	apital (	<b>Gaips</b> tal	Gains		Tot	al Per
				Return of	Common			Re	turn	ı ofCo	mmon
	Income	Short-Term	Long-Term	Capital	Sha <b>fa</b> c	d <b>sho</b> rt-	Terhong-	Term	Сарі	ital	Share
BGR*	\$0.138969	\$	\$	\$0.326631	\$0.465600	30%	%		%	70%	100%
CII*	0.082050			0.414750	0.496800	17				83	100
BDJ	0.081478	0.008302	0.190420		0.280200	29	3	68			100
BOE	0.185780	0.097648		0.184572	0.468000	40	21			39	100
BGY*	0.113511		0.114489		0.228000	50		50			100
BME*	0.047943	0.009451	1.142607		1.200000	4	1	95			100
BCX*	0.108728			0.200872	0.309600	35				65	100
BST*			0.780000		0.780000	0		100			100
BUI	0.288398	0.047828	0.023475	0.366299	0.726000	40	7	3		50	100

\* Certain Trusts estimate that they have distributed more than the amount of earned income and net realized gains; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder s investment in a Trust is returned to the shareholder. A return of capital does not necessarily reflect a Trust s investment performance and should not be confused with yield or income. When distributions exceed total return performance, the difference will reduce the Trust s net asset value per share.

Section 19(a) notices for the Trusts, as applicable, are available on the BlackRock website at **http://www.blackrock.com**.

#### Section 19(b) Disclosure

The Trusts, acting pursuant to a U.S. Securities and Exchange Commission (SEC) exemptive order and with the approval of each Trust s Board of Trustees/Directors (the Board), each have adopted a plan, consistent with its investment objectives and policies to support a level distribution of income, capital gains and/or return of capital (the

Plan ). In accordance with the Plans, the Trusts distribute the following fixed amounts per share on a monthly basis as of June 30, 2018:

	Amount Per	
Exchange Symbol	Common Share	
BGR	\$	0.0776
CII		0.0828
BDJ		0.0467
BOE		0.0780
BGY		0.0380
BME		0.2000
BCX		0.0516
BST		0.1300
BUI		0.1210

The fixed amounts distributed per share are subject to change at the discretion of each Trust s Board. Under its Plan, each Trust will distribute all available investment income to its shareholders, consistent with its primary investment objectives and as required by the Internal Revenue Code of 1986, as amended (the Code ). If sufficient investment income is not available on a monthly basis, the Trusts will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution. Each monthly distribution to shareholders is expected to be at the fixed amount established by the Board, except for extraordinary distributions and potential distribution rate increases or decreases to enable the Trusts to comply with the distribution requirements imposed by the Code.

Shareholders should not draw any conclusions about each Trust s investment performance from the amount of these distributions or from the terms of the Plan. Each Trust s total return performance on net asset value is presented in its financial highlights table.

The Board may amend, suspend or terminate a Trust s Plan at any time without prior notice to the Trust s shareholders if it deems such actions to be in the best interests of the Trust or its shareholders. The suspension or termination of the Plan could have the effect of creating a trading discount (if the Trust s stock is trading at or above net asset value) or widening an existing trading discount. The Trusts are subject to risks that could have an adverse impact on their ability to maintain level distributions. Examples of potential risks include, but are not limited to, economic downturns impacting the markets, decreased market volatility, companies suspending or decreasing corporate dividend distributions and changes in the Code. Please refer to BME s prospectus for a more complete description of its risks.

SUPPLEMENTAL INFORMATION

*.* ח

Table of Contents

	Page
The Markets in Review	2
Section 19(a) Notices	3
Section 19(b) Disclosure	3
<u>Semi-Annual Report:</u>	
The Benefits and Risks of Option Over-Writing	5
Trust Summaries	6
Derivative Financial Instruments	24
Financial Statements:	
Schedules of Investments	25
Statements of Assets and Liabilities	91
Statements of Operations	93
Statements of Changes in Net Assets	95
Statements of Cash Flows	100
Financial Highlights	102
Notes to Financial Statements	111
Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements	122
Trustee and Officer Information	127
Additional Information	128
Glossary of Terms Used in this Report	130

The Benefits and Risks of Option Over-Writing

In general, the goal of each of the Trusts is to provide total return through a combination of current income and realized and unrealized gains (capital appreciation). The Trusts seek to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to enhance the Trusts distribution rate and total return performance. However, these objectives cannot be achieved in all market conditions.

The Trusts primarily write single stock covered call options, and may also from time to time write single stock put options. When writing (selling) a covered call option, the Trust holds an underlying equity security and enters into an option transaction which allows the counterparty to purchase the equity security at an agreed-upon price (strike price) within an agreed-upon time period. The Trusts receive cash premiums from the counterparties upon writing (selling) the option, which along with net investment income and net realized gains, if any, are generally available to support current or future distributions paid by the Trusts. During the option term, the counterparty may elect to exercise the option if the market value of the equity security rises above the strike price, and the Trust is obligated to sell the equity security to the counterparty at the strike price, realizing a gain or loss. Premiums received increase gains or reduce losses realized on the sale of the equity security. If the option may be closed out by an offsetting purchase or sale of an option prior to expiration. The Trust realizes a capital gain from a closing purchase or sale transaction if the premium received from writing the option. The Trust realizes a capital loss from a closing purchase the option.

Writing covered call options entails certain risks, which include, but are not limited to, the following: an increase in the value of the underlying equity security above the strike price can result in the exercise of a written option (sale by the Trust to the counterparty) when the Trust might not otherwise have sold the security; exercise of the option by the counterparty may result in a sale below the current market value and a gain or loss being realized by the Trust; and limiting the potential appreciation that could be realized on the underlying equity security to the extent of the strike price of the option. As such, an option over-writing strategy may outperform the general equity market in flat or falling markets but underperform in rising markets.

Each Trust employs a plan to support a level distribution of income, capital gains and/or return of capital. The goal of the plan is to provide shareholders with consistent and predictable cash flows by setting distribution rates based on expected long-term returns of the Trusts. Such distributions, under certain circumstances, may exceed a Trust s total return performance. When total distributions exceed total return performance for the period, the difference reduces the Trust s total assets and net asset value per share ( NAV ) and, therefore, could have the effect of increasing the Trust s expense ratio and reducing the amount of assets, the Trust has available for long term investment. In order to make these distributions, a Trust may have to sell portfolio securities at less than opportune times.

The final tax characterization of distributions is determined after the fiscal year and is reported in the Trust s annual report to shareholders. Distributions can be characterized as ordinary income, capital gains and/or return of capital. The Trust s taxable net investment income or net realized capital gains ( taxable income ) may not be sufficient to support the level of distributions paid. To the extent that distributions exceed the Trust s current and accumulated earnings and profits, the excess may be treated as a non-taxable return of capital. Distributions that exceed a Trust s taxable income but do not exceed the Trust s current and accumulated earnings and profits, may be classified as ordinary income which are taxable to shareholders. Such distributions are reported as distributions in excess of net investment income.

A return of capital distribution does not necessarily reflect a Trust s investment performance and should not be confused with yield or income. A return of capital is a return of a portion of an investor s original investment. A return

of capital is not taxable, but it reduces a shareholder s tax basis in his or her shares, thus reducing any loss or increasing any gain on a subsequent disposition by the shareholder of his or her shares. It is possible that a substantial portion of the distributions paid during a calendar year may ultimately be classified as return of capital or as distributions in excess of net investment income for U.S. federal income tax purposes when the final determination of the source and character of the distributions is made.

To illustrate these concepts, assume the following: (1) a common stock purchased at and currently trading at \$37.15 per share; (2) a three-month call option is written by a Trust with a strike price of \$40 (i.e., 7.7% higher than the current market price); and (3) the Trust receives \$2.45, or 6.6% of the common stock s value, as a premium. If the stock price remains unchanged, the option expires and there would be a 6.6% return for the three-month period. If the stock were to decline in price by 6.6% (i.e., decline to \$34.70 per share), the option strategy would break-even from an economic perspective resulting in neither a gain nor a loss. If the stock were to climb to a price of \$40 or above, the option would be exercised and the stock would return 7.7% coupled with the option premium received of 6.6% for a total return of 14.3%. Under this scenario, the Trust loses the benefit of any appreciation of the stock above \$40, and thus is limited to a 14.3% total return. The premium from writing the call option serves to offset some of the unrealized loss on the stock in the event that the price of the stock declines, but if the stock were to decline more than 6.6% under this scenario, the Trust s downside protection is eliminated and the stock could eventually become worthless.

Each Trust intends to write covered call options to varying degrees depending upon market conditions. Please refer to each Trust s Schedule of Investments and the Notes to Financial Statements for details of written options.

THE BENEFITS AND RISKS OF OPTION OVER-WRITING

Trust Information as of June 30, 2018

#### **BlackRock Energy and Resources Trust**

#### **Investment Objective**

**BlackRock Energy and Resources Trust s (BGR) (the Trust**) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

#### **Trust Information**

Symbol on New York Stock Exchange ( NYSE )	BGR
Initial Offering Date	December 29, 2004
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$15.22) <sup>(a)</sup>	6.12%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0776
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.9312

(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.

<sup>(b)</sup> The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

#### **Performance and Portfolio Management Commentary**

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On		
	Market Price	Net Asset Value	
BGR <sup>(a)(b)</sup>	10.89%	4.49%	
Lipper Natural Resources Funds <sup>(c)</sup>	(1.38)	(0.70)	

<sup>(a)</sup> All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

(b) The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. <sup>(c)</sup> Average return. Returns reflect reinvestment of dividends and/or distributions at NAV on the ex-dividend as calculated by Lipper.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

## The following discussion relates to the Trust s absolute performance based on NAV:

## What factors influenced performance?

Energy stocks experienced unusually high volatility in the first half of 2018. A strong advance in January gave way to a sharp sell-off in February, bringing the sector into negative territory for the year. After trading sideways for approximately two months, energy stocks staged a significant rally through April and early May. Although its performance cooled thereafter, energy nonetheless finished the second calendar quarter as the top performer among the stock market s eleven major sectors.

The Trust s position in the U.S. exploration and production ( E&P ) company ConocoPhillips made the largest positive contribution to performance. Upstream producers, in general, maintained capital discipline and prioritized shareholder returns over growth. ConocoPhillips participated in this trend by announcing a 7.5% dividend increase and a 33% expansion of its share buyback program, boosting its stock price. The international E&P stock Anadarko Petroleum Corp. was also among the top contributors. Anadarko displayed capital discipline, and it reported robust growth stemming from higher production volume. The company further benefited from a more favorable backdrop in the liquified natural gas market. Other contributors of note include Royal Dutch Shell PLC, Suncor Energy, Inc. and BP PLC.

On the negative side, the Trust s positions in E&Ps that emphasize natural gas generally lagged their more oil-focused peers. In this environment, Cabot Oil & Gas Corp. was a leading detractor from absolute performance. The energy distribution sub-sector also came under pressure as pipeline companies faced bottlenecks, leading to weakness in the Trust s position in TransCanada Corp. Other detractors of note include Cimarex Energy Co., Enbridge, Inc. and Halliburton Co.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy detracted from results.

## Describe recent portfolio activity.

The investment adviser shifted the Trust s positioning within the distribution subsector by initiating an investment in Williams Cos. and exiting its position in Enbridge, Inc. It also sold certain E&P stocks, including EOG Resources, Inc., Cimarex Energy Co., and Cabot Oil & Gas Corp., and initiated a new investment in the international E&P stock CNOOC Ltd.

Trust Information as of June 30, 2018 (continued)

#### **BlackRock Energy and Resources Trust**

### Describe portfolio positioning at period end.

The E&P sector represented the Trust s largest allocation, followed by the integrated, oil services, distribution, and refining & marketing industries, respectively. The investment adviser positioned the Trust with a higher-quality bias, focusing on companies with robust balance sheets and low costs of production.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

#### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 15.22	\$ 14.18	7.33%	\$15.63	\$12.85
Net Asset Value	15.97	15.79	1.14	16.54	14.24
Market Price and Net Asset Value History For the Past Five Years					

#### Overview of the Trust s Total Investments

#### **TEN LARGEST HOLDINGS**

Security	06/30/18
Royal Dutch Shell PLC ADR	10%
Exxon Mobil Corp.	9
BP PLC	7
Chevron Corp.	6
TOTAL SA	5
Suncor Energy, Inc.	5
ConocoPhillips	5
Valero Energy Corp.	4
EOG Resources, Inc.	4
Pioneer Natural Resources Co.	3

\* Excludes option positions and money market funds.

#### **INDUSTRY ALLOCATION**

Industry	06/30/18 1	2/31/17
Oil, Gas & Consumable Fuels	92%	90%
Energy Equipment & Services	8	10
For Trust compliance purposes, the Trust s industry classifications refer to any one or m	ore of the indu	stry

sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

TRUST INFORMATION

7

Trust Information as of June 30, 2018

BlackRock Enhanced Capital and Income Fund, Inc.

## **Investment Objective**

BlackRock Enhanced Capital and Income Fund, Inc. s (CII) (the Trust ) investment objective is to provide investors with a combination of current income and capital appreciation. The Trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust also seeks to achieve its investment policy by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust s investment objective will be achieved.

### **Trust Information**

Symbol on NYSE	CII
Initial Offering Date	April 30, 2004
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$16.22) <sup>(a)</sup>	6.13%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0828
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.9936

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- <sup>(b)</sup> The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

#### Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On		
	Market Price Net Asset Vo		
CII <sup>(a)(b)</sup>	2.13%	1.76%	
S&P 500 <sup>®</sup> Index	N/A	2.65	

(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

(b) The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

## The following discussion relates to the Trust s relative performance based on the index cited above:

### What factors influenced performance?

In the equity allocation of the Trust, the largest contributor to performance for the six-month period was stock selection in the health care sector. Specifically, selection decisions in the managed care industry provided strong relative returns. In financials, stock selection in capital markets and banks enhanced relative performance. Finally, an underweight allocation to as well as stock selection within industrials provided outperformance. In particular, selection among rail road operators contributed positively to return. At the stock level, the largest individual contributor was Urban Outfitters Inc., followed by a position in Humana Inc. and zero exposure to Johnson & Johnson.

In the equity allocation of the Trust, the largest detractor from relative performance for the six-month period was stock selection in the consumer discretionary sector. Most notably, positioning across homebuilders and underweight exposure to internet and direct marketing retail challenged relative performance. This was followed by positioning in information technology ( IT ) where electronic equipment and software holdings lagged. Finally, exposure to the tobacco industry hurt relative results in the consumer staples sector. Zero exposure to Amazon.com Inc. was the largest individual detractor, followed by a lack of exposure to Netflix Inc. and an overweight position to Altria Group Inc.

### Describe recent portfolio activity.

During the six-month period, the Trust significantly boosted exposure to the IT sector. Holdings within industrials and health care also were increased. Conversely, the Trust significantly reduced exposure to the financials sector. The Trust also reduced exposure to consumer discretionary and materials stocks. The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy detracted from results.

## Describe portfolio positioning at period end.

At period end, the Trust s largest allocations were in the IT, health care and financials sectors. Relative to the benchmark, the Trust s largest overweight positions were in the IT, health care, financials and consumer discretionary sectors. Conversely, the Trust s largest relative underweights were in the telecommunication services, real estate, and utilities sectors.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Trust Information as of June 30, 2018 (continued)

BlackRock Enhanced Capital and Income Fund, Inc.

# Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 16.22	\$ 16.38	(0.98)%	\$17.07	\$14.75
Net Asset Value	16.96	17.19	(1.34)	18.04	16.21
Market Price and Net Asset Value History For the Past Five Years					

## Overview of the Trust s Total Investment\*

### **TEN LARGEST HOLDINGS**

Security	06/30/18
Apple, Inc.	6%
Alphabet, Inc.	5
Microsoft Corp.	5
JPMorgan Chase & Co.	3
Bank of America Corp.	3
Pfizer, Inc.	3
Cisco Systems, Inc.	3
Lowe s Cos., Inc.	3
Comcast Corp.	2
United Health Group, Inc.	2

\* Excludes option positions and money market funds.

### SECTOR ALLOCATION

Sector	06/30/18	12/31/17
Information Technology	28%	26%
Health Care	18	16
Financials	14	17
Consumer Discretionary	12	14
Industrials	8	7
Consumer Staples	6	6
Energy	6	6
Materials	5	5

#### Utilities

### 3

3

For Trust compliance purposes, the Trust s sector classifications refer to any one or more of the sector sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

TRUST INFORMATION

9

Trust Information as of June 30, 2018

## BlackRock Enhanced Equity Dividend Trust

#### **Investment Objective**

**BlackRock Enhanced Equity Dividend Trust s (BDJ) (the Trust**) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. The Trust invests, under normal market conditions, at least 80% of its total assets in dividend paying equities. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objectives will be achieved.

#### **Trust Information**

Symbol on NYSE	BDJ
Initial Offering Date	August 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$9.18) <sup>(a)</sup>	6.10%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0467
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.5604

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- <sup>(b)</sup> The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

### Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Retu	Returns Based On		
	Market Price Net Asset Value			
BDJ <sup>(a)(b)</sup>	2.59%	(0.38)%		
Russell 1000 <sup>®</sup> Value Index	N/A	(1.69)		

<sup>(a)</sup> All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

(b) The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s relative performance based on the index cited above:

### What factors influenced performance?

The largest contribution to performance for the six-month period came from stock selection in the consumer staples sector. Notably, selection decisions within the beverages industry boosted relative return. In health care, stock selection within pharmaceuticals and health care equipment & services, and an overweight in health care providers & services enhanced relative performance. Lastly, stock selection within energy and utilities contributed, as did a combination of stock selection and an underweight in industrials.

The largest detractor from relative performance derived from stock selection in the financials sector. In particular, a combination of stock selection within and overweight exposure to the banking and insurance industries weighed on relative performance. Additionally, stock selection in the capital markets industry represented a headwind. Within the consumer discretionary sector, issue selection within the media industry had a negative impact. Finally, a lack of exposure to real estate acted as a constraint on returns.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio s holdings. Premiums generated are recognized as current gains that are intended to enhance distributions payable to shareholders in the form of dividends. The use of options detracted modestly from relative performance.

#### Describe recent portfolio activity.

During the six-month period, the Trust increased exposure to the information technology sector. Holdings within health care and energy also were increased. Conversely, the Trust significantly lowered its exposure to industrials, and also reduced its positioning within financials and materials.

#### Describe portfolio positioning at period end.

The Trust s largest allocations were in the financials, health care and energy sectors. Relative to the benchmark, the Trust s largest overweight positions were in the health care, financials and energy sectors. Conversely, the Trust s largest relative underweights were in the real estate, consumer discretionary and materials sectors.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

Trust Information as of June 30, 2018 (continued)

### BlackRock Enhanced Equity Dividend Trust

## Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 9.18	\$ 9.23	(0.54)%	\$ 9.64	\$8.03
Net Asset Value	9.62	9.96	(3.41)	10.42	9.33
Market Price and Net Asset Value History For the Past Five Years					

### **Overview of the Trust s Total Investment\***

### **TEN LARGEST HOLDINGS**

Security	06/30/18
JPMorgan Chase & Co.	4%
Bank of America Corp.	4
Pfizer, Inc.	4
Citigroup, Inc.	4
Wells Fargo & Co.	3
Oracle Corp.	3
Anthem, Inc.	3
Microsoft Corp.	3
Suncor Energy, Inc.	2
Verizon Communications, Inc.	2

\* Excludes option positions and money market funds.

### SECTOR ALLOCATION

Sector	06/30/18	12/31/17
Financials	28%	29%
Health Care	20	19
Energy	13	12
Information Technology	11	10
Industrials	7	8
Consumer Staples	7	7
Utilities	5	5
Consumer Discretionary	4	4

Telecommunication Services	3	3	
Materials	2	3	
For Trust compliance purposes, the Trust s sector classifications refer to any one or more of the sector			
sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined			
by the investment adviser. These definitions may not apply for purposes of this report, which may combine such			

sector sub-classifications for reporting ease.

TRUST INFORMATION

11

Trust Information as of June 30, 2018

### **BlackRock Enhanced Global Dividend Trust**

#### **Investment Objective**

**BlackRock Enhanced Global Dividend Trust s (BOE) (the Trust**) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies located in countries throughout the world and utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. Under normal circumstances, the Trust invests at least 80% of its net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest in securities of companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objectives will be achieved.

### **Trust Information**

Symbol on NYSE	BOE
Initial Offering Date	May 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$11.12) <sup>(a)</sup>	8.42%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0780
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.9360

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- (b) The monthly distribution per Common Share, declared on July 2, 2018, was decreased to \$0.0630 per share. The current distribution rate on closing market price, current monthly distribution per Common Share and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain.

#### Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Return	Returns Based On		
	Market Price Net Asset Value			
BOE <sup>(a)(b)</sup>	(7.44)%	(6.19)%		
MSCI All Country World Index	N/A	(0.43)		

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- <sup>(b)</sup> The Trust s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
- N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

## The following discussion relates to the Trust s relative performance based on the index cited above:

### What factors influenced performance?

Security selection within and overweight exposure to consumer staples represented the largest detractors from performance. Stock selection within industrials also weighed on returns. Two tobacco companies, British American Tobacco PLC and Altria Group, Inc., were among the top individual detractors. Tobacco stocks suffered due to a market rotation out of defensive sectors, coupled with the FDA s announcement that it would be looking to limit nicotine levels in traditional cigarettes, along with questions about Next Generation smoking products. In addition, the German postal and international courier company Deutsche Post AG detracted after the company lowered its earnings forecast as it launched a series of measures aimed at stemming a decline in profitability at its post, e-commerce and parcel division.

During the six-month period, the Trust s significant underweight to financials contributed to relative return as the sector was one of the worst-performing segments of the index. An underweight to real estate also contributed to performance. The Trust s position in the technology conglomerate Cisco Systems, Inc. was the top individual contributor after the company reported earnings that exceeded expectations and also announced a share buyback. Additionally, the British pharmaceutical firm GlaxoSmithKline PLC was among the top contributors to returns after Novartis AG announced that they will be selling their stake in a consumer health care joint venture to GlaxoSmithKline. Holdings of Chinese sportswear company Anta Sports Products Ltd. also helped performance with positive sentiment driven by the company s continued strong retail sales.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s options writing strategy contributed to Trust performance.

## Describe recent portfolio activity.

The Trust s allocation to tobacco stocks was reduced in May, with the proceeds reinvested in high quality, dividend-paying names in which the investment adviser has high conviction. These included health care, consumer staples and industrials stocks.

Trust Information as of June 30, 2018 (continued)

### **BlackRock Enhanced Global Dividend Trust**

### Describe portfolio positioning at period end.

At period end, the Trust s largest sector overweight positions were in the consumer staples and health care sectors, with an emphasis on the tobacco and pharmaceuticals industries, respectively. The largest underweights were to information technology and financials. The Trust had no exposure to real estate, utilities or energy at the end of the period. From a regional perspective, a majority of portfolio assets was invested either within the United States or Europe, with significant exposure in the United Kingdom and Switzerland.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 11.12	\$ 12.51	(11.11)%	\$13.08	\$10.96
Net Asset Value	11.91	13.22	(9.91)	13.71	11.78
Market Price and Net Asset Value History Fo	or the Past Five Yea	rs			

Net Asset Value History For the Past I

#### **Overview of the Trust s Total Investments**

## **TEN LARGEST HOLDINGS**

Security	06/30/18
Johnson & Johnson	4%
TELUS Corp.	4
Altria Group, Inc.	3
Sanofi	3
Novartis AG, Registered Shares	3
Coca-Cola Co.	3
Rogers Communications, Inc., Class B	3
Cisco Systems, Inc.	3
Nestle SA	3
Unilever PLC	3

\* Excludes option positions and money market funds.

#### **GEOGRAPHIC ALLOCATION**

Country	06/30/18	12/31/17
United States	43%	42%
United Kingdom	17	16
Australia	6	4
Switzerland	6	10
France	4	3
India	4	(a)
Singapore	3	
Taiwan	3	3
Netherlands	3	
Germany	3	2
Canada	3	6
Japan	2	2
Belgium	1	2
Denmark	1	
Finland	1	2
China	(a)	(a)
Sweden	(a)	(a)
Ireland	(a)	
Other <sup>(b)</sup>		5

(a) Representing less than 1% of the Trust s total investments.
(b) Other includes a 1% holding or less in each of the following countries: Denmark, Hong Kong, India, Italy, Netherlands and Spain.

TRUST INFORMATION

Trust Information as of June 30, 2018

## **BlackRock Enhanced International Dividend Trust**

### **Investment Objective**

**BlackRock Enhanced International Dividend Trust s (BGY) (the Trust**) primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies of any market capitalization located in countries throughout the world and utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. The Trust invests, under normal circumstances, at least 80% of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objectives will be achieved.

### **Trust Information**

Symbol on NYSE	BGY
Initial Offering Date	May 30, 2007
Current Distribution Rate on Closing Market Price as of as of June 30, 2018 (\$5.74) <sup>(a)</sup>	7.94%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0380
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.4560

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- <sup>(b)</sup> The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

#### Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On		
	Market Price	Net Asset Value	
BGY <sup>(a)(b)</sup>	(8.61)%	(6.49)%	
MSCI All Country World Index ex-USA	N/A	(3.77)	

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- <sup>(b)</sup> The Trust s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
- N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s relative performance based on the index cited above:

### What factors influenced performance?

Security selection within and an overweight to consumer staples were the largest detractors from performance. Additionally, selection within industrials detracted, including positions in international courier companies Deutsche Post AG (Germany) and bpost SA (Belgium). The Trust s lack of holdings in energy stocks also subtracted from returns.

The leading contributor to relative performance during the period was the Trust s overweight to the health care sector. Additionally, an underweight to financials contributed to performance. Lastly, stock selection within consumer discretionary added to returns, in particular from holdings in the Chinese sportswear company Anta Sports Products Ltd. and the Macau-based resort firm Sands China Ltd.

During the period, the Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s options writing strategy contributed to relative return.

### Describe recent portfolio activity.

The Trust reduced its exposure to tobacco stocks over the period, while retaining an overweight in the industry. The Trust also increased exposure to financials by purchasing two Singapore bank stocks.

#### Describe portfolio positioning at period end.

At period end, the Trust s largest sector overweights were in the consumer staples and health care sectors, with an emphasis on the tobacco and pharmaceuticals industries, respectively. The largest underweight exposure was to financials, particularly banks. The Trust had no exposure to real estate, utilities or energy. In regional terms, the majority of portfolio assets was invested in European equities, with significant exposure to the United Kingdom and Switzerland.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

Trust Information as of June 30, 2018 (continued)

**BlackRock Enhanced International Dividend Trust** 

# Market Price and Net Asset Value Per Share Summary

	06/	/30/18	12/	31/17	Change	High	Low
Market Price	\$	5.74	\$	6.52	(11.96)%	\$6.85	\$5.64
Net Asset Value		6.36		7.06	(9.92)	7.32	6.27
Market Price and Net Asset Value History For the P	Past F	'ive Yea	rs				

## Overview of the Trust s Total Investment\*

### **TEN LARGEST HOLDINGS**

Security	06/30/18
TELUS Corp.	6%
Sanofi	5
Novartis AG, Registered Shares	5
Rogers Communications, Inc., Class B	5
Nestle SA	5
Amcor	5
Imperial Brands PLC	5
Unilever PLC	5
British American Tobacco PLC	4
Deutsche Post AG, Registered Shares	4

\* Excludes option positions and money market funds.

## **GEOGRAPHIC ALLOCATION**

Country	06/30/18	12/31/17
United Kingdom	24%	19%
Switzerland	13	12
Canada	11	7
Australia	9	5
France	7	6
United States	5	6
Germany	4	3
Netherlands	4	6

Taiwan	4	3
Finland	4	2
Singapore	3	
China	2	5
Sweden	2	2
Belgium	2	3
India	2	2
Japan	2	5
Denmark	2	(a)
Hong Kong		2
South Korea		2
South Africa		2
Other		2 <sup>(b)</sup>

<sup>(a)</sup> Representing less than 1% of the Trust s total investments.
<sup>(b)</sup> Other includes a 1% holding or less in each of the following countries: Ireland and Portugal.

TRUST INFORMATION

Trust Information as of June 30, 2018

#### **BlackRock Health Sciences Trust**

### **Investment Objective**

**BlackRock Health Sciences Trust s (BME) (the Trust**) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

#### **Trust Information**

Symbol on NYSE	BME
Initial Offering Date	March 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$38.58) <sup>(a)</sup>	6.22%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.2000
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$2.4000

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- <sup>(b)</sup> The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

### Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Retu	Returns Based On		
	Market Price	Net Asset Value		
BME <sup>(a)(b)</sup>	9.33%	5.90%		
Russell 3000 <sup>®</sup> Healthcare Index	N/A	4.15		

- <sup>(a)</sup> All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- <sup>(b)</sup> The Trust s premium to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.
- N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

### The following discussion relates to the Trust s relative performance based on the index cited above:

### What factors influenced performance?

The Trust added value through its effective individual stock selection. An out-of-benchmark position in Sarepta Therapeutics, Inc., a biotechnology company focused on orphan drugs, was among the largest contributors to relative performance. Sarepta presented preliminary data for its experimental treatment for patients with Duchenne muscular dystrophy, sparking a rally in its shares.

Merger-and-acquisition activity was also a key driver of the Trust s performance. Avexis, Inc., a clinical-stage gene therapy biotechnology company, announced that it would be acquired at a substantial premium by the Swiss pharmaceutical giant Novartis AG. Toward the end of the period, shares of Boston Scientific Corp. rallied on the rumor that the company had received a takeover bid from Stryker Corp.

Other contributors of note included overweight positions in the health care services companies Humana, Inc, and Teladoc, Inc. The Trust s overweight position in the biotechnology stock Alnylam Pharmaceuticals, Inc. was among the largest detractors from returns, as the company came under pressure after Pfizer, Inc. released positive data on a competing drug.

A zero weighting in Align Technology, Inc. was among the largest detractors from relative performance in the medical devices & supplies sub-sector. The stock rallied following an analyst event that dispelled concerns about rising competition and outlined a strong growth outlook.

Other detractors of note included overweight positions in Cigna Corp., Novo Nordisk A/S and Insmed, Inc.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. This strategy detracted from performance in the period.

#### Describe recent portfolio activity.

The Trust increased its allocation to the medical devices & supplies subsector and slightly reduced its weightings in the healthcare providers & services area. Its allocation to biotechnology decreased, while its weighting in pharmaceuticals was largely unchanged.

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

16

Trust Information as of June 30, 2018 (continued)

#### **BlackRock Health Sciences Trust**

### Describe portfolio positioning at period end.

The Trust continued to employ a bottom-up, fundamental investment process in an effort to construct a balanced, diversified portfolio of health care stocks. The portfolio continues to reflect two broad themes: innovation and value-based health care.

Innovation in medical technology remains a secular growth driver for the health care sector as companies continue to develop new therapies or products that are either fulfilling an unmet medical need or are an improvement over current treatments. This encompasses not only the biotechnology industry, but also the pharmaceuticals and medical devices & supplies sub-sectors.

With respect to value-based health care, the Trust has an above-benchmark weighting in the health care providers & services sub-sector largely due to its sizeable overweight in the managed care industry. The investment adviser continues to find a number of companies in this area that it believes are well positioned to leverage their scale and analytical capabilities to reduce health care costs. Additionally, select holdings in the health care services industry feature business models that are benefiting from the shift to lower-cost options such as home health care.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

#### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 38.58	\$ 36.50	5.70%	\$ 39.83	\$ 32.89
Net Asset Value	36.54	35.69	2.38	38.56	34.33
Market Price and Net Asset Value History	y For the Past Five Year	S			

Overview of the Trust s Total Investments

## **TEN LARGEST HOLDINGS**

Security	06/30/18
UnitedHealth Group, Inc.	9%
Pfizer, Inc.	5
Medtronic PLC	4

Abbott Laboratories	4
Stryker Corp.	3
Boston Scientific Corp.	4
Quest Diagnostics, Inc.	3
Anthem, Inc.	3
Humana, Inc.	2
Baxter International, Inc.	2

\* Excludes option positions and money market funds.

## **INDUSTRY ALLOCATION**

Industry	06/30/18 12/	/31/17
Health Care Equipment & Supplies	28%	23%
Health Care Providers & Services	25	25
Biotechnology	20	25
Pharmaceuticals	22	24
Life Sciences Tools & Services	3	2
Diversified Consumer Services	1	1
Health Care Technology	1	

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

TRUST INFORMATION

17

Trust Information as of June 30, 2018

BlackRock Resources & Commodities Strategy Trust

### **Investment Objective**

BlackRock Resources & Commodities Strategy Trust s (BCX) (the Trust ) primary investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources. While permitted, the Trust does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option overwriting strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objectives will be achieved.

### **Trust Information**

Symbol on NYSE	BCX
Initial Offering Date	March 30, 2011
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$9.29) <sup>(a)</sup>	6.67%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.0516
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$0.6192

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- <sup>(b)</sup> The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

#### Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On	
	Market Price	Net Asset Value
BCX <sup>(a)(b)</sup>	(1.71)%	0.07%
Lipper Natural Resources Funds <sup>(c)</sup>	(1.38)	(0.70)

<sup>(a)</sup> All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

- <sup>(b)</sup> The Trust s discount to NAV widened during the period, which accounts for the difference between
- performance based on market price and performance based on NAV.
- (c)

Average return. Returns reflect investment of dividends and/or distributions at NAV on the ex-dividend as calculated by Lipper.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

# The following discussion relates to the Trust s absolute performance based on NAV:

## What factors influenced performance?

The Trust s allocation to energy stocks made a positive contribution to its six-month results. Oil prices rallied behind the combination of tighter supplies and higher-than-expected demand, leading to strong returns for the energy sector. In this environment, the U.S. exploration and production company ConocoPhillips was among the largest contributors to performance. Upstream producers, in general, maintained capital discipline and prioritized shareholder returns over growth. ConocoPhillips participated in this trend by announcing a 7.5% dividend increase and a 33% expansion of its share buyback program, which boosted its stock price. Other contributors of note within energy included Royal Dutch Shell PLC, Suncor Energy, Inc. and BP PLC.

The mining stock Nevsun Resources Ltd., which was bid for by a competitor in May, was also a large contributor to returns.

After performing strongly in 2017, the battery materials industry came under pressure in early 2018 as lithium prices retreated. The downturn stemmed from supply concerns that arose after the lithium miner Sociedad Química y Minera de Chile SA reached an agreement with the Chilean government that would allow it to significantly increase production. The Trust s position in Neo Lithium Corp. detracted from performance as a result. The investment adviser retained the position on the belief that the long-term demand for lithium from electric vehicle sales is likely to outweigh the available supply.

The Brazil-based food producer BRF SA also detracted. The Brazilian Federal Police announced it was investigating the company for manipulating food/meat sample tests that are required to meet export regulatory standards. The company s former chief executive officer was arrested, along with ten other employees. This news introduced significant risk into the BRF investment case, prompting the Trust to sell the position. Other detractors of note included Glencore PLC, Nutrien Ltd. and Arcelormittal.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy detracted from results.

## Describe recent portfolio activity.

The Trust exited three of its positions in the agriculture industry, including Monsanto Co. The investment adviser believed the stock had limited upside since its price was close to the level at which the company was bid for by Bayer AG. The Trust also sold BRF and AGCO Corp., and initiated a position in the agricultural supply-chain company Archer Daniels Midland Co. on the expectation that the company s restructuring effort will lead to higher earnings growth.

Trust Information as of June 30, 2018 (continued)

BlackRock Resources & Commodities Strategy Trust

The investment adviser rotated some of the portfolio s positions in the mining industry based on relative valuations. In addition, the Trust s allocation to the industry was increased through additions to BHP Billiton Ltd. and Glencore.

#### Describe portfolio positioning at period end.

The mining industry represented the largest allocation following the Trust s purchases in this area. Energy and agriculture were the second- and third-largest weightings, respectively.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

#### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 9.29	\$ 9.77	(4.91)%	\$10.49	\$8.69
Net Asset Value	10.30	10.64	(3.20)	11.05	9.68
Market Price and Net Asset Value History For	Past Five Years				

Overview of the Trust s Total Investments

#### **TEN LARGEST HOLDINGS**

Security	06/30/18
Nutrien LTD	6%
Royal Dutch Shell PLC ADR	6
Glencore PLC	5
BP PLC ADR	5
BHP Billiton PLC	5
TOTAL SA	5
Rio Tinto PLC ADR	4
Suncor Energy, Inc.	4
Vale SA ADR	4
Archer-Daniels-Midland Co.	3

\* Excludes option positions and money market funds.

#### **INDUSTRY ALLOCATION**

Industry	06/30/18 12	/31/17
Metals & Mining	36%	34%
Oil, Gas & Consumable Fuels	34	34
Chemicals	12	13
Food Products	8	11
Containers & Packaging	5	3
Energy Equipment & Services	2	3
Paper & Forest Products	1	1
Machinery	1	1
Electronic Equipment, Instruments & Components	1	

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

TRUST INFORMATION

19

Trust Information as of June 30, 2018

#### BlackRock Science and Technology Trust

#### **Investment Objective**

**BlackRock Science and Technology Trust s (BST) (the Trust**) investment objective is to provide income and total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of science and technology companies. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

#### **Trust Information**

Symbol on NYSE	BST
Initial Offering Date	October 30, 2014
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$33.65) <sup>(a)</sup>	4.64%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.1300
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$1.5600

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- <sup>(b)</sup> The monthly distribution per Common Share, declared on July 2, 2018, was increased to \$0.1500 per share. The current distribution rate on closing market price, current monthly distribution per Common Share and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain.

#### **Performance and Portfolio Management Commentary**

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On		
	Market Price Net Asset Value		
BST <sup>(a)(b)</sup>	29.37%	15.46%	
MSCI World Information Technology Index	N/A	9.44	

<sup>(a)</sup> All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

- <sup>(b)</sup> The Trust moved from a discount to NAV to a premium to NAV during the period, which accounts for the difference between performance based on market price and performance based on NAV.
- N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

## The following discussion relates to the Trust s relative performance based on the index cited above:

## What factors influenced performance?

Global markets were flat during the period, as the MSCI World Index returned 0.43%. However, this masked considerable volatility driven by rising trade tensions and broader geopolitical risk.

The Trust s non-benchmark position in Amazon.com, Inc. was the largest contributor to relative performance, as strong e-commerce sales helped Amazon surpass first quarter earnings expectations, boosting the company s share price. Holdings in Netflix, Inc. represented the second largest contributor, as the company beat expectations for growth in subscribers. A non-benchmark position in the mobile payment company Square Inc. was also additive. Square has benefited from an improving macroeconomic backdrop as well as significant growth in mobile payment utilization rates.

The largest detractors from relative performance were the Trust s underweight positions in Facebook, Inc. and Apple, Inc. Facebook shares rallied after strong earnings helped ease fears surrounding the possible impact of user privacy concerns on Facebook s business model. Elsewhere, a non-benchmark position in Linx, a Brazilian management software company, was among the largest detractors from performance as recent political unrest in Brazil weighed on the company s share price.

Also, the Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust s options writing strategy detracted from returns.

#### Describe recent portfolio activity.

During the six-month period, the Trust took profits on a position in a semiconductor company that had performed particularly well. Proceeds from the sale were rotated into a value opportunity within the internet software & services sub-industry.

#### Describe portfolio positioning at period end.

At period end, the Trust held its largest allocation within the software & services industry group, with a focus on idiosyncratic opportunities within the internet software & services and application software sub-industries. Regionally, the Trust maintained most of its exposure in North America, with smaller allocations to the emerging markets and Europe.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Trust Information as of June 30, 2018 (continued)

BlackRock Science and Technology Trust

## Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 33.65	\$ 26.69	26.08%	\$35.71	\$26.00
Net Asset Value	31.20	27.73	12.51	32.73	27.48
Market Price and Net Asset Value History Since Inception					

<sup>(a)</sup> Commencement of operations.Overview of the Trust s Total Investment\*

## TEN LARGEST HOLDINGS

Security	06/30/18
Amazon.com, Inc.	6%
Microsoft Corp.	5
Tencent Holdings Ltd.	5
Alphabet Inc.	5
Apple, Inc.	4
Alibaba Group Holding LTD. ADR.	3
Mastercard, Inc.	3
Square, Inc.	2
Visa, Inc.	2
salesforce.com, Inc.	2

\* Excludes option positions and money market funds.

## **INDUSTRY ALLOCATION**

Industry	06/30/18	12/31/17
Software	30%	22%
Internet Software & Services	28	28
Semiconductors & Semiconductor Equipment	13	18
IT Services	12	10
Internet & Direct Marketing Retail	8	6

Technology Hardware, Storage & Peripherals	4	7
Electronic Equipment, Instruments & Components	1	2
Media	1	1
Other	3(a)	6 <sup>(a)</sup>

(a) Other includes a 1% holding or less in each of the following industries: Automobiles, Chemicals, Consumer Finance, Household Durables, Health Care Technology, Professional Services and Diversified Consumer Services.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

TRUST INFORMATION

21

Trust Information as of June 30, 2018

BlackRock Utilities, Infrastructure & Power Opportunities Trust

#### **Investment Objective**

BlackRock Utilities, Infrastructure & Power Opportunities Trust s (BUI) (the Trust ) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing primarily in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by utilizing an option writing (selling) strategy in an effort to seek total return performance and enhance distributions. The Trust considers the Utilities business segment to include products, technologies and services connected to the management, ownership, operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or telecommunications, the Infrastructure business segment to include companies that own or operate infrastructure assets or that are involved in the development, construction, distribution or financing of infrastructure assets and the Power Opportunities business segment to include companies with a significant involvement in, supporting, or necessary to renewable energy technology and development, alternative fuels, energy efficiency, automotive and sustainable mobility and technologies that enable or support the growth and adoption of new power and energy sources. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objective will be achieved.

## **Trust Information**

Symbol on NYSE	BUI
Initial Offering Date	November 25, 2011
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$20.01) <sup>(a)</sup>	7.26%
Current Monthly Distribution per Common Share <sup>(b)</sup>	\$0.1210
Current Annualized Distribution per Common Share <sup>(b)</sup>	\$1.4520

- (a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.
- <sup>(b)</sup> The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

## Performance and Portfolio Management Commentary

Returns for the six-months ended June 30, 2018:

Returns Based On			
Market Price	Net Asset Value		
(4.06)%	(0.56)%		

Lipper Utility Funds<sup>(c)</sup>

(4.84)

(2.54)

- <sup>(a)</sup> All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- <sup>(b)</sup> The Trust moved from a premium to NAV to a discount to NAV during the period, which accounts for the difference between performance based on market price and performance based on NAV.
- <sup>(c)</sup> Average return. Returns reflect reinvestment of dividends and/or distributions at NAV on the ex-dividend date as calculated by Lipper.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

## The following discussion relates to the Trust s absolute performance based on NAV:

## What factors influenced performance?

Markets were essentially flat during the period, as the MSCI World Index returning 0.43%. However, this masked considerable volatility driven by rising trade tensions and broader geopolitical risks.

A position in Spanish renewable energy company EDP Renovaveis was the largest contributor to the Trust s performance during the six-month period. The company s shares rose on speculation that one or more companies were looking to acquire all or part of the business. Another renewable energy holding, China Longyuan, was among the leading contributors for the period. China is introducing a national emissions trading scheme for carbon dioxide that will incentivize the move to cleaner technologies, boosting the company s shares in the period. Other contributors of note included clean energy company NextEra Energy Inc., Macquarie Infrastructure Corp. and electric utility FirstEnergy Corp.

Exposure to multinational automotive supplier Valeo was the largest detractor from the Trust s absolute performance during the period. Despite a stronger-than-expected order book, the company reported lower year-on-year profits for 2017, especially in the autonomous driving and electric vehicle segments, while lowering forward guidance for organic growth. The Trust has maintained the position on a positive view of both the company and the broader vehicle electrification theme, particularly given the regulatory support emerging from many countries. Elsewhere within the automotive space, temporary disruption related to the move to real world driving testing standards negatively impacted our positions in component manufacturers Continental AG and Osram Licht AG. Other detractors of note included European energy company Enel SpA and Denmark-based wind energy manufacturer Vestas Wind Systems A/S.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy had a negative impact on results.

Trust Information as of June 30, 2018 (continued) BlackRock Utilities, Infrastructure & Power Opportunities Trust

#### Describe recent portfolio activity.

During the period, the Trust reduced exposure to midstream energy companies, exiting Shell Midstream Partners and Plains All American Pipeline in the process. Capital was rotated into the electric vehicle exposed companies, such as semiconductor manufacturer Infineon Technologies AG and Continental AG.

#### Describe portfolio positioning at period end.

At period end, the utilities sector accounted for approximately 63.5% of the Trust s assets, with holdings concentrated in U.S. electric and multi-utilities. Approximately 16% of the portfolio was invested in the industrials sector, with roughly another 12% in the energy sector. The remainder was invested in other infrastructure- and power-related sectors.

Against a backdrop of historically low interest rates, the demand for equity yield has led to valuations for U.S. utilities that are high relative to their historical levels, placing even greater importance on stock selection. As such, the Trust was focused on owning companies with strong management teams that offer the potential for above-sector growth in earnings and dividends. The Trust had a preference for regulated utilities over their non-regulated counterparts given their existing barriers to entry, strong balance sheets, and lower sensitivity to commodity prices.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

#### Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 20.01	\$ 21.62	(7.45)%	\$21.73	\$19.09
Net Asset Value	20.26	21.12	(4.07)	21.27	19.69
Market Price and Net Asset Value History For the Past Five Years					

Market Price and Net Asset Value History For the Past Five Years

#### Overview of the Trust s Total Investments

#### **TEN LARGEST HOLDINGS**

Security	06/30/18
NextEra Energy, Inc.	11%
Enel SpA	5
EDP Renovaveis SA	5

National Grid PLC	4
Public Service Enterprise Group	4
Duke Energy Corp.	4
Dominion Energy, Inc.	3
Atlantia SpA	3
Exelon Corp.	3
TransCanada Corp.	3

\* Excludes option positions and money market funds.

## **INDUSTRY ALLOCATION**

Industry	06/30/18	12/31/17
Electric Utilities	36%	33%
Multi-Utilities	20	20
Oil, Gas & Consumable Fuels	12	12
Transportation Infrastructure	11	15
Independent Power and Renewable Electricity Producers	8	8
Electrical Equipment	4	3
Chemicals	4	3
Water Utilities	1	1
Construction & Engineering		3
Gas Utilities		1
Auto Components	2	
Other	2 <sup>(a)</sup>	1(a)

<sup>(a)</sup> Other includes a 1% holding or less in each of the following industries: Building Products and Semiconductors & Semiconductor Equipment.

For Trust compliance purposes, the Trust s industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

TRUST INFORMATION

23

Derivative Financial Instruments

The Trusts may invest in various derivative financial instruments. These instruments are used to obtain exposure to a security, commodity, index, market, and/or other assets without owning or taking physical custody of securities, commodities and/or other referenced assets or to manage market, equity, credit, interest rate, foreign currency exchange rate, commodity and/or other risks. Derivative financial instruments may give rise to a form of economic leverage and involve risks, including the imperfect correlation between the value of a derivative financial instrument and the underlying asset, possible default of the counterparty to the transaction or illiquidity of the instrument. The Trusts successful use of a derivative financial instrument depends on the investment adviser s ability to predict pertinent market movements accurately, which cannot be assured. The use of these instruments may result in losses greater than if they had not been used, may limit the amount of appreciation a Trust can realize on an investment and/or may result in lower distributions paid to shareholders. The Trusts investments in these instruments, if any, are discussed in detail in the Notes to Financial Statements.

Schedule of Investments (unaudited)	BlackRock Energy and Resources	Trust (BGR)				
June 30, 2018	(Percentages shown are based on Net Asse					
Security Common Stocks 99.8%	Shares	Value				
Energy Equipment & Services 7.6%						
Baker Hughes a GE Co. <sup>(a)</sup>	255,700	\$ 8,445,771				
Halliburton Co. <sup>(a)</sup>	306,900	13,828,914				
Patterson-UTI Energy, Inc. <sup>(a)</sup>	192,557	3,466,026				
Schlumberger Ltd. <sup>(a)</sup>	156,674	10,501,858				
		36,242,569				
Oil, Gas & Consumable Fuels 92.2%						
Anadarko Petroleum Corp. <sup>(a)</sup>	165,033	12,088,667				
Andeavor <sup>(a)</sup>	103,050	13,518,099				
BP PLC	4,427,650	33,687,851				
Cairn Energy PLC <sup>(b)</sup>	1,747,695	5,738,664				
Canadian Natural Resources Ltd.	418,540	15,106,472				
Chevron Corp. <sup>(a)(c)</sup>	242,585	30,670,022				
Cimarex Energy Co. <sup>(a)</sup> CNOOC Ltd.	65,550 4,423,000	6,669,057 7,579,007				
Concho Resources, Inc. <sup>(a)(b)</sup>	4,423,000 26,750	3,700,862				
ConocoPhillips <sup>(a)</sup>	314,800	21,916,376				
Devon Energy Corp. <sup>(a)</sup>	339,050	14,904,638				
Encana Corp.	849,530	11,095,295				
EOG Resources, Inc. <sup>(a)</sup>	142,700	17,756,161				
EQT Corp.	180,450	9,957,231				
Exxon Mobil Corp. <sup>(a)(c)</sup>	487,002	40,289,675				
Galp Energia SGPS SA	14,335	273,455				
Kosmos Energy Ltd. <sup>(b)</sup>	720,108	5,955,293				
Marathon Oil Corp. <sup>(a)</sup>	191,748	3,999,863				
Noble Energy, Inc. <sup>(a)</sup>	303,842	10,719,546				
Oil Search Ltd.	911,863	5,990,891				
Pioneer Natural Resources Co. <sup>(a)</sup>	82,876	15,683,454				
Royal Dutch Shell PLC ADR, Class (A)	713,800	49,416,374				
Royal Dutch Shell PLC, Class A	273,248	9,456,815				
Suncor Energy, Inc.	548,400 Shamaz	22,317,271				
Security Oil Cas & Consumption Fuels (continued)	Shares	Value				
<b>Oil, Gas &amp; Consumable Fuels (continued)</b> TOTAL SA	425,553 \$	25,842,019				
TransCanada Corp.	306,250	13,250,295				
Valero Energy Corp. <sup>(a)</sup>	168,800	18,708,104				
Williams Cos., Inc. <sup>(a)</sup>	482,900	13,091,419				
		439,382,876				

475,625,445

# Total Long-Term Investments 99.8% (Cost \$404,613,943)

Short-Term Securities 1.0%		
BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% <sup>(d)(e)</sup>	4,599,459	4,599,459
Total Short-Term Securities 1.0%		
(Cost \$4,599,459)		4,599,459
Total Investments Before Options Written 100.8%		
(Cost \$409,213,402)		480,224,904
Options Written (0.7)%		
(Premiums Received \$3,574,813)		(3,538,539)
		(-,,,)
Total Investments, Net of Options Written 100.1%		
(Cost \$405,638,589)		476,686,365
Liabilities in Excess of Other Assets (0.1)%		(381,317)
Net Assets 100.0%		\$ 476,305,048
11CL ASSELS 100.070		\$ 470,303,048

<sup>(a)</sup> All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

<sup>(b)</sup> Non-income producing security.

<sup>(c)</sup> All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

<sup>(d)</sup> Annualized 7-day yield as of period end.

<sup>(e)</sup> During the six months ended June 30, 2018, investments in issuers considered to be an affiliate of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

							Change	
							in	
	Shares		Shares			1	Ve�Unrealized	
	Held at	Net	Held at	Value at		Realiz <b>App</b> preciatio		
Affiliate	12/31/17	Activity	06/30/18	06/30/18	Inc <b>Guuia</b> n		(preciation)	
BlackRock Liquidity Funds,								
T-Fund, Institutional Class	3,870,844	728,615	4,599,459	\$4,599,459	\$28,875	\$	\$	

<sup>(a)</sup> Includes net capital gain distributions, if applicable.

For Trust compliance purposes, the Trust s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

# Derivative Financial Instruments Outstanding as of Period End

# **Exchange-Traded Options Written**

	Number of	Expiration	Exercis	e N	lotional	
Description	Contracts	Date	Prie	e Amour	ıt (000)	Value
Call						
Chevron Corp.	154	07/06/18	USD 128.0	0 USD	1,947	\$ (9,086)
ConocoPhillips	164	07/06/18	USD 70.0	0 USD	1,142	(11,890)
Devon Energy Corp.	114	07/06/18	USD 43.5	0 USD	501	(11,856)
Devon Energy Corp.	130	07/06/18	USD 41.0	0 USD	571	(39,975)
EOG Resources, Inc.	89	07/06/18	USD 119.0	0 USD	1,107	(53,400)
Halliburton Co.	290	07/06/18	USD 51.5	0 USD	1,307	(870)
Williams Cos., Inc.	460	07/06/18	USD 27.5	0 USD	1,247	(5,750)
Anadarko Petroleum Corp.	70	07/13/18	USD 72.0	0 USD	513	(16,450)

## Schedules of Investments

# BlackRock Energy and Resources Trust (BGR)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exerc	ise N	lotional	
Description	Contracts	Date	Pr	ice Amour	nt (000)	Value
Call (continued)						
Chevron Corp.	154	07/13/18	USD 129	00 USD	1,947	\$ (13,013)
ConocoPhillips	202	07/13/18	USD 70	00 USD	1,406	(24,139)
EOG Resources, Inc.	38	07/13/18	USD 120	.00 USD	473	(20,900)
Exxon Mobil Corp.	356	07/13/18	USD 83	00 USD	2,945	(36,312)
Pioneer Natural Resources Co.	111	07/13/18	USD 197	.50 USD	2,101	(15,817)
Royal Dutch Shell PLC ADR,						
Class A	205	07/13/18	USD 71	.00 USD	1,419	(7,175)
Valero Energy Corp.	60	07/13/18	USD 116	.00 USD	665	(4,080)
Williams Cos., Inc.	576	07/13/18	USD 27	.00 USD	1,562	(29,088)
Anadarko Petroleum Corp.	259	07/20/18	USD 72	50 USD	1,897	(63,196)
Andeavor	104	07/20/18	USD 145	.00 USD	1,364	(4,160)
Baker Hughes a GE Co.	287	07/20/18	USD 39	.00 USD	948	(2,870)
Baker Hughes a GE Co.	233	07/20/18	USD 36	.00 USD	770	(5,825)
Canadian Natural Resources Ltd.	165	07/20/18	CAD 48	.00 CAD	783	(10,605)
Chevron Corp.	353	07/20/18	USD 130	00 USD	4,463	(33,712)
Cimarex Energy Co.	74	07/20/18	USD 90	00 USD	753	(92,130)
Concho Resources, Inc.	38	07/20/18	USD 152	.75 USD	526	(2,011)
ConocoPhillips	227	07/20/18	USD 72	.50 USD	1,580	(13,393)
ConocoPhillips	164	07/20/18	USD 70	.50 USD	1,142	(20,582)
Devon Energy Corp.	152	07/20/18	USD 38	00 USD	668	(93,860)
Devon Energy Corp.	70	07/20/18	USD 44	.00 USD	308	(10,465)
Devon Energy Corp.	92	07/20/18	USD 46	.00 USD	404	(6,348)
EOG Resources, Inc.	116	07/20/18	USD 125	00 USD	1,443	(33,756)
Encana Corp.	1,255	07/20/18	CAD 17	00 CAD	2,155	(69,210)
Noble Energy, Inc.	492	07/20/18	USD 37	50 USD	1,736	(17,220)
Royal Dutch Shell PLC ADR,						
Class A	289	07/20/18	USD 70	00 USD	2,001	(26,733)
Royal Dutch Shell PLC ADR,						
Class A	405	07/20/18	USD 75	00 USD	2,804	(3,037)
Schlumberger Ltd.	326	07/20/18	USD 73	45 USD	2,185	(3,376)
Suncor Energy, Inc.	982	07/20/18	CAD 54	00 CAD	5,254	(61,625)
Andeavor	131	07/27/18	USD 152	50 USD	1,718	(2,882)
Chevron Corp.	65	07/27/18	USD 130	00 USD	822	(9,782)
ConocoPhillips	108	07/27/18	USD 69	00 USD	752	(25,326)
Devon Energy Corp.	1	07/27/18	USD 44	00 USD	4	(175)
Devon Energy Corp.	92	07/27/18	USD 45	50 USD	404	(9,982)
Devon Energy Corp.	141	07/27/18	USD 45	00 USD	620	(18,118)
EOG Resources, Inc.	91	07/27/18	USD 119	00 USD	1,132	(65,748)

Exxon Mobil Corp.	410	07/27/18	USD	85.00	USD	3,392	(32,800)
Halliburton Co.	392	07/27/18	USD	49.50	USD	1,766	(11,172)
Pioneer Natural Resources Co.	52	07/27/18	USD	202.50	USD	984	(9,880)
Royal Dutch Shell PLC ADR,							
Class A	296	07/27/18	USD	71.00	USD	2,049	(23,680)
Royal Dutch Shell PLC ADR,							
Class A	405	07/27/18	USD	69.50	USD	2,804	(57,713)
Williams Cos., Inc.	139	07/27/18	USD	28.50	USD	377	(2,363)
Williams Cos., Inc.	257	07/27/18	USD	28.00	USD	697	(7,453)
Concho Resources, Inc.	55	07/30/18	USD	128.25	USD	761	(67,595)
Chevron Corp.	58	08/03/18	USD	130.00	USD	733	(10,498)
Devon Energy Corp.	71	08/03/18	USD	43.50	USD	312	(17,821)
Exxon Mobil Corp.	471	08/03/18	USD	83.00	USD	3,897	(92,081)
Pioneer Natural Resources Co.	31	08/03/18	USD	190.00	USD	587	(21,855)
Pioneer Natural Resources Co.	64	08/03/18	USD	200.00	USD	1,211	(20,320)
Valero Energy Corp.	197	08/03/18	USD	116.00	USD	2,183	(41,567)
Chevron Corp.	65	08/10/18	USD	128.00	USD	822	(19,370)
Devon Energy Corp.	141	08/10/18	USD	46.00	USD	620	(21,925)
EOG Resources, Inc.	165	08/10/18	USD	129.00	USD	2,053	(48,180)
Valero Energy Corp.	128	08/10/18	USD	115.00	USD	1,419	(32,832)
Anadarko Petroleum Corp.	248	08/17/18	USD	72.50	USD	1,817	(97,340)
Andeavor	90	08/17/18	USD	140.00	USD	1,181	(15,390)
Canadian Natural Resources Ltd.	670	08/17/18	CAD	44.00	CAD	3,179	(214,049)
Cimarex Energy Co.	167	08/17/18	USD	100.00	USD	1,699	(105,210)
ConocoPhillips	236	08/17/18	USD	70.00	USD	1,643	(60,298)
Devon Energy Corp.	90	08/17/18	USD	42.00	USD	396	(33,525)
Devon Energy Corp.	92	08/17/18	USD	46.00	USD	404	(15,778)
Encana Corp.	2,268	08/17/18	CAD	17.00	CAD	3,894	(187,181)
Exxon Mobil Corp.	467	08/17/18	USD	82.50	USD	3,863	(113,481)

## BlackRock Energy and Resources Trust (BGR)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exercise		Exercise		Ν	otional	
Description	Contracts	Date		Price	Amoun	et (000)	Value		
Call (continued)									
Halliburton Co.	392	08/17/18	USD	50.00	USD	1,766	\$ (20,580)		
Patterson-UTI Energy, Inc.	210	08/17/18	USD	19.00	USD	378	(15,750)		
Pioneer Natural Resources Co.	32	08/17/18	USD	185.00	USD	606	(38,240)		
Royal Dutch Shell PLC ADR	,								
Class A	206	08/17/18	USD	72.50	USD	1,426	(14,420)		
Schlumberger Ltd.	187	08/17/18	USD	67.50	USD	1,253	(42,169)		
Suncor Energy, Inc.	937	08/17/18	CAD	54.00	CAD	5,013	(103,347)		
TransCanada Corp.	1,071	08/17/18	CAD	58.00	CAD	6,092	(68,839)		
Valero Energy Corp.	205	08/17/18	USD	115.00	USD	2,272	(59,245)		
Williams Cos., Inc.	258	08/17/18	USD	28.00	USD	699	(13,674)		

<sup>\$ (2,763,549)</sup> 

# **OTC Options Written**

<i>Description</i> Call	Counterparty	Number of Contracts	Expiration Date	E.	xercise Price	N Amoun	otional et (000)	Value
Noble								
Energy, Inc.	Bank of America N.A.	59,000	07/09/18	USD	35.40	USD	2,082	\$ (42,265)
BP PLC	Goldman Sachs International	311,600	07/10/18	GBP	5.83	GBP	1,798	(23,239)
Oil Search								
Ltd.	Morgan Stanley & Co. International PLC	157,000	07/10/18	AUD	8.81	AUD	1,394	(21,568)
Patterson-UTI								
Energy, Inc.	UBS AG	35,300	07/10/18	USD	23.63	USD	635	
TOTAL SA	Credit Suisse International	10,700	07/11/18	EUR	53.41	EUR	556	(2,456)
TOTAL SA	UBS AG	18,600	07/11/18	EUR	54.88	EUR	967	(524)
Canadian								
Natural								
Resources								
Ltd.	Credit Suisse International	67,900	07/16/18	CAD	46.25	CAD	3,222	(91,397)
BP PLC	Barclays Bank PLC	262,800	07/18/18	GBP	5.85	GBP	1,516	(25,083)
CNOOC Ltd.	Goldman Sachs International	207,000	07/18/18	HKD	14.07	HKD	2,782	(3,447)
TOTAL SA	Goldman Sachs International	26,500	07/25/18	EUR	53.15	EUR	1,378	(13,724)
BP PLC	Citibank N.A.	230,000	07/26/18	GBP	5.96	GBP	1,327	(15,927)
CNOOC Ltd.	JPMorgan Chase Bank N.A.	261,000	07/26/18	HKD	14.07	HKD	3,508	(6,498)

Royal Dutch Shell PLC,								
Class A	Goldman Sachs International	95,700	07/26/18	GBP	25.93	GBP	2,509	(94,603)
TOTAL SA	Citibank N.A.	47,000	07/26/18	EUR	53.63	EUR	2,307	(19,103)
BP PLC	Barclays Bank PLC	213,300	07/27/18	GBP	5.86	GBP	1,231	(26,684)
BP PLC	Citibank N.A.	221,000	07/27/18	GBP	5.70	GBP	1,275	(50,760)
CNOOC Ltd.	Societe Generale	300,000	08/01/18	HKD	12.78	HKD	4,032	(32,136)
TOTAL SA	UBS AG	30,000	08/01/18	EUR	53.87	EUR	1,560	(16,207)
Patterson-UTI								
Energy, Inc.	UBS AG	11,000	08/06/18	USD	20.20	USD	198	(3,321)
Royal Dutch								
Shell PLC								
ADR,								
Class A	Citibank N.A.	34,600	08/06/18	USD	70.97	USD	2,395	(39,852)
Oil Search								
Ltd.	Citibank N.A.	190,000	08/07/18	AUD	8.35	AUD	1,687	(86,874)
BP PLC	Goldman Sachs International	311,000	08/08/18	GBP	5.85	GBP	1,794	(55,006)
TOTAL SA	Goldman Sachs International	16,100	08/08/18	EUR	52.17	EUR	837	(21,605)
Baker Hughes								
a GE Co.	Citibank N.A.	31,300	08/13/18	USD	33.93	USD	1,034	(39,343)
Royal Dutch								
Shell PLC								
ADR,								
Class A	Citibank N.A.	34,600	08/20/18	USD	70.97	USD	2,395	(43,368)
								¢ (774.000)
								\$(774,990)

## Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap					
	Premiums	Premiums	Unrealized	Unrealized			
	Paid	Received	Appreciation	Depreciation	Value		
Options Written	N/A	N/A	\$ 966,746	\$ (930,472)	\$(3,538,539)		
Derivative Financial Instruments Categorized by Risk Exposure							

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

				Foreign	n		
			0	Currency	y Interest		
	Commodity	Credit	Equity E	xchange	e Rate	Other	
	Contracts C	Contracts	Contracts C	ontract.	s Contracts C	Contracts	Total
Liabilities Derivative							
<b>Financial Instruments</b>							
Options written							
Options written at value	\$	\$	\$ 3,538,539	\$	\$	\$	\$ 3,538,539

Schedules of Investments

## BlackRock Energy and Resources Trust (BGR)

June 30, 2018

For the six months ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

Net Realized Gain (Loss)	Commodity Contract.Co		C	C EquityEx	change	, Interest	Other ontracts		Tota	ıl
<b>from:</b> Options purchased <sup>(a)</sup> Options written	\$	\$	\$ (14,	(841) 337,904)	\$	\$	\$	\$ (1	(84 4,337,90	
	\$	\$	\$(14,	338,745)	\$	\$	\$	\$(1	4,338,74	5)
<ul> <li><sup>(a)</sup>Options purchased are incl</li> <li>Net Change in Unrealized</li> <li>Appreciation (Depreciation on:</li> <li>Options written</li> <li>Average Quarterly Balances</li> </ul>	h) \$	\$	\$4,	386,198	\$	\$	\$	\$	4,386,19	8
Options: Average value of option con Average value of option con	-	ed						\$ \$3,	(; 136,477	a)

<sup>(a)</sup> Derivative not held at quarter-end. The amount shown in the Statements of Operations reflect the results of activity during the period.

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

<b>Derivative Financial Instruments:</b> Options	\$	\$ 3,538,539
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA	)	(2,763,549)
Total derivative assets and liabilities subject to an MNA	\$	\$ 774,990

The following table presents the Trust s derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collater received (and pledged) by the Trust:

	_	<i>Derivative</i> Liabilities				Na	t Amount
		Subject to 1 MNA by	Derivatives Available	Non-cash Collateral	Cash Collateral	of D	erivative iabilities
Counterparty	Сои	nterparty	for Offset	Pledged <sup>(a)</sup>	Pledged	1	(b)
Bank of America N.A.	\$	42,265	\$	\$	\$	\$	42,265
Barclays Bank PLC		51,767		(51,767)			
Citibank N.A.		295,227		(295,227)			
Credit Suisse International		93,853		(93,240)			613
Goldman Sachs International		211,624		(211,624)			
JPMorgan Chase Bank N.A.		6,498					6,498
Morgan Stanley & Co. International							
PLC		21,568					21,568
Societe Generale		32,136					32,136
UBS AG		20,052		(20,052)			
	\$	774,990	\$	\$ (671,910)	\$	\$	103,080

<sup>(a)</sup> Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

<sup>(b)</sup> Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

BlackRock Energy and Resources Trust (BGR)

June 30, 2018

## Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Energy Equipment & Services	\$ 36,242,569	\$	\$	\$ 36,242,569
Oil, Gas & Consumable Fuels	350,814,174	88,568,702		439,382,876
Short-Term Securities	4,599,459			4,599,459
	\$ 391,656,202	\$88,568,702	\$	\$480,224,904
Derivative Financial Instruments <sup>(a)</sup> Liabilities:				
Equity contracts	\$ (2,690,567)	\$ (847,972)	\$	\$ (3,538,539)

<sup>(a)</sup> Derivative financial instruments are options written, which are shown at value. During the six months ended June 30, 2018, there were no transfers between levels.

See notes to financial statements.

Schedules of Investments

29

Schedule of Investments (unaudited)	BlackRock Enhanced Capital and Income Fund, Inc. (CII)				
June 30, 2018	(Percentages shown are based	on Net Assets)			
Security Common Stocks 100.3%	Shares	Value			
Airlines 1.4% Delta Air Lines, Inc.	204,085	\$ 10,110,371			
Banks 10.4% Bank of America Corp. <sup>(a)(b)</sup> JPMorgan Chase & Co. <sup>(b)</sup> Regions Financial Corp. SunTrust Banks, Inc. U.S. Bancorp	710,271 239,356 327,605 205,255 263,202	20,022,540 24,940,895 5,824,817 13,550,935 13,165,364			
<b>Biotechnology</b> 3.5% Biogen, Inc. <sup>(c)</sup> Gilead Sciences, Inc.	55,904 138,969	77,504,551 16,225,577 9,844,564			
<b>Capital Markets</b> 1.2% E*Trade Financial Corp. <sup>(c)</sup>	150,986	26,070,141 9,234,304			
Chemicals 2.1% DowDuPont, Inc.	243,080	16,023,834			
Commercial Services & Supplies1.1%KAR Auction Services, Inc.	154,771	8,481,451			
Communications Equipment2.7%Cisco Systems, Inc.	474,074	20,399,404			
Consumer Finance1.6%Ally Financial, Inc.SLM Corp. <sup>(c)</sup>	213,891 537,693	5,618,916 6,156,585			
Containers & Packaging 1.2%		11,775,501			
Packaging Corp. of America	82,529	9,225,917			
Electric Utilities 2.9% FirstEnergy Corp. PG&E Corp.	363,947 206,492	13,069,337 8,788,299			
Electronic Equipment, Instruments & Components	2.5%	21,857,636			

5 5		
CDW Corp.	154,847	12,510,089
Flex Ltd. <sup>(c)</sup>	443,330	6,255,386
		18,765,475
Food & Staples Retailing 2.2%		
Walmart, Inc.	191,513	16,403,088
Food Products 1.3%		
J.M. Smucker Co.	89,440	9,613,011
Health Care Equipment & Supplies 1.5%		
Baxter International, Inc.	150,208	11,091,359
Health Care Providers & Services 9.1%		
Centene Corp. <sup>(c)</sup>	79,887	9,842,877
CVS Health Corp. <sup>(a)</sup>	124,485	8,010,610
Humana, Inc.	57,029	16,973,541
Laboratory Corp. of America Holdings <sup>(c)</sup>	81,168	14,572,091
UnitedHealth Group, Inc.	77,355	18,978,276
		68,377,395
Hotels, Restaurants & Leisure 1.1%		
Carnival Corp.	147,293	8,441,362
Household Durables 2.9%		
D.R. Horton, Inc.	337,430	13,834,630
Lennar Corp., Class A	90,366	4,744,215
NVR, Inc. <sup>(c)</sup>	1,081	3,210,948
		21 700 702
	CI.	21,789,793
Security	Shares	Value
Household Products 0.2%	<b>22</b> 475 ¢	1 415 026
Energizer Holdings, Inc.	22,475 \$	1,415,026
Industrial Conglomerates 0.9% General Electric Co.	491 041	6 550 217
General Elecuric Co.	481,941	6,559,217
Insurance 1.4%		
Assured Guaranty Ltd.	105,887	3,783,343
Hartford Financial Services Group, Inc.	135,210	6,913,287
Hartford Financial Scivices Group, inc.	155,210	0,915,207
		10,696,630
Internet Software & Services 5.0%		10,070,050
Alphabet, Inc., Class A <sup>(c)</sup>	33,203	37,492,496
	55,205	57,772,770
IT Services 3.0%		
Amdocs Ltd.	83,760	5,544,075
Cognizant Technology Solutions Corp., Class A	209,862	16,576,999
	202,002	-0,0,0,0,000
		22,121,074
Machinery 2.3%		

Allison Transmission Holdings, Inc. Fortive Corp.	142,313 150,060	5,762,253 11,571,127
		17,333,380
Media 2.5% Comcast Corp., Class A <sup>(a)</sup>	565,618	18,557,927
Metals & Mining 1.5%		
Freeport-McMoRan, Inc. Rio Tinto PLC ADR	433,357 59,686	7,479,742 3,311,379
Oil, Gas & Consumable Fuels 6.6%		10,791,121
BP PLC ADR	202,348	9,239,210
Chevron Corp.	134,226	16,970,193
Marathon Oil Corp.	239,650 404,193	4,999,099
Suncor Energy, Inc. TOTAL SA ADR	404,193 32,322	16,442,571 1,957,420
		49,608,493
Pharmaceuticals4.1%Novo Nordisk A/SADR	188,798	9 707 264
Pfizer, Inc.	608,765	8,707,364 22,085,994
		30,793,358
Road & Rail 2.1% Norfolk Southern Corp.	102,299	15,433,850
Software 8.7%		
Dell Technologies, Inc., Class V <sup>(c)</sup>	122,393	10,352,000
Microsoft Corp. <sup>(a)</sup>	395,647	39,014,751
Oracle Corp.	351,281	15,477,441
Specialty Retail 5.2%		64,844,192
Home Depot, Inc.	45,995	8,973,625
Lowe s Cos., Iné?	204,067	19,502,683
Urban Outfitters, Inc. <sup>(c)</sup>	233,622	10,407,860
Technology Hardware, Storage & Peripherals 5.9%		38,884,168
Apple, Inc. <sup>(b)</sup>	237,136	43,896,245
<b>Tobacco 2.2%</b> Altria Group, Inc. <sup>(a)</sup>	288,708	16,395,726
· · · · · · · · · · · · · · · · · · ·		,-,-,-,-0
Total Long-Term Investments 100.3% (Cost \$584,059,977)		749,987,496

Schedule of Investments (unaudited) (continued)	BlackRock Enhanced Capital and Income Fund, Inc. (CII)					
June 30, 2018	(Percentages shown are based on Net Assets)					
Security Short-Term Securities 0.6%	Shares Value					
BlackRock Liquidity Funds, T-Fund, Institutional Class $1.80\%^{(d)(e)}$	s, 4,630,300 \$ 4,630,300					
Total Short-Term Securities 0.6% (Cost \$4,630,300)	4,630,300					
Options Purchased 0.0% (Cost \$1,360)	1,605					
Total Investments Before Options Written 100.9% (Cost \$588,691,637)	<i>7</i> 54,619,401					
Options Written (0.9)% (Premiums Received \$8,067,614)	(6,477,238)					
Total Investments, Net of Options Written 100.0% (Cost \$580,624,023) Liabilities in Excess of Other Assets (0.0)%	6 748,142,163 (18,462)					
Net Assets 100.0%	\$ 748,123,701					

<sup>(a)</sup> All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

<sup>(b)</sup> All or a portion of security has been pledged as collateral in connection with OTC derivatives.

<sup>(c)</sup> Non-income producing security.

<sup>(d)</sup> Annualized 7-day yield as of period end.

<sup>(e)</sup> During the six months ended June 30, 2018, investments in issuers considered to be an affiliate of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

							Change in
	Shares		Shares				NetUnrealized
	Held at	Net	Held at	Value at		Real	iz <b>A</b> ppreciation
Affiliate	12/31/17	Activity	06/30/18	06/30/18	Incomein	ı (Loss	(Depreciation)
BlackRock Liquidity							
Funds, T-Fund,							
Institutional Class	3,142,974	1,487,326	4,630,300	\$4,630,300	\$ 29,997	\$	\$

<sup>(a)</sup> Includes net capital gain distributions, if applicable.

For Trust compliance purposes, the Trust s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

## Derivative Financial Instruments Outstanding as of Period End

## **Exchange-Traded Options Purchased**

Description	Number of Contracts	Expiration Date	Exercise Price	Notional Amount (000)	Value	
Call General Electric Co.	321	07/13/18	USD 14.50	USD 437	\$ 1,605	

## **Exchange-Traded Options Written**

Description	Number of Contracts	Expiration Date	Exercise Price		Notional Amount (000)		Value
1	Commucis	Dule		The	Amoun	u (000)	vaiue
Call	100						<b>.</b>
Bank of America Corp.	188	07/02/18	USD	31.35	USD	530	\$
Pfizer, Inc.	38	07/02/18	USD	36.25	USD	138	(755)
General Electric Co.	414	07/05/18	USD	14.75	USD	563	(213)
Bank of America Corp.	669	07/06/18	USD	30.50	USD	1,886	(1,003)
Baxter International, Inc.	37	07/06/18	USD	73.50	USD	273	(3,108)
CVS Health Corp.	278	07/06/18	USD	66.00	USD	1,789	(8,479)
Carnival Corp.	285	07/06/18	USD	64.00	USD	1,633	(1,425)
Chevron Corp.	104	07/06/18	USD	128.00	USD	1,315	(6,136)
Cisco Systems, Inc.	610	07/06/18	USD	44.50	USD	2,625	(1,525)
Cognizant Technology Solutions							
Corp., Class A	337	07/06/18	USD	77.00	USD	2,662	(75,825)
Comcast Corp., Class A	368	07/06/18	USD	32.00	USD	1,207	(35,880)
D.R. Horton, Inc.	114	07/06/18	USD	43.50	USD	467	(627)
Delta Air Lines, Inc.	284	07/06/18	USD	56.00	USD	1,407	(852)

Schedules of Investments

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	N	otional	
Description	Contracts	Date		Price	Amour	nt (000)	Value
Call (continued)							
DowDuPont, Inc.	54	07/06/18	USD	67.50	USD	356	\$ (1,026)
Flex Ltd.	372	07/06/18	USD	14.00	USD	525	(9,300)
General Electric Co.	82	07/06/18	USD	15.25	USD	112	(12)
General Electric Co.	146	07/06/18	USD	14.50	USD	199	(292)
Gilead Sciences, Inc.	82	07/06/18	USD	69.50	USD	581	(13,489)
Hartford Financial Services							
Group, Inc.	178	07/06/18	USD	54.00	USD	910	(712)
Humana, Inc.	43	07/06/18	USD	297.50	USD	1,280	(14,513)
Microsoft Corp.	327	07/06/18	USD	101.00	USD	3,225	(7,357)
Norfolk Southern Corp.	135	07/06/18	USD	160.00	USD	2,037	(1,350)
Oracle Corp.	123	07/06/18	USD	48.00	USD	542	(246)
Pfizer, Inc.	78	07/06/18	USD	36.00	USD	283	(3,471)
Pfizer, Inc.	103	07/06/18	USD	36.50	USD	374	(1,339)
Pfizer, Inc.	39	07/06/18	USD	37.00	USD	141	(175)
Suncor Energy, Inc.	256	07/06/18	USD	40.00	USD	1,041	(23,936)
U.S. Bancorp	154	07/06/18	USD	52.50	USD	770	(308)
U.S. Bancorp	43	07/06/18	USD	53.00	USD	215	(430)
UnitedHealth Group, Inc.	57	07/06/18	USD	245.00	USD	1,398	(14,421)
Urban Outfitters, Inc.	278	07/06/18	USD	42.50	USD	1,238	(56,295)
Novo Nordisk A/S ADR	124	07/09/18	USD	50.00	USD	572	(46)
Suncor Energy, Inc.	8	07/09/18	USD	38.40	USD	33	(1,920)
FirstEnergy Corp.	442	07/11/18	USD	34.01	USD	1,587	(87,636)
Alphabet, Inc., Class A	18	07/13/18	USD	1,145.00	USD	2,033	(19,980)
Altria Group, Inc.	383	07/13/18	USD	57.50	USD	2,175	(21,257)
Apple, Inc.	129	07/13/18	USD	192.50	USD	2,388	(5,160)
Apple, Inc.	101	07/13/18	USD	187.50	USD	1,870	(18,685)
BP PLC ADR	133	07/13/18	USD	46.00	USD	607	(7,315)
Bank of America Corp.	318	07/13/18	USD	30.50	USD	896	(1,431)
Bank of America Corp.	161	07/13/18	USD	31.00	USD	454	(563)
Biogen, Inc.	28	07/13/18	USD	295.00	USD	813	(9,660)
Carnival Corp.	70	07/13/18	USD	65.00	USD	401	(350)
Carnival Corp.	70	07/13/18	USD	66.50	USD	401	(350)
Chevron Corp.	104	07/13/18	USD	129.00	USD	1,315	(8,788)
Cisco Systems, Inc.	81	07/13/18	USD	45.00	USD	349	(486)
D.R. Horton, Inc.	114	07/13/18	USD	44.00	USD	467	(1,425)
DowDuPont, Inc.	189	07/13/18	USD	67.00	USD	1,246	(13,136)
DowDuPont, Inc.	126	07/13/18	USD	69.00	USD	831	(2,331)
FirstEnergy Corp.	154	07/13/18	USD	34.50	USD	553	(24,476)

Flex Ltd.	378	07/13/18	USD	14.50	USD	533	(5,103)
Hartford Financial Services							
Group, Inc.	152	07/13/18	USD	54.00	USD	777	(1,216)
Humana, Inc.	88	07/13/18	USD	307.50	USD	2,619	(9,020)
JPMorgan Chase & Co.	128	07/13/18	USD	111.00	USD	1,334	(2,560)
Microsoft Corp.	71	07/13/18	USD	103.00	USD	700	(1,704)
Microsoft Corp.	260	07/13/18	USD	102.00	USD	2,564	(10,400)
Oracle Corp.	45	07/13/18	USD	49.00	USD	198	(90)
Oracle Corp.	303	07/13/18	USD	48.00	USD	1,335	(1,212)
PG&E Corp.	522	07/13/18	USD	42.50	USD	2,222	(126,585)
Pfizer, Inc.	155	07/13/18	USD	36.50	USD	562	(4,417)
Pfizer, Inc.	38	07/13/18	USD	37.00	USD	138	(418)
SunTrust Banks, Inc.	389	07/13/18	USD	70.00	USD	2,568	(5,815)
U.S. Bancorp	360	07/13/18	USD	50.50	USD	1,801	(17,460)
U.S. Bancorp	43	07/13/18	USD	52.50	USD	215	(236)
U.S. Bancorp	129	07/13/18	USD	51.00	USD	645	(3,805)
U.S. Bancorp	65	07/13/18	USD	51.50	USD	325	(1,105)
Urban Outfitters, Inc.	165	07/13/18	USD	43.00	USD	735	(36,713)
Walmart Inc.	374	07/13/18	USD	85.00	USD	3,203	(55,726)
SunTrust Banks, Inc.	97	07/18/18	USD	70.50	USD	640	(1,880)
Allison Transmission Holdings,							
Inc.	200	07/20/18	USD	42.51	USD	810	(5,899)
Ally Financial, Inc.	348	07/20/18	USD	27.00	USD	914	(12,180)
Ally Financial, Inc.	120	07/20/18	USD	26.00	USD	315	(9,600)
Alphabet, Inc., Class A	34	07/20/18	USD	1,100.00	USD	3,839	(146,030)
Alphabet, Inc., Class A	7	07/20/18	USD	1,190.00	USD	790	(3,185)
Altria Group, Inc.	470	07/20/18	USD	57.50	USD	2,669	(38,540)
-							

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	N	otional		
Description	Contracts	Date		Price	Amoun	nt (000)		Value
Call (continued)								
Apple, Inc.	520	07/20/18	USD	190.00	USD	9,626	\$	(68,380)
Assured Guaranty Ltd.	200	07/20/18	USD	37.00	USD	715		(4,400)
Assured Guaranty Ltd.	200	07/20/18	USD	39.00	USD	715		(600)
BP PLC ADR	357	07/20/18	USD	47.00	USD	1,630		(12,138)
Bank of America Corp.	297	07/20/18	USD	32.00	USD	837		(1,336)
Bank of America Corp.	274	07/20/18	USD	31.00	USD	772		(1,781)
Baxter International, Inc.	121	07/20/18	USD	72.50	USD	893		(25,592)
Biogen, Inc.	58	07/20/18	USD	280.00	USD	1,683		(80,040)
CDW Corp.	645	07/20/18	USD	80.00	USD	5,211	(	158,025)
CVS Health Corp.	283	07/20/18	USD	72.50	USD	1,821		(4,103)
Carnival Corp.	154	07/20/18	USD	64.50	USD	883		(770)
Centene Corp.	211	07/20/18	USD	125.00	USD	2,600		(41,145)
Chevron Corp.	310	07/20/18	USD	130.00	USD	3,919		(29,605)
Cisco Systems, Inc.	344	07/20/18	USD	45.00	USD	1,480		(4,816)
Cisco Systems, Inc.	240	07/20/18	USD	44.00	USD	1,033		(8,040)
Cognizant Technology Solutions								
Corp., Class A	239	07/20/18	USD	80.00	USD	1,888		(23,900)
Comcast Corp., Class A	141	07/20/18	USD	33.01	USD	463		(12,455)
Comcast Corp., Class A	389	07/20/18	USD	32.50	USD	1,276		(43,374)
D.R. Horton, Inc.	114	07/20/18	USD	45.00	USD	467		(1,482)
Dell Technologies, Inc., Class V	434	07/20/18	USD	90.00	USD	3,671		(77,035)
DowDuPont, Inc.	231	07/20/18	USD	70.00	USD	1,523		(4,504)
DowDuPont, Inc.	94	07/20/18	USD	67.50	USD	620		(7,332)
E*Trade Financial Corp.	113	07/20/18	USD	65.00	USD	691		(5,819)
Energizer Holdings, Inc.	150	07/20/18	USD	60.00	USD	944		(53,250)
FirstEnergy Corp.	242	07/20/18	USD	35.00	USD	869		(29,645)
Flex Ltd.	372	07/20/18	USD	14.00	USD	525		(15,066)
Fortive Corp.	464	07/20/18	USD	80.00	USD	3,578		(25,520)
Freeport-McMoRan, Inc.	414	07/20/18	USD	16.00	USD	715		(62,100)
Freeport-McMoRan, Inc.	213	07/20/18	USD	16.50	USD	368		(23,856)
Freeport-McMoRan, Inc.	267	07/20/18	USD	17.50	USD	461		(14,819)
General Electric Co.	113	07/20/18	USD	15.00	USD	154		(734)
General Electric Co.	52	07/20/18	USD	13.50	USD	71		(2,600)
Gilead Sciences, Inc.	167	07/20/18	USD	67.50	USD	1,183		(64,713)
Hartford Financial Services Group	,							
Inc.	135	07/20/18	USD	55.00	USD	690		(1,080)
J.M. Smucker Co.	227	07/20/18	USD	115.00	USD	2,440		(13,052)
JPMorgan Chase & Co.	103	07/20/18	USD	113.85	USD	1,073		(1,060)

JPMorgan Chase & Co.	79	07/20/18	USD	110.00	USD	823	(4,108)
KAR Auction Services, Inc.	272	07/20/18	USD	55.00	USD	1,491	(23,120)
Laboratory Corp. of America						,	
Holdings	15	07/20/18	USD	195.00	USD	269	(450)
Lennar Corp., Class A	188	07/20/18	USD	57.50	USD	987	(3,478)
Lennar Corp., Class A	128	07/20/18	USD	52.50	USD	672	(18,304)
Lowe s Cos., Inc.	281	07/20/18	USD	86.20	USD	2,686	(287,158)
Marathon Oil Corp.	83	07/20/18	USD	21.00	USD	173	(5,893)
Marathon Oil Corp.	125	07/20/18	USD	22.00	USD	261	(4,312)
Microsoft Corp.	200	07/20/18	USD	100.00	USD	1,972	(40,400)
Norfolk Southern Corp.	223	07/20/18	USD	155.00	USD	3,364	(31,778)
Novo Nordisk A/S ADR	295	07/20/18	USD	48.90	USD	1,361	(5,578)
Oracle Corp.	301	07/20/18	USD	48.00	USD	1,326	(903)
Packaging Corp. of America	128	07/20/18	USD	125.00	USD	1,431	(1,280)
Pfizer, Inc.	2	07/20/18	USD	36.00	USD	7	(137)
Pfizer, Inc.	105	07/20/18	USD	35.00	USD	381	(15,540)
Pfizer, Inc.	159	07/20/18	USD	37.00	USD	577	(3,100)
Regions Financial Corp.	348	07/20/18	USD	19.00	USD	619	(6,090)
Rio Tinto PLC ADR	47	07/20/18	USD	60.00	USD	261	(705)
SLM Corp.	863	07/20/18	USD	11.55	USD	988	(24,351)
SunTrust Banks, Inc.	177	07/20/18	USD	70.00	USD	1,169	(5,133)
Suncor Energy, Inc.	34	07/20/18	USD	40.00	USD	138	(4,658)
TOTAL SA ADR	75	07/20/18	USD	60.00	USD	454	(11,250)
TOTAL SA ADR	60	07/20/18	USD	62.50	USD	363	(2,100)
U.S. Bancorp	130	07/20/18	USD	51.50	USD	650	(4,810)
Walmart Inc.	77	07/20/18	USD	87.50	USD	660	(4,889)
FirstEnergy Corp.	154	07/24/18	USD	34.75	USD	553	(24,317)

## Schedules of Investments

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	Ν	otional	
Description	Contracts	Date		Price	Amoun	nt (000)	Value
Call (continued)							
CDW Corp.	219	07/25/18	USD	79.65	USD	1,769	\$ (63,069)
Alphabet, Inc., Class A	18	07/27/18	USD	1,160.00	USD	2,033	(42,750)
Apple, Inc.	101	07/27/18	USD	190.00	USD	1,870	(22,523)
Apple, Inc.	101	07/27/18	USD	187.50	USD	1,870	(28,028)
BP PLC ADR	133	07/27/18	USD	47.00	USD	607	(6,450)
BP PLC ADR	82	07/27/18	USD	46.00	USD	374	(7,257)
Bank of America Corp.	275	07/27/18	USD	31.00	USD	775	(2,612)
Baxter International, Inc.	121	07/27/18	USD	76.00	USD	893	(11,313)
Biogen, Inc.	57	07/27/18	USD	310.00	USD	1,654	(18,668)
Carnival Corp.	154	07/27/18	USD	64.50	USD	883	(1,540)
Chevron Corp.	39	07/27/18	USD	130.00	USD	493	(5,869)
Cisco Systems, Inc.	163	07/27/18	USD	45.00	USD	701	(3,423)
Cognizant Technology Solutions	5						
Corp., Class A	167	07/27/18	USD	80.00	USD	1,319	(20,875)
Comcast Corp., Class A	96	07/27/18	USD	33.00	USD	315	(11,088)
D.R. Horton, Inc.	137	07/27/18	USD	45.00	USD	562	(4,589)
Delta Air Lines, Inc.	169	07/27/18	USD	52.00	USD	837	(11,745)
DowDuPont, Inc.	117	07/27/18	USD	72.00	USD	771	(1,345)
DowDuPont, Inc.	139	07/27/18	USD	67.50	USD	916	(13,831)
DowDuPont, Inc.	35	07/27/18	USD	66.50	USD	231	(5,040)
E*Trade Financial Corp.	372	07/27/18	USD	65.50	USD	2,275	(55,428)
Flex Ltd.	380	07/27/18	USD	14.50	USD	536	(19,190)
Freeport-McMoRan, Inc.	400	07/27/18	USD	18.00	USD	690	(22,000)
Freeport-McMoRan, Inc.	213	07/27/18	USD	17.00	USD	368	(21,407)
General Electric Co.	578	07/27/18	USD	14.50	USD	787	(9,826)
General Electric Co.	52	07/27/18	USD	14.00	USD	71	(1,664)
Gilead Sciences, Inc.	317	07/27/18	USD	72.00	USD	2,246	(58,487)
Hartford Financial Services Grou	up,						
Inc.	152	07/27/18	USD	54.00	USD	777	(5,320)
JPMorgan Chase & Co.	149	07/27/18	USD	112.00	USD	1,553	(6,034)
Lowe s Cos., Inc.	199	07/27/18	USD	101.00	USD	1,902	(9,552)
Marathon Oil Corp.	125	07/27/18	USD	22.00	USD	261	(5,875)
Marathon Oil Corp.	121	07/27/18	USD	21.00	USD	252	(10,406)
Microsoft Corp.	71	07/27/18	USD	103.00	USD	700	(8,023)
Microsoft Corp.	133	07/27/18	USD	101.00	USD	1,312	(24,273)
Oracle Corp.	179	07/27/18	USD	49.00	USD	789	(895)
Pfizer, Inc.	324	07/27/18	USD	37.00	USD	1,175	(8,748)
Pfizer, Inc.	60	07/27/18	USD	36.50	USD	218	(2,910)

	202			10.00			(12 (10)
Suncor Energy, Inc.	393	07/27/18	USD	40.00	USD	1,599	(63,666)
U.S. Bancorp	138	07/27/18	USD	52.00	USD	690	(4,554)
UnitedHealth Group, Inc.	155	07/27/18	USD	255.00	USD	3,803	(38,053)
Urban Outfitters, Inc.	340	07/27/18	USD	46.50	USD	1,515	(33,150)
Walmart Inc.	75	07/27/18	USD	86.50	USD	642	(9,262)
Walmart Inc.	153	07/27/18	USD	86.00	USD	1,310	(22,568)
Pfizer, Inc.	59	07/30/18	USD	36.75	USD	214	(2,580)
Pfizer, Inc.	385	07/30/18	USD	36.50	USD	1,397	(18,691)
Bank of America Corp.	88	07/31/18	USD	30.25	USD	248	(1,845)
Cisco Systems, Inc.	240	07/31/18	USD	44.60	USD	1,033	(8,113)
FirstEnergy Corp.	302	07/31/18	USD	34.75	USD	1,084	(50,824)
Altria Group, Inc.	266	08/03/18	USD	58.50	USD	1,511	(24,738)
BP PLC ADR	164	08/03/18	USD	46.00	USD	749	(19,106)
Bank of America Corp.	146	08/03/18	USD	30.00	USD	412	(3,723)
Bank of America Corp.	90	08/03/18	USD	29.00	USD	254	(5,040)
Baxter International, Inc.	82	08/03/18	USD	75.00	USD	605	(10,619)
Baxter International, Inc.	43	08/03/18	USD	73.50	USD	318	(8,772)
Biogen, Inc.	19	08/03/18	USD	300.00	USD	551	(13,205)
Chevron Corp.	92	08/03/18	USD	130.00	USD	1,163	(16,652)
Comcast Corp., Class A	141	08/03/18	USD	34.00	USD	463	(11,844)
D.R. Horton, Inc.	291	08/03/18	USD	42.50	USD	1,193	(32,738)
Delta Air Lines, Inc.	500	08/03/18	USD	55.00	USD	2,477	(13,250)
E*Trade Financial Corp.	128	08/03/18	USD	66.00	USD	783	(7,680)
Freeport-McMoRan, Inc.	267	08/03/18	USD	17.50	USD	461	(22,695)
General Electric Co.	205	08/03/18	USD	13.50	USD	279	(12,300)
General Electric Co.	203 295	08/03/18	USD	15.00	USD	401	(3,392)
Seneral Dictate Col	2,5	50/02/10	0.00	10.00	0.00	101	(0,0)2)

34

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	Ν	otional	
Description	Contracts	Date		Price	Amoun	nt (000)	Value
Call (continued)							
JPMorgan Chase & Co.	35	08/03/18	USD	110.00	USD	365	\$ (3,045)
JPMorgan Chase & Co.	79	08/03/18	USD	111.00	USD	823	(5,411)
Lowe s Cos., Inc.	245	08/03/18	USD	99.00	USD	2,341	(27,563)
Marathon Oil Corp.	245	08/03/18	USD	21.50	USD	511	(20,213)
Microsoft Corp.	133	08/03/18	USD	102.00	USD	1,312	(22,145)
Oracle Corp.	155	08/03/18	USD	44.00	USD	683	(15,810)
Pfizer, Inc.	100	08/03/18	USD	36.50	USD	363	(6,050)
Suncor Energy, Inc.	7	08/03/18	USD	41.00	USD	28	(850)
Urban Outfitters, Inc.	250	08/03/18	USD	47.50	USD	1,114	(20,625)
Novo Nordisk A/S ADR	567	08/06/18	USD	45.01	USD	2,615	(111,182)
SunTrust Banks, Inc.	368	08/06/18	USD	68.30	USD	2,430	(40,062)
UnitedHealth Group, Inc.	107	08/09/18	USD	255.00	USD	2,625	(38,690)
Bank of America Corp.	516	08/10/18	USD	30.10	USD	1,455	(15,495)
Bank of America Corp.	305	08/10/18	USD	29.01	USD	860	(18,629)
Chevron Corp.	39	08/10/18	USD	128.00	USD	493	(11,622)
Comcast Corp., Class A	344	08/10/18	USD	33.50	USD	1,129	(39,904)
DowDuPont, Inc.	247	08/10/18	USD	66.00	USD	1,628	(57,428)
FirstEnergy Corp.	301	08/10/18	USD	33.75	USD	1,081	(71,285)
Flex Ltd.	379	08/10/18	USD	14.50	USD	535	(18,950)
General Electric Co.	118	08/10/18	USD	14.00	USD	161	(4,838)
Hartford Financial Services G	roup,						
Inc.	63	08/10/18	USD	52.00	USD	322	(7,497)
JPMorgan Chase & Co.	60	08/10/18	USD	108.25	USD	625	(9,219)
Lowe s Cos., Inc.	116	08/10/18	USD	98.50	USD	1,109	(17,284)
Marathon Oil Corp.	121	08/10/18	USD	21.50	USD	252	(11,192)
Microsoft Corp.	133	08/10/18	USD	102.00	USD	1,312	(24,871)
Oracle Corp.	551	08/10/18	USD	45.10	USD	2,428	(35,791)
PG&E Corp.	200	08/10/18	USD	44.00	USD	851	(52,000)
Pfizer, Inc.	385	08/10/18	USD	36.50	USD	1,397	(25,025)
U.S. Bancorp	191	08/10/18	USD	50.00	USD	955	(26,072)
Urban Outfitters, Inc.	251	08/10/18	USD	47.50	USD	1,118	(26,983)
Ally Financial, Inc.	348	08/17/18	USD	27.00	USD	914	(24,360)
Ally Financial, Inc.	120	08/17/18	USD	26.00	USD	315	(14,400)
Alphabet, Inc., Class A	39	08/17/18	USD	1,105.00	USD	4,404	(234,585)
Altria Group, Inc.	468	08/17/18	USD	59.20	USD	2,658	(48,271)
Apple, Inc.	352	08/17/18	USD	190.00	USD	6,516	(147,840)
BP PLC ADR	161	08/17/18	USD	46.00	USD	735	(19,964)
BP PLC ADR	82	08/17/18	USD	47.00	USD	374	(6,724)

Bank of America Corp.	274	08/17/18	USD	31.00	USD	772	(5,343)
Bank of America Corp.	305	08/17/18	USD	29.00	USD	860	(20,893)
Baxter International, Inc.	121	08/17/18	USD	72.50	USD	893	(36,300)
Biogen, Inc.	33	08/17/18	USD	300.00	USD	958	(28,875)
CVS Health Corp.	128	08/17/18	USD	72.50	USD	824	(5,952)
Chevron Corp.	50	08/17/18	USD	130.00	USD	632	(11,625)
Comcast Corp., Class A	501	08/17/18	USD	35.00	USD	1,644	(34,820)
D.R. Horton, Inc.	137	08/17/18	USD	43.00	USD	562	(14,454)
D.R. Horton, Inc.	274	08/17/18	USD	41.00	USD	1,123	(55,896)
Delta Air Lines, Inc.	169	08/17/18	USD	52.50	USD	837	(15,126)
DowDuPont, Inc.	34	08/17/18	USD	70.00	USD	224	(2,958)
DowDuPont, Inc.	70	08/17/18	USD	67.50	USD	461	(12,145)
E*Trade Financial Corp.	217	08/17/18	USD	63.75	USD	1,327	(29,719)
Flex Ltd.	557	08/17/18	USD	15.00	USD	786	(19,774)
Fortive Corp.	61	08/17/18	USD	76.01	USD	470	(23,071)
Freeport-McMoRan, Inc.	210	08/17/18	USD	17.00	USD	362	(25,935)
Freeport-McMoRan, Inc.	400	08/17/18	USD	18.00	USD	690	(31,800)
General Electric Co.	175	08/17/18	USD	15.00	USD	238	(2,887)
Gilead Sciences, Inc.	217	08/17/18	USD	75.00	USD	1,537	(29,512)
Hartford Financial Services Group,							
Inc.	63	08/17/18	USD	53.05	USD	322	(6,152)
Home Depot, Inc.	274	08/17/18	USD	200.00	USD	5,346	(104,120)
Humana, Inc.	68	08/17/18	USD	300.00	USD	2,024	(63,580)
J.M. Smucker Co.	264	08/17/18	USD	110.00	USD	2,837	(76,560)
JPMorgan Chase & Co.	204	08/17/18	USD	115.00	USD	2,126	(9,792)
KAR Auction Services, Inc.	269	08/17/18	USD	55.00	USD	1,474	(45,730)

SCHEDULES OF INVESTMENTS

35

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exercise		Notional		
Description	<b>Contracts</b>	Date		Price	Amoun	et (000)	Value
Call (continued)							
Lowe s Cos., Inc.	281	08/17/18	USD	97.50	USD	2,686	\$ (59,572)
Marathon Oil Corp.	373	08/17/18	USD	22.00	USD	778	(30,027)
Marathon Oil Corp.	125	08/17/18	USD	23.00	USD	261	(6,437)
Microsoft Corp.	56	08/17/18	USD	105.00	USD	552	(6,272)
Oracle Corp.	275	08/17/18	USD	44.00	USD	1,212	(34,513)
Packaging Corp. of America	160	08/17/18	USD	120.00	USD	1,789	(20,800)
Pfizer, Inc.	100	08/17/18	USD	37.00	USD	363	(4,600)
SunTrust Banks, Inc.	97	08/17/18	USD	72.50	USD	640	(3,492)
Suncor Energy, Inc.	35	08/17/18	USD	41.00	USD	142	(5,075)
TOTAL SA ADR	42	08/17/18	USD	62.50	USD	254	(4,095)
U.S. Bancorp	194	08/17/18	USD	52.50	USD	970	(9,118)
Walmart Inc.	374	08/17/18	USD	85.00	USD	3,203	(108,460)
UnitedHealth Group, Inc.	107	08/20/18	USD	255.00	USD	2,625	(47,841)

\$ (5,814,712)

## **OTC Options Written**

<i>Description</i> Call	Counterparty	Number of Contracts	Expiration Date		Exercise Price		otional nt (000)	Value
Allison Transmission								
Holdings, Inc.	Credit Suisse International	20,300	07/06/18	USD	43.10	USD	822	\$ (358)
SLM Corp.	Citibank N.A.	30,400	07/09/18	USD	11.42	USD	348	(7,273)
Suncor								
Energy, Inc.	Citibank N.A.	68,100	07/09/18	USD	38.95	USD	2,770	(128,037)
Amdocs Ltd.	JPMorgan Chase Bank N.A.	23,500	07/10/18	USD	66.43	USD	1,555	(17,802)
Laboratory								
Corp. of								
America								
Holdings	UBS AG	21,000	07/10/18	USD	177.00	USD	3,770	(87,241)
Ally								
Financial, Inc.	Citibank N.A.	24,000	07/11/18	USD	27.24	USD	630	(2 579)
1110.	UBS AG	24,000	07/19/18	USD	177.00	USD	3,770	(3,578) (107,192)
		21,000	0//19/10	03D	177.00	USD	5,110	(107,192)

Laboratory Corp. of America Holdings Centene								
Corp. Regions Financial	Citibank N.A.	22,800	07/23/18	USD	118.90	USD	2,809	(146,941)
Corp.	Morgan Stanley & Co. International PLC	75,000	07/24/18	USD	19.58	USD	1,334	(8,423)
SLM Corp. Novo Nordisk	UBS AG	81,500	07/24/18	USD	12.01	USD	933	(12,623)
A/S ADR	Barclays Bank PLC	5,200	07/26/18	USD	45.41	USD	240	(7,887)
Rio Tinto								
PLC ADR	Morgan Stanley & Co. International PLC	21,100	08/03/18	USD	58.75	USD	1,171	(12,758)
SLM Corp. Assured	Morgan Stanley & Co. International PLC	97,500	08/07/18	USD	12.15	USD	1,116	(19,150)
Guaranty Ltd.	Citibank N.A.	18,200	08/13/18	USD	36.51	USD	650	(11,926)
Amdocs Ltd.	JPMorgan Chase Bank N.A.	22,500	08/16/18	USD	67.10	USD	1,489	(27,933)
Regions Financial								
Corp.	JPMorgan Chase Bank N.A.	35,200	08/16/18	USD	19.45	USD	626	(7,458)
Rio Tinto	-							
PLC ADR	Morgan Stanley & Co. International PLC	21,100	08/20/18	USD	58.75	USD	1,171	(12,288)
Regions								
Financial								
Corp.	Morgan Stanley & Co. International PLC	35,100	08/27/18	USD	18.81	USD	624	(14,867)
FirstEnergy		10 (00	00/00/10	LICD	26.65	LICD	1 450	
Corp.	JPMorgan Chase Bank N.A.	40,600	08/29/18	USD	36.65	USD	1,458	(28,791)

\$ (662,526)

## Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap			
	Premium	Premium	Unrealized	Unrealized	
	Paid	Received	Appreciation	Depreciation	Value
Options Written	N/A	N/A	\$ 2,911,349	\$ (1,320,973)	\$(6,477,238)

36

Schedule of Investments (unaudited) (continued) BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

#### Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Foreign								
				C	Currency	Interest			
	Commodity	Credit		Equity E.	xchange	Rate	Other		
	Contracts	Contracts	Са	ontracts C	ontracts	Contracts C	Contracts		Total
Assets Derivative Finance	cial								
Instruments									
Options purchased									
Investments at value									
unaffiliated <sup>(a)</sup>	\$	\$	\$	1,605	\$	\$	\$	\$	1,605
Liabilities Derivative									
Financial Instruments									
Options written									
Options written at value	\$	\$	\$6,4	477,238	\$	\$	\$	\$6,4	477,238
	\$	\$	\$6,4	477,238	\$	\$	\$	\$6,4	477,238

<sup>(a)</sup> Includes options purchased at value as reported in the schedule of Investments. For the period ended June 30, 2018, the effect of derivative financial instruments in the Statement

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity ContractsC	r s Total			
Net Realized Gain (Loss) from: Options purchased <sup>(a)</sup>	\$	\$ \$ (2,570)	\$	\$\$	\$ (2,570)
Options written		(4,323,450)			(4,323,450)
	\$	\$ \$ (4,326,020)	\$ 5	\$\$	\$ (4,326,020)

<sup>(a)</sup> Options purchased are included in net realized gain (loss) from investments.

Net Change in Unrealized Appreciation						
(Depreciation) on:						
Options purchased	\$ \$	\$	245	\$ \$	\$ \$	245
Options written	3,616,469				3,6	16,469
	\$ \$	\$3,6	16,714	\$ \$	\$ \$3,6	16,714

<sup>(a)</sup> Options purchased are included in net change in unrealized appreciation (depreciation) from investments. Average Quarterly Balances of Outstanding Derivative Financial Instruments

**Options:** 

Average value of option contracts purchased\$ 803Average value of option contracts written\$ 5,340,856For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

#### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

	Assets	Liabilities
<b>Derivative Financial Instruments:</b> Options	\$ 1,605 <sup>(a)</sup>	\$ 6,477,238
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)	(1,605)	(5,814,712)
Total derivative assets and liabilities subject to an MNA	\$	\$ 662,526

<sup>(a)</sup> Includes options purchased at value which is included in Investments at value unaffiliated in the Statements of Assets and Liabilities and reported in the Schedule of Investments.

Schedules of Investments

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

The following table presents the Trust s derivative assets and liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral received and pledged by the Trust:

	L	Derivative					
	1	Liabilities				Ne	t Amount
	2	Subject to	Derivatives	Non-cash	Cash		Perivative
	an	MNA by	Available	Collateral	Collateral	v	iabilities
Counterparty	Сои	nterparty	for Offset	Pledged <sup>(a)</sup>	Pledged	Ľ	(b)
Barclays Bank PLC	\$	7,887	\$	\$	\$	\$	7,887
Citibank N.A.		297,755		(297,755)			
Credit Suisse International		358					358
JPMorgan Chase Bank N.A.		81,984					81,984
Morgan Stanley & Co. International							
PLC		67,486					67,486
UBS AG		207,056		(207,056)			
	\$	662,526	\$	\$ (504,811)	\$	\$	157,715

<sup>(a)</sup> Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

<sup>(b)</sup> Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

#### Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks <sup>(a)</sup>	\$ 749,987,496	\$	\$	\$ 749,987,496
Short-Term Securities	4,630,300			4,630,300
Options Purchased:				
Equity Contracts	1,605			1,605

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS								
	\$754,619,401	\$	\$	\$754,619,401				
Derivative Financial Instruments <sup>(b)</sup> Liabilities: Equity contracts	\$ (4,690,612)	\$(1,786,626)	\$	\$ (6,477,238)				

<sup>(a)</sup> See above Schedule of Investments for values in each industry.

<sup>(b)</sup> Derivative financial instruments are options written, which are shown at value. During the six months ended June 30, 2018, there were no transfers between levels.

See notes to financial statements.

Schedule of Investments (unaudited)	BlackRock Enhanced Equity Dividend Trust (BDJ)					
June 30, 2018	(Percentages shown are based	on Net Assets)				
Security Common Stocks 100.2%	Shares	Value				
Aerospace & Defense 1.1%						
Lockheed Martin Corp. <sup>(a)</sup>	20,920					
Northrop Grumman Corp. <sup>(a)</sup>	46,090	14,181,893				
Banks 17.8%		20,362,289				
Bank of America Corp. <sup>(a)(b)</sup>	2,540,170	71,607,392				
Citigroup, Inc. <sup>(a)(b)</sup>	983,479	65,814,415				
JPMorgan Chase & Co. <sup>(a)(b)</sup>	696,148	72,538,622				
KeyCorp <sup>(a)</sup>	501,280	9,795,011				
SunTrust Banks, Inc. <sup>(a)</sup>	293,049	19,347,095				
U.S. Bancorp <sup>(a)</sup>	479,743	23,996,745				
Wells Fargo & Co. <sup>(a)</sup>	1,033,491	57,296,741				
		320,396,021				
Beverages 2.2%	507 (00	10 000 014				
Diageo PLC	507,609	18,236,314				
Dr. Pepper Snapple Group, Inc. <sup>(a)</sup> PepsiCo, Inc. <sup>(a)</sup>	84,850 110,300	10,351,700 12,008,361				
repsico, me.	110,500	12,000,501				
Carital Markata 2.407		40,596,375				
Capital Markets 3.4%	170.420	0 700 462				
Charles Schwab Corp. <sup>(a)</sup> Goldman Sachs Group, Inc. <sup>(a)</sup>	170,420 106,920	8,708,462 23,583,344				
Morgan Stanley <sup>(a)</sup>	621,970	29,481,378				
Morgan Stanley *	021,970	29,401,570				
Chemicals 1.2%		61,773,184				
DowDuPont, Inc. <sup>(a)</sup>	315,265	20,782,269				
Communications Equipment 170						
Communications Equipment 1.7%	226 610	10 101 220				
Cisco Systems, Inc. <sup>(a)</sup> Motorola Solutions, Inc. <sup>(a)</sup>	236,610 171,600	10,181,328 19,969,092				
Motorola Solutions, Inc.	171,000	19,909,092				
		30,150,420				
Construction Materials 0.8% CRH PLC	387,800	13,602,955				
Containers & Packaging 0.4%						
International Paper Co. <sup>(a)</sup>	135,700	7,067,256				
Diversified Financial Services 0.3%						

Edgar Filing: BlackRock Health Sciences Trust - Form N-CS	RS	
AXA Equitable Holdings, Inc. <sup>(a)(c)</sup>	273,200	5,630,652
<b>Diversified Telecommunication Services</b> 2.9% AT&T, Inc. BCE, Inc. <sup>(a)</sup> Verizon Communications, Inc. <sup>(a)</sup>	37,469 122,500 911,410	1,203,130 4,960,025 45,853,037
Electric Utilities 3.8% Edison International <sup>(a)</sup> FirstEnergy Corp. <sup>(a)</sup> NextEra Energy, Inc. <sup>(a)</sup> PG&E Corp. <sup>(a)</sup>	80,393 673,530 115,512 481,290	52,016,192 5,086,465 24,186,462 19,293,969 20,483,703
Electrical Equipment 0.1% nVent Electric PLC <sup>(c)</sup>	109,190	69,050,599 2,740,669
Electronic Equipment, Instruments & Components 0.7% CDW Corp. <sup>(a)</sup>	161,890	13,079,093
<b>Food &amp; Staples Retailing 0.7%</b> Kroger Co. <sup>(a)</sup>	436,290	12,412,451
Food Products1.4%Danone SAGeneral Mills, Inc. <sup>(a)</sup> SecurityFood Products (continued)Kellogg Co. <sup>(a)</sup>	58,500 193,760 <i>Shares</i> 165,540 \$	4,271,230 8,575,817 <i>Value</i> 5 11,566,280
Health Care Equipment & Supplies 3.1% Koninklijke Philips NV Medtronic PLC <sup>(a)</sup>	716,440 301,650	24,413,327 30,354,090 25,824,257
Health Care Providers & Services 8.7% Aetna, Inc. <sup>(a)</sup> Anthem, Inc. <sup>(a)</sup> Cardinal Health, Inc. <sup>(a)</sup> CVS Health Corp. <sup>(a)</sup> Humana, Inc. <sup>(a)</sup> McKesson Corp. <sup>(a)</sup> Quest Diagnostics, Inc. <sup>(a)</sup> UnitedHealth Group, Inc. <sup>(a)</sup>	167,946 205,890 169,200 206,260 27,590 120,390 75,810 90,460	56,178,347 30,818,091 49,007,997 8,262,036 13,272,831 8,211,612 16,060,026 8,334,551 22,193,456
Household Products 0.9% Procter & Gamble Co. <sup>(a)</sup>	209,320	156,160,600 16,339,519

Industrial Conglomerates 3.0%	
3M Co. <sup>(a)</sup> 44,99	0 8,850,433
General Electric Co. <sup>(a)</sup> 1,710,59	
Honeywell International, Inc. <sup>(a)</sup> 152,39	
-	54 000 040
Insurance 6.2%	54,083,342
American International Group, Inc. <sup>(a)</sup> 681,33	0 36,124,116
Arthur J Gallagher & Co. 23,43	
Brighthouse Financial, Inc. <sup>(a)(c)</sup> 44,51	
Lincoln National Corp. <sup>(a)</sup> 46,32	
Marsh & McLennan Cos., Inc. <sup>(a)</sup> 183,80	
MetLife, Inc. <sup>(a)</sup> 798,25	
Travelers Cos., Inc. <sup>(a)</sup> 165,15	
	112,395,166
IT Services 0.4%	112,395,100
Cognizant Technology Solutions Corp., Class A <sup>(a)</sup> 82,58	0 6,522,994
Leisure Products 0.5%	0 (27 010
Mattel, Inc. <sup>(a)(d)</sup> 586,95	6 9,637,818
Machinery 0.3%	
Pentair PLC <sup>(a)</sup> 109,19	0 4,594,715
Media 2.1%	0 00 000 550
Comcast Corp., Class A <sup>(a)</sup> 895,11	
Interpublic Group of Cos., Inc. <sup>(a)</sup> 397,97	0 9,328,417
	38,696,976
Multi-Utilities 1.3%	
Public Service Enterprise Group, Inc. <sup>(a)</sup> 437,43	0 23,682,460
Multiline Retail 0.3%	7 5 202 270
Dollar General Corp. <sup>(a)</sup> 54,58	7 5,382,278
Oil, Gas & Consumable Fuels 13.0%	
Anadarko Petroleum Corp. <sup>(a)</sup> 51,70	0 3,787,025
BP PLC 5,057,21	0 38,477,869
Chevron Corp. <sup>(a)</sup> 118,26	14,951,612
Devon Energy Corp. <sup>(a)</sup> 536,16	0 23,569,594
Enterprise Products Partners LP <sup>(a)</sup> 758,40	0 20,984,928
Hess Corp. <sup>(a)</sup> 411,11	0 27,499,148
Marathon Oil Corp. <sup>(a)</sup> 169,82	0 3,542,445
Marathon Petroleum Corp. <sup>(a)</sup> 201,45	
ONEOK, Inc. <sup>(a)</sup> 138,18	
Royal Dutch Shell PLC ADR, Class (A) 156,71	
Suncor Energy, Inc. <sup>(a)</sup> 1,141,58	0 46,439,474

Schedules of Investments

Schedule of Investments (unaudited) (continued)	BlackRock Enhanced Equity Dividend Trust (BDJ)				
June 30, 2018	(Percentages shown are based on Net Asset				
Security Oil, Gas & Consumable Fuels (continued)	Shares Value				
TOTAL SA ADR <sup>)</sup> Williams Cos., Inc. <sup>(a)</sup>	211,897 \$ 12,832,482 259,552 7,036,455				
	233,753,538				
Personal Products0.8%Unilever NVNY Sharé®	255,590 14,241,475				
Pharmaceuticals8.5%AstraZeneca PLCBayer AG, Registered SharesMerck & Co., Inc. <sup>(a)</sup> Novo Nordisk A/SADR <sup>)</sup> Pfizer, Inc. <sup>(a)(b)</sup>	480,84633,258,762107,84511,843,916413,57025,103,699298,91013,785,7291,911,74069,357,927				
<b>Professional Services</b> 1.3% Experian PLC Nielsen Holdings PLC <sup>(a)</sup>	153,350,033 530,780 13,093,606 343,020 10,609,609				
<b>Road &amp; Rail 0.7%</b> Union Pacific Corp. <sup>(a)</sup>	23,703,215 83,780 11,869,950				
Semiconductors & Semiconductor Equipment1.8%QUALCOMM, Inc. <sup>(a)</sup> Taiwan Semiconductor Manufacturing Co. Ltd.ADR <sup>)</sup>	418,24023,471,629237,5608,685,193				
<b>Software 5.9%</b> Constellation Software, Inc. Microsoft Corp. <sup>(a)</sup> Oracle Corp. <sup>(a)</sup>	32,156,822 14,240 11,043,542 476,210 46,959,068 1,118,660 49,288,159				
Specialty Retail 0.7% Lowe s Cos., Iné <sup>a)</sup>	107,290,769 137,050 13,097,869				
<b>Technology Hardware, Storage &amp; Peripherals</b> 0.8% Lenovo Group Ltd. Samsung Electronics Co. Ltd. GDR	13,220,000 7,115,799 7,819 8,109,582				
Security	15,225,381 Shares Value				

Tobacco 1.4%		• • • • • • • • • •
Altria Group, Inc. <sup>(a)</sup> Philip Morris International, Inc. <sup>(a)</sup>	340,020 69,830	\$ 19,309,736 5,638,074
	09,850	5,050,074
		24,947,810
Total Long-Term Investments 100.2%		
(Cost \$1,400,287,297)		1,807,384,829
Short-Term Securities 0.8%		
BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% <sup>(e)(g)</sup>	13,793,172	13,793,172
SL Liquidity Series, LLC, Money Market Series, 2.16% <sup>(e)(f)(g)</sup>	12,294	12,294
2.10%	12,27	12,271
Total Short-Term Securities 0.8%		12 005 466
(Cost \$13,805,466)		13,805,466
Options Purchased 0.0%		
(Cost \$3,195)		3,770
Total Investments Before Options Written 101.0% (Cost \$1,414,095,958)		1,821,194,065
(0051 \$1,717,070,750)		1,021,174,005
Options Written (0.9)%		
(Premiums Received \$17,508,135)		(15,288,978)
Total Investments, Net of Options Written 100.1%		
(Cost \$1,396,587,823)		1,805,905,087
Liabilities in Excess of Other Assets (0.1)%		(1,936,617)
Net Assets 100.0%		\$ 1,803,968,470
	1	φ 1,00 <i>3</i> ,200, <del>4</del> 70

- <sup>(a)</sup> All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- <sup>(b)</sup> All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.
- <sup>(c)</sup> Non-income producing security.
- <sup>(d)</sup> Security, or a portion of the security, is on loan.

<sup>(e)</sup> Annualized 7-day yield as of period end.

- <sup>(f)</sup> Security was purchased with the cash collateral from loaned securities.
- <sup>(g)</sup> During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate	Shares	Net	Shares	Value at	Income	Net	Change
	Held at	Activity	Held at	06/30/18		Realized	in
	12/31/17		06/30/18		Gair	ı (Loss) Onr	ealized

						 eciation ciation)
BlackRock Liquidity Funds, T-Fund,						
Institutional Class SL Liquidity Series,	4,967,189	8,825,983	13,793,172	\$13,793,172	\$ 67,095	\$ \$
LLC, Money Market Series		12,294	12,294	12,294	7(b)	
				\$13,805,466	\$67,102	\$ \$

<sup>(a)</sup> Includes net capital gain distributions, if applicable.

<sup>(b)</sup> Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.
 For Trust compliance purposes, the Trust s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

40

### BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

#### Derivative Financial Instruments Outstanding as of Period End

## **Exchange-Traded Options Purchased**

Description	Number of Contracts	Expiration Date	Exercise Price	Notional Amount (000)	Value
Call General Electric Co.	754	07/13/18	USD 14.50	USD 1,026	\$3,770

#### **Exchange-Traded Options Written**

	Number of	Expiration	Exercise		Notional		
Description	Contracts	Date		Price	Amoun	nt (000)	Value
Call							
Bank of America Corp.	722	07/02/18	USD	31.35	USD	2,035	\$
Pfizer, Inc.	253	07/02/18	USD	36.25	USD	918	(5,028)
General Electric Co.	992	07/05/18	USD	14.75	USD	1,350	(511)
Aetna, Inc.	131	07/06/18	USD 2	32.50	USD	3,118	(84,168)
Bank of America Corp.	2,146	07/06/18	USD	30.50	USD	6,050	(3,219)
CVS Health Corp.	279	07/06/18	USD	66.00	USD	1,795	(8,509)
Charles Schwab Corp.	205	07/06/18	USD :	59.00	USD	1,048	(1,025)
Citigroup, Inc.	351	07/06/18	USD	69.50	USD	2,349	(4,036)
Comcast Corp., Class A	224	07/06/18	USD	32.00	USD	735	(21,840)
Devon Energy Corp.	64	07/06/18	USD 4	43.50	USD	281	(6,656)
Devon Energy Corp.	72	07/06/18	USD 4	41.00	USD	317	(22,140)
DowDuPont, Inc.	56	07/06/18	USD	67.50	USD	369	(1,064)
General Electric Co.	177	07/06/18	USD	15.25	USD	241	(25)
General Electric Co.	339	07/06/18	USD	14.50	USD	461	(678)
Goldman Sachs Group, Inc.	162	07/06/18	USD 2	35.00	USD	3,573	(1,053)
Hess Corp.	655	07/06/18	USD	62.00	USD	4,381	(324,225)
Honeywell International, Inc.	113	07/06/18	USD 1	52.50	USD	1,628	(452)
Humana, Inc.	27	07/06/18	USD 2	97.50	USD	804	(9,112)
Marathon Oil Corp.	181	07/06/18	USD	82.00	USD	1,270	(5,792)
McKesson Corp.	108	07/06/18	USD 14	46.00	USD	1,441	(1,620)
MetLife, Inc.	570	07/06/18	USD 4	48.00	USD	2,485	(6,270)
Microsoft Corp.	492	07/06/18	USD 1	01.00	USD	4,852	(11,070)
Morgan Stanley	206	07/06/18	USD .	54.00	USD	976	(1,648)
Morgan Stanley	136	07/06/18	USD .	52.00	USD	645	(816)
Oracle Corp.	475	07/06/18	USD 4	48.00	USD	2,093	(950)
Pfizer, Inc.	514	07/06/18		36.00	USD	1,865	(22,873)
Pfizer, Inc.	470	07/06/18	USD	36.50	USD	1,705	(6,110)

Pfizer, Inc.	176	07/06/18	USD	37.00	USD	639	(792)
QUALCOMM, Inc.	440	07/06/18	USD	60.00	USD	2,469	(3,740)
QUALCOMM, Inc.	605	07/06/18	USD	62.00	USD	3,395	(4,840)
Suncor Energy, Inc.	215	07/06/18	USD	40.00	USD	875	(20,102)
U.S. Bancorp	338	07/06/18	USD	52.50	USD	1,691	(676)
U.S. Bancorp	69	07/06/18	USD	53.00	USD	345	(690)
Union Pacific Corp.	188	07/06/18	USD	147.00	USD	2,664	(1,786)
Verizon Communications, Inc.	495	07/06/18	USD	49.00	USD	2,490	(72,270)
Wells Fargo & Co.	470	07/06/18	USD	55.50	USD	2,606	(28,905)
Wells Fargo & Co.	873	07/06/18	USD	55.00	USD	4,840	(79,007)
Williams Cos., Inc.	224	07/06/18	USD	27.50	USD	607	(2,800)
BCE, Inc.	251	07/09/18	USD	42.45	USD	1,016	(264)
Interpublic Group of Cos., Inc.	450	07/09/18	USD	23.20	USD	1,055	(25,440)
Novo Nordisk A/S ADR	451	07/09/18	USD	50.00	USD	2,080	(168)
Suncor Energy, Inc.	366	07/09/18	USD	38.40	USD	1,489	(87,819)
Pentair PLC	545	07/10/18	USD	46.51	USD	2,293	(96)
FirstEnergy Corp.	368	07/11/18	USD	34.01	USD	1,321	(72,964)
Altria Group, Inc.	253	07/13/18	USD	57.50	USD	1,437	(14,041)
American International Group, Inc.	719	07/13/18	USD	54.00	USD	3,812	(26,603)
Anthem, Inc.	217	07/13/18	USD	235.00	USD	5,165	(124,233)
Bank of America Corp.	987	07/13/18	USD	30.50	USD	2,782	(4,441)
Bank of America Corp.	484	07/13/18	USD	31.00	USD	1,364	(1,694)
Cisco Systems, Inc.	108	07/13/18	USD	45.00	USD	465	(648)
Citigroup, Inc.	186	07/13/18	USD	70.50	USD	1,245	(5,301)
Dollar General Corp.	354	07/13/18	USD	97.50	USD	3,490	(79,650)

SCHEDULES OF INVESTMENTS

41

# BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exer	cise N	lotional	
Description	Contracts	Date	Р	rice Amoui	nt (000)	Value
Call (continued)						
DowDuPont, Inc.	220	07/13/18	USD 6	7.00 USD	1,450	\$ (15,290)
DowDuPont, Inc.	136	07/13/18	USD 69	9.00 USD	897	(2,516)
FirstEnergy Corp.	239	07/13/18	USD 34	4.50 USD	858	(37,985)
Goldman Sachs Group, Inc.	93	07/13/18	USD 23	7.50 USD	2,051	(1,953)
JPMorgan Chase & Co.	679	07/13/18	USD 11	1.00 USD	7,075	(13,580)
KeyCorp	270	07/13/18	USD 20	0.50 USD	528	(2,160)
Kroger Co.	823	07/13/18	USD 25	5.00 USD	2,341	(288,050)
Marathon Petroleum Corp.	136	07/13/18	USD 78	8.00 USD	954	(1,020)
McKesson Corp.	65	07/13/18	USD 148	8.00 USD	867	(975)
Medtronic PLC	146	07/13/18	USD 88	8.50 USD	1,250	(1,606)
Microsoft Corp.	201	07/13/18	USD 103	3.00 USD	1,982	(4,824)
Microsoft Corp.	369	07/13/18	USD 102	2.00 USD	3,639	(14,760)
Morgan Stanley	225	07/13/18	USD 53	3.00 USD	1,067	(900)
Morgan Stanley	257	07/13/18	USD 54	4.00 USD	1,218	(5,654)
ONEOK, Inc.	138	07/13/18	USD 69	9.50 USD	964	(18,285)
Oracle Corp.	141	07/13/18	USD 49	0.00 USD	621	(282)
Oracle Corp.	961	07/13/18	USD 48	8.00 USD	4,234	(3,844)
PG&E Corp.	1,334	07/13/18	USD 42	2.50 USD	5,678	(323,495)
PepsiCo, Inc.	191	07/13/18	USD 102	2.00 USD	2,079	(137,520)
Pfizer, Inc.	704	07/13/18	USD 30	6.50 USD	2,554	(20,064)
Pfizer, Inc.	176	07/13/18	USD 37	7.00 USD	639	(1,936)
Procter & Gamble Co.	226	07/13/18	USD 74	4.00 USD	1,764	(97,745)
SunTrust Banks, Inc.	466	07/13/18	USD 70	0.00 USD	3,077	(6,966)
U.S. Bancorp	640	07/13/18	USD 50	0.50 USD	3,201	(31,040)
U.S. Bancorp	69	07/13/18	USD 52	2.50 USD	345	(379)
U.S. Bancorp	189	07/13/18	USD 5	l.00 USD	945	(5,575)
U.S. Bancorp	94	07/13/18	USD 5	1.50 USD	470	(1,598)
Wells Fargo & Co.	539	07/13/18	USD 50	5.50 USD	2,988	(36,113)
Williams Cos., Inc.	224	07/13/18		7.00 USD	607	(11,312)
SunTrust Banks, Inc.	118	07/18/18	USD 70	0.50 USD	779	(2,287)
Wells Fargo & Co.	873	07/19/18	USD 50	5.25 USD	4,840	(83,303)
3M Co.	105	07/20/18		0.00 USD	2,066	(23,258)
AXA Equitable Holdings, Inc.	437	07/20/18	USD 22	2.50 USD	901	(4,370)
Aetna, Inc.	218	07/20/18	USD 180	0.00 USD	4,000	(116,085)
Aetna, Inc.	415	07/20/18	USD 195	5.00 USD	7,615	(25,730)
Altria Group, Inc.	391	07/20/18		7.50 USD	2,220	(32,062)
Anadarko Petroleum Corp.	129	07/20/18		2.50 USD	945	(31,476)
Anthem, Inc.	144	07/20/18	USD 240	0.00 USD	3,428	(57,600)

Anthem, Inc.	262	07/20/18	USD	245.00	USD	6,236	(55,675)
Bank of America Corp.	1,190	07/20/18	USD	32.00	USD	3,355	(5,355)
Bank of America Corp.	822	07/20/18	USD	31.00	USD	2,317	(5,343)
Brighthouse Financial, Inc.	155	07/20/18	USD	50.00	USD	621	(1,550)
CDW Corp.	445	07/20/18	USD	80.00	USD	3,595	(109,025)
CVS Health Corp.	349	07/20/18	USD	72.50	USD	2,246	(5,060)
Charles Schwab Corp.	205	07/20/18	USD	60.00	USD	1,048	(1,025)
Chevron Corp.	425	07/20/18	USD	130.00	USD	5,373	(40,588)
Cisco Systems, Inc.	404	07/20/18	USD	45.00	USD	1,738	(5,656)
Cisco Systems, Inc.	336	07/20/18	USD	44.00	USD	1,446	(11,256)
Citigroup, Inc.	757	07/20/18	USD	72.50	USD	5,066	(12,490)
Cognizant Technology Solutions							
Corp., Class A	103	07/20/18	USD	77.50	USD	814	(25,235)
Cognizant Technology Solutions							
Corp., Class A	103	07/20/18	USD	80.00	USD	814	(10,300)
Comcast Corp., Class A	254	07/20/18	USD	33.01	USD	833	(22,436)
Comcast Corp., Class A	568	07/20/18	USD	32.50	USD	1,864	(63,332)
Devon Energy Corp.	182	07/20/18	USD	38.00	USD	800	(112,385)
Devon Energy Corp.	153	07/20/18	USD	44.00	USD	673	(22,874)
Devon Energy Corp.	99	07/20/18	USD	46.00	USD	435	(6,831)
DowDuPont, Inc.	244	07/20/18	USD	70.00	USD	1,608	(4,758)
DowDuPont, Inc.	108	07/20/18	USD	67.50	USD	712	(8,424)
Enterprise Products Partners LP	1,264	07/20/18	USD	29.00	USD	3,497	(12,640)
FirstEnergy Corp.	311	07/20/18	USD	35.00	USD	1,117	(38,098)
General Electric Co.	244	07/20/18	USD	15.00	USD	332	(1,586)
General Electric Co.	120	07/20/18	USD	13.50	USD	163	(6,000)

# BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	1	Exercise	Ν	otional	
Description	Contracts	Date		Price	Amoun	nt (000)	Value
Call (continued)							
General Mills, Inc.	301	07/20/18	USD	45.00	USD	1,332	\$ (14,147)
General Mills, Inc.	667	07/20/18	USD	47.50	USD	2,952	(6,336)
Goldman Sachs Group, Inc.	279	07/20/18	USD	240.00	USD	6,154	(14,508)
Hess Corp.	485	07/20/18	USD	65.00	USD	3,244	(155,200)
Honeywell International, Inc.	75	07/20/18	USD	149.00	USD	1,080	(7,275)
International Paper Co.	176	07/20/18	USD	57.50	USD	917	(1,056)
Interpublic Group of Cos., Inc.	770	07/20/18	USD	24.00	USD	1,805	(28,875)
JPMorgan Chase & Co.	516	07/20/18	USD	113.85	USD	5,377	(5,310)
JPMorgan Chase & Co.	218	07/20/18	USD	110.00	USD	2,272	(11,336)
Kellogg Co.	349	07/20/18	USD	65.00	USD	2,438	(184,970)
KeyCorp	387	07/20/18	USD	21.00	USD	756	(3,483)
Kroger Co.	1,005	07/20/18	USD	26.00	USD	2,859	(260,798)
Lincoln National Corp.	116	07/20/18	USD	72.50	USD	722	(812)
Lincoln National Corp.	115	07/20/18	USD	67.50	USD	716	(1,610)
Lowe s Cos., Inc.	46	07/20/18	USD	86.20	USD	440	(47,008)
Marathon Oil Corp.	419	07/20/18	USD	77.50	USD	2,940	(7,961)
Marathon Oil Corp.	269	07/20/18	USD	22.00	USD	561	(9,280)
Marsh & McLennan Cos., Inc.	596	07/20/18	USD	83.50	USD	4,885	(30,611)
Mattel, Inc.	144	07/20/18	USD	16.00	USD	236	(12,600)
Medtronic PLC	138	07/20/18	USD	87.50	USD	1,181	(6,141)
Medtronic PLC	147	07/20/18	USD	90.00	USD	1,258	(1,323)
Merck & Co., Inc.	339	07/20/18	USD	60.00	USD	2,058	(51,698)
Merck & Co., Inc.	537	07/20/18	USD	62.50	USD	3,260	(20,675)
MetLife, Inc.	248	07/20/18	USD	50.00	USD	1,081	(3,720)
Microsoft Corp.	238	07/20/18	USD	100.00	USD	2,347	(48,076)
Morgan Stanley	284	07/20/18	USD	53.15	USD	1,346	(2,317)
Motorola Solutions, Inc.	214	07/20/18	USD	110.00	USD	2,490	(150,335)
Motorola Solutions, Inc.	429	07/20/18	USD	115.00	USD	4,992	(126,555)
NextEra Energy, Inc.	247	07/20/18	USD	166.25	USD	4,126	(71,079)
NextEra Energy, Inc.	83	07/20/18	USD	165.00	USD	1,386	(29,880)
Nielsen Holdings PLC	570	07/20/18	USD	32.00	USD	1,763	(12,825)
Northrop Grumman Corp.	73	07/20/18	USD	340.00	USD	2,246	(1,460)
Novo Nordisk A/S ADR	352	07/20/18	USD	48.90	USD	1,623	(6,655)
ONEOK, Inc.	138	07/20/18	USD	70.00	USD	964	(17,940)
Oracle Corp.	818	07/20/18	USD	48.00	USD	3,604	(2,454)
Pepsico, Inc.	112	07/20/18	USD	102.95	USD	1,219	(69,128)
Pfizer, Inc.	821	07/20/18	USD	36.00	USD	2,979	(56,239)
Pfizer, Inc.	894	07/20/18	USD	35.00	USD	3,243	(132,312)

Pfizer, Inc.	736	07/20/18	USD	37.00	USD	2,670	(14,352)
Philip Morris International, Inc.	349	07/20/18	USD	85.00	USD	2,818	(22,685)
Procter & Gamble Co.	220	07/20/18	USD	76.00	USD	1,717	(55,000)
QUALCOMM, Inc.	605	07/20/18	USD	62.50	USD	3,395	(11,495)
Quest Diagnostics, Inc.	216	07/20/18	USD	106.90	USD	2,375	(81,583)
SunTrust Banks, Inc.	235	07/20/18	USD	70.00	USD	1,551	(6,815)
Suncor Energy, Inc.	534	07/20/18	USD	40.00	USD	2,172	(73,158)
TOTAL SA ADR	530	07/20/18	USD	62.50	USD	3,210	(18,550)
Taiwan Semiconductor							
Manufacturing Co. Ltd. ADR	1,030	07/20/18	USD	41.00	USD	3,766	(10,300)
Travelers Cos., Inc.	272	07/20/18	USD	135.00	USD	3,328	(2,720)
Travelers Cos., Inc.	276	07/20/18	USD	130.00	USD	3,377	(11,730)
U.S. Bancorp	189	07/20/18	USD	51.50	USD	945	(6,993)
Unilever NV NY Shares	639	07/20/18	USD	57.50	USD	3,561	(19,170)
Union Pacific Corp.	120	07/20/18	USD	150.00	USD	1,700	(7,500)
Verizon Communications, Inc.	477	07/20/18	USD	50.00	USD	2,400	(38,160)
Wells Fargo & Co.	540	07/20/18	USD	55.00	USD	2,994	(85,320)
Williams Cos., Inc.	369	07/20/18	USD	28.00	USD	1,000	(7,933)
FirstEnergy Corp.	238	07/24/18	USD	34.75	USD	855	(37,581)
Public Service Enterprise Group,							
Inc.	514	07/24/18	USD	52.01	USD	2,783	(119,901)
CDW Corp.	366	07/25/18	USD	79.65	USD	2,957	(105,402)
Nextera Energy, Inc.	247	07/25/18	USD	156.00	USD	4,126	(280,248)
Aetna, Inc.	150	07/27/18	USD	185.00	USD	2,753	(41,625)
American International Group, Inc.	289	07/27/18	USD	56.00	USD	1,532	(5,057)
Anthem, Inc.	131	07/27/18	USD	235.00	USD	3,118	(108,730)

Schedules of Investments

43

## BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	1	Exercise	N	otional	
Description	Contracts	Date		Price	Amour	nt (000)	Value
Call (continued)							
Bank of America Corp.	823	07/27/18	USD	31.00	USD	2,320	\$ (7,818)
Cardinal Health, Inc.	303	07/27/18	USD	55.00	USD	1,480	(6,817)
Charles Schwab Corp.	196	07/27/18	USD	58.00	USD	1,002	(1,960)
Chevron Corp.	177	07/27/18	USD	127.00	USD	2,238	(49,560)
Cisco Systems, Inc.	215	07/27/18	USD	45.00	USD	925	(4,515)
Citigroup, Inc.	538	07/27/18	USD	70.00	USD	3,600	(37,391)
Citigroup, Inc.	139	07/27/18	USD	67.50	USD	930	(22,171)
Comcast Corp., Class A	241	07/27/18	USD	33.00	USD	791	(27,836)
Devon Energy Corp.	455	07/27/18	USD	44.00	USD	2,000	(79,625)
Devon Energy Corp.	99	07/27/18	USD	45.50	USD	435	(10,741)
Devon Energy Corp.	353	07/27/18	USD	45.00	USD	1,552	(45,361)
DowDuPont, Inc.	144	07/27/18	USD	72.00	USD	949	(1,656)
DowDuPont, Inc.	204	07/27/18	USD	67.50	USD	1,345	(20,298)
DowDuPont, Inc.	51	07/27/18	USD	66.50	USD	336	(7,344)
Enterprise Products Partners LP	1,264	07/27/18	USD	29.00	USD	3,497	(15,800)
General Electric Co.	1,316	07/27/18	USD	14.50	USD	1,791	(22,372)
General Electric Co.	122	07/27/18	USD	14.00	USD	166	(3,904)
Honeywell International, Inc.	460	07/27/18	USD	152.50	USD	6,626	(22,540)
International Paper Co.	149	07/27/18	USD	59.00	USD	776	(1,341)
JPMorgan Chase & Co.	473	07/27/18	USD	112.00	USD	4,929	(19,156)
KeyCorp	855	07/27/18	USD	21.50	USD	1,671	(11,970)
Lockheed Martin Corp.	52	07/27/18	USD	310.00	USD	1,536	(15,470)
Lowe s Cos., Inc.	150	07/27/18	USD	101.00	USD	1,434	(7,200)
Marathon Oil Corp.	269	07/27/18	USD	22.00	USD	561	(12,643)
Marsh & McLennan Cos., Inc.	598	07/27/18	USD	82.60	USD	4,902	(57,753)
Mattel, Inc.	1,479	07/27/18	USD	19.00	USD	2,429	(162,690)
Medtronic PLC	170	07/27/18	USD	86.50	USD	1,455	(16,830)
Merck & Co., Inc.	537	07/27/18	USD	63.50	USD	3,260	(25,239)
MetLife, Inc.	1,274	07/27/18	USD	48.00	USD	5,555	(14,014)
Microsoft Corp.	201	07/27/18	USD	103.00	USD	1,982	(22,713)
Microsoft Corp.	180	07/27/18	USD	101.00	USD	1,775	(32,850)
Morgan Stanley	731	07/27/18	USD	53.00	USD	3,465	(8,772)
Motorola Solutions, Inc.	215	07/27/18	USD	112.00	USD	2,502	(123,124)
ONEOK, Inc.	276	07/27/18	USD	70.00	USD	1,927	(42,780)
Oracle Corp.	278	07/27/18	USD	49.00	USD	1,225	(1,390)
PepsiCo, Inc.	248	07/27/18	USD	106.00	USD	2,700	(101,680)
Pfizer, Inc.	1,535	07/27/18	USD	37.00	USD	5,569	(41,445)
Pfizer, Inc.	299	07/27/18	USD	36.50	USD	1,085	(14,501)

Royal Dutch Shell PLC ADR,							
Class A	783	07/27/18	USD	71.00	USD	5,421	(62,640)
Suncor Energy, Inc.	2,098	07/27/18	USD	40.00	USD	8,535	(339,876)
U.S. Bancorp	241	07/27/18	USD	52.00	USD	1,205	(7,953)
Union Pacific Corp.	126	07/27/18	USD	146.00	USD	1,785	(24,759)
UnitedHealth Group, Inc.	173	07/27/18	USD	255.00	USD	4,244	(42,472)
Verizon Communications, Inc.	157	07/27/18	USD	50.00	USD	790	(16,720)
Verizon Communications, Inc.	675	07/27/18	USD	49.00	USD	3,396	(113,738)
Wells Fargo & Co.	245	07/27/18	USD	56.50	USD	1,358	(24,255)
Williams Cos., Inc.	251	07/27/18	USD	28.00	USD	680	(7,279)
Pfizer, Inc.	295	07/30/18	USD	36.75	USD	1,070	(12,902)
Pfizer, Inc.	591	07/30/18	USD	36.50	USD	2,144	(28,692)
Travelers Cos., Inc.	277	07/30/18	USD	133.00	USD	3,389	(10,994)
Bank of America Corp.	244	07/31/18	USD	30.25	USD	688	(5,115)
Cisco Systems, Inc.	337	07/31/18	USD	44.60	USD	1,450	(11,393)
FirstEnergy Corp.	366	07/31/18	USD	34.75	USD	1,314	(61,595)
Kellogg Co.	362	07/31/18	USD	67.00	USD	2,529	(150,416)
Altria Group, Inc.	423	08/03/18	USD	58.50	USD	2,402	(39,339)
Anthem, Inc.	144	08/03/18	USD	242.50	USD	3,428	(74,520)
Bank of America Corp.	912	08/03/18	USD	30.00	USD	2,571	(23,256)
Bank of America Corp.	274	08/03/18	USD	29.00	USD	772	(15,344)
Citigroup, Inc.	1,162	08/03/18	USD	68.50	USD	7,776	(165,585)
Comcast Corp., Class A	254	08/03/18	USD	34.00	USD	833	(21,336)
Devon Energy Corp.	507	08/03/18	USD	43.50	USD	2,229	(127,257)
General Electric Co.	461	08/03/18	USD	13.50	USD	627	(27,660)

## BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

Description         Contracts         Date         Price         Amount (000)         Value           Call (continued)         General Electric Co.         663         08/03/18         USD         15.00         USD         902         \$             (7,624)           International Paper Co.         176         08/03/18         USD         110.00         USD         9.17         (14,256)           JPMorgan Chase & Co.         217         08/03/18         USD         110.00         USD         2,61         (14,864)           Lowe s Cos., Inc.         139         08/03/18         USD         110.00         USD         3,091         (43,140)           Microsoft Corp.         360         08/03/18         USD         30.00         USD         3,55         (55,940)           Morgan Stanley         161         08/03/18         USD         32.00         USD         7,53         (43,070)           Oracle Corp.         493         08/03/18         USD         36.50         USD         2,725         (45,436)           Pricer & Gamble Co.         190         08/03/18         USD         55.00         USD         3,435         (56,622)           Suncor Energy, Inc.         727         08/03/18 <t< th=""><th></th><th>Number of</th><th>Expiration</th><th>1</th><th>Exercise</th><th>N</th><th>otional</th><th></th></t<>		Number of	Expiration	1	Exercise	N	otional	
General Electric Co.         663         08/03/18         USD         15.00         USD         902         \$ (7,624)           International Paper Co.         176         08/03/18         USD         110.00         USD         917         (14,256)           JPMorgan Chase & Co.         217         08/03/18         USD         111.00         USD         2,261         (14,864)           Low s Cos., Inc.         139         08/03/18         USD         86.50         USD         3,228         (15,637)           Medtronic PLC         361         08/03/18         USD         80.50         USD         3,550         (59,940)           Morgan Stanley         161         08/03/18         USD         317.50         USD         2,246         (43,070)           Oracle Corp.         73         08/03/18         USD         36.50         USD         2,725         (45,436)           Procter & Gamble Co.         190         08/03/18         USD         14.00         USD         1,483         (26,125)           Suncor Energy, Inc.         727         08/03/18         USD         50.00         USD         5,492         (137,587)           Wells Fargo & Co.         572         08/03/18         US	Description	Contracts	Date		Price	Amour	nt (000)	Value
International Paper Co.176 $08/03/18$ USD $54.50$ USD $917$ $(14.256)$ JPMorgan Chase & Co.305 $08/03/18$ USD $111.00$ USD $3,178$ $(26.535)$ JPMorgan Chase & Co.217 $08/03/18$ USD $111.00$ USD $2,261$ $(14.864)$ Lowe s Cos., Inc.139 $08/03/18$ USD $99.00$ USD $1,328$ $(15.637)$ Mctronic PLC361 $08/03/18$ USD $80.50$ USD $3,091$ $(43,140)$ Microsoft Corp.360 $08/03/18$ USD $102.00$ USD $2,246$ $(43,070)$ Oracle Corp.493 $08/03/18$ USD $31.50$ USD $2,272$ $(43,070)$ Oracle Corp.493 $08/03/18$ USD $44.00$ USD $2,172$ $(50,286)$ Prizer, Inc.751 $08/03/18$ USD $55.00$ USD $2,275$ $(88,331)$ Verizor Communications, Inc.727 $08/03/18$ USD $55.00$ USD $3,435$ $(56,474)$ Novo Nordisk A/S ADR339 $08/06/18$ USD $55.00$ USD $3,436$ $(57,480)$ UnitedHealth Group, Inc.140 $08/09/18$ USD $55.00$ USD $3,435$ $(56,22)$ Amadrako Petroleum Corp.129 $08/10/18$ USD $25.500$ USD $3,435$ $(56,22)$ Amadrako Petroleum Corp.129 $08/10/18$ USD $25.00$ USD $3,435$ $(56,22)$ Amadrako Petroleum Corp. <t< td=""><td>Call (continued)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Call (continued)							
JPMorgan Chase & Co.         305         08/03/18         USD         110.00         USD         3,178         (26,535)           JPMorgan Chase & Co.         217         08/03/18         USD         111.00         USD         2,261         (14,864)           Lowe s Cos., Inc.         139         08/03/18         USD         99.00         USD         1,328         (15,637)           Medtronic PLC         361         08/03/18         USD         102.00         USD         3,550         (59,940)           Morgan Stanley         161         08/03/18         USD         52.00         USD         2,246         (43,070)           Oracle Corp.         493         08/03/18         USD         36.50         USD         2,242         (45,436)           Procter & Gamble Co.         190         08/03/18         USD         78.50         USD         1,483         (26,125)           Suncor Energy, Inc.         727         08/03/18         USD         5.00         USD         5,422         (137,587)           Wells Fargo & Co.         572         08/03/18         USD         5.00         USD         3,435         (50,622)           Anderko Petroleum Corp.         129         08/10/18 <td< td=""><td>General Electric Co.</td><td>663</td><td>08/03/18</td><td>USD</td><td>15.00</td><td>USD</td><td>902</td><td>\$ (7,624)</td></td<>	General Electric Co.	663	08/03/18	USD	15.00	USD	902	\$ (7,624)
JPMorgan Chase & Co.       217       08/03/18       USD       111.00       USD       2,261       (14,864)         Lowe s Cos., Inc.       139       08/03/18       USD       99.00       USD       1,328       (15,637)         Medtronic PLC       361       08/03/18       USD       86.50       USD       3,091       (43,140)         Microsoft Corp.       360       08/03/18       USD       52.00       USD       763       (4,186)         Northrop Grumman Corp.       73       08/03/18       USD       34.00       USD       2,725       (45,436)         Procter & Gamble Co.       190       08/03/18       USD       78.50       USD       1,483       (26,125)         Suncor Energy, Inc.       727       08/03/18       USD       41.00       USD       5,942       (13,7587)         Verizon Communications, Inc.       1,181       08/03/18       USD       55.00       USD       3,471       (103,246)         Novo Nordisk A/S       ADR       339       08/06/18       USD       45.01       USD       3,436       (57,480)         UnitedHealth Group, Inc.       140       08/09/18       USD       55.00       USD       3,435       (50,622)	International Paper Co.	176	08/03/18	USD	54.50	USD	917	(14,256)
Lowe s Cos., Inc.         139         08/03/18         USD         99.00         USD         1,328         (15,637)           Medronic PLC         361         08/03/18         USD         86.50         USD         3,091         (43,140)           Microsoft Corp.         360         08/03/18         USD         52.00         USD         7,63         (59,940)           Northrop Grumman Corp.         73         08/03/18         USD         317.50         USD         2,46         (43,070)           Oracle Corp.         493         08/03/18         USD         44.00         USD         2,172         (50,286)           Prizer, Inc.         751         08/03/18         USD         78.50         USD         1,483         (26,125)           Suncor Energy, Inc.         727         08/03/18         USD         41.00         USD         5,942         (137,587)           Wells Fargo & Co.         572         08/03/18         USD         55.00         USD         3,435         (50,622)           Novo Nordisk A/S ADR         339         08/06/18         USD         45.01         USD         3,435         (50,622)           American International Group, Inc.         140         08/09/18         <	JPMorgan Chase & Co.	305	08/03/18	USD	110.00	USD	3,178	(26,535)
Medtronic PLC         361         08/03/18         USD         86.50         USD         3.091         (43,140)           Microsoft Corp.         360         08/03/18         USD         102.00         USD         3.550         (59,940)           Morgan Stanley         161         08/03/18         USD         52.00         USD         7.63         (4,186)           Northrop Grumman Corp.         73         08/03/18         USD         44.00         USD         2,246         (43,070)           Oracle Corp.         493         08/03/18         USD         44.00         USD         2,725         (45,436)           Procter & Gamble Co.         190         08/03/18         USD         78.50         USD         2,957         (88,331)           Verizon Communications, Inc.         1,181         08/03/18         USD         50.00         USD         3,171         (103,246)           Novo Nordisk A/S         ADR         339         08/06/18         USD         45.01         USD         3,436         (57,480)           UnitedHealth Group, Inc.         145         08/10/18         USD         25.00         USD         3,435         (50,622)           Amadarko Petroleum Corp.         29	JPMorgan Chase & Co.	217	08/03/18	USD	111.00	USD	2,261	(14,864)
Microsoft Corp.         360         08/03/18         USD         102.00         USD         3,550         (59,940)           Morgan Stanley         161         08/03/18         USD         52.00         USD         763         (4,186)           Northrop Grumman Corp.         73         08/03/18         USD         317.50         USD         2,246         (43,070)           Oracle Corp.         493         08/03/18         USD         44.00         USD         2,172         (50,286)           Prizer, Inc.         751         08/03/18         USD         44.00         USD         2,977         (48,331)           Verizon Communications, Inc.         1,181         08/03/18         USD         55.00         USD         3,171         (103,246)           Novo Nordisk A/S         ADR         339         08/06/18         USD         45.01         USD         3,486         (57,480)           UnitedHealth Group, Inc.         140         08/09/18         USD         55.00         USD         3,445         (50,622)           American International Group, Inc.         145         08/10/18         USD         55.00         USD         3,445         (57,480)           Bank of America Corp.         129	Lowe s Cos., Inc.	139	08/03/18	USD	99.00	USD	1,328	(15,637)
Morgan Stanley161 $08/03/18$ USD $52.00$ USD $763$ $(4,186)$ Northrop Grumman Corp.73 $08/03/18$ USD $317.50$ USD $2,246$ $(43,070)$ Oracle Corp.493 $08/03/18$ USD $44.00$ USD $2,172$ $(50,286)$ Prizer, Inc.751 $08/03/18$ USD $36.50$ USD $2,725$ $(45,436)$ Procter & Gamble Co.190 $08/03/18$ USD $36.50$ USD $2,725$ $(45,436)$ Verizon Communications, Inc.1,181 $08/03/18$ USD $41.00$ USD $5,942$ $(137,587)$ Verizon Communications, Inc.1,181 $08/03/18$ USD $55.00$ USD $3,171$ $(103,246)$ Novo Nordisk A/SADR339 $08/06/18$ USD $55.00$ USD $3,436$ $(57,480)$ UnitedHealth Group, Inc.140 $08/09/18$ USD $55.00$ USD $3,435$ $(50,622)$ Amarican International Group, Inc.145 $08/10/18$ USD $55.00$ USD $3,219$ $(69,751)$ CVS Health Corp.283 $08/10/18$ USD $30.10$ USD $2,788$ $(29,699)$ Bank of America Corp.989 $08/10/18$ USD $33.50$ USD $1,226$ $(68,092)$ Devon Energy Corp.283 $08/10/18$ USD $33.50$ USD $1,226$ $(68,092)$ Devon Energy Corp.353 $08/10/18$ USD $14.00$ USD $3.51$ $(10,865)$	Medtronic PLC	361	08/03/18	USD	86.50	USD	3,091	(43,140)
Northrop Grumman Corp.         73         08/03/18         USD         317.50         USD         2,246         (43,070)           Oracle Corp.         493         08/03/18         USD         44.00         USD         2,172         (50,286)           Prizer, Inc.         751         08/03/18         USD         36.50         USD         2,725         (45,436)           Procter & Gamble Co.         190         08/03/18         USD         78.50         USD         1,483         (26,125)           Suncor Energy, Inc.         727         08/03/18         USD         50.00         USD         5,942         (137,587)           Wells Fargo & Co.         572         08/03/18         USD         55.00         USD         3,171         (103,246)           Noro Nordisk A/S         ADR         339         08/06/18         USD         68.30         USD         3,435         (50,622)           American International Group, Inc.         145         08/10/18         USD         55.00         USD         3,435         (50,622)           Anadarko Petroleum Corp.         129         08/10/18         USD         769         (12,832)           Anadarko America Corp.         1,142         08/10/18 <td< td=""><td>Microsoft Corp.</td><td>360</td><td>08/03/18</td><td>USD</td><td>102.00</td><td>USD</td><td>3,550</td><td>(59,940)</td></td<>	Microsoft Corp.	360	08/03/18	USD	102.00	USD	3,550	(59,940)
Oracle Corp.49308/03/18USD44.00USD2,172(50,286)Pfizer, Inc.75108/03/18USD36.50USD2,725(45,436)Proter & Gamble Co.19008/03/18USD78.50USD1,483(26,125)Suncor Energy, Inc.72708/03/18USD50.00USD2,957(88,331)Verizon Communications, Inc.1,18108/03/18USD50.00USD5,942(137,587)Wells Fargo & Co.57208/03/18USD55.00USD3,171(103,246)Novo Nordisk A/SADR33908/06/18USD45.01USD1,563(66,474)SunTrust Banks, Inc.52808/06/18USD55.00USD3,435(50,622)American International Group, Inc.14008/09/18USD55.00USD3,435(50,622)Anadrko Petroleum Corp.12908/10/18USD76.50USD945(24,188)Bank of America Corp.1,14208/10/18USD29.01USD3,219(69,751)CVS Health Corp.28308/10/18USD33.50USD1,821(47,120)Comcast Corp., Class A58708/10/18USD33.50USD1,926(68,092)Devon Energy Corp.35308/10/18USD46.00USD1,552(54,882)DowDuPont, Inc.26008/10/18USD14.00USD361(10,865) </td <td>Morgan Stanley</td> <td>161</td> <td>08/03/18</td> <td>USD</td> <td>52.00</td> <td>USD</td> <td>763</td> <td>(4,186)</td>	Morgan Stanley	161	08/03/18	USD	52.00	USD	763	(4,186)
Pfizer, Inc.         751         08/03/18         USD         36.50         USD         2,725         (45,436)           Procter & Gamble Co.         190         08/03/18         USD         78.50         USD         1,483         (26,125)           Suncor Energy, Inc.         727         08/03/18         USD         41.00         USD         2,957         (88,331)           Verizon Communications, Inc.         1,181         08/03/18         USD         50.00         USD         5,942         (137,587)           Wells Fargo & Co.         572         08/06/18         USD         55.00         USD         3,171         (103,246)           Novo Nordisk A/S         ADR         339         08/06/18         USD         45.01         USD         3,171         (103,246)           UnitedHealth Group, Inc.         140         08/09/18         USD         255.00         USD         3,435         (50,622)           American International Group, Inc.         145         08/10/18         USD         76.50         USD         945         (24,188)           Bank of America Corp.         1,142         08/10/18         USD         30.10         USD         3,219         (69,751)           CVS Health Corp.	Northrop Grumman Corp.	73	08/03/18	USD	317.50	USD	2,246	(43,070)
Procter & Gamble Co.190 $08/03/18$ USD $78.50$ USD $1,483$ $(22,125)$ Suncor Energy, Inc.727 $08/03/18$ USD $41.00$ USD $2,957$ $(88,331)$ Verizon Communications, Inc. $1,181$ $08/03/18$ USD $50.00$ USD $5,942$ $(137,587)$ Wells Fargo & Co. $572$ $08/03/18$ USD $55.00$ USD $3,171$ $(103,246)$ Novo Nordisk A/SADR $339$ $08/06/18$ USD $45.01$ USD $3,486$ $(57,480)$ UnitedHealth Group, Inc.140 $08/09/18$ USD $255.00$ USD $3,435$ $(50,622)$ Amarican International Group, Inc.145 $08/10/18$ USD $55.00$ USD $9,455$ $(24,188)$ Bank of America Corp.129 $08/10/18$ USD $25.00$ USD $9,45$ $(24,188)$ Bank of America Corp.1,142 $08/10/18$ USD $29.01$ USD $3,219$ $(69,751)$ CVS Health Corp.283 $08/10/18$ USD $33.50$ USD $1,926$ $(68,092)$ Devon Energy Corp. $353$ $08/10/18$ USD $33.75$ USD $1,552$ $(54,892)$ DowDuPont, Inc.260 $08/10/18$ USD $30.75$ USD $1,512$ $(54,892)$ DowDuPont, Inc.260 $08/10/18$ USD $46.00$ USD $1,552$ $(54,892)$ DowDuPont, Inc.260 $08/10/18$ USD $14.00$ USD $66.10$ $10,8651$ </td <td>Oracle Corp.</td> <td>493</td> <td>08/03/18</td> <td>USD</td> <td>44.00</td> <td>USD</td> <td>2,172</td> <td>(50,286)</td>	Oracle Corp.	493	08/03/18	USD	44.00	USD	2,172	(50,286)
Suncor Energy, Inc.         727         08/03/18         USD         41.00         USD         2,957         (88,331)           Verizon Communications, Inc.         1,181         08/03/18         USD         50.00         USD         5,942         (137,587)           Wells Fargo & Co.         572         08/03/18         USD         55.00         USD         3,171         (103,246)           Novo Nordisk A/S         ADR         339         08/06/18         USD         45.01         USD         1,563         (66,474)           SunTrust Banks, Inc.         528         08/06/18         USD         255.00         USD         3,486         (57,480)           UnitedHealth Group, Inc.         140         08/09/18         USD         255.00         USD         769         (12,832)           Anadarko Petroleum Corp.         129         08/10/18         USD         30.10         USD         2,788         (29,699)           Bank of America Corp.         1,142         08/10/18         USD         29.01         USD         3,219         (69,751)           CVS Health Corp.         283         08/10/18         USD         33.50         USD         1,926         (68,092)           Devon Energy Corp.	Pfizer, Inc.	751	08/03/18	USD	36.50	USD	2,725	(45,436)
Verizon Communications, Inc.1,181 $08/03/18$ USD $50.00$ USD $5,942$ $(137,587)$ Wells Fargo & Co. $572$ $08/03/18$ USD $55.00$ USD $3,171$ $(103,246)$ Novo Nordisk A/SADR $339$ $08/06/18$ USD $45.01$ USD $1,563$ $(66,474)$ SunTrust Banks, Inc. $528$ $08/06/18$ USD $68.30$ USD $3,486$ $(57,480)$ UnitedHealth Group, Inc.140 $08/09/18$ USD $55.00$ USD $3,435$ $(50,622)$ American International Group, Inc.145 $08/10/18$ USD $55.00$ USD $769$ $(12,832)$ Anadrko Petroleum Corp.129 $08/10/18$ USD $76.50$ USD $945$ $(24,188)$ Bank of America Corp.989 $08/10/18$ USD $30.10$ USD $2,788$ $(29,699)$ Bank of America Corp.1,142 $08/10/18$ USD $29.01$ USD $3,219$ $(69,751)$ CVS Health Corp.283 $08/10/18$ USD $33.50$ USD $1,926$ $(68,092)$ Devon Energy Corp.353 $08/10/18$ USD $66.00$ USD $1,714$ $(60,450)$ FirstEnergy Corp.367 $08/10/18$ USD $33.75$ USD $1,318$ $(86,915)$ General Electric Co.265 $08/10/18$ USD $14.00$ USD $361$ $(10,865)$ Hess Corp.915 $08/10/18$ USD $17.00$ USD $4,11$ $(25,113)$ <td>Procter &amp; Gamble Co.</td> <td>190</td> <td>08/03/18</td> <td>USD</td> <td>78.50</td> <td>USD</td> <td>1,483</td> <td>(26,125)</td>	Procter & Gamble Co.	190	08/03/18	USD	78.50	USD	1,483	(26,125)
Wells Fargo & Co.57208/03/18USD55.00USD3,171(103,246)Novo Nordisk A/SADR33908/06/18USD45.01USD1,563(66,474)SunTrust Banks, Inc.52808/06/18USD68.30USD3,486(57,480)UnitedHealth Group, Inc.14008/09/18USD255.00USD3,435(50,622)American International Group, Inc.14508/10/18USD55.00USD769(12,832)Anadarko Petroleum Corp.12908/10/18USD30.10USD2,788(29,699)Bank of America Corp.1,14208/10/18USD30.10USD3,219(69,751)CVS Health Corp.28308/10/18USD33.50USD1,821(47,120)Comcast Corp., Class A58708/10/18USD33.50USD1,552(54,892)Devon Energy Corp.35308/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD14.00USD3,61(10,865)Hess Corp.91508/10/18USD17.00USD4,11(25,113)McKesson Corp.12408/10/18USD17.00USD4,71(25,113)McKesson Corp.12408/10/18USD138.00USD1,654(47,120)Mettrift, Inc.28708/10/18USD138.00USD4,022(59,311)<	Suncor Energy, Inc.	727	08/03/18	USD	41.00	USD	2,957	(88,331)
Wells Fargo & Co.57208/03/18USD55.00USD3,171(103,246)Novo Nordisk A/SADR33908/06/18USD45.01USD1,563(66,474)SunTrust Banks, Inc.52808/06/18USD68.30USD3,486(57,480)UnitedHealth Group, Inc.14008/09/18USD255.00USD3,435(50,622)American International Group, Inc.14508/10/18USD55.00USD769(12,832)Anadarko Petroleum Corp.12908/10/18USD30.10USD2,788(29,699)Bank of America Corp.1,14208/10/18USD30.10USD3,219(69,751)CVS Health Corp.28308/10/18USD33.50USD1,821(47,120)Comcast Corp., Class A58708/10/18USD33.50USD1,552(54,892)Devon Energy Corp.35308/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD14.00USD3,61(10,865)Hess Corp.91508/10/18USD17.00USD4,11(25,113)McKesson Corp.12408/10/18USD17.00USD4,71(25,113)McKesson Corp.12408/10/18USD138.00USD1,654(47,120)Mettrift, Inc.28708/10/18USD138.00USD4,022(59,311)<	Verizon Communications, Inc.	1,181	08/03/18	USD	50.00	USD	5,942	(137,587)
SunTrust Banks, Inc.52808/06/18USD68.30USD3,486(57,480)UnitedHealth Group, Inc.14008/09/18USD255.00USD3,435(50,622)American International Group, Inc.14508/10/18USD55.00USD769(12,832)Anadarko Petroleum Corp.12908/10/18USD76.50USD945(24,188)Bank of America Corp.98908/10/18USD30.10USD2,788(29,699)Bank of America Corp.1,14208/10/18USD29.01USD3,219(69,751)CVS Health Corp.28308/10/18USD33.50USD1,926(68,092)Devon Energy Corp.35308/10/18USD33.50USD1,552(54,892)DowDuPont, Inc.26008/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD14.00USD3,61(10,865)Hess Corp.91508/10/18USD14.00USD4,022(59,311)Mattel, Inc.28708/10/18USD17.00USD4,012(59,113)McKesson Corp.12408/10/18USD18.00USD1,654(47,120)Mettrine, Inc.1,44808/10/18USD18.00USD1,654(47,120)Metcine, Inc.1,44808/10/18USD18.00USD3,091(42,598)MetLife, Inc	Wells Fargo & Co.	572	08/03/18	USD	55.00	USD	3,171	
UnitedHealth Group, Inc.140 $08/09/18$ USD $255.00$ USD $3,435$ $(50,622)$ American International Group, Inc.145 $08/10/18$ USD $55.00$ USD $769$ $(12,832)$ Anadarko Petroleum Corp.129 $08/10/18$ USD $76.50$ USD $945$ $(24,188)$ Bank of America Corp.989 $08/10/18$ USD $30.10$ USD $2,788$ $(29,699)$ Bank of America Corp.1,142 $08/10/18$ USD $29.01$ USD $3,219$ $(69,751)$ CVS Health Corp.283 $08/10/18$ USD $33.50$ USD $1,821$ $(47,120)$ Comcast Corp., Class A587 $08/10/18$ USD $33.50$ USD $1,926$ $(68,092)$ Devon Energy Corp.353 $08/10/18$ USD $46.00$ USD $1,552$ $(54,892)$ DowDuPont, Inc.260 $08/10/18$ USD $46.00$ USD $1,714$ $(60,450)$ FirstEnergy Corp.367 $08/10/18$ USD $14.00$ USD $361$ $(10,865)$ General Electric Co.265 $08/10/18$ USD $108.25$ USD $4,022$ $(59,311)$ Mattel, Inc.287 $08/10/18$ USD $138.00$ USD $4,64$ $47,120$ Medtronic PLC361 $08/10/18$ USD $138.00$ USD $4,64$ $47,120$ MetLife, Inc.124 $08/10/18$ USD $108.25$ USD $4,022$ $(59,311)$ MetLife, Inc.1,448<	Novo Nordisk A/S ADR	339	08/06/18	USD	45.01	USD	1,563	(66,474)
UnitedHealth Group, Inc.14008/09/18USD255.00USD3,435(50,622)American International Group, Inc.14508/10/18USD55.00USD769(12,832)Anadarko Petroleum Corp.12908/10/18USD76.50USD945(24,188)Bank of America Corp.98908/10/18USD30.10USD2,788(29,699)Bank of America Corp.1,14208/10/18USD29.01USD3,219(69,751)CVS Health Corp.28308/10/18USD33.50USD1,926(68,092)Devon Energy Corp.35308/10/18USD33.50USD1,926(68,092)Devon Energy Corp.35308/10/18USD46.00USD1,552(54,892)DowDuPont, Inc.26008/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD14.00USD361(10,865)JPMorgan Chase & Co.38608/10/18USD108.25USD4,022(59,311)Mattel, Inc.28708/10/18USD13.00USD1,654(47,120)Medtronic PLC36108/10/18USD138.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD102.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD102.00USD6,313(187,516)Mi	SunTrust Banks, Inc.	528	08/06/18	USD	68.30	USD	3,486	(57,480)
Anadarko Petroleum Corp.129 $08/10/18$ USD $76.50$ USD $945$ $(24,188)$ Bank of America Corp.989 $08/10/18$ USD $30.10$ USD $2,788$ $(29,699)$ Bank of America Corp. $1,142$ $08/10/18$ USD $29.01$ USD $3,219$ $(69,751)$ CVS Health Corp.283 $08/10/18$ USD $66.50$ USD $1,821$ $(47,120)$ Comcast Corp., Class A587 $08/10/18$ USD $33.50$ USD $1,926$ $(68,092)$ Devon Energy Corp.353 $08/10/18$ USD $46.00$ USD $1,552$ $(54,892)$ DowDuPont, Inc.260 $08/10/18$ USD $33.75$ USD $1,141$ $(60,450)$ FirstEnergy Corp.367 $08/10/18$ USD $33.75$ USD $1,318$ $(86,915)$ General Electric Co.265 $08/10/18$ USD $14.00$ USD $361$ $(10,865)$ Hess Corp.915 $08/10/18$ USD $108.25$ USD $4,022$ $(59,311)$ Mattel, Inc.287 $08/10/18$ USD $17.00$ USD $4,022$ $(59,311)$ McKesson Corp.124 $08/10/18$ USD $18.00$ USD $1,654$ $(47,120)$ Medtronic PLC361 $08/10/18$ USD $87.00$ USD $3,091$ $(42,598)$ MetLife, Inc. $1,448$ $08/10/18$ USD $44.00$ USD $6,313$ $(187,516)$ Microsoft Corp.181 $08/10/18$	UnitedHealth Group, Inc.	140	08/09/18	USD	255.00	USD	3,435	
Bank of America Corp.98908/10/18USD30.10USD2,788(29,699)Bank of America Corp.1,14208/10/18USD29.01USD3,219(69,751)CVS Health Corp.28308/10/18USD66.50USD1,821(47,120)Comcast Corp., Class A58708/10/18USD33.50USD1,926(68,092)Devon Energy Corp.35308/10/18USD46.00USD1,552(54,892)DowDuPont, Inc.26008/10/18USD66.00USD1,714(60,450)FirstEnergy Corp.36708/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD70.50USD6,120(161,955)JPMorgan Chase & Co.38608/10/18USD17.00USD471(25,113)McKesson Corp.12408/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD50.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	American International Group, Inc	. 145	08/10/18	USD	55.00	USD	769	(12,832)
Bank of America Corp.1,14208/10/18USD29.01USD3,219(69,751)CVS Health Corp.28308/10/18USD66.50USD1,821(47,120)Comcast Corp., Class A58708/10/18USD33.50USD1,926(68,092)Devon Energy Corp.35308/10/18USD46.00USD1,552(54,892)DowDuPont, Inc.26008/10/18USD66.00USD1,714(60,450)FirstEnergy Corp.36708/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD14.00USD361(10,865)Hess Corp.91508/10/18USD108.25USD4,022(59,311)Mattel, Inc.28708/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD138.00USD1,654(47,120)MetLife, Inc.1,44808/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	Anadarko Petroleum Corp.	129	08/10/18	USD	76.50	USD	945	(24,188)
CVS Health Corp.28308/10/18USD66.50USD1,821(47,120)Comcast Corp., Class A58708/10/18USD33.50USD1,926(68,092)Devon Energy Corp.35308/10/18USD46.00USD1,552(54,892)DowDuPont, Inc.26008/10/18USD66.00USD1,714(60,450)FirstEnergy Corp.36708/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD70.50USD6,120(161,955)JPMorgan Chase & Co.38608/10/18USD108.25USD4,022(59,311)Mattel, Inc.28708/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD44.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	Bank of America Corp.	989	08/10/18	USD	30.10	USD	2,788	(29,699)
Comcast Corp., Class A58708/10/18USD33.50USD1,926(68,092)Devon Energy Corp.35308/10/18USD46.00USD1,552(54,892)DowDuPont, Inc.26008/10/18USD66.00USD1,714(60,450)FirstEnergy Corp.36708/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD14.00USD361(10,865)Hess Corp.91508/10/18USD70.50USD6,120(161,955)JPMorgan Chase & Co.38608/10/18USD17.00USD471(25,113)Mattel, Inc.28708/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	Bank of America Corp.	1,142	08/10/18	USD	29.01	USD	3,219	(69,751)
Devon Energy Corp.35308/10/18USD46.00USD1,552(54,892)DowDuPont, Inc.26008/10/18USD66.00USD1,714(60,450)FirstEnergy Corp.36708/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD14.00USD361(10,865)Hess Corp.91508/10/18USD70.50USD6,120(161,955)JPMorgan Chase & Co.38608/10/18USD108.25USD4,022(59,311)Mattel, Inc.28708/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD138.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD102.00USD6,313(187,516)Microsoft Corp.18108/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	CVS Health Corp.	283	08/10/18	USD	66.50	USD	1,821	(47,120)
DowDuPont, Inc.26008/10/18USD66.00USD1,714(60,450)FirstEnergy Corp.36708/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD14.00USD361(10,865)Hess Corp.91508/10/18USD70.50USD6,120(161,955)JPMorgan Chase & Co.38608/10/18USD108.25USD4,022(59,311)Mattel, Inc.28708/10/18USD138.00USD1,654(47,120)McKesson Corp.12408/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	Comcast Corp., Class A	587	08/10/18	USD	33.50	USD	1,926	(68,092)
FirstEnergy Corp.36708/10/18USD33.75USD1,318(86,915)General Electric Co.26508/10/18USD14.00USD361(10,865)Hess Corp.91508/10/18USD70.50USD6,120(161,955)JPMorgan Chase & Co.38608/10/18USD108.25USD4,022(59,311)Mattel, Inc.28708/10/18USD17.00USD471(25,113)McKesson Corp.12408/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	Devon Energy Corp.	353	08/10/18	USD	46.00	USD	1,552	(54,892)
General Electric Co.26508/10/18USD14.00USD361(10,865)Hess Corp.91508/10/18USD70.50USD6,120(161,955)JPMorgan Chase & Co.38608/10/18USD108.25USD4,022(59,311)Mattel, Inc.28708/10/18USD17.00USD471(25,113)McKesson Corp.12408/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	DowDuPont, Inc.	260	08/10/18	USD	66.00	USD	1,714	(60,450)
Hess Corp.91508/10/18USD70.50USD6,120(161,955)JPMorgan Chase & Co.38608/10/18USD108.25USD4,022(59,311)Mattel, Inc.28708/10/18USD17.00USD471(25,113)McKesson Corp.12408/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	FirstEnergy Corp.	367	08/10/18	USD	33.75	USD	1,318	(86,915)
JPMorgan Chase & Co.38608/10/18USD108.25USD4,022(59,311)Mattel, Inc.28708/10/18USD17.00USD471(25,113)McKesson Corp.12408/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	General Electric Co.	265	08/10/18	USD	14.00	USD	361	(10,865)
Mattel, Inc.28708/10/18USD17.00USD471(25,113)McKesson Corp.12408/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	Hess Corp.	915	08/10/18	USD	70.50	USD	6,120	(161,955)
McKesson Corp.12408/10/18USD138.00USD1,654(47,120)Medtronic PLC36108/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	JPMorgan Chase & Co.	386	08/10/18	USD	108.25	USD	4,022	(59,311)
Medtronic PLC36108/10/18USD87.00USD3,091(42,598)MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	Mattel, Inc.	287	08/10/18	USD	17.00	USD	471	(25,113)
MetLife, Inc.1,44808/10/18USD44.00USD6,313(187,516)Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	McKesson Corp.	124	08/10/18	USD	138.00	USD	1,654	(47,120)
Microsoft Corp.18108/10/18USD102.00USD1,785(33,847)Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	Medtronic PLC	361	08/10/18	USD	87.00	USD	3,091	(42,598)
Morgan Stanley80608/10/18USD50.00USD3,820(55,614)Oracle Corp.1,55008/10/18USD45.10USD6,829(100,682)	MetLife, Inc.	1,448	08/10/18	USD	44.00	USD	6,313	(187,516)
Oracle Corp. 1,550 08/10/18 USD 45.10 USD 6,829 (100,682)	Microsoft Corp.	181	08/10/18	USD	102.00	USD	1,785	(33,847)
Oracle Corp. 1,550 08/10/18 USD 45.10 USD 6,829 (100,682)	Morgan Stanley	806	08/10/18	USD	50.00	USD	3,820	(55,614)
		1,550	08/10/18	USD	45.10	USD	6,829	(100,682)
	PG&E Corp.	350	08/10/18	USD	44.00	USD	1,490	(91,000)

Pfizer, Inc.	592	08/10/18	USD	36.50	USD	2,148	(38,480)
QUALCOMM, Inc.	441	08/10/18	USD	58.00	USD	2,475	(78,498)
U.S. Bancorp	1,006	08/10/18	USD	50.00	USD	5,032	(137,319)
Union Pacific Corp.	110	08/10/18	USD	142.00	USD	1,558	(47,300)
Verizon Communications, Inc.	620	08/10/18	USD	52.00	USD	3,119	(31,620)
Wells Fargo & Co.	483	08/10/18	USD	58.00	USD	2,678	(31,154)
3M Co.	119	08/17/18	USD	210.00	USD	2,341	(21,658)
AXA Equitable Holdings, Inc.	465	08/17/18	USD	22.50	USD	958	(11,625)
Altria Group, Inc.	633	08/17/18	USD	59.20	USD	3,595	(65,290)
American International Group, Inc.	1,231	08/17/18	USD	57.50	USD	6,527	(32,622)
Bank of America Corp.	823	08/17/18	USD	31.00	USD	2,320	(16,048)
Bank of America Corp.	1,142	08/17/18	USD	29.00	USD	3,219	(78,227)
CVS Health Corp.	120	08/17/18	USD	72.50	USD	772	(5,580)
Cardinal Health, Inc.	289	08/17/18	USD	55.00	USD	1,411	(17,340)
Charles Schwab Corp.	32	08/17/18	USD	55.00	USD	164	(2,160)
Chevron Corp.	166	08/17/18	USD	130.00	USD	2,099	(38,595)
Cisco Systems, Inc.	137	08/17/18	USD	44.00	USD	590	(14,248)
Citigroup, Inc.	309	08/17/18	USD	67.50	USD	2,068	(61,800)
Cognizant Technology Solutions							
Corp., Class A	206	08/17/18	USD	80.00	USD	1,627	(48,410)
Comcast Corp., Class A	1,004	08/17/18	USD	35.00	USD	3,294	(69,778)
Devon Energy Corp.	244	08/17/18	USD	42.00	USD	1,073	(90,890)
Devon Energy Corp.	99	08/17/18	USD	46.00	USD	435	(16,978)
DowDuPont, Inc.	51	08/17/18	USD	70.00	USD	336	(4,437)
DowDuPont, Inc.	102	08/17/18	USD	67.50	USD	672	(17,697)
-							

SCHEDULES OF INVESTMENTS

45

# BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exercise	Notional	
Description	Contracts	Date	Price	Amount (000)	Value
Call (continued)					
Dr. Pepper Snapple Group, Inc.	424	08/17/18	USD 120.00	USD 5,173	
Enterprise Products Partners LP		08/17/18	USD 29.00	USD 3,497	(25,280)
FirstEnergy Corp.	468	08/17/18	USD 36.00	USD 1,681	(43,290)
General Electric Co.	406	08/17/18	USD 15.00	USD 553	(6,699)
Honeywell International, Inc.	113	08/17/18	USD 148.75	USD 1,628	(21,857)
Humana, Inc.	41	08/17/18	USD 300.00	USD 1,220	(38,335)
Humana, Inc.	69	08/17/18	USD 305.00	USD 2,054	(48,645)
International Paper Co.	177	08/17/18	USD 55.00	USD 922	(14,425)
Interpublic Group of Cos., Inc.	769	08/17/18	USD 24.00	USD 1,803	(61,520)
JPMorgan Chase & Co.	686	08/17/18	USD 115.00	USD 7,148	(32,928)
Kellogg Co.	116	08/17/18	USD 68.75	USD 810	(38,802)
KeyCorp	994	08/17/18	USD 20.45	USD 1,942	(36,752)
Kroger Co.	353	08/17/18	USD 30.00	USD 1,004	(16,414)
Lockheed Martin Corp.	52	08/17/18	USD 315.00	USD 1,536	(17,420)
Lowe s Cos., Inc.	144	08/17/18	USD 97.50	USD 1,376	(30,528)
Marathon Oil Corp.	42	08/17/18	USD 22.00	USD 88	(3,381)
Marathon Oil Corp.	269	08/17/18	USD 23.00	USD 561	(13,853)
Marathon Petroleum Corp.	271	08/17/18	USD 72.50	USD 1,901	(59,620)
Mattel, Inc.	144	08/17/18	USD 18.00	USD 236	(8,280)
McKesson Corp.	124	08/17/18	USD 140.00	USD 1,654	(38,750)
Medtronic PLC	186	08/17/18	USD 87.50	USD 1,592	(21,111)
Merck & Co., Inc.	335	08/17/18	USD 62.50	USD 2,033	(38,358)
Merck & Co., Inc.	537	08/17/18	USD 65.00	USD 3,260	(24,434)
MetLife, Inc.	451	08/17/18	USD 47.50	USD 1,966	(12,177)
Microsoft Corp.	159	08/17/18	USD 105.00	USD 1,568	(17,808)
Morgan Stanley	303	08/17/18	USD 51.75	USD 1,436	(12,875)
Northrop Grumman Corp.	84	08/17/18	USD 335.00	USD 2,585	(20,370)
ONEOK, Inc.	138	08/17/18	USD 70.00	USD 964	(27,255)
Oracle Corp.	877	08/17/18	USD 44.00	USD 3,864	(110,064)
Pfizer, Inc.	751	08/17/18	USD 37.00	USD 2,725	(34,546)
Procter & Gamble Co.	410	08/17/18	USD 77.50	USD 3,200	(87,535)
Quest Diagnostics, Inc.	216	08/17/18	USD 106.90	USD 2,375	(107,635)
SunTrust Banks, Inc.	118	08/17/18	USD 72.50	USD 779	(4,248)
Suncor Energy, Inc.	534	08/17/18	USD 41.00	USD 2,172	(77,430)
TOTAL SA ADR	530	08/17/18	USD 62.50	USD 3,210	
Taiwan Semiconductor					
Manufacturing Co. Ltd. ADR	514	08/17/18	USD 39.50	USD 1,879	(20,770)
U.S. Bancorp	283	08/17/18	USD 52.50	USD 1,416	

Unilever NV NY Shares	638	08/17/18	USD	55.00	USD	3,555	(108,460)
Verizon Communications, Inc.	952	08/17/18	USD	49.00	USD	4,790	(187,068)
Wells Fargo & Co.	572	08/17/18	USD	55.00	USD	3,171	(113,828)
Williams Cos., Inc.	251	08/17/18	USD	28.00	USD	680	(13,303)
UnitedHealth Group, Inc.	140	08/20/18	USD	255.00	USD	3,435	(62,596)
Public Service Enterprise Group, Inc. Edison International	421 281	08/22/18 08/27/18	USD USD	54.05 63.25	USD USD	2,279 1,778	(65,209) (59,496)

\$ (13,659,306)

## **OTC Options Written**

Description	Countormarty	Number of	-	1	<i>Exercise</i> Price		Notional	Value
<i>Description</i> Call	Counterparty	Contracts	Date		Price	Amou	nt (000)	Value
Suncor								
Energy, Inc.	Citibank N.A.	123,300	07/09/18	USD	38.95	USD	5,016	\$ (231,820)
BP PLC	Goldman Sachs International	88,400	07/10/18	GBP	5.83	GBP	510	(6,593)
Bayer AG,		,		-		-		(-)/
Registered								
Shares	Credit Suisse International	19,917	07/10/18	EUR	102.39	EUR	1,873	(572)
Constellation								
Software,								
Inc.	Citibank N.A.	7,700	07/10/18	CAD	981.42	CAD	7,850	(240,823)
Diageo PLC	Goldman Sachs International	28,400	07/10/18	GBP	26.86	GBP	773	(22,641)
AstraZeneca								
PLC	Morgan Stanley & Co. International PLC	99,800	07/11/18	GBP	54.55	GBP	5,231	(14,525)
CRH PLC	UBS AG	72,500	07/11/18	GBP	28.27	GBP	1,927	(911)
Experian		101 000	0=11110	<b>655</b>	10.04	<b>655</b>		
PLC	Credit Suisse International	121,000	07/11/18	GBP	19.04	GBP	2,261	(20,653)
Koninklijke		222 400	07/10/10		07.10		0.070	
Philips N.V.	Morgan Stanley & Co. International PLC	222,400	07/12/18	EUR	37.12	EUR	8,069	(62,386)
Lenovo Croup I td		2 206 000	07/12/19		2.06		12 051	(111 200)
Group Ltd.	UBS AG	3,306,000	07/12/18	HKD	3.96	HKD	13,951	(111,388)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

## **OTC Options Written (continued)**

		Number of	Expiration		Exercise	N	otional	
<i>Description</i> Call	Counterparty	Contracts	Date		Price	Amour	ıt (000)	Value
(continued)								
Public								
Service								
Enterprise								
Group, Inc.	Bank of America N.A.	125,200	07/16/18	USD	53.44	USD	6,778	\$ (137,595)
BCE, Inc.	Barclays Bank PLC	36,100	07/17/18	USD	41.90	USD	1,462	(3,955)
AstraZeneca		22.000	07/10/10	CDD	54.00	CDD	1 720	(14.120)
PLC	Goldman Sachs International	33,000	07/18/18	GBP	54.00	GBP	1,730	(14,138)
CRH PLC	Morgan Stanley & Co. International PLC	25,500	07/18/18	GBP	28.61	GBP	678	(577)
Danone SA	Credit Suisse International	29,300	07/18/18	EUR	65.87	EUR	1,832	(2,155)
Diageo PLC	Goldman Sachs International	56,350	07/18/18	GBP	27.45	GBP	1,534	(27,917)
Experian PLC	Goldman Sachs International	181,000	07/18/18	GBP	19.09	GBP	3,383	(40,311)
Diageo PLC	Goldman Sachs International	44,600	07/25/18	GBP	27.90	GBP	1,214	(40,311) (14,539)
BP PLC	Citibank N.A.	1,175,000	07/26/18	GBP	5.96	GBP	6,780	(81,367)
CRH PLC	Citibank N.A.	36,000	07/26/18	GBP	29.14	GBP	957	(637)
Koninklijke		50,000	0//20/10	ODI	27.11	ODI	201	(057)
	Goldman Sachs International	135,800	07/26/18	EUR	37.04	EUR	4,927	(74,385)
Novo		,					.,,	(, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Nordisk A/S								
ADR	Barclays Bank PLC	35,200	07/26/18	USD	45.41	USD	1,623	(53,392)
BP PLC	Barclays Bank PLC	1,176,000	07/27/18	GBP	5.86	GBP	6,786	(147,117)
Bayer AG,								
Registered								
Shares	UBS AG	30,500	07/27/18	EUR	103.22	EUR	2,868	(7,642)
TOTAL SA								
ADR	Barclays Bank PLC	31,700	07/31/18	USD	61.39	USD	1,920	(35,273)
Samsung								
Electronics								
Co. Ltd.								
GDR	UBS AG	5,000	08/02/18	USD	1,158.42	USD	5,186	(34,431)
AstraZeneca								
PLC	Goldman Sachs International	35,500	08/08/18	GBP	52.35	GBP	1,861	(64,406)
BP PLC	Goldman Sachs International	89,200	08/08/18	GBP	5.85	GBP	515	(15,777)
Diageo PLC	Morgan Stanley & Co. International PLC	124,500	08/08/18	GBP	27.03	GBP	3,389	(136,100)
CRH PLC	UBS AG	59,900	08/09/18	GBP	28.20	GBP	1,592	(12,848)
Charles	Citibank N.A.	46,900	08/14/18	USD	57.40	USD	2,397	(12,798)
Schwab								

#### \$ (1,629,672)

## Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap			
	Premium	Premium	Unrealized	Unrealized	
	Paid	Received	Appreciation	Depreciation	Value
Options Written	N/A	N/A	\$ 6,136,175	\$ (3,917,018)	\$(15,288,978)
Derivative Financial Instruments C	ategorized by	<b>Risk Expos</b>	ure		

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	001111100	y Credit Contracts	C		xchang	y Interes e Rate	e Other		Total
Assets Derivative Financi	al								
Instruments									
Options purchased									
Investments at value									
unaffiliated <sup>(a)</sup>	\$	\$	\$	3,770	\$	\$	\$	\$	3,770
Liabilities Derivative Fin	ancial								
Instruments									
Options written									
Options written, at value	\$	\$	\$15	,288,978	\$	\$	\$	\$15	,288,978

<sup>(a)</sup> Includes options purchased at value as reported in the Schedule of Investments.

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

					Foreig	n			
				С	urrenc	y Interes	t		
	Commodity	Credit		Equity E:	xchang	e Rate	e Other		
	<b>Contracts</b>	Contracts		Contracts Co	ontract	sContract.	sContracts		Total
Net Realized Gain (Loss	s)								
from:									
Options purchased <sup>(a)</sup>	\$	\$	\$	(10,020)	\$	\$	\$	\$	(10,020)
Options written			(	9,659,803)				(	9,659,803)

Edgar							
	\$	\$	\$ (9,669,823)	\$	\$	\$	\$ (9,669,823)

<sup>(a)</sup> Options purchased are included in net realized gain (loss) from investments.

Schedules of Investments

47

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

	Commodity Contracts C	Credit Contracts		C Equity E	Foreign Currency Exchange Contracts	Interest	Other Contracts		Total
<b>Net Change in Unrealized</b> <b>Appreciation on:</b> Options purchased <sup>(a)</sup> Options written	\$	\$	\$ 6,32	575 23,305	\$	\$	\$	\$ 6,3	575 23,305
	\$	\$	\$6,32	23,880	\$	\$	\$	\$6,3	23,880

<sup>(a)</sup> Options purchased are included in net change in unrealized appreciation (depreciation) from investments. Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:		
Average value of option contracts purchased	\$	3,218
Average value of option contracts written	\$13,	467,680
For more information about the Trust s investment risks regarding derivative financial instruments	, refer to	o the Notes
to Financial Statements.		

#### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) were as follows:

	Assets	Liabilities
<b>Derivative Financial Instruments:</b> Options	\$ 3,770 <sup>(a)</sup>	\$ 15,288,978
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)	(3,770)	(13,659,306)
Total derivative assets and liabilities subject to an MNA	\$	\$ 1,629,672

<sup>(a)</sup> Includes options purchased at value which is included in Investments at value unaffiliated in the Statements of Assets and Liabilities and reported in the Schedule of Investments.

The following table presents the Trust s derivative assets and liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral received and pledged by the Trust:

Counterparty	Derivative Liabilities Subject to an MNA by Counterparty	Derivatives Available for Offset	Non-cash Collateral Pledged <sup>(a)</sup>	Cash Collateral Pledged	Net Amount of Derivative Liabilities (b)
Bank of America N.A.	\$ 137,595	\$	\$	\$	\$ 137,595
Barclays Bank PLC	239,737		(239,737)		
Citibank N.A.	567,445		(567,445)		
Credit Suisse International	23,380		(23,380)		
Goldman Sachs International	280,707		(242,630)		38,077
Morgan Stanley & Co.					
International PLC	213,588		(213,588)		
UBS AG	167,220		(167,220)		
	\$ 1,629,672	\$	\$ (1,454,000)	\$	\$ 175,672

<sup>(a)</sup> Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

<sup>(b)</sup> Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

48

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

#### Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Aerospace & Defense	\$ 20,362,289	\$	\$	\$ 20,362,289
Banks	320,396,021			320,396,021
Beverages	22,360,061	18,236,314		40,596,375
Capital Markets	61,773,184			61,773,184
Chemicals	20,782,269			20,782,269
Communications Equipment	30,150,420			30,150,420
Construction Materials		13,602,955		13,602,955
Containers & Packaging	7,067,256			7,067,256
Diversified Financial Services	5,630,652			5,630,652
Diversified Telecommunication Services	52,016,192			52,016,192
Electric Utilities	69,050,599			69,050,599
Electrical Equipment	2,740,669			2,740,669
Electronic Equipment, Instruments &				
Components	13,079,093			13,079,093
Food & Staples Retailing	12,412,451			12,412,451
Food Products	20,142,097	4,271,230		24,413,327
Health Care Equipment & Supplies	25,824,257	30,354,090		56,178,347
Health Care Providers & Services	156,160,600			156,160,600
Household Products	16,339,519			16,339,519
IT Services	6,522,994			6,522,994
Industrial Conglomerates	54,083,342			54,083,342
Insurance	112,395,166			112,395,166
Leisure Products	9,637,818			9,637,818
Machinery	4,594,715			4,594,715
Media	38,696,976			38,696,976
Multi-Utilities	23,682,460			23,682,460
Multiline Retail	5,382,278			5,382,278
Oil, Gas & Consumable Fuels	195,275,669	38,477,869		233,753,538
Personal Products	14,241,475			14,241,475
Pharmaceuticals	108,247,355	45,102,678		153,350,033

Edgar Filing: BlackRock Health	Sciences Trust -	Form N-CSRS
--------------------------------	------------------	-------------

Professional Services	10,609,609	13,093,606		23,703,215
Road & Rail	11,869,950	15,075,000		11,869,950
Semiconductors & Semiconductor	11,007,750			11,007,750
Equipment	32,156,822			32,156,822
Software	107,290,769			107,290,769
Specialty Retail	13,097,869			13,097,869
Technology Hardware, Storage &				
Peripherals		15,225,381		15,225,381
Tobacco	24,947,810			24,947,810
Short-Term Securities	13,793,172			13,793,172
Options Purchased:	- , , -			- , , -
Equity Contracts	3,770			3,770
Equity Contracts	5,110			5,110
	\$ 1,642,817,648	\$178,364,123	\$	\$ 1,821,181,771
	\$ 1,042,017,040	\$176,304,123	ψ	\$ 1,021,101,771
Investments Valued at NAV <sup>(a)</sup>				12,294
investments valueu at INA V				,
				\$1,821,194,065
Derivative Financial Instruments <sup>(b)</sup>				
Liabilities:				
Equity contracts	\$ (10,982,991)	\$ (4,305,987)	\$	\$ (15,288,978)

<sup>(a)</sup> As of June 30, 2018, certain of the Trust s Investments were fair valued using net asset value ( NAV ) per share and have been excluded from the fair value hierarchy.

<sup>(b)</sup> Derivative financial instruments are options written, which are shown at value. During the six months ended June 30, 2018, there were no transfers between levels.

See notes to financial statements.

Schedules of Investments

Schedule of Investments (unaudited)	BlackRock Enhanced Global Dividend Trust (BOE)				
June 30, 2018	(Percentages shown are based on Net Assets)				
Security Common Stocks 98.9%	Shares	Value			
Australia5.4%Amcor Ltd.Ansell Ltd.Ensogo Ltd.(a)(b)Sonic Healthcare Ltd.	2,166,058 476,285 418,198 666,385	\$23,078,661 9,569,000 3 12,088,268 44,735,932			
Belgium 1.5% Anheuser-Busch InBev SA bpost SA	60,431 373,254	6,095,366 5,897,538			
Canada 6.7% Rogers Communications, Inc., Class B TELUS Corp.	541,683 815,027	11,992,904 25,727,522 28,952,011			
China 1.0% ANTA Sports Products Ltd.	1,514,000	54,679,533 7,983,785			
<b>Denmark 1.0%</b> Novo Nordisk A/S, Class B	186,453	8,612,368			
Finland 2.3% Kone OYJ, Class B	368,057	18,714,053			
France 4.4% Sanofi Schneider Electric SE	334,985 111,650	26,885,729 9,285,566			
Germany 2.2% Deutsche Post AG, Registered Shares	545,851	36,171,295 17,734,889			
<b>India 1.0%</b> Hero MotoCorp Ltd.	167,596	8,497,945			
Ireland 1.5% Medtronic PLC <sup>(c)</sup>	143,502	12,285,206			
<b>Japan 1.0%</b> Japan Tobacco, Inc.	310,500	8,677,361			

Netherlands 2.6%		
Heineken NV	111,338	11,154,782
Koninklijke Philips NV	237,749	10,072,937
		21,227,719
Singapore 2.7%		
DBS Group Holdings Ltd.	575,568	11,193,081
United Overseas Bank Ltd.	557,900	10,934,131
		00 107 010
Sweden 1.3%		22,127,212
Sweden 1.5% Svenska Handelsbanken AB, Class A	937,035	10,378,079
Sveliska Halidelsbalikell AD, Class A	957,055	10,378,079
Switzerland 7.8%		
Nestle SA, Registered Shares	305,978	23,713,541
Novartis AG, Registered Shares	347,751	26,342,460
SGS SA, Registered Shares	5,218	13,865,236
	5,210	15,005,250
		63,921,237
Taiwan 2.4%		,,
Far EasTone Telecommunications Co. Ltd.	2,705,000	6,987,454
Taiwan Semiconductor Manufacturing Co. Ltd.	1,796,000	12,753,528
		19,740,982
United Kingdom 14.4%		
AstraZeneca PLC	241,470	16,701,799
British American Tobacco PLC	447,851	22,559,764
Diageo PLC	384,545	13,815,128
Security	Shares	Value
United Kingdom (continued)		
GlaxoSmithKline PLC	910,852 \$	18,363,626
Imperial Brands PLC	626,898	23,281,806
Unilever PLC	427,866	23,635,512
		118,357,635
United States 39.7%	75.050	14.040.450
$3M \operatorname{Co.}^{(c)}$	75,958	14,942,458
AbbVie, Inc. <sup>(c)</sup>	95,833	8,878,927
Altria Group, Inc. $^{(c)(d)}$	491,905	27,935,285
Cisco Systems, Inc. $^{(c)(d)}$	573,725	24,687,387
Citizens Financial Group, Inc. <sup>(c)</sup>	167,555	6,517,889
Coca-Cola Co. <sup>(c)</sup>	589,989	25,876,943
FirstSun Capital Bancorp, (Acquired $3/10/14$ , cost $5,461,692$ ) <sup>(a)(e)</sup>	120,312	4,411,841
Genuine Parts Co. <sup>(c)</sup>	242,320	22,242,553
International Paper Co. <sup>(c)</sup> Johnson & Johnson <sup>(c)(d)</sup>	303,694	15,816,384
	250,145	30,352,594
M&T Bank Corp. <sup>(c)</sup>	69,614 84,480	11,844,822
Microsoft Corp. <sup>(c)</sup>	84,489	8,331,460
PepsiCo, Inc. <sup>(c)</sup>	199,047	21,670,247
Pfizer, Inc. <sup>(c)(d)</sup>	463,707	16,823,290

Philip Morris International, Inc. <sup>(c)(d)</sup> Procter & Gamble Co. <sup>(c)</sup> U.S. Bancorp <sup>(c)</sup> United Parcel Service, Inc., Class B <sup>(c)</sup> United Technologies Corp. <sup>(c)</sup> Wells Fargo & Co. <sup>(c)</sup> <b>Total Common Stocks</b> 98.9% (Cost \$840,788,043)	219,915 220,742 249,836 76,232 138,181 228,446	17,755,937 17,231,121 12,496,797 8,098,125 17,276,770 12,665,046 325,855,876 811,694,011
Preferred Stocks 1.0%		
India 0.1% Jasper Infotech Private Ltd., Series F, (Acquired 05/07/14, cost 1,895,230), 0.00% <sup>(a)(b)(e)</sup> Jasper Infotech Private Ltd., Series G, (Acquired 10/29/14,	266	465,324
$\cos t 741,913$ , $0.00\%^{(a)(b)(e)}$	88	187,962
United States 0.9% Palantir Technologies, Inc., Series I (Acquired 3/27/14, cost $3,118,944$ ), $0.00\%^{(a)(b)(e)}$ Uber Technologies, Inc., Series D (Acquired 06/01/14, cost $1,611,693$ ), $0.00\%^{(a)(b)(e)}$	508,800 103,893	653,286 2,940,864 4,155,720 7,096,584
Total Preferred Stocks 1.0% (Cost \$7,367,781)		7,749,870
Total Long-Term Investments 99.9% (Cost \$848,155,824)		819,443,881
Total Investments Before Options Written 99.9% (Cost \$848,155,824)		819,443,881
Options Written (0.8)% (Premiums Received \$6,227,625)		(6,213,872)
Total Investments, Net of Options Written 99.1% (Cost \$841,928,199) Other Assets Less Liabilities 0.9%		813,230,009 7,377,581
Net Assets 100.0%		\$ 820,607,590

### BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

- <sup>(a)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
- <sup>(b)</sup> Non-income producing security.
- <sup>(c)</sup> All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- <sup>(d)</sup> All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.
- <sup>(e)</sup> Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$12,167,736 and an original cost of \$7,367,780, which was 1.5% of its net assets.

During the year ended December 31, 2017, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

						Change
		Share	25			in
	Shares	Hel	d Value		Λ	let Unrealized
	Held at	Net a	at at		Realiz	<i>etappreciation</i>
Affiliate	12/31/17	Activity06/30/1	806/30/18	Incomain	ı (Lossø	Depreciation)
BlackRock Liquidity Funds,						
T-Fund, Institutional Class <sup>(a)</sup>	13,118,524	(13,118,524)	\$	\$56,205	\$	\$

<sup>(a)</sup> No longer held by the Trust.

<sup>(b)</sup> Includes net capital gain distributions, if applicable.

#### Derivative Financial Instruments Outstanding as of Period End

#### **Exchange-Traded Options Written**

	Number of	Expiration	i	Exercise	N	otional	
Description	<i>Contracts</i>	Date		Price	Amour	nt (000)	Value
Call							
Pfizer, Inc.	18	07/02/18	USD	36.25	USD	65	\$ (358)
Cisco Systems, Inc.	314	07/06/18	USD	44.50	USD	1,351	(785)
Coca-Cola Co.	556	07/06/18	USD	44.00	USD	2,439	(12,788)
Genuine Parts Co.	151	07/06/18	USD	93.00	USD	1,386	(5,285)
International Paper Co.	181	07/06/18	USD	55.00	USD	943	(1,267)
International Paper Co.	93	07/06/18	USD	56.00	USD	484	(372)
Johnson & Johnson	344	07/06/18	USD	122.00	USD	4,174	(24,252)
Pfizer, Inc.	19	07/06/18	USD	36.00	USD	69	(845)
Pfizer, Inc.	104	07/06/18	USD	36.50	USD	377	(1,352)

Pfizer, Inc.	38	07/06/18	USD	37.00	USD	138	(171)
U.S. Bancorp	245	07/06/18	USD	52.50	USD	1,225	(490)
U.S. Bancorp	34	07/06/18	USD	53.00	USD	170	(340)
United Technologies Corp.	245	07/06/18	USD	128.00	USD	3,063	(3,675)
Wells Fargo & Co.	103	07/06/18	USD	55.50	USD	571	(6,334)
Wells Fargo & Co.	175	07/06/18	USD	55.00	USD	970	(15,838)
Altria Group, Inc.	478	07/13/18	USD	57.50	USD	2,715	(26,529)
Cisco Systems, Inc.	598	07/13/18	USD	45.00	USD	2,573	(3,588)
Coca-Cola Co.	158	07/13/18	USD	44.00	USD	693	(6,320)
Genuine Parts Co.	180	07/13/18	USD	92.00	USD	1,652	(23,400)
Genuine Parts Co.	163	07/13/18	USD	95.50	USD	1,496	(2,852)
International Paper Co.	181	07/13/18	USD	55.50	USD	943	(1,900)
Medtronic PLC	110	07/13/18	USD	88.50	USD	942	(1,210)
Microsoft Corp.	76	07/13/18	USD	103.00	USD	749	(1,824)
Microsoft Corp.	82	07/13/18	USD	102.00	USD	809	(3,280)
PepsiCo, Inc.	6	07/13/18	USD	102.00	USD	65	(4,320)
Pfizer, Inc.	156	07/13/18	USD	36.50	USD	566	(4,446)
Pfizer, Inc.	39	07/13/18	USD	37.00	USD	141	(429)
Procter & Gamble Co.	306	07/13/18	USD	74.00	USD	2,389	(132,345)
U.S. Bancorp	101	07/13/18	USD	50.50	USD	505	(4,898)
U.S. Bancorp	34	07/13/18	USD	52.50	USD	170	(187)
U.S. Bancorp	147	07/13/18	USD	51.00	USD	735	(4,336)
U.S. Bancorp	73	07/13/18	USD	51.50	USD	365	(1,241)
Wells Fargo & Co.	93	07/13/18	USD	56.50	USD	516	(6,231)
Wells Fargo & Co.	175	07/19/18	USD	56.25	USD	970	(16,699)
3M Co.	234	07/20/18	USD	200.00	USD	4,603	(51,831)
AbbVie, Inc.	67	07/20/18	USD	100.00	USD	621	(1,440)
Altria Group, Inc.	620	07/20/18	USD	57.50	USD	3,521	(50,840)
Cisco Systems, Inc.	811	07/20/18	USD	45.00	USD	3,490	(11,354)
Cisco Systems, Inc.	361	07/20/18	USD	44.00	USD	1,553	(12,094)
Citizens Financial Group, Inc.	507	07/20/18	USD	42.95	USD	1,972	(3,791)
Coca-Cola Co.	557	07/20/18	USD	44.00	USD	2,443	(28,686)

Schedules of Investments

51

## BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	1	Exercise	N	otional	
Description	Contracts	Date		Price	Amour	ıt (000)	Value
Call (continued)							
Genuine Parts Co.	151	07/20/18	USD	92.50	USD	1,386	\$ (26,803)
Genuine Parts Co.	163	07/20/18	USD	97.50	USD	1,496	(4,482)
International Paper Co.	153	07/20/18	USD	57.50	USD	797	(918)
Johnson & Johnson	286	07/20/18	USD	125.00	USD	3,470	(24,310)
M&T Bank Corp.	164	07/20/18	USD	190.00	USD	2,790	(2,460)
M&T Bank Corp.	163	07/20/18	USD	180.00	USD	2,773	(11,410)
Medtronic PLC	167	07/20/18	USD	87.50	USD	1,430	(7,432)
Microsoft Corp.	88	07/20/18	USD	100.00	USD	868	(17,776)
PepsiCo, Inc.	225	07/20/18	USD	102.95	USD	2,450	(138,873)
Pfizer, Inc.	612	07/20/18	USD	36.00	USD	2,220	(41,922)
Pfizer, Inc.	253	07/20/18	USD	35.00	USD	918	(37,444)
Pfizer, Inc.	158	07/20/18	USD	37.00	USD	573	(3,081)
Philip Morris International, Inc.	316	07/20/18	USD	85.00	USD	2,551	(20,540)
Procter & Gamble Co.	57	07/20/18	USD	76.00	USD	445	(14,250)
Rogers Communications, Inc.,							
Class B	247	07/20/18	CAD	62.00	CAD	1,542	(21,794)
TELUS Corp.	127	07/20/18	CAD	46.00	CAD	584	(9,322)
U.S. Bancorp	146	07/20/18	USD	51.50	USD	730	(5,402)
United Parcel Service, Inc.	57	07/20/18	USD	120.00	USD	606	(256)
Wells Fargo & Co.	93	07/20/18	USD	55.00	USD	516	(14,694)
3M Co.	34	07/27/18	USD	200.00	USD	669	(12,835)
AbbVie, Inc.	158	07/27/18	USD	102.00	USD	1,464	(4,582)
Cisco Systems, Inc.	998	07/27/18	USD	45.00	USD	4,294	(20,958)
Coca-Cola Co.	751	07/27/18	USD	44.50	USD	3,294	(39,803)
International Paper Co.	66	07/27/18	USD	59.00	USD	344	(594)
Medtronic PLC	177	07/27/18	USD	86.50	USD	1,515	(17,523)
Microsoft Corp.	76	07/27/18	USD	103.00	USD	749	(8,588)
Microsoft Corp.	55	07/27/18	USD	101.00	USD	542	(10,038)
PepsiCo, Inc.	223	07/27/18	USD	106.00	USD	2,428	(91,430)
Pfizer, Inc.	320	07/27/18	USD	37.00	USD	1,161	(8,640)
Pfizer, Inc.	26	07/27/18	USD	36.50	USD	94	(1,261)
U.S. Bancorp	77	07/27/18	USD	52.00	USD	385	(2,541)
United Parcel Service, Inc., Class	B 301	07/27/18	USD	118.00	USD	3,198	(7,374)
United Technologies Corp.	112	07/27/18	USD	128.00	USD	1,400	(16,800)
Wells Fargo & Co.	42	07/27/18	USD	56.50	USD	233	(4,158)
Pfizer, Inc.	25	07/30/18	USD	36.75	USD	91	(1,093)
Pfizer, Inc.	54	07/30/18	USD	36.50	USD	196	(2,622)
Cisco Systems, Inc.	360	07/31/18	USD	44.60	USD	1,549	(12,170)

A 1 1 X 7' X		00/02/10	LICD	05.50	LICD	(01	(10.50())
AbbVie, Inc.	67	08/03/18	USD	95.50	USD	621	(12,596)
Altria Group, Inc.	3	08/03/18	USD	58.50	USD	17	(279)
International Paper Co.	400	08/03/18	USD	54.50	USD	2,083	(32,400)
Johnson & Johnson	122	08/03/18	USD	126.00	USD	1,480	(12,566)
Medtronic PLC	110	08/03/18	USD	86.50	USD	942	(13,145)
Microsoft Corp.	45	08/03/18	USD	102.00	USD	444	(7,493)
Pfizer, Inc.	151	08/03/18	USD	36.50	USD	548	(9,136)
Procter & Gamble Co.	216	08/03/18	USD	78.50	USD	1,686	(29,700)
Wells Fargo & Co.	150	08/03/18	USD	55.00	USD	832	(27,075)
Genuine Parts Co.	152	08/10/18	USD	93.00	USD	1,395	(25,840)
Medtronic PLC	110	08/10/18	USD	87.00	USD	942	(12,980)
Microsoft Corp.	55	08/10/18	USD	102.00	USD	542	(10,285)
Pfizer, Inc.	54	08/10/18	USD	36.50	USD	196	(3,510)
U.S. Bancorp	97	08/10/18	USD	50.00	USD	485	(13,241)
Wells Fargo & Co.	92	08/10/18	USD	58.00	USD	510	(5,934)
3M Co.	89	08/17/18	USD	210.00	USD	1,751	(16,198)
AbbVie, Inc.	158	08/17/18	USD	105.00	USD	1,464	(8,058)
Altria Group, Inc.	620	08/17/18	USD	59.20	USD	3,521	(63,949)
Coca-Cola Co.	750	08/17/18	USD	45.00	USD	3,290	(38,250)
Genuine Parts Co.	178	08/17/18	USD	95.00	USD	1,634	(28,035)
International Paper Co.	353	08/17/18	USD	55.00	USD	1,838	(28,770)
Johnson & Johnson	123	08/17/18	USD	125.00	USD	1,492	(22,017)
Microsoft Corp.	29	08/17/18	USD	105.00	USD	286	(3,248)
PepsiCo, Inc.	481	08/17/18	USD	105.00	USD	5,237	(263,348)
Pfizer, Inc.	152	08/17/18	USD	37.00	USD	551	(6,992)

### BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

### **Exchange-Traded Options Written (continued)**

	Number of	Expiration	i	Exercise	N	otional	
Description	Contracts	Date		Price	Amour	nt (000)	Value
Call (continued)							
Philip Morris International, Inc.	534	08/17/18	USD	82.50	USD	4,312	\$ (113,742)
Procter & Gamble Co.	458	08/17/18	USD	77.50	USD	3,575	(97,783)
Rogers Communications, Inc.,							
Class B	750	08/17/18	CAD	64.00	CAD	4,683	(38,794)
TELUS Corp.	666	08/17/18	CAD	46.00	CAD	3,110	(65,605)
U.S. Bancorp	220	08/17/18	USD	52.50	USD	1,100	(10,340)
United Technologies Corp.	126	08/17/18	USD	125.00	USD	1,575	(46,305)
Wells Fargo & Co.	150	08/17/18	USD	55.00	USD	832	(29,850)

\$ (2,243,866)

### **OTC Options Written**

	Λ	Number of	Expiration		Exercise		Notional		
escription	Counterparty	Contracts	Date		Price	Ame	ount (000)		Value
all									
ELUS Corp.	Goldman Sachs International	7,641	07/09/18	CAD	46.27	CAD	357	\$	(3,616
BS Group Holdings									
td.	Deutsche Bank AG	68,000	07/10/18	SGD	29.99	SGD	1,802		(42
BS Group Holdings									
td.	Deutsche Bank AG	67,000	07/10/18	SGD	29.91	SGD	1,776		(49
iageo PLC	Goldman Sachs International	12,800	07/10/18	GBP	26.86	GBP	348	(	10,204
ar EasTone									
elecommincations									
o. Ltd.	Goldman Sachs International	136,000	07/10/18	USD	75.75	USD	10,711	(	13,329
eineken NV	UBS AG	24,000	07/10/18	EUR	86.63	EUR	2,059	(	18,269
GS SA, Registered									
nares	Goldman Sachs International	1,300	07/10/18	CHF	2,577.54	CHF	3,421	(	92,472
chneider Electric									
E	UBS AG	22,000	07/10/18	EUR	79.66	EUR	1,567		(131
post SA	Credit Suisse International	15,800	07/10/18	EUR	17.43	EUR	214		(9
straZeneca PLC	UBS AG	69,200	07/11/18	GBP	55.20	GBP	3,627		(4,820
eutsche Post AG,									
egistered Shares	Goldman Sachs International	128,000	07/11/18	EUR	33.57	EUR	3,561		(37
-	Morgan Stanley & Co. International PLC	218,000	07/11/18	USD	77.89	USD	17,170		(8,820

o. Ltd.								
oninklijke Philips								
V	Morgan Stanley & Co. International PLC	112,000	07/11/18	EUR	36.27	EUR	4,063	(73,730
ovo Nordisk A/S,								
lass B	Goldman Sachs International	26,100	07/11/18	DKK	306.74	DKK	7,691	(3,329
ogers								
ommunications,								
c., Class B	Morgan Stanley & Co. International PLC	44,000	07/11/18	CAD	63.00	CAD	2,747	(15,666
nsell Ltd.	JPMorgan Chase Bank N.A.	24,200	07/12/18	AUD	26.93	AUD	657	(8,916
ritish American								
obacco PLC	Citibank N.A.	210,900	07/12/18	GBP	39.09	GBP	8,050	(97,123
pan Tobacco, Inc.	Goldman Sachs International	41,200	07/12/18	JPY	3,040.60	JPY	127,477	(30,331
one OYJ, Class B	UBS AG	38,800	07/12/18	EUR	43.39	EUR	1,689	(38,679
ELUS Corp.	Citibank N.A.	32,400	07/13/18	CAD	46.34	CAD	1,513	(16,442
mcor Ltd.	Goldman Sachs International	256,000	07/18/18	AUD	13.88	AUD	3,686	(109,795
nheuser-Busch		<b>2</b> 0 <b>5</b> 00	0=110110	EUD	02.00		2.462	(101.004
Bev SA	Morgan Stanley & Co. International PLC	28,500	07/18/18	EUR	83.88	EUR	2,462	(101,994
nsell Ltd.	Goldman Sachs International	27,000	07/18/18	AUD	26.80	AUD	733	(12,577
eutsche Post AG,		(1.000	07/10/10		22.40		1 700	(614
egistered Shares	Credit Suisse International	64,000	07/18/18	EUR	33.48	EUR	1,780	(614
ar EasTone								
elecommunications	Caldman Sasha International	270.000	07/10/10	UCD	77 12	UCD	20 141	(22.802
o. Ltd.	Goldman Sachs International	370,000	07/18/18	USD	77.13	USD	29,141	(22,892
nperial Brands PLC		65,400	07/18/18 07/18/18	GBP	26.85	GBP	1,840	(126,258
one OYJ, Class B anofi	Credit Suisse International Morgan Stanlay, & Co. International BLC	46,000 28,150	07/18/18	EUR EUR	43.47 65.82	EUR EUR	2,003 1,935	(51,419
chneider Electric	Morgan Stanley & Co. International PLC	28,130	0//10/10	EUK	03.82	EUK	1,955	(108,851
	Barclays Bank PLC	8,500	07/18/18	EUR	76.74	EUR	605	(699
ELUS Corp.	Citibank N.A.	16,700	07/18/18	CAD	45.85	CAD	780	(13,682
nited Overseas	Chibalik N.A.	10,700	0//10/10	CAD	45.65	CAD	780	(15,082
ank Ltd.	JPMorgan Chase Bank N.A.	139,000	07/18/18	SGD	28.67	SGD	3,711	(4,316
post SA	Credit Suisse International	42,000	07/18/18	EUR	15.21	EUR	568	(4,310)
NTA Sports	creant Suisse International	42,000	07/10/10	LUK	13.21	LUK	500	(740
roducts Ltd.	Goldman Sachs International	206,000	07/19/18	HKD	44.78	HKD	8,522	(16,373
ovartis AG,	Goldman Sachs International	200,000	0//19/10	IIKD	44.70	IIKD	0,322	(10,373
egistered Shares	Morgan Stanley & Co. International PLC	106 400	07/19/18	CHF	76.10	CHF	7,982	(79,253
onic Healthcare	Worgan Stanie'y & Co. International TEC	100,400	0//1//10	CIII	70.10	CIII	7,702	(1),200
td.	UBS AG	68,700	07/24/18	AUD	23.80	AUD	1,684	(45,937
nited Overseas	000110	00,700	0//24/10	neb	23.00	neb	1,001	(13,757
ank Ltd.	UBS AG	123,300	07/24/18	SGD	29.32	SGD	3,292	(2,207
NTA Sports	020110	120,000	0//2//10	502	27.52	502	5,272	(2,207
oducts Ltd.	UBS AG	295,000	07/25/18	HKD	49.34	HKD	12,204	(6,819
nsell Ltd.	Morgan Stanley & Co. International PLC	33,500	07/25/18	AUD	26.66	AUD	910	(20,674
iageo PLC	Goldman Sachs International	68,800	07/25/18	GBP	27.90	GBP	1,873	(22,428
laxoSmithKline		00,000	01120110	021		021	1,070	(,
LC	Citibank N.A.	99,900	07/25/18	GBP	15.50	GBP	1,526	(23,619
eineken NV	Deutsche Bank AG	28,300	07/25/18	EUR	87.76	EUR	2,428	(24,416
one OYJ, Class B	UBS AG	12,000	07/25/18	EUR	42.77	EUR	522	(20,691
estle SA,		,000	<b>_</b> 2,10		,,			(_0,0)1
egistered Shares	Morgan Stanley & Co. International PLC	73,000	07/25/18	CHF	76.40	CHF	5,603	(96,268
-Distored Shares	UBS AG	61,600	07/25/18	DKK	308.50	DKK	18,153	(17,246
		,000			2 3 0 . 2 0		,	(=,,=,0

ovo Nordisk A/S,								
lass B								
anofi	UBS AG	58,100	07/25/18	EUR	67.27	EUR	3,993	(153,582
onic Healthcare								ļ
td.	UBS AG	60,300	07/25/18	AUD	24.52	AUD	1,478	(21,816
venska								
andelsbanken AB,								
lass A	UBS AG	206,500	07/25/18	SEK	101.02	SEK	20,485	(35,170
1								

SCHEDULES OF INVESTMENTS

53

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

## **OTC Options Written (continued)**

scription		Number of Contracts	Expiration Date		Exercise Price	Am	Notional ount (000)	Valu
ll (continued)								
LUS Corp.	Citibank N.A.	29,200	07/25/18	CAD	46.49	CAD	1,364	\$ (15,35
iwan								
miconductor anufacturing Co.								
1.	UBS AG	844,000	07/25/18	USD	228.60	USD	182,726	(29,47)
ost SA	Deutsche Bank AG	24,200	07/25/18	EUR	16.07	EUR	327	(44.
NTA Sports								
oducts Ltd.	JPMorgan Chase Bank N.A.	192,000	07/26/18	HKD	50.34	HKD	7,943	(2,94
ncor Ltd.	UBS AG	398,100	07/26/18	AUD	14.13	AUD	5,733	(126,21)
sell Ltd.	Morgan Stanley & Co. International PLC	31,200	07/26/18	AUD	27.05	AUD	847	(13,32
r EasTone	-							
lecommunications								
. Ltd.	Citibank N.A.	297,000	07/26/18	USD	78.15	USD	23,392	(13,29
r EasTone								1
lecommunications								
. Ltd.	Goldman Sachs International	250,000	07/26/18	USD	78.76	USD	19,690	(8,65
vartis AG,								· · · · · ·
gistered Shares	Morgan Stanley & Co. International PLC	18,250	07/26/18	CHF	75.85	CHF	1,369	(18,18
ilever PLC	Citibank N.A.	141,100	07/26/18	GBP	41.71	GBP	5,906	(174,67
LUS Corp.	Goldman Sachs International	24,300	07/27/18	CAD	46.23	CAD	1,135	(16,40)
LUS Corp.	Goldman Sachs International	24,300	07/31/18	CAD	46.46	CAD	1,135	(14,33
sell Ltd.	Citibank N.A.	32,000	08/01/18	AUD	26.57	AUD	869	(24,55
utsche Post AG,		- ,						
gistered Shares	HSBC Bank PLC	64,500	08/01/18	EUR	28.30	EUR	1,794	(46,69
ne OYJ, Class B	Credit Suisse International	46,000	08/01/18	EUR	43.47	EUR	2,003	(60,57)
nic Healthcare		10,000	00/01/10	2011	10111	2011	-,	(00,01
1	Morgan Stanley & Co. International PLC	95,000	08/01/18	AUD	24.40	AUD	2,328	(38,38
LUS Corp.	Citibank N.A.	29,200	08/01/18	CAD	46.49	CAD	1,364	(18,65)
ost SA	Credit Suisse International	59,400	08/01/18	EUR	15.15	EUR	804	(4,24)
gers	Credit Subse memutoha	57,100	00/01/10	LUK	10,10	LUK		( 1,2 .
mmunications,								ļ
., Class B	Morgan Stanley & Co. International PLC	55,400	08/02/18	CAD	62.10	CAD	3,459	(55,61
LUS Corp.	Goldman Sachs International	33,800	08/02/18	CAD	47.00	CAD	1,578	(10,60
S SA, Registered		33,000	00/03/10	CAD	47.00	CAD	1,370	(10,00
ares	UBS AG	1,100	08/07/18	CHF	2,574.49	CHF	2,895	(101,34
sell Ltd.	Citibank N.A.	32,000	08/08/18	AUD	26.57	AUD	869	(26,60
traZeneca PLC	Goldman Sachs International	44,300	08/08/18	GBP	52.35	GBP	2,322	(80,37
	UBS AG	135,000	08/08/18	SGD	27.16	SGD	3,578	(47,79
1								

S Group Holdings								
1.								
ageo PLC axoSmithKline	Morgan Stanley & Co. International PLC	99,500	08/08/18	GBP	27.03	GBP	2,708	(108,77
С	Morgan Stanley & Co. International PLC	328,200	08/08/18	GBP	15.25	GBP	5,015	(164,19
perial Brands PLC	UBSAG	155,000	08/08/18	GBP	27.66	GBP	4,362	(219,95
an Tobacco, Inc.	Goldman Sachs International	71,700	08/08/18	JPY	3,078.48	JPY	221,846	(57,42
ne OYJ, Class B	Credit Suisse International	30,100	08/08/18	EUR	43.32	EUR	1,311	(45,58
nofi nneider Electric	Morgan Stanley & Co. International PLC	71,100	08/08/18	EUR	69.52	EUR	4,887	(100,39
nic Healthcare	Morgan Stanley & Co. International PLC	22,000	08/08/18	EUR	71.59	EUR	1,567	(48,91
	JPMorgan Chase Bank N.A.	89,300	08/08/18	AUD	25.08	AUD	2,189	(20,59
n. enska	JE WOIgall Chase Dalik IV.A.	69,500	00/00/10	AUD	23.00	AUD	2,107	(20,5)
ndelsbanken AB,								
ass A	JPMorgan Chase Bank N.A.	234,000	08/08/18	SEK	98.45	SEK	23,213	(72,72
ilever PLC	Goldman Sachs International	60,000	08/08/18	GBP	41.88	GBP	2,512	(61,67
LUS Corp.	Citibank N.A.	16,600	08/09/18	CAD	45.90	CAD	775	(16,22
JTA Sports								
oducts Ltd.	Goldman Sachs International	215,000	08/10/18	HKD	41.32	HKD	8,895	(75,47
sell Ltd.	Citibank N.A.	31,200	08/14/18	AUD	26.94	AUD	847	(21,10
vartis AG,								
gistered Shares stle SA,	Morgan Stanley & Co. International PLC	38,800	08/14/18	CHF	73.40	CHF	2,911	(113,21
gistered Shares	Morgan Stanley & Co. International PLC	70,800	08/15/18	CHF	77.24	CHF	5,434	(92,45
LUS Corp.	Royal Bank of Canada	30,600	08/15/18	CAD	47.24	CAD	1,429	(14,75
ncor Ltd. izens Financial	JPMorgan Chase Bank N.A.	364,000	08/16/18	AUD	14.52	AUD	5,242	(82,60
oup, Inc.	Morgan Stanley & Co. International PLC	28,000	08/20/18	USD	41.84	USD	1,089	(15,17
sell Ltd. gers	Morgan Stanley & Co. International PLC	12,800	08/22/18	AUD	27.62	AUD	348	(4,79
mmunications,								
., Class B	Citibank N.A.	55,400	08/28/18	CAD	62.50	CAD	3,459	(64,02
LUS Corp.	Royal Bank of Canada	59,000	08/29/18	CAD	46.70	CAD	2,755	(44,83

\$(3,970,00

## Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap			
	Premium	Premium	Unrealized	Unrealized	
	Paid	Received	Appreciation	Depreciation	Value
Options Written	N/A	N/A	\$ 1,779,580	\$ (1,765,827)	\$(6,213,872)

#### BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

#### Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

		~	C	Foreign Currenc	y Interest		
	Commodity	Credit	Equity E	0		Other	
Liabilities Derivative Financial Instruments Options written	Contracts (	Contracts	Contracts C	ontract	s Contracts	Contracts	Total
Options written at value	\$	\$	\$6,213,872	\$	\$	\$	\$6,213,872

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodit Contract	y Credit sContracts	Co	C EquityEx	0	y Interest	Other		Total
Net Realized Gain (Loss) fr Options purchased <sup>(a)</sup>	om: \$	\$	\$	(687)	¢	\$	\$	\$	(687)
Options written	φ	Ψ		305,969	ψ	ψ	Ψ		(087) 605,969
	\$	\$	\$2,3	305,282	\$	\$	\$	\$2,3	05,282

<sup>(a)</sup> Options purchased are included in net realized gain (loss) from investments.

Net Change in Unrealized				
Appreciation on:				
Options written	\$ \$	\$ (63,217)	\$ \$	\$ \$ (63,217)

#### Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:	
Average value of option contracts purchased	\$ (a)

Average value of option contracts written

\$5,532,778

<sup>(a)</sup> Derivative not held at quarter-end. The amount shown in the Statements of Operations reflect the results of activity during the period.

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

#### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

	Assets	Liabilities
<b>Derivative Financial Instruments:</b> Options	\$	\$ 6,213,872
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA	)	(2,243,866)
Total derivative assets and liabilities subject to an MNA	\$	\$ 3,970,006

The following table presents the Trust s derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

Counterparty	Lic Su an N		Derivatives Available for Offset	Ca	on-cash ollateral edged <sup>(a)</sup>	Cash Collateral Pledged	Net Amount of Derivative Liabilities (b)
Barclays Bank PLC	\$	699	\$	\$	(699)	\$	\$
Citibank N.A.	4	525,371		(.	525,371)		
Credit Suisse International	1	63,196		(	163,196)		
Deutsche Bank AG		24,952			(24,952)		
Goldman Sachs International	e	662,326		(	662,326)		
HSBC Bank PLC	]	72,956					172,956
JPMorgan Chase Bank N.A.	1	92,104		(	138,470)	(53,634)	
Morgan Stanley & Co.						,	
International PLC	1,2	278,672		(1,	278,672)		

Schedules of Investments

Schedule of Investments (unaudited) (continued) BlackRock Enhanced G

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

<i>Counterparty</i> Royal Bank of Canada UBS AG	Derivative Liabilities Subject to an MNA by Counterparty \$ 59,582 890,148	Derivatives Available for Offset \$	Non-cash Collateral Pledged <sup>(a)</sup> \$ (890,148)	Cash Collateral Pledged \$	Net Amount of Derivative Liabilities (b) \$ 59,582
UBS AG	890,148		(890,148)		
	\$ 3,970,006	\$	\$ (3,683,834)	\$ (53,634)	\$ 232,538

<sup>(a)</sup> Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

<sup>(b)</sup> Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

#### Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Australia	\$	\$ 44,735,932	\$	\$ 44,735,932
Belgium	5,897,538	6,095,366		11,992,904
Canada	54,679,533			54,679,533
China		7,983,785		7,983,785
Denmark		8,612,368		8,612,368
Finland		18,714,053		18,714,053
France		36,171,295		36,171,295
Germany		17,734,889		17,734,889
India		8,497,945		8,497,945
Ireland	12,285,206			12,285,206
Japan		8,677,361		8,677,361
Netherlands		21,227,719		21,227,719
Singapore		22,127,212		22,127,212
Sweden		10,378,079		10,378,079
Switzerland		63,921,237		63,921,237

Taiwan United Kingdom United States Preferred Stocks	321,444,035	19,740,982 118,357,635	4,411,841 7,749,870	19,740,982 118,357,635 325,855,876 7,749,870
	\$ 394,306,312	\$412,975,858	\$12,161,711	\$819,443,881
Derivative Financial Instruments <sup>(a)</sup> Liabilities: Equity contracts	\$ (1,994,988)	\$ (4,218,884)	\$	\$ (6,213,872)

<sup>(a)</sup> Derivative financial instruments are options written, which are shown at value. Transfers between Level 1 and Level 2 were as follows:

	Transfers into Level 1 <sup>(a)</sup>	Transfers out of Level 1 <sup>(a)</sup>	Transfers Into Level 2 <sup>(a)</sup>	Transfers out of Level 2 <sup>(a)</sup>
Assets: Long-Term Investments:				
Common Stocks	\$ 11,359,711	\$ 19,072,931	\$ 19,072,931	\$ 11,359,711

 (a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

56

### BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

Assets:         Opening Balance, as of December 31, 2017         \$ 4,411,841         \$ 11,646,491         \$ 16,058,332           Transfers into Level 3         \$ 4,411,841         \$ 11,646,491         \$ 16,058,332
Transfers into Level 3
Transfers out of Level 3
Accrued discounts/premiums
Net realized gain (loss)         2,510,578         2,510,578
Net change in unrealized appreciation (depreciation) <sup>(a)(b)</sup> $(1,662,515)$ $(1,662,515)$
Purchases
Sales (4,744,684) (4,744,684)
Closing Balance, as of June 30, 2018 \$4,411,841 \$7,749,870 \$12,161,711
Net change in unrealized appreciation (depreciation) on
investments still held at June 30, 2018 <sup>(b)</sup> \$ (1,662,515) \$ (1,662,515)

<sup>(a)</sup> Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

(b) Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on derivative financial instruments still held at June 30, 2018 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee ) to determine the value of certain of the Trust s Level 3 investments as of period end.

						Weighted Average
					ange of ervableUne	of observable
	Value	Valuation A	App <b>&amp;mabs</b> ervable Inputs	Inputs U	Itilized	Inputs
Assets: Common						
Stocks Preferred	\$ 4,411,841	Market	Tangible Book Value Multiple <sup>(a)</sup>		1.90x	
Stocks	7,749,870	Market	Revenue Multiple <sup>(a)</sup>	7.50x	14.50x	13.23x

Time to Exit<sup>(b)</sup> Volatility<sup>(b)</sup> Recent Transactions<sup>(a)</sup> 2.5 years 35%

### \$12,161,711

- <sup>(a)</sup> Increase in unobservable input may result in a significant increase to value, while a decrease in the unobservable input may result in a significant decrease to value.
- (b) Decrease in unobservable input may result in a significant increase to value, while an increase in the unobservable input may result in a significant decrease to value.
- See notes to financial statements.

Schedules of Investments

Schedule of Investments (unaudited)	BlackRock Enhanced International Dividend Trust (BGY)						
June 30, 2018	(Percentages shown are based	l on Net Assets)					
Security Common Stocks 98.7%	Shares	Value					
Australia 8.7% Amcor Ltd. Ansell Ltd. Sonic Healthcare Ltd.	3,033,685 657,064 816,976	\$ 32,322,952 13,201,015 14,819,998					
Belgium 2.3%		60,343,965					
Anheuser-Busch InBev SA bpost SA	82,168 506,122	8,287,867 7,996,897					
		16,284,764					
Canada 10.6% Rogers Communications, Inc., Class B TELUS Corp.	743,612 1,076,118	35,318,247 38,226,684					
		73,544,931					
China 1.8% ANTA Sports Products Ltd.	2,377,600	12,537,812					
<b>Denmark</b> 1.7% Novo Nordisk A/S, Class B	252,763	11,675,264					
Finland 3.8% Kone OYJ, Class B	521,612	26,521,638					
France 7.3% Sanofi	459,696	36,894,971					
Schneider Electric SE	164,273	13,662,050					
Germany 4.3%		50,557,021					
Deutsche Post AG, Registered Shares	928,368	30,162,999					
India 1.7% Hero MotoCorp Ltd.	225,738	11,446,031					
<b>Japan 1.7%</b> Japan Tobacco, Inc.	421,300	11,773,823					
Netherlands 4.3% Heineken NV Koninklijke Philips NV	149,488 347,780	14,976,972 14,734,724					

Simon 2007		29,711,696
Singapore 2.9%	511 200	0.042.200
DBS Group Holdings Ltd.	511,300	9,943,260
United Overseas Bank Ltd.	507,200	9,940,475
		10 002 725
		19,883,735
Sweden 2.3%	1 451 000	16 005 555
Svenska Handelsbanken AB, Class A	1,471,323	16,295,557
Switzerland 13.0%	100 ((0	
Nestle SA, Registered Shares	430,668	33,377,116
Novartis AG, Registered Shares	486,345	36,841,085
SGS SA, Registered Shares	7,522	19,987,410
		90,205,611
Taiwan 4.3%		90,203,011
Far EasTone Telecommunications Co. Ltd.	3,663,000	9,462,123
Taiwan Semiconductor Manufacturing Co. Ltd.	2,845,000	20,202,554
č	, ,	, ,
		29,664,677
United Kingdom 23.4%		
AstraZeneca PLC	310,495	21,476,063
British American Tobacco PLC	608,013	30,627,664
Diageo PLC	596,483	21,429,193
GlaxoSmithKline PLC	1,291,186	26,031,515
Imperial Brands PLC	850,881	31,600,110
Unilever PLC	562,299	31,061,652
		- , ,
		162,226,197
Security	Shares	Value
United States 4.6%		
3M Co. <sup>(a)</sup>	102,009 \$	20,067,210
Microsoft Corp. <sup>(a)</sup>	116,534	11,491,418
1	,	, ,
		31,558,628
Total Common Stocks 98.7%		
(Cost \$715,814,039)		684,394,349
Preferred Stocks 0.7%		
China 0.6%		
Xiaoju Kuaizhi, Inc., Series A-17		
(Acquired 7/28/15, cost \$2,106,332),		
0.00%(b)(c)(d)	76 800	3 911 424
0.00% <sup>(b)(c)(d)</sup>	76,800	3,911,424
	76,800	3,911,424
India 0.1%	76,800	3,911,424
India 0.1% Jasper Infotech Private Ltd., Series F,	76,800	3,911,424
India 0.1% Jasper Infotech Private Ltd., Series F, (Acquired 5/7/14, cost \$2,835,730),		
India 0.1% Jasper Infotech Private Ltd., Series F,	76,800 398	3,911,424 696,237

Jasper Infotech Private Ltd., Series G, (Acquired 10/29/14, cost \$1,112,870),		
$0.00\%^{(b)(c)(d)}$	132	281,943
		978,180
Total Preferred Stocks 0.7% (Cost \$6,054,932)		4,889,604
Total Long-Term Investments 99.4% (Cost \$721,868,971)		689,283,953
<b>Short-Term Securities</b> 0.1% BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% <sup>(e)(f)</sup>	943,659	943,659
Total Short-Term Securities 0.1% (Cost \$943,659)		943,659
Total Investments Before Options Written 99.5% (Cost \$722,812,630)		690,227,612
Options Written (0.8)% (Premiums Received \$5,304,238)		(5,608,380)
Total Investments, Net of Options Written 98.7% (Cost \$717,508,392) Other Assets Less Liabilities 1.3%		684,619,232 8,816,866
Net Assets 100.0%		\$ 693,436,098

<sup>(a)</sup> All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

<sup>(b)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

<sup>(c)</sup> Non-income producing security.

<sup>(d)</sup> Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$4,889,604 and an original cost of \$6,054,935, which was 0.7% of its net assets.

<sup>(e)</sup> Annualized 7-day yield as of period end.

Schedule of Investments (unaudited) (continued)BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

(e) During the period ended June 30, 2018, investments in issuers considered to be an affiliate of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

							Change	
							in	
	Shares		Shares				Ne <b>W</b> nrealized	
	Held at	Net	Held at	Value at		Realiz <b>ep</b> preciation		
Affiliate	12/31/17	Activity	06/30/18	06/30/18	Inc <b>Gmin</b>	(Loss	Depreciation)	
BlackRock Liquidity Funds,								
T-Fund, Institutional Class	5,073,700	(4,130,041)	943,659	\$943,659	\$ 53,789	\$	\$	

<sup>(a)</sup> Includes net capital gain distributions, if applicable.

For Trust compliance purposes, the Trust s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

#### Derivative Financial Instruments Outstanding as of Period End

#### **Exchange-Traded Options Written**

Description	Number of Contracts	Expiration Date		ercise Price		otional at (000)	Value
Call							
Microsoft Corp.	100	07/06/18	USD 1	01.00	USD	986	\$ (2,250)
Microsoft Corp.	71	07/13/18	USD 1	03.00	USD	700	(1,704)
Microsoft Corp.	80	07/13/18	USD 1	02.00	USD	789	(3,200)
3M Co.	268	07/20/18	USD 2	200.00	USD	5,272	(59,362)
Rogers Communications, Inc.,							
Class B	819	07/20/18	CAD	62.00	CAD	5,114	(72,266)
TELUS Corp.	265	07/20/18	CAD	46.00	CAD	1,238	(19,452)
3M Co.	60	07/27/18	USD 2	210.00	USD	1,180	(5,940)
3M Co.	34	07/27/18	USD 2	200.00	USD	669	(12,835)
Microsoft Corp.	71	07/27/18	USD 1	03.00	USD	700	(8,023)
Microsoft Corp.	299	08/03/18	USD 1	02.00	USD	2,948	(49,783)
3M Co.	117	08/17/18	USD 2	210.00	USD	2,302	(21,294)
Microsoft Corp.	57	08/17/18	USD 1	05.00	USD	562	(6,384)
Rogers Communications, Inc.,							
Class B	970	08/17/18	CAD	64.00	CAD	6,057	(50,173)
TELUS Corp.	947	08/17/18	CAD	46.00	CAD	4,422	(93,285)

# \$ (405,951)

## **OTC Options Written**

	1	Number of	Expiration		Exercise		Notional	
n	Counterparty	Contracts Date			Price		Amount (000)	
orp.	Goldman Sachs International	15,959	07/09/18	CAD	46.27	CAD	745	
p Holdings Ltd.	Deutsche Bank AG	60,000	07/10/18	SGD	29.99	SGD	1,590	
p Holdings Ltd.	Deutsche Bank AG	60,000	07/10/18	SGD	29.91	SGD	1,590	
С	Goldman Sachs International	77,900	07/10/18	GBP	26.86	GBP	2,120	
ne Telecommincations Co. Ltd.	Goldman Sachs International	109,000	07/10/18	USD	75.75	USD	8,585	
NV	UBS AG	45,000	07/10/18	EUR	86.63	EUR	3,861	
legistered Shares	Goldman Sachs International	1,300	07/10/18	CHF	2,577.54	CHF	3,421	
Electric SE	UBS AG	29,500	07/10/18	EUR	79.66	EUR	2,101	
	Credit Suisse International	34,200	07/10/18	EUR	17.43	EUR	463	
ca PLC	UBS AG	129,800	07/11/18	GBP	55.20	GBP	6,803	
Post AG, Registered Shares	Goldman Sachs International	143,000	07/11/18	EUR	33.57	EUR	3,978	
ne Telecommincations Co. Ltd.	Morgan Stanley & Co. International PLC	218,000	07/11/18	USD	77.89	USD	17,170	
e Philips NV	Morgan Stanley & Co. International PLC	163,000	07/11/18	EUR	36.27	EUR	5,914	
lisk A/S, Class B	Goldman Sachs International	74,100	07/11/18	DKK	306.74	DKK	21,837	
mmunications, Inc., Class B	Morgan Stanley & Co. International PLC	25,900	07/11/18	CAD	63.00	CAD	1,617	
	JPMorgan Chase Bank N.A.	32,000	07/12/18	AUD	26.93	AUD	869	
erican Tobacco PLC	Citibank N.A.	296,800	07/12/18	GBP	39.09	GBP	11,329	
rands PLC	UBS AG	113,000	07/12/18	GBP	29.02	GBP	3,180	
acco, Inc.	Goldman Sachs International	44,000	07/12/18	JPY	3,040.60	JPY	136,140	
, Class B	UBS AG	34,600	07/12/18	EUR	43.39	EUR	1,506	
	Morgan Stanley & Co. International PLC	60,000	07/12/18	EUR	66.89	EUR	4,124	
miconductor Manufacturing Co.								
	Goldman Sachs International	350,000	07/12/18	USD	237.08	USD	75,775	
orp.	Citibank N.A.	33,400	07/13/18	CAD	46.34	CAD	1,560	

Schedules of Investments

59

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

## **OTC Options Written (continued)**

			f Expiration		Exercise		Notional	
Description Call (continued)	Counterparty	Contracts	s Date		Price	Amo	ount (000)	Value
Amcor Ltd.	Goldman Sachs International	624,700	07/18/18		13.88	AUD	8 006	\$ (267,926)
Anheuser-Busch	Golullian Sachs International	024,700	0//10/10	AUD	15.00	AUD	0,990	\$ (207,920)
nBev SA	Morgan Stanley & Co. International PLC	22,000	07/18/18	FUR	83.88	EUR	1,900	(78,733)
Ansell Ltd.	Goldman Sachs International	52,600				AUD	-	,
Deutsche Post AG,	Golullian Sachs International	52,000	0//10/10	AUD	20.00	AUD	1,420	(24,301)
	Morgan Stanley & Co. International PLC	C 110,000	07/18/18		33 57	EUR	3,060	(959)
Registered Shares Diageo PLC	Goldman Sachs International	88,950				GBP	2,421	. ,
Far EasTone	Goldman Sachs miemauonai	00,950	0//10/10	UDr	27.43	UDF	∠,4∠1	(44,000)
Far East one relecommunications								
Co. Ltd.	Goldman Sachs International	544 000	07/18/18	USD	77 12	USD	42,845	(33 657)
		544,000				GBP	42,843	,
mperial Brands PLC		17,000						,
Kone OYJ, Class B	Credit Suisse International	52,000				EUR	2,264	
Sanofi Sahnaidan Elaatria	Morgan Stanley & Co. International PLC	20,850	0 07/18/18	EUK	03.82	EUR	1,433	(80,623)
Schneider Electric		19 500	07/10/10	סידי	76 74	מדיד	1 210	(1.501)
	Barclays Bank PLC	18,500				EUR	1,318	
TELUS Corp.	Citibank N.A.	46,000	07/18/18	CAD	43.83	CAD	2,148	(37,687)
United Overseas	IDM	106 500	07/10/10		29 (7		2 270	(2,029)
Bank Ltd.	JPMorgan Chase Bank N.A.	126,500			28.67		3,378	
post SA	Credit Suisse International	57,000	07/18/18	EUK	15.21	EUR	771	(1,014)
ANTA Sports		<i></i>	07/10/10		44 70		22 754	(12 71 4)
roducts Ltd.	Goldman Sachs International	550,000	07/19/18	HKD	44./8	HKD	22,754	(43,714)
Novartis AG,		~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	07/10/10	CUIE	76.10	CUL	7 0 4 4	(72.001)
Registered Shares	Morgan Stanley & Co. International PLC					CHF	7,344	,
Jnilever PLC	Morgan Stanley & Co. International PLC	2 96,700	07/19/18	GBP	42.83	GBP	4,048	(37,595)
Sonic Healthcare		<b>(2.20</b> )	°7/24/10		22.00		1 507	
Ltd.	UBS AG	62,300	07/24/18	AUD	23.80	AUD	1,527	(41,658)
United Overseas				~ ~ ~ ~	20.22	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	• • • • •	
Bank Ltd.	UBS AG	111,900	07/24/18	SGD	29.32	SGD	2,988	(2,003)
ANTA Sports								
Products Ltd.	UBS AG	309,000	07/25/18	HKD	49.34	HKD	12,783	(7,142)
Anheuser-Busch								
nBev SA	UBS AG	16,700				EUR	1,442	
Ansell Ltd.	Morgan Stanley & Co. International PLC					AUD		,
Diageo PLC	Goldman Sachs International	5,000	07/25/18	GBP	27.90	GBP	136	(1,630)
GlaxoSmithKline								
PLC	Citibank N.A.	572,700	07/25/18	GBP	15.50	GBP	8,751	(135,399)
Heineken NV	Deutsche Bank AG	25,300	07/25/18	EUR	87.76	EUR	2,170	(21,828)
Kone OYJ, Class B	UBS AG	83,000	07/25/18	EUR	42.77	EUR	3,614	(143,110)
1								

Nestle S.A., Registered Shares	Morgan Stanley & Co. International PLC	68,000	07/25/18	CHF	76.40	CHF	5,219	(89,674)
Novo Nordisk A/S,			0 <b>- 10 - 11</b> 0	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	200 50		10,150	
Class B	UBS AG	44,700	07/25/18		308.50		13,173	(12,515)
Sanofi	UBS AG	71,300	07/25/18	EUK	67.27	EUK	4,900	(188,475)
onic Healthcare		122 000	07/05/10		24.52		2 202	(49 442)
.td.	UBS AG	133,900	07/25/18	AUD	24.52	AUD	3,282	(48,443)
Svenska								
Handelsbanken AB,		270 500	07/25/18	SEV	101.02	SEV	26 021	(16.070)
Class A	UBS AG Citibank N.A.	270,500 28,500	07/25/18		101.02 46.49		26,834	(46,070) (14,982)
TELUS Corp. Taiwan	Chibalik N.A.	28,300	0//23/16	CAD	40.49	CAD	1,331	(14,962)
Semiconductor								
Manufacturing Co.								
Ltd.	UBS AG	987,000	07/25/18	USD	228.60	USD	213,686	(34,466)
post SA	Deutsche Bank AG	28,800	07/25/18		16.07		213,080 390	(54,400)
ANTA Sports	Deutsene Daik AG	28,800	07723710	LUK	10.07	LUK	590	(329)
Products Ltd.	JPMorgan Chase Bank N.A.	258,000	07/26/18	нкр	50 34	HKD	10,673	(3,960)
Amcor Ltd.	UBS AG	317,300	07/26/18			AUD	4,569	(100,596)
Ansell Ltd.	Morgan Stanley & Co. International PLC	54,800	07/26/18			AUD	1,488	(23,397)
Far EasTone	Morgan Stanley & Co. International TEC	54,000	07720/10	neb	27.05	neb	1,100	(23,377)
Felecommunications								
Co. Ltd.	Citibank N.A.	401,000	07/26/18	USD	78.15	USD	31,583	(17,953)
Far EasTone		.01,000	01120110	0.52	10110	0.52	01,000	(1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Felecommunications								
Co. Ltd.	Goldman Sachs International	450,000	07/26/18	USD	78.76	USD	35,442	(15,575)
apan Tobacco, Inc.	Citibank N.A.	38,800	07/26/18		3,114.06		120,051	(15,119)
Novartis AG,		,			,		,	
Registered Shares	Morgan Stanley & Co. International PLC	6,750	07/26/18	CHF	75.85	CHF	506	(6,725)
Jnilever PLC	Citibank N.A.	123,300	07/26/18	GBP	41.71	GBP	5,161	(152,640)
TELUS Corp.	Goldman Sachs International	24,600	07/27/18	CAD	46.23	CAD	1,149	(16,605)
TELUS Corp.	Goldman Sachs International	24,600	07/31/18	CAD	46.46	CAD	1,149	(14,516)
Ansell Ltd.	Citibank N.A.	35,000	08/01/18	AUD	26.57	AUD	950	(26,861)
Deutsche Post AG,								
Registered Shares	HSBC Bank PLC	183,500	08/01/18	EUR	28.30	EUR	5,105	(132,854)
Diageo PLC	Citibank N.A.	26,200	08/01/18		27.89	GBP	713	(11,797)
Kone OYJ, Class B	Credit Suisse International	52,000	08/01/18	EUR	43.47	EUR	2,264	(68,480)
Sonic Healthcare								
Ltd.	Morgan Stanley & Co. International PLC	78,800	08/01/18			AUD	1,931	(31,841)
TELUS Corp.	Citibank N.A.	28,500	08/01/18		46.49		1,331	(18,211)
post SA	Credit Suisse International	76,800	08/01/18	EUR	15.15	EUR	1,039	(5,483)
Rogers								
Communications,								
nc., Class B	Morgan Stanley & Co. International PLC	72,300	08/02/18		62.10		4,514	(72,581)
TELUS Corp.	Goldman Sachs International	32,400	08/03/18	CAD	47.00	CAD	1,513	(10,165)
GS SA, Registered			00.07	a	a =	a	=-	/4 = 4
Shares	UBS AG	1,700	08/07/18		2,574.49		4,473	(156,618)
Ansell Ltd.	Citibank N.A.	35,000	08/08/18			AUD	950	(29,095)
AstraZeneca PLC	Goldman Sachs International	16,200	08/08/18	GBP	52.35	GBP	849	(29,391)
OBS Group Holdings		100.000	00/00/11 0	COP	07.14	0.05	0.100	(10, 10, 0
Ltd.	UBS AG	120,000	08/08/18	SGD	27.16	SGD	3,180	(42,486)

GlaxoSmithKline								
PLC	Morgan Stanley & Co. International PLC	34,100	08/08/18	GBP	15.25	GBP	521	(17,060)
mperial Brands PLC	UBS AG	165,000	08/08/18	GBP	27.66	GBP	4,643	(234,149)
apan Tobacco, Inc.	Goldman Sachs International	64,700	08/08/18	JPY	3,078.48	JPY	200,188	(51,819)
Kone OYJ, Class B	Credit Suisse International	23,600	08/08/18	EUR	43.32	EUR	1,028	(35,744)
Sanofi	Morgan Stanley & Co. International PLC	63,900	08/08/18	EUR	69.52	EUR	4,392	(90,225)
Schneider Electric								
SE	Morgan Stanley & Co. International PLC	29,300	08/08/18	EUR	71.59	EUR	2,087	(65,142)

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

#### **OTC Options Written (continued)**

Description	Counterparty	Number of Contracts	Expiration Date	E.	xercise Price		Notional unt (000)	Value
Call (continued)	Counterparty	Contracts	Dule		17100	Αποι	<i>ini</i> (000)	vuiue
Sonic Healthcare								
Ltd.	IDMorgon Chose Denk N A	109,000	08/08/18		25.08		2,672 \$	(25, 126)
	JPMorgan Chase Bank N.A.	109,000	08/08/18	AUD	23.08	AUD	2,072 \$	(25,136)
Svenska								
Handelsbanken		421 000	00/00/10	OFIZ	00.45	OFIZ	41 762	(120.042)
AB, Class A	JPMorgan Chase Bank N.A.	421,000	08/08/18		98.45		41,763	(130,843)
Unilever PLC	Goldman Sachs International	72,000	08/08/18	GBP	41.88	GBP	3,014	(74,014)
TELUS Corp.	Citibank N.A.	46,100	08/09/18	CAD	45.90	CAD	2,153	(45,062)
ANTA Sports								
Products Ltd.	Goldman Sachs International	310,000	08/10/18	HKD	41.32	HKD	12,825	(108,817)
Diageo PLC	Deutsche Bank AG	82,300	08/10/18	GBP	27.66	GBP	2,240	(41,224)
Ansell Ltd.	Citibank N.A.	28,800	08/14/18	AUD	26.94	AUD	782	(19,485)
Novartis AG,								
<b>Registered Shares</b>	Morgan Stanley & Co. International PLC	124,000	08/14/18	CHF	73.40	CHF	9,302	(361,833)
Nestle S.A.,	c i							,
Registered Shares	Morgan Stanley & Co. International PLC	134,500	08/15/18	CHF	77.24	CHF	10,323	(175,636)
TELUS Corp.	Royal Bank of Canada	63,500	08/15/18	CAD	47.24	CAD	2,965	(30,610)
Amcor Ltd.	JPMorgan Chase Bank N.A.	483,800	08/16/18	AUD	14.52	AUD	6,967	(109,795)
Ansell Ltd.	Morgan Stanley & Co. International PLC	-	08/22/18		27.62		1,048	(14,459)
Rogers					_,		_,	(,,
Communications,								
Inc., Class B	Citibank N.A.	72,300	08/28/18	CAD	62.50	CAD	4,514	(83,559)
TELUS Corp.	Royal Bank of Canada	41,000	08/29/18		46.70	-	1,915	(31,154)
TLL05 Colp.	Royar Dank of Canada	+1,000	00/27/10	CAD	+0.70	CIID	1,715	(31,134)

\$(5,202,429)

#### Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap								
	Premium	Premium	Unrealized	Unrealized						
	Paid	Received	Appreciation	Depreciation	Value					
Options Written	N/A	N/A	\$ 1,388,709	\$ (1,692,850)	\$ (5,608,380)					
Derivative Financial Instruments Categorized by Risk Exposure										

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	Commodity						
Liabilities Derivative Financial Instruments Options written	Contracts	Contracts	Contracts C	ontract	s Contracts	Contracts	Total
Options written at value	\$	\$	\$ 5,608,380	\$	\$	\$	\$ 5,608,380

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

Commodity ContractsC	Credit Contracts	C EquityEx	urrency cchange	Interest Rate		Total
¢	¢	¢ 2 505 791	¢	¢	¢	¢ 2 505 791
\$	<b>Þ</b>	\$ 3,505,781	<b>Þ</b>	\$	\$	\$ 3,505,781
on)	¢	¢ (1 000 176)	¢	¢	¢	\$ (1,888,476)
	ContractsC \$	ContractsContracts \$ \$ \$	Commodity Credit EquityEx ContractsContracts ContractsCo \$ \$ \$ 3,505,781	Currency Commodity Credit EquityExchange ContractsContracts ContractsContracts \$ \$ \$ 3,505,781 \$	Commodity Credit EquityExchange Rate ContractsContracts \$\$\$3,505,781 \$\$	Currency Interest Commodity Credit ContractsContracts \$ \$ \$ 3,505,781 \$ \$ \$ Currency Interest EquityExchange Rate Other ContractsContractsContractsContracts \$ \$ \$ \$ \$, 3,505,781 \$ \$ ContractsContracts

#### Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options: Average value of option contracts written \$4,967,544 For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Schedules of Investments

61

Schedule of Investments (unaudited) (continued)BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

#### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

Options	Assets \$	<i>Liabilities</i> \$ 5,608,380
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA	)	(405,951)
Total derivative assets and liabilities subject to an MNA	\$	\$ 5,202,429

The following table presents the Trust s derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

	Derivative Liabilities Subject to an MNA by	Derivatives Available	Non-cash Collateral	Cash Collateral	Net Amount of Derivative Liabilities
Counterparty	Counterparty	for Offset	Pledged <sup>(a)</sup>	Pledged	(b)
Barclays Bank PLC	\$ 1,521	\$	\$	\$	\$ 1,521
Citibank N.A.	761,481		(761,481)		
Credit Suisse International	168,867		(168,867)		
Deutsche Bank AG	63,662		(63,662)		
Goldman Sachs International	951,424		(951,424)		
HSBC Bank PLC	165,674				165,674
JPMorgan Chase Bank N.A.	285,452			(285,452)	
Morgan Stanley & Co.					
International PLC	1,517,647		(1,517,647)		
Royal Bank of Canada	61,764				61,764
UBS AG	1,224,937		(1,224,937)		
	\$ 5,202,429	\$	\$ (4,688,018)	\$ (285,452)	\$ 228,869

<sup>(a)</sup> Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

<sup>(b)</sup> Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Australia	\$	\$ 60,343,965	\$	\$ 60,343,965
Belgium	7,996,897	8,287,867		16,284,764
Canada	73,544,931			73,544,931
China		12,537,812		12,537,812
Denmark		11,675,264		11,675,264
Finland		26,521,638		26,521,638
France		50,557,021		50,557,021
Germany		30,162,999		30,162,999
India		11,446,031		11,446,031
Japan		11,773,823		11,773,823
Netherlands		29,711,696		29,711,696
Singapore		19,883,735		19,883,735
Sweden		16,295,557		16,295,557
Switzerland		90,205,611		90,205,611
Taiwan		29,664,677		29,664,677
United Kingdom		162,226,197		162,226,197
United States	31,558,628			31,558,628
Preferred Stocks			4,889,604	4,889,604
Short-Term Securities	943,659			943,659
	\$114,044,115	\$ 571,293,893	\$4,889,604	\$690,227,612

Schedule of Investments (unaudited) (continued)	BlackRock Enhanced International Dividend Trust (BGY				
June 30, 2018					
Derivative Financial Instruments <sup>(a)</sup> Liabilities:	Level 1	Level 2	Level 3	Total	
Equity contracts	\$ (386,499)	\$(5,221,881)	\$	\$ (5,608,380)	

<sup>(a)</sup> Derivative financial instruments are options written, which are shown at value. Transfers between Level 1 and Level 2 were as follows:

	Transfers into Level 1 <sup>(a)</sup>	Transfers out of Level 1 <sup>(a)</sup>	Transfers Into Level 2 <sup>(a)</sup>	Transfers out of Level 2 <sup>(a)</sup>
Assets: Long-Term Investments:				
Common Stocks	\$ 12,033,525	\$ 17,468,213	\$ 17,468,213	\$ 12,033,525

 (a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

See notes to financial statements.

Schedules of Investments

63

### Schedule of Investments (unaudited)

## BlackRock Health Sciences Trust (BME)

### June 30, 2018

## (Percentages shown are based on Net Assets)

Common Stocks         98.3%           Biotechnology         19.7%           ACADIA Pharmaceuticals, Inc. <sup>(a)(b)</sup> 37,400         \$571098           Acceleron Pharma, Inc. <sup>(a)(b)</sup> 35,700         1,732,164           Acceleron Pharmaceuticals, Inc. <sup>(a)(b)</sup> 17,146,440         1,839,813           Algios Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,400         3,525,860           Alnylan Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,160         5,198,054           Amgen, Inc. <sup>(a)</sup> 28,160         5,198,054           Amicus Therapeutics, Inc. <sup>(a)(b)</sup> 22,430         350,357           AnapysBio, Inc. <sup>(a)</sup> 14,547         320,034           Arena Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144         1,096,278           Argens, SE, ADR <sup>(a)</sup> 4,536         737,853           Biogen, Inc. <sup>(a)(b)</sup> 25,248         7,327,979           Biohaven Pharmaceutical, Inc. <sup>(a)(b)</sup> 2,200         345,290           Bluebird Bio, Inc. <sup>(a)(b)</sup> 3,500         222,180           Cellectis SA, ADR <sup>(a)</sup> 12,000         3,500         222,180           Cellectis SA, ADR <sup>(a)</sup> 11,300         93,790         53,88         243,538           Bluebird Bio, Inc. <sup>(a)(b)</sup> 5,700         522,4	Security	Shares	Value
ACADIA Pharmaceuticals, Inc. <sup>(a)(b)</sup> 37,400       \$ 571,098         Acceteron Pharma, Inc. <sup>(a)(b)</sup> 1,732,164       1,839,813         Agios Pharmaceuticals, Inc. <sup>(a)(b)</sup> 15,700       1,732,164         Alextan Pharmaceuticals, Inc. <sup>(a)(b)</sup> 15,700       1,322,411         Alexion Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,400       3,525,860         Angen, Inc. <sup>(b)</sup> 28,100       1,477,350         Amgen, Inc. <sup>(b)</sup> 28,160       5,198,054         Annapty-Bio, Inc. <sup>(a)</sup> 1,500       106,550         Apellis Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144       1,096,278         Argenx SE, ADR <sup>(a)</sup> 4,556       375,853         Biogen, Inc. <sup>(a)(b)</sup> 25,248       7,327,979         Biohaven Pharmaceutical, Inc. <sup>(a)(b)</sup> 2,200       345,200         Biuebird Bio, Inc. <sup>(a)(b)</sup> 2,200       345,200         Bluebird Bio, Inc. <sup>(a)(b)</sup> 2,200       345,200         Bluebird Bio, Inc. <sup>(a)(b)</sup> 2,200       345,200         Bluebird Bio, Inc. <sup>(a)(b)</sup> 3,500       222,180         Cellectis SA, ADR <sup>(a)</sup> 1,000       93,790         Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,500       66,304         Galagos NV, ADR <sup>(a)(b)</sup> 5,600       66,30	Common Stocks 98.3%		
ACADIA Pharmaceuticals, Inc. <sup>(a)(b)</sup> 37,400       \$ 571,098         Acceteron Pharma, Inc. <sup>(a)(b)</sup> 1,732,164       1,839,813         Agios Pharmaceuticals, Inc. <sup>(a)(b)</sup> 15,700       1,732,164         Alextan Pharmaceuticals, Inc. <sup>(a)(b)</sup> 15,700       1,322,411         Alexion Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,400       3,525,860         Angen, Inc. <sup>(b)</sup> 28,100       1,477,350         Amgen, Inc. <sup>(b)</sup> 28,160       5,198,054         Annapty-Bio, Inc. <sup>(a)</sup> 1,500       106,550         Apellis Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144       1,096,278         Argenx SE, ADR <sup>(a)</sup> 4,556       375,853         Biogen, Inc. <sup>(a)(b)</sup> 25,248       7,327,979         Biohaven Pharmaceutical, Inc. <sup>(a)(b)</sup> 2,200       345,200         Biuebird Bio, Inc. <sup>(a)(b)</sup> 2,200       345,200         Bluebird Bio, Inc. <sup>(a)(b)</sup> 2,200       345,200         Bluebird Bio, Inc. <sup>(a)(b)</sup> 2,200       345,200         Bluebird Bio, Inc. <sup>(a)(b)</sup> 3,500       222,180         Cellectis SA, ADR <sup>(a)</sup> 1,000       93,790         Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,500       66,304         Galagos NV, ADR <sup>(a)(b)</sup> 5,600       66,30	Biotechnology 19.7%		
Acerta Pharma BV, Series B, (Acquired 02/01/16, cost \$986,402) <sup>(c)(d)</sup> 17,146,440         1,839,813           Agios Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,400         3,525,860           Alnylam Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,100         5,128,054           Amicus Therapeutics, Inc. <sup>(a)(b)</sup> 22,430         350,357           AnaptysBio, Inc. <sup>(a)</sup> 15,000         106,550           Apellis Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144         1,096,278           Argenx SE, ADR <sup>(a)</sup> 45,36         375,853           Biogen, Inc. <sup>(a)(b)</sup> 25,248         7,327,979           BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> 25,248         7,327,979           BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> 350,0         22,2400         3,052,080           Bluebird Bio, Inc. <sup>(a)(b)</sup> 25,248         7,327,979         350,350           BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> 22,000         345,290         345,290           Blueprint Medicines Corp. <sup>(a)(b)</sup> 2,000         345,290         350,937           Blueprint Medicines Corp. <sup>(a)(b)</sup> 5,000         5,020         52,426           Giolab Dio On therapeutics, Inc. <sup>(a)(b)</sup> 5,000         5,030         52,932           Gilabapaos NV, ADR <sup>(a)(b)</sup> 5,388		37,400	\$ 571,098
Agios Pharmaceuticals, Inc. <sup>(a)(b)</sup> 15,700       1,322,411         Alexion Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,400       3,525,860         Alnylam Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,160       5,198,054         Ameen, Inc. <sup>(b)</sup> 28,160       5,198,054         Amicus Therapeutics, Inc. <sup>(a)(b)</sup> 22,430       350,357         AnaptysBio, Inc. <sup>(a)</sup> 14,547       320,034         Arena Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144       1,096,278         Argenx SE, ADR <sup>(a)</sup> 45,36       375,853         Biogen, Inc. <sup>(a)(b)</sup> 25,248       7,327,979         Biohaven Pharmaceutical, Inc. <sup>(a)(b)</sup> 7,050       278,616         Biuebird Bio, Inc. <sup>(a)(b)</sup> 3,052,080       3052,080         Bluebird Bio, Inc. <sup>(a)(b)</sup> 2,200       345,290         Blueprint Medicines Corp. <sup>(a)(b)</sup> 3,500       222,180         Cellectis SA, ADR <sup>(a)</sup> 15,095       427,038         Cytokinetics, Inc. <sup>(a)(b)</sup> 11,300       93,790         Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,700       525,426         Galapagos NV, ADR <sup>(a)(b)</sup> 5,700       525,426         Gilabal Siond Therapeutics, Inc. <sup>(a)(b)</sup> 5,388       243,538         HuA Medicine, Series D (Acquired 03/13/18, cost	Acceleron Pharma, Inc. <sup>(a)(b)</sup>	35,700	1,732,164
Agios Pharmaceuticals, Inc. <sup>(a)(b)</sup> 15,700       1,322,411         Alexion Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,400       3,525,860         Alnylam Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,160       5,198,054         Ameen, Inc. <sup>(b)</sup> 28,160       5,198,054         Amicus Therapeutics, Inc. <sup>(a)(b)</sup> 22,430       350,357         AnaptysBio, Inc. <sup>(a)</sup> 14,547       320,034         Arena Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144       1,096,278         Argenx SE, ADR <sup>(a)</sup> 4,536       375,853         Biogen, Inc. <sup>(a)(b)</sup> 7,050       278,616         Biodarin Pharmaceutical, Inc. <sup>(a)(b)</sup> 7,050       278,616         Biuebird Bio, Inc. <sup>(a)(b)</sup> 2,200       345,290         Bluebird Bio, Inc. <sup>(a)(b)</sup> 2,200       345,290         Blueprint Medicines Corp. <sup>(a)(b)</sup> 2,200       345,290         Blueprint Medicines, Inc. <sup>(a)(b)</sup> 11,300       93,790         Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,700       525,426         Gilaapagos NV, ADR <sup>(a)(b)</sup> 5,388       243,538         Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 5,388       243,538         HuA Medicine, Series D (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup> 19,588       260,147         Icycyc Corp.	Acerta Pharma BV, Series B, (Acquired 02/01/16, cost \$986,402) <sup>(c)(d)</sup>	17,146,440	1,839,813
Alexion Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,400       3,525,860         Alnylam Pharmaceuticals, Inc. <sup>(a)(b)</sup> 28,160       5,198,054         Amicus Therapeutics, Inc. <sup>(a)(b)</sup> 22,430       350,357         AnaptysBio, Inc. <sup>(a)</sup> 1,500       11,647       320,034         Arena Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144       1,006,278         Arena Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144       1,006,278         Arena Pharmaceutical, Inc. <sup>(a)(b)</sup> 25,248       7,327,979         Biobaven Pharmaceutical, Inc. <sup>(a)(b)</sup> 7,050       278,616         BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> 7,050       278,616         Biueprint Medicines Corp. <sup>(a)(b)</sup> 3,500       222,180         Cellectis SA, ADR <sup>(a)</sup> 3,500       222,180         Cellectis SA, ADR <sup>(a)</sup> 11,300       93,790         Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,700       525,426         Gilapagos NV, ADR <sup>(a)(b)</sup> 5,700       525,426         Gilabagos NV, A		15,700	1,322,411
Amgen, Inc. <sup>(b)</sup> 28,160         5,198,054           Amicus Therapeutics, Inc. <sup>(a)(b)</sup> 22,430         350,357           AnaptysBio, Inc. <sup>(a)</sup> 14,547         320,034           Arena Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144         1,096,278           Argenx SE, ADR <sup>(a)</sup> 4,536         375,853           Biogen, Inc. <sup>(a)(b)</sup> 25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. <sup>(a)(b)</sup> 7,050         278,616           BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> 32,400         3,052,080           Blueprint Medicines Corp. <sup>(a)(b)</sup> 3,500         222,180           Cytokinetics, Inc. <sup>(a)(b)</sup> 15,005         427,038           Cytokinetics, Inc. <sup>(a)(b)</sup> 11,300         93,790           Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,700         525,426           Gilead Sciences, Inc. <sup>(b)</sup> 85,600         6,063,904           Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 19,558         260,147           Incyte Corp. <sup>(a)(b)</sup> 29,508         951,633           Insmed, Inc. <sup>(a)</sup> 19,558 <t< td=""><td></td><td>28,400</td><td></td></t<>		28,400	
Amgen, Inc. <sup>(b)</sup> 28,160         5,198,054           Amicus Therapeutics, Inc. <sup>(a)(b)</sup> 22,430         350,357           AnaptysBio, Inc. <sup>(a)</sup> 14,547         320,034           Arena Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144         1,096,278           Argenx SE, ADR <sup>(a)</sup> 4,536         375,853           Biogen, Inc. <sup>(a)(b)</sup> 25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. <sup>(a)(b)</sup> 7,050         278,616           BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> 32,400         3,052,080           Blueprint Medicines Corp. <sup>(a)(b)</sup> 3,500         222,180           Cytokinetics, Inc. <sup>(a)(b)</sup> 15,005         427,038           Cytokinetics, Inc. <sup>(a)(b)</sup> 11,300         93,790           Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,700         525,426           Gilead Sciences, Inc. <sup>(b)</sup> 85,600         6,063,904           Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 19,558         260,147           Incyte Corp. <sup>(a)(b)</sup> 29,508         951,633           Insmed, Inc. <sup>(a)</sup> 19,558 <t< td=""><td>Alnylam Pharmaceuticals, Inc.<sup>(a)(b)</sup></td><td>15,000</td><td>1,477,350</td></t<>	Alnylam Pharmaceuticals, Inc. <sup>(a)(b)</sup>	15,000	1,477,350
Amicus Therapeutics, Inc. <sup>(a)(b)</sup> 22,430         350,357           AnaptysBio, Inc. <sup>(a)</sup> 1,500         106,560           Apellis Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144         1,096,278           Argenx SE, ADR <sup>(a)</sup> 4,536         375,853           Biogen, Inc. <sup>(a)(b)</sup> 25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. <sup>(a)(b)</sup> 7,050         278,616           BioMarin Pharmaceutical Holding Co. Ltd. <sup>(a)(b)</sup> 3,2400         3,052,080           Bluebird Bio, Inc. <sup>(a)(b)</sup> 2,200         345,290           Blueprint Medicines Corp. <sup>(a)(b)</sup> 2,200         345,290           Bluebird Bio, Inc. <sup>(a)(b)</sup> 11,300         93,790           Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 11,300         93,790           Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,700         525,426           Gilaad Sciences, Inc. <sup>(b)</sup> 85,600         6,603,904           Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Haloxyme Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Hola Wedicine, Series D (Acquired 03/13/18, cost \$26,147) <sup>(d)</sup> 19,558         260,147           Incyte Corp. <sup>(a)(b)</sup> 29,500         1,534,300         1,634		28,160	5,198,054
AnaptysBio, Inc. <sup>(a)</sup> 1,500       106,560         Apellis Pharmaceuticals, Inc. <sup>(a)</sup> 14,547       320,034         Arena Pharmaceuticals, Inc. <sup>(a)</sup> (b)       25,144       1,096,278         Argenx SE, ADR <sup>(a)</sup> 25,363       356         Biogen, Inc. <sup>(a)(b)</sup> 25,248       7,327,979         Biohaven Pharmaceutical Holding Co. Ltd. <sup>(a)(b)</sup> 7,050       278,616         BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> 32,400       3,052,080         Bluebrid Bio, Inc. <sup>(a)(b)</sup> 2,200       345,290         Bluebrid Bio, Inc. <sup>(a)(b)</sup> 3,500       222,180         Cellectis SA, ADR <sup>(a)</sup> 15,095       427,038         Cytokinetics, Inc. <sup>(a)(b)</sup> 11,300       93,790         Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,700       525,426         Gilaad Sciences, Inc. <sup>(b)</sup> 85,600       6,063,904         Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> 5,388       243,538         Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 7,449       82,789         HUA Medicine, Series D (Acquired 03/13/18, cost \$26,0,147) <sup>(d)</sup> 19,558       260,147         Incyte Corp. <sup>(a)(b)</sup> 22,900       1,534,300       1,534,300         Inflark NV. <sup>(A)</sup> 29,508       951,633       1,534,301		22,430	350,357
Apellis Pharmaceuticals, Inc. <sup>(a)</sup> 14,547         320,034           Arena Pharmaceuticals, Inc. <sup>(a)(b)</sup> 25,144         1,096,278           Argenx SE, ADR <sup>(a)</sup> 4,536         375,853           Biogen, Inc. <sup>(a)(b)</sup> 25,248         7,327,979           Biohaven Pharmaceutical, Inc. <sup>(a)(b)</sup> 7,050         278,616           BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> 32,400         3,052,080           Blueprint Medicines Corp. <sup>(a)(b)</sup> 2,200         345,290           Blueprint Medicines Corp. <sup>(a)(b)</sup> 3,500         222,180           Cellectis SA, ADR <sup>(a)</sup> 15,095         427,038           Cytokinetics, Inc. <sup>(a)(b)</sup> 11,300         93,790           Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,700         525,425           Gilead Sciences, Inc. <sup>(b)</sup> 85,600         6,063,904           Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 7,449         82,789           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup> 7,449         82,789           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,0147) <sup>(d)</sup> 19,558         260,147           Incyte Corp. <sup>(a)(b)</sup> 29,000         1,534,300         1,544,888<		1,500	106,560
Arena Pharmaceuticals, Inc. (a)(b)25,1441,096,278Argenx SE, ADR(a)4,536375,853Biogen, Inc. (a)(b)25,2487,327,979Biohaven Pharmaceutical Holding Co. Ltd. (a)(b)7,050278,616BioMarin Pharmaceutical, Inc. (a)(b)32,4003,052,080Bluebird Bio, Inc. (a)(b)2,200345,290Blueprint Medicines Corp. (a)(b)3,500222,180Cellectis SA, ADR(a)15,095427,038Cytokinetics, Inc. (a)(b)11,30093,790Eidos Therapeutics, Inc. (a)4,48691,245Galapagos NV, ADR(a)(b)5,700525,426Gilead Sciences, Inc. (b)5,388243,538Halozyme Therapeutics, Inc. (a)(b)41,600701,792HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)7,44982,789HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)19,558260,147Incyte Corp. (a)(b)19,488628,488111300Inflark NV(a)29,508951,63315,633Insmed, Inc. (a)67,2861,591,314Intercept Pharmaceuticals, Inc. (a)(b)26,000218,166Madrigal Pharmaceuticals, Inc. (a)(b)67,286371,317Neurocrine Biosciences, Inc. (a)9,300913,632Ovid therapeutics, Inc. (a)9,300913,632Ovid therapeutics, Inc. (a)(b)3,552328,013Regeneron Pharmaceuticals, Inc. (a)(b)3,52328,013Regeneron Pharmaceuticals, Inc. (a)(b)3,52328,013Regeneron Pha	Apellis Pharmaceuticals, Inc. <sup>(a)</sup>	14,547	320,034
Biogen, Inc. (a)(b)         25,248         7,327,979           Biohaven Pharmaceutical Holding Co. Ltd. (a)(b)         7,050         278,616           BioMarin Pharmaceutical, Inc. (a)(b)         32,400         3,052,080           Bluebird Bio, Inc. (a)(b)         2,200         345,290           Blueprint Medicines Corp. (a)(b)         2,000         242,038           Cellectis SA, ADR(a)         15,095         427,038           Cytokinetics, Inc. (a)(b)         11,300         93,790           Eidos Therapeutics, Inc. (a)(b)         5,700         525,426           Galapagos NV, ADR(a)(b)         5,300         6,063,904           Global Blood Therapeutics, Inc. (a)(b)         5,388         243,538           Halozyme Therapeutics, Inc. (a)(b)         5,388         243,538           HuA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)         7,449         82,789           HUA Medicine, Series D (Acquired 03/13/18, cost \$260,147)(d)         19,558         260,147           Incyte Corp. (a)(b)         22,900         1,534,300           Inflark NV, (Acquired 11/08/17, cost \$253,349)(d)         19,488         628,488           Inflark NV(a)         29,508         951,633           Insmed, Inc. (a)         67,286         1,591,314           Myovant Science	•	25,144	1,096,278
Biohaven Pharmaceutical Holding Co. Ltd. <sup>(a)(b)</sup> 7,050         278,616           BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> 32,400         3,052,080           Bluebird Bio, Inc. <sup>(a)(b)</sup> 2,200         345,290           Blueprint Medicines Corp. <sup>(a)(b)</sup> 3,500         222,180           Cellectis SA, ADR <sup>(a)</sup> 15,095         427,038           Cytokinetics, Inc. <sup>(a)(b)</sup> 11,300         93,790           Eidos Therapeutics, Inc. <sup>(a)(b)</sup> 5,700         525,426           Galapagos NV, ADR <sup>(a)(b)</sup> 5,700         525,426           Gilead Sciences, Inc. <sup>(b)</sup> 85,600         6,063,904           Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           HuA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup> 7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup> 19,558         260,147           Incyte Corp. <sup>(a)(b)</sup> 22,900         1,534,300           Inflark NV (Acquired 11/08/17, cost \$253,349) <sup>(d)</sup> 19,488         628,488           Inflark NV <sup>(a)</sup> 29,508         951,633           Insmed, Inc. <sup>(a)</sup> 2,100         587,349	Argenx SE, ADR <sup>(a)</sup>	4,536	375,853
BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> $32,400$ $3,052,080$ Bluebird Bio, Inc. <sup>(a)(b)</sup> $2,200$ $345,290$ Blueprint Medicines Corp. <sup>(a)(b)</sup> $3,500$ $222,180$ Cellectis SA, ADR <sup>(a)</sup> $15,095$ $427,038$ Cytokinetics, Inc. <sup>(a)(b)</sup> $11,300$ $93,790$ Eidos Therapeutics, Inc. <sup>(a)(b)</sup> $4,486$ $91,245$ Galapagos NV, ADR <sup>(a)(b)</sup> $5,700$ $525,426$ Gilead Sciences, Inc. <sup>(b)</sup> $85,600$ $6,063,904$ Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> $5,388$ $243,538$ Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> $41,600$ $701,792$ HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup> $7,449$ $82,789$ HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup> $19,558$ $260,147$ Incyte Corp. <sup>(a)(b)</sup> $22,900$ $1,534,300$ InflaRx NV(Acquired 11/08/17, cost \$253,349) <sup>(d)</sup> $19,488$ $628,488$ InflaRx NV <sup>(a)</sup> $29,508$ $951,633$ $951,633$ Insmed, Inc. <sup>(a)</sup> $67,286$ $1,591,314$ Intercept Pharmaceuticals, Inc. <sup>(a)(b)</sup> $2,600$ $218,166$ $371,317$ $89,000$ $913,632$ Ovid therapeutics, Inc. <sup>(a)(b)</sup> $4,958$ $1,710,460$ $32,503$ $328,013$ Regeneron Pharmaceuticals, Inc. <sup>(a)(b)</sup> $4,958$ $1,710,460$ Sage Therapeutics, Inc. <sup>(a)(b)</sup> $33,650$ $5,108,757$	Biogen, Inc. <sup>(a)(b)</sup>	25,248	7,327,979
BioMarin Pharmaceutical, Inc. <sup>(a)(b)</sup> $32,400$ $3,052,080$ Bluebird Bio, Inc. <sup>(a)(b)</sup> $2,200$ $345,290$ Blueprint Medicines Corp. <sup>(a)(b)</sup> $3,500$ $222,180$ Cellectis SA, ADR <sup>(a)</sup> $15,095$ $427,038$ Cytokinetics, Inc. <sup>(a)(b)</sup> $11,300$ $93,790$ Eidos Therapeutics, Inc. <sup>(a)</sup> $4,486$ $91,245$ Galapagos NV, ADR <sup>(a)(b)</sup> $5,700$ $525,426$ Gilead Sciences, Inc. <sup>(b)</sup> $85,600$ $6,063,904$ Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> $5,388$ $243,538$ Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> $41,600$ $701,792$ HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup> $7,449$ $82,789$ HUA Medicine, Series L (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup> $19,558$ $260,147$ Incyte Corp. <sup>(a)(b)</sup> $22,900$ $1,534,300$ $1nflaRx NV_{(Acquired 11/08/17, cost $253,349)^{(d)}$ $19,488$ $628,488$ InflaRx NV <sup>(a)</sup> $29,508$ $951,633$ $951,633$ $15,000$ $218,166$ Madrigal Pharmaceuticals, Inc. <sup>(a)(b)</sup> $2,600$ $218,166$ $371,317$ Neurocrine Biosciences, Inc. <sup>(a)(b)</sup> $42,053$ $328,013$ Regeneron Pharmaceuticals, Inc. <sup>(a)(b)</sup> $42,053$ $328,013$ Regeneron Pharmaceuticals, Inc. <sup>(a)(b)</sup> $49,58$ $1,710,460$ Sage Therapeutics, Inc. <sup>(a)(b)</sup> $38,650$ $5,108,757$	Biohaven Pharmaceutical Holding Co. Ltd. <sup>(a)(b)</sup>	7,050	278,616
Blueprint Medicines Corp. <sup>(a)(b)</sup> 3,500         222,180           Cellectis SA, ADR <sup>(a)</sup> 15,095         427,038           Cytokinetics, Inc. <sup>(a)(b)</sup> 11,300         93,790           Eidos Therapeutics, Inc. <sup>(a)</sup> 4,486         91,245           Galapagos NV, ADR <sup>(a)(b)</sup> 5,700         525,426           Gilead Sciences, Inc. <sup>(b)</sup> 85,600         6,063,904           Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 7,449         82,789           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup> 7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup> 19,558         260,147           Incyte Corp. <sup>(a)(b)</sup> 22,900         1,534,300           InflaRx NV, (Acquired 11/08/17, cost \$253,349) <sup>(d)</sup> 19,488         628,488           InflaRx NV <sup>(a)</sup> 29,508         951,633           Insmed, Inc. <sup>(a)</sup> 67,286         1,591,314           Intercept Pharmaceuticals, Inc. <sup>(a)(b)</sup> 2,600         218,166           Madrigal Pharmaceuticals, Inc. <sup>(a)(b)</sup> 9,300         913,632           Ovid therapeutics, Inc. <sup>(a)(b)</sup> 9,300         913,632 <td< td=""><td>÷</td><td>32,400</td><td>3,052,080</td></td<>	÷	32,400	3,052,080
Cellectis SA, ADR15,095427,038Cytokinetics, Inc.11,30093,790Eidos Therapeutics, Inc.4,48691,245Galapagos NV, ADR5,700525,426Gilead Sciences, Inc.85,6006,063,904Global Blood Therapeutics, Inc.5,388243,538Halozyme Therapeutics, Inc.41,600701,792HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)41,600701,792HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)19,558260,147Incyte Corp.19,0558260,14719,558Incyte Corp.22,9001,534,30011,184InflaRx NV, (Acquired 11/08/17, cost \$253,349)19,488628,488InflaRx NV(a)29,508951,633Insmed, Inc.67,2861,591,314Intercept Pharmaceuticals, Inc.16,236371,317Neurocrine Biosciences, Inc.9,300913,632Ovid therapeutics, Inc.42,053328,013Regeneron Pharmaceuticals, Inc.49,581,70,460Sage Therapeutics, Inc.49,581,70,460Sage Therapeutics, Inc.38,6505,108,757	Bluebird Bio, Inc. <sup>(a)(b)</sup>	2,200	345,290
Cytokinetics, Inc. <sup>(a)(b)</sup> 11,300         93,790           Eidos Therapeutics, Inc. <sup>(a)</sup> 4,486         91,245           Galapagos NV, ADR <sup>(a)(b)</sup> 5,700         525,426           Gilead Sciences, Inc. <sup>(b)</sup> 85,600         6,063,904           Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 5,388         243,538           Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 41,600         701,792           HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup> 7,449         82,789           HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup> 19,558         260,147           Incyte Corp. <sup>(a)(b)</sup> 22,900         1,534,300           InflaRx NV, (Acquired 11/08/17, cost \$253,349) <sup>(d)</sup> 19,488         628,488           InflaRx NV <sup>(a)</sup> 29,508         951,633           Insmed, Inc. <sup>(a)</sup> 2,600         218,166           Madrigal Pharmaceuticals, Inc. <sup>(a)(b)</sup> 2,600         218,166           Madrigal Pharmaceuticals, Inc. <sup>(a)(b)</sup> 9,300         913,632           Ovid therapeutics, Inc. <sup>(a)(b)</sup> 9,300         913,632           Ovid therapeutics, Inc. <sup>(a)(b)</sup> 42,053         328,013	Blueprint Medicines Corp. <sup>(a)(b)</sup>	3,500	222,180
Eidos Therapeutics, Inc. (a) $4,486$ $91,245$ Galapagos NV, ADR <sup>(a)(b)</sup> $5,700$ $525,426$ Gilead Sciences, Inc. (b) $85,600$ $6,063,904$ Global Blood Therapeutics, Inc. (a)(b) $5,388$ $243,538$ Halozyme Therapeutics, Inc. (a)(b) $41,600$ $701,792$ HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d) $7,449$ $82,789$ HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d) $19,558$ $260,147$ Incyte Corp. (a)(b) $22,900$ $1,534,300$ InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d) $19,488$ $628,488$ InflaRx NV(a) $29,508$ $951,633$ Insmed, Inc. (a) $67,286$ $1,591,314$ Intercept Pharmaceuticals, Inc. (a)(b) $2,600$ $218,166$ Madrigal Pharmaceuticals, Inc. (a)(b) $9,300$ $913,632$ Ovid therapeutics, Inc. (a)(b) $9,300$ $913,632$ Ovid therapeutics, Inc. (a)(b) $49,58$ $1,710,460$ Sage Therapeutics, Inc. (a)(b) $49,58$ $1,710,460$ Sage Therapeutics, Inc. (a)(b) $38,650$ $5,108,757$	Cellectis SA, ADR <sup>(a)</sup>	15,095	427,038
Galapagos NV, ADR <sup>(a)(b)</sup> $5,700$ $525,426$ Gilead Sciences, Inc. <sup>(b)</sup> $85,600$ $6,063,904$ Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> $5,388$ $243,538$ Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> $41,600$ $701,792$ HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup> $7,449$ $82,789$ HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup> $19,558$ $260,147$ Incyte Corp. <sup>(a)(b)</sup> $22,900$ $1,534,300$ InflaRx NV, (Acquired 11/08/17, cost \$253,349) <sup>(d)</sup> $19,488$ $628,488$ InflaRx NV <sup>(a)</sup> $29,508$ $951,633$ Insmed, Inc. <sup>(a)</sup> $67,286$ $1,591,314$ Intercept Pharmaceuticals, Inc. <sup>(a)(b)</sup> $2,600$ $218,166$ Madrigal Pharmaceuticals, Inc. <sup>(a)(b)</sup> $9,300$ $913,632$ Ovid therapeutics, Inc. <sup>(a)(b)</sup> $42,053$ $328,013$ Regeneron Pharmaceuticals, Inc. <sup>(a)(b)</sup> $4,958$ $1,710,460$ Sage Therapeutics, Inc. <sup>(a)(b)</sup> $38,650$ $5,108,757$	Cytokinetics, Inc. <sup>(a)(b)</sup>	11,300	93,790
Gilead Sciences, Inc. <sup>(b)</sup> $85,600$ $6,063,904$ Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> $5,388$ $243,538$ Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> $41,600$ $701,792$ HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup> $7,449$ $82,789$ HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup> $19,558$ $260,147$ Incyte Corp. <sup>(a)(b)</sup> $22,900$ $1,534,300$ InflaRx NV, (Acquired 11/08/17, cost \$253,349) <sup>(d)</sup> $19,488$ $628,488$ InflaRx NV <sup>(a)</sup> $29,508$ $951,633$ Insmed, Inc. <sup>(a)</sup> $67,286$ $1,591,314$ Intercept Pharmaceuticals, Inc. <sup>(a)(b)</sup> $2,600$ $218,166$ Madrigal Pharmaceuticals, Inc. <sup>(a)</sup> $16,236$ $371,317$ Neurocrine Biosciences, Inc. <sup>(a)(b)</sup> $9,300$ $913,632$ Ovid therapeutics, Inc. <sup>(a)(b)</sup> $4,958$ $1,710,460$ Sage Therapeutics, Inc. <sup>(a)(b)</sup> $38,650$ $5,108,757$	Eidos Therapeutics, Inc. <sup>(a)</sup>	4,486	91,245
Global Blood Therapeutics, Inc. <sup>(a)(b)</sup> 5,388       243,538         Halozyme Therapeutics, Inc. <sup>(a)(b)</sup> 41,600       701,792         HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup> 7,449       82,789         HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup> 19,558       260,147         Incyte Corp. <sup>(a)(b)</sup> 22,900       1,534,300         InflaRx NV, (Acquired 11/08/17, cost \$253,349) <sup>(d)</sup> 19,488       628,488         InflaRx NV <sup>(a)</sup> 29,508       951,633         Insmed, Inc. <sup>(a)</sup> 67,286       1,591,314         Intercept Pharmaceuticals, Inc. <sup>(a)(b)</sup> 2,100       587,349         Myovant Sciences Ltd. <sup>(a)</sup> 16,236       371,317         Neurocrine Biosciences, Inc. <sup>(a)(b)</sup> 9,300       913,632         Ovid therapeutics, Inc. <sup>(a)(b)</sup> 4,958       1,710,460         Sage Therapeutics, Inc. <sup>(a)(b)</sup> 4,958       1,710,460         Sage Therapeutics, Inc. <sup>(a)(b)</sup> 38,650       5,108,757	Galapagos NV, ADR <sup>(a)(b)</sup>	5,700	525,426
Halozyme Therapeutics, Inc. $^{(a)(b)}$ 41,600701,792HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) $^{(d)}$ 7,44982,789HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) $^{(d)}$ 19,558260,147Incyte Corp. $^{(a)(b)}$ 22,9001,534,300InflaRx NV, (Acquired 11/08/17, cost \$253,349) $^{(d)}$ 19,488628,488InflaRx NV $^{(a)}$ 29,508951,633Insmed, Inc. $^{(a)}$ 67,2861,591,314Intercept Pharmaceuticals, Inc. $^{(a)(b)}$ 2,100587,349Myovant Sciences Ltd. $^{(a)}$ 9,300913,632Ovid therapeutics, Inc. $^{(a)(b)}$ 9,300913,632Ovid therapeutics, Inc. $^{(a)(b)}$ 49,581,710,460Sage Therapeutics, Inc. $^{(a)(b)}$ 13,5522,121,295Sarepta Therapeutics, Inc. $^{(a)(b)}$ 38,6505,108,757	Gilead Sciences, Inc. <sup>(b)</sup>	85,600	6,063,904
HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789)(d)7,44982,789HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)(d)19,558260,147Incyte Corp. $^{(a)(b)}$ 22,9001,534,300InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)19,488628,488InflaRx NV(a)29,508951,633Insmed, Inc. $^{(a)}$ 67,2861,591,314Intercept Pharmaceuticals, Inc. $^{(a)(b)}$ 2,600218,166Madrigal Pharmaceuticals, Inc. $^{(a)}$ 16,236371,317Neurocrine Biosciences, Inc. $^{(a)(b)}$ 9,300913,632Ovid therapeutics, Inc. $^{(a)}$ 42,053328,013Regeneron Pharmaceuticals, Inc. $^{(a)(b)}$ 4,9581,710,460Sage Therapeutics, Inc. $^{(a)(b)}$ 13,5522,121,295Sarepta Therapeutics, Inc. $^{(a)(b)}$ 38,6505,108,757	Global Blood Therapeutics, Inc. <sup>(a)(b)</sup>	5,388	243,538
HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147)19,558260,147Incyte Corp. $^{(a)(b)}$ 22,9001,534,300InflaRx NV, (Acquired 11/08/17, cost \$253,349)19,488628,488InflaRx NV(a)29,508951,633Insmed, Inc. $^{(a)}$ 67,2861,591,314Intercept Pharmaceuticals, Inc. $^{(a)(b)}$ 2,600218,166Madrigal Pharmaceuticals, Inc. $^{(a)(b)}$ 2,100587,349Myovant Sciences Ltd. $^{(a)}$ 16,236371,317Neurocrine Biosciences, Inc. $^{(a)(b)}$ 9,300913,632Ovid therapeutics, Inc. $^{(a)(b)}$ 4,9581,710,460Sage Therapeutics, Inc. $^{(a)(b)}$ 13,5522,121,295Sarepta Therapeutics, Inc. $^{(a)(b)}$ 38,6505,108,757	Halozyme Therapeutics, Inc. <sup>(a)(b)</sup>	41,600	701,792
$\begin{array}{llllllllllllllllllllllllllllllllllll$	HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) <sup>(d)</sup>	7,449	82,789
InflaRx NV, (Acquired 11/08/17, cost \$253,349)(d)19,488 $628,488$ InflaRx NV(a)29,508951,633Insmed, Inc.(a) $67,286$ 1,591,314Intercept Pharmaceuticals, Inc.(a)(b)2,600218,166Madrigal Pharmaceuticals, Inc.(a)2,100587,349Myovant Sciences Ltd.(a)16,236371,317Neurocrine Biosciences, Inc.(a)(b)9,300913,632Ovid therapeutics, Inc.(a)42,053328,013Regeneron Pharmaceuticals, Inc.(a)(b)4,9581,710,460Sage Therapeutics, Inc.(a)(b)13,5522,121,295Sarepta Therapeutics, Inc.(a)(b)38,6505,108,757	HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) <sup>(d)</sup>	19,558	260,147
InflaRx NV(a)29,508951,633Insmed, Inc. (a) $67,286$ $1,591,314$ Intercept Pharmaceuticals, Inc. (a)(b) $2,600$ $218,166$ Madrigal Pharmaceuticals, Inc. (a) $2,100$ $587,349$ Myovant Sciences Ltd. (a) $16,236$ $371,317$ Neurocrine Biosciences, Inc. (a)(b) $9,300$ $913,632$ Ovid therapeutics, Inc. (a) $42,053$ $328,013$ Regeneron Pharmaceuticals, Inc. (a)(b) $4,958$ $1,710,460$ Sage Therapeutics, Inc. (a)(b) $13,552$ $2,121,295$ Sarepta Therapeutics, Inc. (a)(b) $38,650$ $5,108,757$	Incyte Corp. <sup>(a)(b)</sup>	22,900	1,534,300
Insmed, Inc. $67,286$ $1,591,314$ Intercept Pharmaceuticals, Inc. $2,600$ $218,166$ Madrigal Pharmaceuticals, Inc. $2,100$ $587,349$ Myovant Sciences Ltd. $2,100$ $587,349$ Myovant Sciences, Inc. $16,236$ $371,317$ Neurocrine Biosciences, Inc. $9,300$ $913,632$ Ovid therapeutics, Inc. $42,053$ $328,013$ Regeneron Pharmaceuticals, Inc. $4,958$ $1,710,460$ Sage Therapeutics, Inc. $13,552$ $2,121,295$ Sarepta Therapeutics, Inc. $38,650$ $5,108,757$	InflaRx NV, (Acquired 11/08/17, cost \$253,349) <sup>(d)</sup>	19,488	628,488
Intercept Pharmaceuticals, Inc. $^{(a)(b)}$ 2,600218,166Madrigal Pharmaceuticals, Inc. $^{(a)}$ 2,100587,349Myovant Sciences Ltd. $^{(a)}$ 16,236371,317Neurocrine Biosciences, Inc. $^{(a)(b)}$ 9,300913,632Ovid therapeutics, Inc. $^{(a)}$ 42,053328,013Regeneron Pharmaceuticals, Inc. $^{(a)(b)}$ 4,9581,710,460Sage Therapeutics, Inc. $^{(a)(b)}$ 13,5522,121,295Sarepta Therapeutics, Inc. $^{(a)(b)}$ 38,6505,108,757	InflaRx NV <sup>(a)</sup>	29,508	951,633
Madrigal Pharmaceuticals, Inc. (a) $2,100$ $587,349$ Myovant Sciences Ltd. (a) $16,236$ $371,317$ Neurocrine Biosciences, Inc. (a)(b) $9,300$ $913,632$ Ovid therapeutics, Inc. (a) $42,053$ $328,013$ Regeneron Pharmaceuticals, Inc. (a)(b) $4,958$ $1,710,460$ Sage Therapeutics, Inc. (a)(b) $13,552$ $2,121,295$ Sarepta Therapeutics, Inc. (a)(b) $38,650$ $5,108,757$	Insmed, Inc. <sup>(a)</sup>	67,286	1,591,314
Myovant Sciences Ltd.16,236371,317Neurocrine Biosciences, Inc.9,300913,632Ovid therapeutics, Inc.42,053328,013Regeneron Pharmaceuticals, Inc.4,9581,710,460Sage Therapeutics, Inc.13,5522,121,295Sarepta Therapeutics, Inc.38,6505,108,757	Intercept Pharmaceuticals, Inc. <sup>(a)(b)</sup>	2,600	218,166
Neurocrine Biosciences, Inc. <sup>(a)(b)</sup> 9,300         913,632           Ovid therapeutics, Inc. <sup>(a)</sup> 42,053         328,013           Regeneron Pharmaceuticals, Inc. <sup>(a)(b)</sup> 4,958         1,710,460           Sage Therapeutics, Inc. <sup>(a)(b)</sup> 13,552         2,121,295           Sarepta Therapeutics, Inc. <sup>(a)(b)</sup> 38,650         5,108,757	Madrigal Pharmaceuticals, Inc. <sup>(a)</sup>	2,100	587,349
Ovid therapeutics, Inc. <sup>(a)</sup> 42,053       328,013         Regeneron Pharmaceuticals, Inc. <sup>(a)(b)</sup> 4,958       1,710,460         Sage Therapeutics, Inc. <sup>(a)(b)</sup> 13,552       2,121,295         Sarepta Therapeutics, Inc. <sup>(a)(b)</sup> 38,650       5,108,757	Myovant Sciences Ltd. <sup>(a)</sup>	16,236	371,317
Regeneron Pharmaceuticals, Inc. <sup>(a)(b)</sup> 4,958         1,710,460           Sage Therapeutics, Inc. <sup>(a)(b)</sup> 13,552         2,121,295           Sarepta Therapeutics, Inc. <sup>(a)(b)</sup> 38,650         5,108,757	Neurocrine Biosciences, Inc. <sup>(a)(b)</sup>	9,300	913,632
Sage Therapeutics, Inc. <sup>(a)(b)</sup> 13,552         2,121,295           Sarepta Therapeutics, Inc. <sup>(a)(b)</sup> 38,650         5,108,757	Ovid therapeutics, Inc. <sup>(a)</sup>	42,053	328,013
Sarepta Therapeutics, Inc. <sup>(a)(b)</sup> 38,650         5,108,757	Regeneron Pharmaceuticals, Inc. <sup>(a)(b)</sup>	4,958	1,710,460
	Sage Therapeutics, Inc. <sup>(a)(b)</sup>	13,552	2,121,295
Seattle Genetics Inc $^{(a)(b)}$ 50.467 3.350.504		38,650	5,108,757
Seattle Genetics, Inc. (3) 30,407 3,530,504	Seattle Genetics, Inc. <sup>(a)(b)</sup>	50,467	3,350,504
Spark Therapeutics, Inc. <sup>(a)(b)</sup> 9,010745,668		9,010	745,668
Spectrum Pharmaceuticals, Inc. <sup>(a)(b)</sup> 55,6001,165,376	Spectrum Pharmaceuticals, Inc. <sup>(a)(b)</sup>	55,600	1,165,376

(a)(b)	15 70 4	110.004
Syndax Pharmaceuticals, Inc. <sup>(a)(b)</sup>	15,784	110,804
TESARO, Inc. <sup>(a)</sup>	17,831	792,945
Ultragenyx Pharmaceutical, Inc. <sup>(a)(b)</sup>	21,300	1,637,331
Vertex Pharmaceuticals, Inc. <sup>(a)(b)</sup>	34,005	5,779,490
		67 770 100
Diversified Consumer Services 0.6%		67,278,488
Service Corp. International <sup>(b)</sup>	59,800	2,140,242
Service Corp. International	57,000	2,110,212
Health Care Equipment & Supplies 28.0%		
Abbott Laboratories <sup>(b)</sup>	239,600	14,613,204
Baxter International, Inc. <sup>(b)</sup>	108,800	8,033,792
Becton Dickinson & Co. <sup>(b)</sup>	27,633	6,619,761
Boston Scientific Corp. <sup>(a)(b)</sup>	415,484	13,586,327
Cooper Cos., Inc. <sup>(b)</sup>	4,915	1,157,237
Edwards Lifesciences Corp. <sup>(a)(b)</sup>	31,500	4,585,455
Globus Medical, Inc., Class A <sup>(a)(b)</sup>	24,500	1,236,270
Intuitive Surgical, Inc. <sup>(a)(b)</sup>	12,100	5,789,608
iRhythm Technologies, Inc. <sup>(a)(b)</sup>	15,083	1,223,684
Security	Shares	Value
Health Care Equipment & Supplies (continued)		
Masimo Corp. <sup>(a)(b)</sup>	38,600 \$	3,769,290
Medtronic PLC <sup>(b)</sup>	169,100	14,476,651
Nevro Corp. <sup>(a)(b)</sup>	24,600	1,964,310
ResMed, Inc. <sup>(b)</sup>	31,900	3,304,202
Stryker Corp. <sup>(b)</sup>	69,200	11,685,112
Teleflex, Inc. <sup>(b)</sup>	8,400	2,252,964
Varian Medical Systems, Inc. <sup>(a)(b)</sup>	14,900	1,694,428
		05 000 005
Harlet Come Describer 9 Compiler 24 10		95,992,295
Health Care Providers & Services 24.1%	20.7(0	2 207 900
Amedisys, Inc. <sup>(a)(b)</sup>	39,760	3,397,890
AmerisourceBergen Corp. <sup>(b)</sup>	16,300	1,389,901
Anthem, Inc.	35,800	8,521,474
Centene Corp. <sup>(a)</sup> Cigna Corp. <sup>(b)</sup>	42,800	5,273,388
DaVita, Inc. <sup>(a)(b)</sup>	39,500 55,604	6,713,025
HCA Healthcare, Inc. <sup>(b)</sup>	55,694 18,094	3,867,391 1,856,444
HealthEquity, Inc. <sup>(a)(b)</sup>	12,400	931,240
Humana, Inc. <sup>(b)</sup>	27,600	8,214,588
Molina Healthcare, Inc. <sup>(a)(b)</sup>	11,300	1,106,722
Quest Diagnostics, Inc. <sup>(b)</sup>	80,100	8,806,194
UnitedHealth Group, Inc.	118,302	29,024,213
Universal Health Services, Inc., Class B <sup>(b)</sup>	16,800	
WellCare Health Plans, Inc. <sup>(a)(b)</sup>	6,400	1,872,192 1,575,936
	0,400	1,373,930
		82,550,598
Health Care Technology 0.6%		-
Teladoc, Inc. <sup>(a)(b)</sup>	37,100	2,153,655
Life Sciences Tools & Services 34%		

### Life Sciences Tools & Services 3.4%

Agilent Technologies, Inc. <sup>(b)</sup>	32,200	1,991,248
Charles River Laboratories International, Inc. <sup>(a)(b)</sup>	7,771	872,372
QIAGEN NV <sup>(a)</sup>	48,300	1,746,528
Thermo Fisher Scientific, Inc. <sup>(b)</sup>	27,300	5,654,922
Wuxi Biologics Cayman, Inc. <sup>(a)(e)</sup>	120,500	1,336,723
		11,601,793
Pharmaceuticals 21.9%		
Allergan PLC <sup>(b)</sup>	34,985	5,832,699
Assembly Biosciences, Inc. <sup>(a)</sup>	2,200	86,262
AstraZeneca PLC	69,576	4,812,376
AstraZeneca PLC $ADR^{()}$	63,100	2,215,441
Bristol-Myers Squibb Co. <sup>(b)</sup>	104,762	5,797,529
Chugai Pharmaceutical Co. Ltd.	15,900	832,532
Eli Lilly & Co. <sup>(b)</sup>	65,800	5,614,714
Jazz Pharmaceuticals PLC <sup>(a)(b)</sup>	10,400	1,791,920
Johnson & Johnson <sup>(b)</sup>	41,970	5,092,640
Medicines Co. <sup>(a)(b)</sup>	18,600	682,620
Merck & Co., Inc. <sup>(b)</sup>	109,579	6,651,445
Merck KGaA	28,300	2,754,930
Nektar Therapeutics <sup>(a)(b)</sup>	7,400	361,342
Novartis AG, ADR <sup>(b)</sup>	33,900	2,560,806
Novo Nordisk A/S $AD\mathbb{R}^{0}$	74,300	3,426,716
Pfizer, Inc. <sup>(b)</sup>	465,298	16,881,012
Reata Pharmaceuticals, Inc., Class A <sup>(a)(b)</sup>	5,860	204,924
Sanofi	20,400	1,637,294
Sanofi AD <sup>®</sup> )	50,200	2,008,502
Teva Pharmaceutical Industries Ltd. ADR	35,500	863,360
Theravance Biopharma, Inc. <sup>(a)(b)</sup>	4,700	106,596
Tricida, Inc. <sup>(a)</sup>	9,249	276,545
Zoetis, Inc. <sup>(b)</sup>	54,500	4,642,855
		75,135,060
Total Common Stocks 08.20%		

Total Common Stocks 98.3% (Cost \$226,041,590)

336,852,131

Schedule of Investments (unaudited) (continued)	BlackRock Health Sciences Trust (B	BME)
June 30, 2018	(Percentages shown are based on Net As	ssets)
Security Other Interests <sup>(f)</sup> 0.0%	Shares V	alue
<b>Pharmaceuticals</b> 0.0% Afferent Pharmaceuticals, Inc., Series C, (Acquired 09/30/15, Cost \$0)	) <sup>(c)(d)</sup> 190 \$ 115	5,997
Total Other Interests 0.0% (Cost \$ )	115	5,997
Preferred Stock		
<b>Biotechnology 0.2%</b> Rubius Therapeutics, Inc., (Acquired 2/23/18, cost \$505,410), 0.00% <sup>(a)</sup>	a)(c)(d) 39,516 505	5,410
Total Preferred Stocks 0.2% (Cost \$505,410)	505	5,410
Rights 0.0%		
Health Care Technology 0.0% Dyax Corp., CVR (Expires 12/31/19) <sup>(c)</sup>	61,727 141	,355
Total Rights 0.0% (Cost \$25,848)	141	,355
Total Long-Term Investments 98.5% (Cost \$226,572,848)	337,614	l,893
Security	Shares Va	alue
<b>Short-Term Securities</b> 2.1% BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% <sup>(g)(h)</sup>	7,272,162 \$ 7,272,	.162
Total Short-Term Securities 2.1% (Cost \$7,272,162)	7,272,	.162
Total Investments Before Options Written 100.6% (Cost \$233,845,010)	344,887,	055
Options Written (0.8)% (Premiums Received \$2,899,524)	(2,688,	.836)
Total Investments, Net of Options Written 99.8% (Cost \$230,945,486)	342,198,	219

Other Assets Less Liabilities 0.2%

Net Assets 100.0%

531,212

\$ 342,729,431

 $\sim$ 

<sup>(a)</sup> Non-income producing security.

- <sup>(b)</sup> All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- <sup>(c)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
- <sup>(d)</sup> Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$3,432,644 and an original cost of \$2,088,097, which was 0.8% of its net assets.
- <sup>(e)</sup> Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
- <sup>(f)</sup> Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.
- <sup>(g)</sup> Annualized 7-day yield as of period end.
- <sup>(h)</sup> During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

								Char	ıge
									in
	Shares		Shares				Nem	realiz	zed
	Held at	Net	Held at	Value at		Real	Applro	eciat	ion
Affiliate	12/31/17	Activity	06/30/18	06/30/18	InconGeain	(LøÐ	)¢pre	ciati	on)
BlackRock Liquidity									
Funds, T-Fund,									
Institutional Class	14,301,421	(7,029,259)	7,272,162	\$7,272,162	\$ 83,489	\$		\$	
SL Liquidity Series,									
LLC, Money Market									
Series	120,903	(120,903)			1,241 <sup>(b)</sup>		13		7
				\$7,272,162	\$84,730	\$	13	\$	7

<sup>(a)</sup> Includes net capital gain distributions, if applicable.

<sup>(b)</sup> Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

For Trust compliance purposes, the Trust s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

# Derivative Financial Instruments Outstanding as of Period End

# **Exchange-Traded Options Written**

	Number of	Expiration	Exercise No		otional	
Description	<b>Contracts</b>	Date	Price	Price Amount (000)		Value
Call						
Pfizer, Inc.	30	07/02/18	USD 36.25	USD	109	\$ (596)
Allergan PLC	63	07/06/18	USD 157.50	USD	1,050	(61,583)
Amgen, Inc.	7	07/06/18	USD 187.50	USD	129	(420)
AstraZeneca PLC	247	07/06/18	USD 37.50	USD	867	(1,235)
Baxter International, Inc.	45	07/06/18	USD 73.50	USD	332	(3,780)

Schedules of Investments

65

# BlackRock Health Sciences Trust (BME)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exercise		Notional		
Description	Contracts	Date		Price	Amoun	nt (000)	Value
Call (continued)				<i></i>			
Gilead Sciences, Inc.	65	07/06/18	USD	69.50	USD	460	\$ (10,693)
Humana, Inc.	67	07/06/18	USD	297.50	USD	1,994	(22,613)
Pfizer, Inc.	101	07/06/18	USD	36.00	USD	366	(4,494)
Pfizer, Inc.	101	07/06/18	USD	36.50	USD	366	(1,313)
Pfizer, Inc.	38	07/06/18	USD	37.00	USD	138	(171)
Zoetis, Inc.	148	07/06/18	USD	85.50	USD	1,261	(9,620)
Novo Nordisk A/S ADR	229	07/09/18	USD	50.00	USD	1,056	(85)
AmerisourceBergen Corp.	44	07/13/18	USD	87.00	USD	375	(5,500)
Amgen, Inc.	72	07/13/18	USD	182.50	USD	1,329	(29,160)
Becton Dickinson & Co.	61	07/13/18	USD	232.50	USD	1,461	(53,070)
Biogen, Inc.	26	07/13/18	USD	295.00	USD	755	(8,970)
Humana, Inc.	22	07/13/18	USD	307.50	USD	655	(2,255)
Medtronic PLC	37	07/13/18	USD	88.50	USD	317	(407)
Pfizer, Inc.	152	07/13/18	USD	36.50	USD	551	(4,332)
Pfizer, Inc.	38	07/13/18	USD	37.00	USD	138	(418)
Vertex Pharmaceuticals, Inc.	109	07/13/18	USD	157.50	USD	1,853	(148,240)
ACADIA Pharmaceuticals, Inc.	149	07/20/18	USD	18.00	USD	228	(4,097)
Acceleron Pharma, Inc.	142	07/20/18	USD	40.00	USD	689	(129,220)
Agilent Technologies, Inc.	40	07/20/18	USD	67.50	USD	247	(180)
Agios Pharmaceuticals, Inc.	62	07/20/18	USD	105.00	USD	522	(1,240)
Alexion Pharmaceuticals, Inc.	56	07/20/18	USD	125.00	USD	695	(19,600)
Allergan PLC	76	07/20/18	USD	180.00	USD	1,267	(4,902)
Alnylam Pharmaceuticals, Inc.	60	07/20/18	USD	120.00	USD	591	(2,400)
Amedisys, Inc.	102	07/20/18	USD	80.00	USD	872	(55,845)
Amedisys, Inc.	58	07/20/18	USD	85.00	USD	496	(16,066)
Arena Pharmaceuticals, Inc.	16	07/20/18	USD	50.00	USD	70	(704)
Baxter International, Inc.	69	07/20/18	USD	72.50	USD	509	(14,594)
BioMarin Pharmaceutical, Inc.	56	07/20/18	USD	95.00	USD	528	(17,500)
BioMarin Pharmaceutical, Inc.	73	07/20/18	USD	100.00	USD	688	(11,498)
Biogen, Inc.	24	07/20/18	USD	280.00	USD	697	(33,120)
Biohaven Pharmaceutical Holding							
Co. Ltd.	28	07/20/18	USD	40.00	USD	111	(6,300)
Bluebird Bio, Inc.	8	07/20/18	USD	195.00	USD	126	(620)
Blueprint Medicines Corp.	14	07/20/18	USD	85.00	USD	89	(1,260)
Boston Scientific Corp.	658	07/20/18	USD	31.00	USD	2,152	(135,548)
Bristol-Myers Squibb Co.	142	07/20/18	USD	55.00	USD	786	(16,046)
Cooper Cos., Inc.	19	07/20/18	USD	230.00	USD	447	(15,580)
Cytokinetics, Inc.	45	07/20/18	USD	10.00	USD	37	(450)
							. ,

DeVite Inc	105	07/20/19	UCD	70.00	UCD	060	(10.275)
DaVita, Inc.	125	07/20/18	USD	70.00	USD	868	(19,375)
Edwards Lifesciences Corp.	33	07/20/18	USD	145.00	USD	480	(11,385)
Galapagos NV, ADR	22	07/20/18	USD	105.00	USD	203	(10,780)
Gilead Sciences, Inc.	156	07/20/18	USD	67.50	USD	1,105	(60,450)
Global Blood Therapeutics, Inc.	21	07/20/18	USD	50.00	USD	95	(3,202)
Globus Medical, Inc., Class A	88	07/20/18	USD	57.50	USD	444	(1,760)
HCA Healthcare, Inc.	41	07/20/18	USD	105.00	USD	421	(3,997)
Halozyme Therapeutics, Inc.	170	07/20/18	USD	20.00	USD	287	(1,700)
HealthEquity, Inc.	49	07/20/18	USD	85.00	USD	368	(980)
Incyte Corp.	82	07/20/18	USD	75.00	USD	549	(2,665)
Jazz Pharmaceuticals PLC	40	07/20/18	USD	180.00	USD	689	(7,300)
Johnson & Johnson	102	07/20/18	USD	125.00	USD	1,238	(8,670)
Masimo Corp.	151	07/20/18	USD	100.00	USD	1,475	(18,875)
Medicines Co.	74	07/20/18	USD	39.00	USD	272	(5,180)
Medtronic PLC	5	07/20/18	USD	87.50	USD	43	(222)
Medtronic PLC	21	07/20/18	USD	90.00	USD	180	(189)
Merck & Co., Inc.	25	07/20/18	USD	60.00	USD	152	(3,812)
Merck & Co., Inc.	106	07/20/18	USD	62.50	USD	643	(4,081)
Molina Healthcare, Inc.	45	07/20/18	USD	100.00	USD	441	(8,100)
Nektar Therapeutics	29	07/20/18	USD	65.00	USD	142	(1,087)
Neurocrine Biosciences, Inc.	36	07/20/18	USD	94.25	USD	354	(22,744)
Nevro Corp.	98	07/20/18	USD	85.00	USD	783	(8,330)
Novartis AG, ADR	86	07/20/18	USD	80.00	USD	650	(1,075)
Novo Nordisk A/S ADR	58	07/20/18	USD	48.90	USD	267	(1,097)

# BlackRock Health Sciences Trust (BME)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	N	otional	
Description	<b>Contracts</b>	Date		Price	Amour	nt (000)	Value
Call (continued)							
Pfizer, Inc.	137	07/20/18	USD	36.00	USD	497	\$ (9,385)
Pfizer, Inc.	169	07/20/18	USD	35.00	USD	613	(25,012)
Pfizer, Inc.	139	07/20/18	USD	37.00	USD	504	(2,710)
Quest Diagnostics, Inc.	83	07/20/18	USD	106.90	USD	913	(31,349)
Regeneron Pharmaceuticals, Inc.	8	07/20/18	USD	320.00	USD	276	(22,200)
Resmed, Inc.	130	07/20/18	USD	106.95	USD	1,347	(9,808)
Sage Therapeutics, Inc.	39	07/20/18	USD	185.00	USD	610	(1,755)
Sanofi ADR	200	07/20/18	USD	40.00	USD	800	(13,000)
Seattle Genetics, Inc.	201	07/20/18	USD	75.00	USD	1,334	(4,522)
Spark Therapeutics, Inc.	36	07/20/18	USD	79.00	USD	298	(23,431)
Stryker Corp.	280	07/20/18	USD	175.00	USD	4,728	(36,400)
Syndax Pharmaceuticals, Inc.	63	07/20/18	USD	10.00	USD	44	(1,260)
Teladoc, Inc.	148	07/20/18	USD	60.00	USD	859	(26,270)
Theravance Biopharma, Inc.	18	07/20/18	USD	25.00	USD	41	(585)
Thermo Fisher Scientific, Inc.	109	07/20/18	USD	220.00	USD	2,258	(2,725)
Universal Health Services, Inc.,							
Class B	34	07/20/18	USD	120.00	USD	379	(1,020)
Varian Medical Systems, Inc.	59	07/20/18	USD	125.00	USD	671	(885)
Vertex Pharmaceuticals, Inc.	27	07/20/18	USD	160.00	USD	459	(33,345)
WellCare Health Plans, Inc.	25	07/20/18	USD	240.00	USD	616	(23,250)
iRhythm Technologies, Inc.	57	07/20/18	USD	85.00	USD	462	(8,408)
Universal Health Services, Inc.,							
Class B	33	07/23/18	USD	116.50	USD	368	(2,189)
Novartis AG, ADR	66	07/25/18	USD	76.45	USD	499	(7,301)
Abbott Laboratories	486	07/27/18	USD	63.00	USD	2,964	(25,029)
Baxter International, Inc.	71	07/27/18	USD	76.00	USD	524	(6,638)
Biogen, Inc.	8	07/27/18	USD	310.00	USD	232	(2,620)
Boston Scientific Corp.	181	07/27/18	USD	31.50	USD	592	(38,553)
Boston Scientific Corp.	186	07/27/18	USD	33.50	USD	608	(18,600)
Bristol-Myers Squibb Co.	73	07/27/18	USD	55.00	USD	404	(11,826)
Cigna Corp.	158	07/27/18	USD	180.00	USD	2,685	(16,432)
Edwards Lifesciences Corp.	60	07/27/18	USD	155.00	USD	873	(16,650)
Gilead Sciences, Inc.	63	07/27/18	USD	72.00	USD	446	(11,624)
Intercept Pharmaceuticals, Inc.	10	07/27/18	USD	85.00	USD	84	(4,600)
Medtronic PLC	61	07/27/18	USD	88.50	USD	522	(2,318)
Medtronic PLC	85	07/27/18	USD	86.50	USD	728	(8,415)
Merck & Co., Inc.	106	07/27/18	USD	63.50	USD	643	(4,982)
Pfizer, Inc.	255	07/27/18	USD	37.00	USD	925	(6,885)

Pfizer, Inc.	73	07/27/18	USD	36.50	USD	265	(3,540)
Sage Therapeutics, Inc.	15	07/27/18	USD	165.00	USD	235	(8,025)
Pfizer, Inc.	71	07/30/18	USD	36.75	USD	258	(3,105)
Pfizer, Inc.	121	07/30/18	USD	36.50	USD	439	(5,874)
Amicus Therapeutics, Inc.	89	08/03/18	USD	16.00	USD	139	(8,455)
Baxter International, Inc.	136	08/03/18	USD	75.00	USD	1,004	(17,612)
Baxter International, Inc.	45	08/03/18	USD	73.50	USD	332	(9,180)
Biogen, Inc.	3	08/03/18	USD	300.00	USD	87	(2,085)
Bristol-Myers Squibb Co.	175	08/03/18	USD	56.00	USD	968	(22,838)
Johnson & Johnson	33	08/03/18	USD	126.00	USD	400	(3,399)
Medtronic PLC	74	08/03/18	USD	86.50	USD	634	(8,843)
Pfizer, Inc.	157	08/03/18	USD	36.50	USD	570	(9,499)
Novo Nordisk A/S ADR	33	08/06/18	USD	45.01	USD	152	(6,471)
Abbott Laboratories	251	08/09/18	USD	62.50	USD	1,531	(22,009)
AmerisourceBergen Corp.	21	08/10/18	USD	88.00	USD	179	(5,512)
Boston Scientific Corp.	318	08/10/18	USD	32.50	USD	1,040	(50,403)
Edwards Lifesciences Corp.	33	08/10/18	USD	149.00	USD	480	(18,645)
Eli Lilly & Co.	133	08/10/18	USD	86.00	USD	1,135	(25,337)
HCA Healthcare, Inc.	31	08/10/18	USD	106.00	USD	318	(5,425)
Intuitive Surgical, Inc.	48	08/10/18	USD	495.00	USD	2,297	(58,800)
Medtronic PLC	74	08/10/18	USD	87.00	USD	634	(8,732)
Pfizer, Inc.	121	08/10/18	USD	36.50	USD	439	(7,865)
Zoetis, Inc.	70	08/10/18	USD	87.50	USD	596	(11,375)
Abbott Laboratories	221	08/17/18	USD	62.82	USD	1,348	(20,353)
Agilent Technologies, Inc.	88	08/17/18	USD	62.50	USD	544	(18,480)
Alexion Pharmaceuticals, Inc.	57	08/17/18	USD	125.00	USD	708	(35,625)

SCHEDULES OF INVESTMENTS

67

### BlackRock Health Sciences Trust (BME)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exercise	Notional	
Description	Contracts	Date	Price	Amount (000)	Value
Call (continued)					
Amgen, Inc.	33	08/17/18	USD 190.00	USD 609	\$ (11,715)
Baxter International, Inc.	69	08/17/18	USD 72.50	USD 509	(20,700)
Becton Dickinson & Co.	49	08/17/18	USD 240.00	USD 1,174	(37,485)
Biogen, Inc.	39	08/17/18	USD 300.00	USD 1,132	(34,125)
Boston Scientific Corp.	318	08/17/18	USD 33.00	USD 1,040	(46,746)
Charles River Laboratories					
International, Inc.	36	08/17/18	USD 115.00	USD 404	(10,980)
Eli Lilly & Co.	130	08/17/18	USD 87.50	USD 1,109	(18,720)
Gilead Sciences, Inc.	37	08/17/18	USD 75.00	USD 262	(5,032)
Humana, Inc.	21	08/17/18	USD 305.00	USD 625	(14,805)
Johnson & Johnson	32	08/17/18	USD 125.00	USD 388	(5,728)
Medtronic PLC	319	08/17/18	USD 87.50	USD 2,731	(36,207)
Merck & Co., Inc.	95	08/17/18	USD 62.50	USD 577	(10,878)
Merck & Co., Inc.	106	08/17/18	USD 65.00	USD 643	(4,823)
Pfizer, Inc.	158	08/17/18	USD 37.00	USD 573	(7,268)
Quest Diagnostics, Inc.	83	08/17/18	USD 106.90	USD 913	(41,360)
Quest Diagnostics, Inc.	154	08/17/18	USD 110.00	USD 1,693	(49,280)
Reata Pharmaceuticals, Inc.,					
Class A	23	08/17/18	USD 40.00	USD 80	(4,197)
Regeneron Pharmaceuticals, Inc.,	,				
Class A	11	08/17/18	USD 340.00	USD 379	(23,100)
Sarepta Therapeutics, Inc., Class	A 154	08/17/18	USD 145.00	USD 2,036	(107,415)
Spectrum Pharmaceuticals, Inc.,					
Class A	222	08/17/18	USD 20.00	USD 465	(61,605)
Teleflex, Inc , Class A	33	08/17/18	USD 290.00	USD 885	(16,500)
Teva Pharmaceutical Industries					
Ltd. ADR, Class A	124	08/17/18	USD 25.00	USD 302	(15,810)
Ultragenyx Pharmaceutical, Inc.,					
Class A	85	08/17/18	USD 80.00	USD 653	(36,125)
Service Corp. International,					
Class A	53	08/20/18	USD 36.75	USD 190	(5,977)

\$ (2,548,831)

**OTC Options Written** 

	Ν	Number of	Expiration	E.	xercise	$N_{i}$	otional		
Description	Counterparty	Contracts	Date		Price	Amoun	t (000)		Value
Call									
InflaRx NV	UBS AG	11,800	07/02/18	USD	39.00	USD	381	\$	
Insmed, Inc.	Barclays Bank PLC	13,500	07/09/18	USD	27.50	USD	319		(897)
DaVita, Inc.	UBS AG	9,700	07/10/18	USD	70.46	USD	674		(8,289)
Myovant									
Sciences Ltd.	Bank of America N.A.	7,100	07/11/18	USD	24.98	USD	162		(1,492)
Merck &									
Co., Inc.	Morgan Stanley & Co. International PLC	11,300	07/19/18	EUR	89.51	EUR	942		(1,907)
Service									
Corp.									
International	Barclays Bank PLC	18,600	07/24/18	USD	35.48	USD	666		(18,247)
Wuxi									
Biologics									
Cayman, Inc.	JPMorgan Chase Bank N.A.	48,000	07/24/18	HKD	89.71	HKD	4,177		(22,519)
Insmed, Inc.	Barclays Bank PLC	13,500	07/25/18	USD	27.50	USD	319		(5,098)
Sanofi	UBS AG	8,100	07/25/18	EUR	67.27	EUR	557		(21,412)
Novo									
Nordisk A/S									
ADR	Barclays Bank PLC	6,400	07/26/18	USD	45.41	USD	295		(9,708)
AstraZeneca									
PLC	Goldman Sachs International	27,800	08/08/18	GBP	52.35	GBP	1,457		(50,436)
								\$(]	140,005)

# Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap			
	Premium	Premium	Unrealized	Unrealized	
	Paid	Received	Appreciation	Depreciation	Value
Options Written	N/A	N/A	\$ 893,309	\$ (682,621)	\$ (2,688,836)

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

68

### BlackRock Health Sciences Trust (BME)

June 30, 2018

### Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

Liabilities Derivative Financial Instruments	Commodity Contracts C	Credit ontracts		Foreign Currency Exchange Contracts	Interest Rate	Other	Total
Options written Options written, at value	\$	\$	\$ 2,688,836	\$	\$	\$	\$ 2,688,836

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts C	Credit Contracts	Equity H	U	Interest	Other ontracts		Total
<b>Net Realized Gain</b> (Loss) from: Options purchased <sup>(a)</sup> Options written	\$	\$	\$ (360) (2,080,545)	\$	\$	\$	\$ (2,0	(360) 980,545)
	\$	\$	\$(2,080,905)	\$	\$	\$	\$(2,0	80,905)

<sup>(a)</sup> Options purchased are included in net realized gain (loss) from investments.

Net Change in Unrealized Appreciation				
on:				
Options written	\$ \$	\$6,401	\$ \$	\$ \$6,401

### Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:		
Average value of option contracts written	\$	(a)
Average value of option contracts written	\$ 2,243,25	50

<sup>(a)</sup> Derivative not held at quarter-end. The amount shown in the Statements of Operation reflect the results of activity during the period.

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

#### Derivative Financial Instruments Offsetting as of Period End:

The Trust s derivative assets and liabilities (by type) were as follows:

	Assets	Liabilities
<b>Derivative Financial Instruments:</b> Options	\$	\$ 2,688,836
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA	)	(2,548,831)
Total derivative assets and liabilities subject to an MNA	\$	\$ 140,005

The following table presents the Trust s derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

	) ai	Derivative Liabilities Subject to 1 MNA by	Derivatives Available	Non-cash Collateral	Cash Collateral	of D	t Amount Derivative iabilities
Counterparty		nterparty	for Offset	Pledged	Pledged		(a)
Bank of America N.A.	\$	1,492	\$	\$	\$	\$	1,492
Barclays Bank PLC		33,950					33,950
Goldman Sachs International		50,436					50,436
JPMorgan Chase Bank N.A.		22,519					22,519
Morgan Stanley & Co. International							
PLC		1,907					1,907
UBS AG		29,701					29,701
	\$	140,005	\$	\$	\$	\$	140,005

<sup>(a)</sup> Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Schedules of Investments

BlackRock Health Sciences Trust (BME)

June 30, 2018

### Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Biotechnology	\$ 64,467,251	\$ 628,488	\$2,182,749	\$ 67,278,488
Diversified Consumer Services	2,140,242			2,140,242
Health Care Equipment & Supplies	95,992,295			95,992,295
Health Care Providers & Services	82,550,598			82,550,598
Health Care Technology	2,153,655			2,153,655
Life Sciences Tools & Services	10,265,070	1,336,723		11,601,793
Pharmaceuticals	65,097,928	10,037,132		75,135,060
Other Interests			115,997	115,997
Preferred Stock			505,410	505,410
Rights			141,355	141,355
Short-Term Securities	7,272,162			7,272,162
	\$ 329,939,201	\$12,002,343	\$2,945,511	\$ 344,887,055
Derivative Financial Instruments <sup>(a)</sup> Liabilities:				
Equity contracts	\$ (2,345,082)	\$ (343,754)	\$	\$ (2,688,836)

<sup>(a)</sup> Derivative financial instruments are options written, which are shown at value. Transfers between Level 1 and Level 2 were as follows:

	Transfers into Level 1	Transfers out of Level 1 <sup>(a)</sup>	Transfers Into Level 2 <sup>(a)</sup>	Transfers out of Level 2		
Assets: Long-Term Investments:						
Common Stocks	\$	\$ 548,148	\$ 548,148	\$		

(a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common	Preferred			
	Stocks	Stocks	Other Interests	Rights	Total
Assets:				U U	
Opening Balance, as of December 31, 2017 Transfers into Level 3	\$ 1,916,972	\$	\$ 387,926	\$ 141,355	\$ 2,446,253
Transfers out of Level 3 Accrued discounts/premiums Net realized gain (loss)					
Net change in unrealized appreciation (depreciation) <sup>(a)(b)</sup>	(77,160)	505 410	(271,928)		(349,088)
Purchases Sales	342,936	505,410			848,346
Closing Balance, as of June 30, 2018	\$2,182,748	\$ 505,410	\$ 115,998	\$ 141,355	\$ 2,945,511
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2018 <sup>(b)</sup>	\$ (77,159)	\$	\$ (271,929)	\$	\$ (349,088)

<sup>(a)</sup> Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

(b) Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on derivative financial instruments still held at June 30, 2018 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end.

See notes to financial statements.

BlackRock Resources & Commodities Strategy Trust (BCX) Schedule of Investments (unaudited) June 30, 2018 (Percentages shown are based on Net Assets) Security Shares Value Common Stocks 98.4% Chemicals 11.9% Albemarle Corp.<sup>(a)</sup> 91,502 \$ 8,631,384 CF Industries Holdings, Inc.(a) 144,743 6,426,589 FMC Corp.(a) 196,837 17,559,829 Nufarm Ltd. 1,447,185 9,485,131 Nutrien Ltd.<sup>(a)</sup> 1,094,186 59,501,835 Umicore SA 132,428 7,559,973 Yara International ASA 210,760 8,719,600 117,884,341 Containers & Packaging 4.6% International Paper Co.(a) 138,669 7,221,881 Packaging Corp. of America<sup>(a)</sup> 177,059 19,793,426 Smurfit Kappa Group PLC 464,673 18,759,400 45,774,707 Electronic Equipment, Instruments & Components 0.7% Trimble, Inc.<sup>(a)(b)</sup> 201,408 6,614,239 Energy Equipment & Services 1.7% Baker Hughes a GE Co.<sup>(a)</sup> 212.620 7.022.839 Halliburton Co.(a) 221,372 9,975,022 16,997,861 Food Products 7.7% Archer-Daniels-Midland Co.(a) 680.887 31,205,051 Bunge Ltd.<sup>(a)</sup> 96,788 6,747,091 Glanbia PLC 628,916 11,677,725 Hormel Foods Corp.<sup>(a)</sup> 426,641 15,875,312 **Origin Enterprises PLC** 583,252 4,202,521 Tyson Foods, Inc., Class A<sup>(a)</sup> 83,491 5,748,355 75,456,055 Machinery 1.3% Deere & Co.<sup>(a)</sup> 88,995 12,441,501 Metals & Mining 34.9% ArcelorMittal 776,992 22,669,328 50,814,714 **BHP Billiton PLC** 2,264,226 First Quantum Minerals Ltd. 1,023,945 15,086,764 Franco-Nevada Corp. 110.278 8.048.662 Fresnillo PLC 564,708 8,509,983

Glencore PLC <sup>(b)</sup>	11,099,845	52,699,723
Lundin Mining Corp.	1,509,300	8,392,335
Neo Lithium Corp. <sup>(b)</sup>	5,022,674	5,004,908
Nevsun Resources Ltd.	3,527,285	12,261,585
Newcrest Mining Ltd.	1,174,528	19,070,967
OZ Minerals Ltd.	1,292,966	9,016,014
Polyus PJSC	128,648	4,220,500
Rio Tinto PLC ADR <sup>)</sup>	767,833	42,599,375
Stelco Holdings, Inc.	1,079,971	20,824,756
Teck Resources Ltd., Class B <sup>(a)</sup>	725,386	18,461,074
Vale SA $ADR^{0}$	2,713,425	34,786,108
Wheaton Precious Metals Corp.	571,192	12,600,496
		345,067,292
Oil, Gas & Consumable Fuels 34.1%		
BP PLC $ADR^{0}$	1,143,873	52,229,241
Cairn Energy PLC <sup>(b)</sup>	1,965,097	6,452,517
Canadian Natural Resources Ltd.	407,563	14,710,276
Chevron Corp. <sup>(a)</sup>	129,953	16,429,958
CNOOC Ltd.	6,962,000	11,929,696
ConocoPhillips <sup>(a)</sup>	212,222	14,774,896
Devon Energy Corp. <sup>(a)</sup>	231,866	10,192,829
Encana Corp.	374,738	4,894,270
EQT Corp.	115,770	6,388,189
Exxon Mobil Corp. <sup>(a)</sup>	337,908	27,955,129
*	Shares	27,955,129 Value
Security	Snares	vaiue
Oil, Gas & Consumable Fuels (continued)	(00,000, ¢	4.0(2.744
Kosmos Energy Ltd. <sup>(b)</sup>	600,090 \$	
Pioneer Natural Resources Co. <sup>(a)</sup>	61,744	11,684,435
Royal Dutch Shell PLC ADR,		
Class A <sup>(a)</sup>	833,537	57,705,766
Suncor Energy, Inc.	913,331	37,168,226
TOTAL SA	757,330	45,989,421
Valero Energy Corp.	121,400	13,454,762
		336,922,355
Paper & Forest Products 1.5%		•
Mondi PLC	538,826	14,536,491
Precious Woods Holding AG <sup>(b)</sup>	20,000	153,489
Quintis Ltd. <sup>(b)(c)(d)</sup>	7,903,565	67
		14 600 047
		14,690,047
Total Common Stocks 98.4%		
(Cost \$805,565,896)		971,848,398
	Par	
	(000)	
Corporate Bonds 1.6%		
Metals & Mining 1.6%		

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS								
Beadell Resources LTD, 6.00%, 06/30/23 <sup>(c)</sup> Pilgangoora Operations Pty Ltd, 12.00%, 06/21/22 Osisko Gold Royalties, Ltd., 4.00%, 12/31/22	USD CAD	1,800 9,000 5,652	1,799,820 10,077,705 4,299,243					
			16,176,768					
Total Corporate Bonds 1.6% (Cost \$15,311,494)			16,176,768					
Total Long-Term Investments 100.0% (Cost \$820,877,390)			988,025,166					
		Shares						
<ul> <li>Short-Term Securities 0.8%</li> <li>BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80%<sup>(e)(g)</sup></li> <li>SL Liquidity Series, LLC, Money Market Series, 2.16%<sup>(e)(f)(g)</sup></li> <li>Total Short-Term Securities 0.8%</li> <li>(Cost \$7,923,928)</li> </ul>		7,893,261 30,670	7,893,261 30,673 7,923,934					
Total Investments Before Options Written 100.8% (Cost \$828,801,318)			\$ 995,949,100					
Options Written (0.7)% (Premiums Received \$9,065,805)			(7,080,083)					
Total Investments, Net of Options Written 100.1% (Cost \$819,735,513) Liabilities in Excess of Other Assets (0.1)%			988,869,017 (693,588)					
Net Assets Applicable to Common Shares 100.0%			\$ 988,175,429					

<sup>(a)</sup> All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

<sup>(b)</sup> Non-income producing security.

<sup>(c)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

<sup>(d)</sup> Security, or a portion of the security, is on loan.

<sup>(e)</sup> Annualized 7-day yield as of period end.

<sup>(f)</sup> Security was purchased with the cash collateral from loaned securities.

Schedules of Investments

71

Schedule of Investments (unaudited) (continued) BlackRock Resources & Commodities Strategy Trust (BCX)

June 30, 2018

<sup>(g)</sup> During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

								Cha	inge in
	Shares Shares NetInreal						lized		
	Held at	Net	Held at	Value at	1	Reali <b>Aqu</b> preciatio			ition
Affiliate	12/31/17	Activity	06/30/18	06/30/18	Inco <b>ta</b> in (	Incomain (LofDepreciation			ion)
BlackRock Liquidity									
Funds, T-Fund,									
Institutional Class	16,156,750	(8,263,489)	7,893,261	\$7,893,261	\$73,740	\$		\$	
SL Liquidity Series,									
LLC, Money Market									
Series	488,032	(457,362)	30,670	30,673	2,510 <sup>(b)</sup>		2		45
				\$7,923,934	\$76,250	\$	2	\$	45

<sup>(a)</sup> Includes net capital gain distributions, if applicable.

(b) Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

For Trust compliance purposes, the Trust s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

### Derivative Financial Instruments Outstanding as of Period End

### **Exchange-Traded Options Written**

	Number of	Expiration	Exercise		Notional		
Description	Contracts	Date		Price	Amoun	nt (000)	Value
Call							
Archer-Daniels-Midland Co.	501	07/06/18	USD	45.00	USD	2,296	\$ (51,854)
Chevron Corp.	151	07/06/18	USD	128.00	USD	1,909	(8,909)
ConocoPhillips	236	07/06/18	USD	70.00	USD	1,643	(17,110)
Deere & Co.	66	07/06/18	USD	165.00	USD	923	(924)
Devon Energy Corp.	114	07/06/18	USD	43.50	USD	501	(11,856)
Devon Energy Corp.	129	07/06/18	USD	41.00	USD	567	(39,668)
Halliburton Co.	143	07/06/18	USD	51.50	USD	644	(429)
Hormel Foods Corp.	240	07/06/18	USD	36.50	USD	893	(20,400)

International Paper Co.	134	07/06/18	USD	55.00	USD	698	(938)
International Paper Co.	70	07/06/18	USD	56.00	USD	365	(280)
Tyson Foods, Inc., Class A	84	07/06/18	USD	73.00	USD	578	(840)
Tyson Foods, Inc., Class A	96	07/06/18	USD	72.00	USD	661	(1,440)
Vale SA ADR	852	07/06/18	USD	15.00	USD	1,092	(1,704)
Archer-Daniels-Midland Co.	330	07/13/18	USD	44.00	USD	1,512	(68,475)
BP PLC ADR	534	07/13/18	USD	46.00	USD	2,438	(29,370)
Chevron Corp.	150	07/13/18	USD	129.00	USD	1,896	(12,675)
ConocoPhillips	278	07/13/18	USD	70.00	USD	1,935	(33,221)
Exxon Mobil Corp.	251	07/13/18	USD	83.00	USD	2,077	(25,602)
Hormel Foods Corp.	215	07/13/18	USD	36.00	USD	800	(29,563)
Hormel Foods Corp.	215	07/13/18	USD	36.50	USD	800	(22,037)
International Paper Co.	134	07/13/18	USD	55.50	USD	698	(1,407)
Pioneer Natural Resources Co.	87	07/13/18	USD	197.50	USD	1,646	(12,397)
Royal Dutch Shell PLC ADR,							
Class A	157	07/13/18	USD	71.00	USD	1,087	(5,495)
Teck Resources Ltd., Class B	619	07/13/18	USD	31.50	USD	1,575	(103,992)
Tyson Foods, Inc., Class A	332	07/13/18	USD	69.00	USD	2,286	(35,690)
Vale SA ADR	590	07/13/18	USD	14.00	USD	756	(3,835)
Vale SA ADR	752	07/13/18	USD	14.50	USD	964	(2,632)
Albemarle Corp.	370	07/20/18	USD	95.00	USD	3,490	(81,400)
Archer-Daniels-Midland Co.	410	07/20/18	USD	45.00	USD	1,879	(54,120)
BP PLC ADR	1,498	07/20/18	USD	47.00	USD	6,840	(50,932)
Baker Hughes a GE Co.	233	07/20/18	USD	39.00	USD	770	(2,330)
Baker Hughes a GE Co.	311	07/20/18	USD	36.00	USD	1,027	(7,775)
Bunge Ltd.	116	07/20/18	USD	72.50	USD	809	(11,020)
CF Industries Holdings, Inc.	110	07/20/18	USD	42.50	USD	488	(29,095)
Canadian Natural Resources Ltd.	195	07/20/18	CAD	48.00	CAD	925	(12,534)
Chevron Corp.	149	07/20/18	USD	130.00	USD	1,884	(14,229)
ConocoPhillips	30	07/20/18	USD	72.50	USD	209	(1,770)
ConocoPhillips	236	07/20/18	USD	70.50	USD	1,643	(29,618)
Deere & Co.	80	07/20/18	USD	165.00	USD	1,118	(1,360)
Devon Energy Corp.	150	07/20/18	USD	38.00	USD	659	(92,625)
							/

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

Schedule of Investments (unaudited) (continued) BlackRock Resources & Commodities Strategy Trust (BCX)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration	ion Exercise Notional		Votional		
Description	Contracts	Date		Price	Атои	nt (000)	Value
Call (continued)							
Devon Energy Corp.	69	07/20/18	USD	44.00	USD	303	\$ (10,315)
Devon Energy Corp.	82	07/20/18	USD	46.00	USD	360	(5,658)
Encana Corp.	860	07/20/18	CAD	17.00	CAD	1,477	(47,427)
FMC Corp.	304	07/20/18	USD	92.50	USD	2,712	(25,840)
First Quantum Minerals Ltd.	1,000	07/20/18	CAD	18.00	CAD	1,937	(140,342)
First Quantum Minerals Ltd.	391	07/20/18	CAD	23.00	CAD	757	(3,272)
First Quantum Minerals Ltd.	1,299	07/20/18	CAD	22.00	CAD	2,516	(18,280)
Franco-Nevada Corp.	299	07/20/18	CAD	94.00	CAD	2,869	(65,616)
Hormel Foods Corp.	139	07/20/18	USD	36.25	USD	517	(17,337)
International Paper Co.	19	07/20/18	USD	57.50	USD	99	(114)
Lundin Mining Corp.	633	07/20/18	CAD	9.00	CAD	463	(1,926)
Nutrien Ltd.	250	07/20/18	USD	51.55	USD	1,360	(80,311)
Nutrien Ltd.	800	07/20/18	USD	55.00	USD	4,350	(72,000)
Packaging Corp. of America	480	07/20/18	USD	125.00	USD	5,366	(4,800)
Rio Tinto PLC ADR	373	07/20/18	USD	62.50	USD	2,069	(3,730)
Rio Tinto PLC ADR	249	07/20/18	USD	60.00	USD	1,381	(3,735)
Royal Dutch Shell PLC ADR,							
Class A	558	07/20/18	USD	70.00	USD	3,863	(51,615)
Royal Dutch Shell PLC ADR,							
Class A	579	07/20/18	USD	75.00	USD	4,008	(4,342)
Suncor Energy, Inc.	2,088	07/20/18	CAD	54.00	CAD	11,171	(131,031)
Teck Resources Ltd., Class B	264	07/20/18	USD	29.00	USD	672	(2,376)
Trimble, Inc.	148	07/20/18	USD	35.00	USD	486	(1,850)
Vale SA ADR	1,325	07/20/18	USD	15.00	USD	1,699	(4,637)
Archer-Daniels-Midland Co.	254	07/27/18	USD	46.00	USD	1,164	(21,082)
Archer-Daniels-Midland Co.	264	07/27/18	USD	47.00	USD	1,210	(10,824)
BP PLC ADR	535	07/27/18	USD	47.00	USD	2,443	(25,948)
BP PLC ADR	338	07/27/18	USD	46.00	USD	1,543	(29,913)
CF Industries Holdings, Inc.	361	07/27/18	USD	45.50	USD	1,603	(41,335)
Chevron Corp.	56	07/27/18	USD	130.00	USD	708	(8,428)
ConocoPhillips	1	07/27/18	USD	69.00	USD	7	(234)
Deere & Co.	130	07/27/18	USD	147.00	USD	1,817	(25,025)
Devon Energy Corp.	82	07/27/18	USD	45.50	USD	360	(8,897)
Devon Energy Corp.	31	07/27/18	USD	45.00	USD	136	(3,983)
Exxon Mobil Corp.	820	07/27/18	USD	85.00	USD	6,784	(65,600)
Halliburton Co.	374	07/27/18	USD	49.50	USD	1,685	(10,659)
International Paper Co.	18	07/27/18	USD	59.00	USD	94	(162)
Nutrien Ltd.	735	07/27/18	USD	52.50	USD	3,997	(191,100)

Nutrien Ltd.	500	07/27/18	USD	55.00	USD	2,719	(56,250)
Pioneer Natural Resources Co.	75	07/27/18	USD	202.50	USD	1,419	(14,250)
Royal Dutch Shell PLC ADR,							
Class A	186	07/27/18	USD	71.00	USD	1,288	(14,880)
Royal Dutch Shell PLC ADR,							
Class A	579	07/27/18	USD	69.50	USD	4,008	(82,508)
Teck Resources Ltd., Class B	410	07/27/18	USD	29.50	USD	1,043	(20,090)
Vale SA ADR	398	07/27/18	USD	14.50	USD	510	(3,980)
Vale SA ADR	1,030	07/27/18	USD	13.50	USD	1,320	(28,840)
Bunge Ltd.	85	08/02/18	USD	72.01	USD	593	(13,504)
Archer-Daniels-Midland Co.	264	08/03/18	USD	47.00	USD	1,210	(20,460)
BP PLC ADR	686	08/03/18	USD	46.00	USD	3,132	(79,919)
Devon Energy Corp.	69	08/03/18	USD	43.50	USD	303	(17,319)
Exxon Mobil Corp.	137	08/03/18	USD	83.00	USD	1,133	(26,784)
International Paper Co.	105	08/03/18	USD	54.50	USD	547	(8,505)
Pioneer Natural Resources Co.	22	08/03/18	USD	190.00	USD	416	(15,510)
Pioneer Natural Resources Co.	41	08/03/18	USD	200.00	USD	776	(13,017)
Teck Resources Ltd., Class B	210	08/03/18	USD	27.00	USD	534	(13,650)
Vale SA ADR	1,545	08/03/18	USD	13.50	USD	1,981	(50,985)
Archer-Daniels-Midland Co.	350	08/10/18	USD	46.00	USD	1,604	(46,725)
CF Industries Holdings, Inc.	107	08/10/18	USD	46.00	USD	475	(16,157)
Chevron Corp.	13	08/10/18	USD	128.00	USD	164	(3,874)
Devon Energy Corp.	31	08/10/18	USD	46.00	USD	136	(4,820)
Hormel Foods Corp.	367	08/10/18	USD	37.50	USD	1,366	(37,618)
Teck Resources Ltd., Class B	800	08/10/18	USD	26.00	USD	2,036	(94,400)
Valero Energy Corp.	480	08/10/18	USD	115.00	USD	5,320	(123,120)
Archer-Daniels-Midland Co.	350	08/17/18	USD	46.00	USD	1,604	(48,125)
BP PLC ADR	671	08/17/18	USD	46.00	USD	3,064	(83,204)

Schedules of Investments

Schedule of Investments (unaudited) (continued) BlackRock Resources & Commodities Strategy Trust (BCX)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	Exercise				
Description	Contracts	Date		Price	Amoun	et (000)	Value
Call (continued)							
BP PLC ADR	338	08/17/18	USD	47.00	USD	1,543	\$ (27,716)
Bunge Ltd.	101	08/17/18	USD	72.50	USD	704	(23,987)
Canadian Natural Resources Ltd.	778	08/17/18	CAD	44.00	CAD	3,692	(248,553)
ConocoPhillips	72	08/17/18	USD	70.00	USD	501	(18,396)
Deere & Co.	79	08/17/18	USD	150.00	USD	1,104	(22,712)
Devon Energy Corp.	89	08/17/18	USD	42.00	USD	391	(33,153)
Devon Energy Corp.	82	08/17/18	USD	46.00	USD	360	(14,063)
Encana Corp.	1,995	08/17/18	CAD	17.00	CAD	3,425	(164,650)
Exxon Mobil Corp.	143	08/17/18	USD	82.50	USD	1,183	(34,749)
Halliburton Co.	374	08/17/18	USD	50.00	USD	1,685	(19,635)
International Paper Co.	74	08/17/18	USD	55.00	USD	385	(6,031)
Nutrien Ltd.	735	08/17/18	USD	55.00	USD	3,997	(132,300)
Packaging Corp. of America	228	08/17/18	USD	120.00	USD	2,549	(29,640)
Pioneer Natural Resources Co.	21	08/17/18	USD	185.00	USD	397	(25,095)
Royal Dutch Shell PLC ADR,							
Class A	139	08/17/18	USD	72.50	USD	962	(9,730)
Suncor Energy, Inc.	1,565	08/17/18	CAD	54.00	CAD	8,373	(172,612)
Teck Resources Ltd., Class B	600	08/17/18	USD	30.00	USD	1,527	(17, 100)
Trimble, Inc.	220	08/17/18	USD	35.00	USD	722	(14,300)
Vale SA ADR	1,775	08/17/18	USD	15.00	USD	2,276	(20,412)
Vale SA ADR	437	08/17/18	USD	14.00	USD	560	(12,673)
Vale SA ADR	2,150	09/21/18	USD	13.00	USD	2,756	(178,450)

\$ (4,235,746)

## **OTC Options Written**

		Number of	Expiration	on Exercis		ercise Notional		
Description	Counterparty	Contracts	Date		Price	Price Amount (000)		Value
Call								
FMC Corp.	Citibank N.A.	35,000	07/09/18	USD	90.75	USD	3,122	\$ (29,217)
First Quantum								
Minerals Ltd.	Goldman Sachs International	142,800	07/09/18	CAD	20.76	CAD	2,766	(21,334)
Nutrien Ltd.	Citibank N.A.	50,000	07/09/18	USD	47.93	USD	2,719	(326,789)
Stelco								
Holdings, Inc.	Goldman Sachs International	36,300	07/09/18	CAD	27.21	CAD	920	(1,356)

	0 0							
Glanbia PLC	Goldman Sachs International	79,700	07/10/18	EUR	14.45	EUR	1,267	(135,048)
Rio Tinto PLC		52 400	07/10/10	LICD	55.05	LICD	0.000	(47,440)
ADR	Citibank N.A.	53,400	07/10/18	USD	55.85	USD	2,963	(47,448)
BHP Billiton	USDC Deals DI C	222 700	07/11/10	CDD	17 65	CDD	2.059	(42.220)
PLC	HSBC Bank PLC	232,700	07/11/18	GBP	17.65	GBP	3,958	(42,220)
TOTAL SA	UBS AG Margan Stanlay, & Co. International PLC	81,800	07/11/18	EUR	54.88	EUR	4,254	(2,306)
Glencore PLC Lundin Mining	Morgan Stanley & Co. International PLC	1,038,000	07/12/18	GBP	3.94	GBP	.3,737	(17,051)
Corp.	Credit Suisse International	126,600	07/12/18	CAD	8.70	CAD	925	(1,830)
Nufarm Ltd.	Morgan Stanley & Co. International PLC	96,000	07/12/18	AUD	9.69	AUD	923 851	(1,850)
Smurfit Kappa	Morgan Stanley & Co. International TLC	70,000	07/12/10	AUD	7.07	AUD	0.51	(31)
Group PLC	Goldman Sachs International	58,000	07/12/18	EUR	35.54	EUR	2,005	(12,710)
Stelco	Solumin Suchs International	50,000	07/12/10	LUK	55.54	LUK	2,005	(12,710)
Holdings, Inc.	Goldman Sachs International	50,000	07/12/18	CAD	26.52	CAD	1,268	(7,079)
Umicore SA	Morgan Stanley & Co. International PLC	26,700	07/12/18	EUR	50.02	EUR	1,305	(18,255)
Canadian		,,					-,	(,)
Natural								
Resources Ltd.	Credit Suisse International	77,900	07/16/18	CAD	46.25	CAD	3,696	(104,857)
CNOOC Ltd.	Goldman Sachs International	810,000	07/18/18	HKD	14.07	HKD	10,886	(13,486)
Fresnillo PLC	Morgan Stanley & Co. International PLC	40,000	07/18/18	GBP	13.52	GBP	457	(21)
Glanbia PLC	Morgan Stanley & Co. International PLC	93,500	07/18/18	EUR	15.94	EUR	1,487	(24,510)
Glencore PLC	Credit Suisse International	1,453,000	07/18/18	GBP	4.20	GBP	5,231	(8,564)
Oz Minerals								
Ltd.	Societe Generale	520,000	07/18/18	AUD	10.59	AUD	4,898	(1,725)
Stelco								
Holdings, Inc.	Goldman Sachs International	27,600	07/18/18	CAD	25.20	CAD	700	(16,399)
Umicore SA	HSBC Bank PLC	26,500	07/18/18	EUR	51.37	EUR	1,295	(11,853)
ArcelorMittal	UBS AG	24,700	07/19/18	EUR	28.16	EUR	617	(1,856)
Franco-Nevada								
Corp.	Goldman Sachs International	14,400	07/19/18	CAD	96.00	CAD	1,382	(17,191)
Hormel Foods		<b>2</b> 4 000	0	LICE	06.10	LIGE	000	
Corp.	Bank of America N.A.	24,000	07/19/18	USD	36.13	USD	893	(31,580)
Mondi PLC	Morgan Stanley & Co. International PLC	77,400	07/19/18	GBP	20.91	GBP	1,582	(14,984)
Trimble, Inc.	Citibank N.A.	22,200	07/23/18	USD	35.83	USD	729	(1,491)
Fresnillo PLC Stelco	Goldman Sachs International	123,400	07/24/18	GBP	13.55	GBP	1,409	(1,166)
Holdings, Inc.	Goldman Sachs International	27,600	07/24/18		25.20	CAD	700	(18,567)
Lundin Mining	Goldman Sachs International	27,000	0//24/10	CAD	23.20	CAD	700	(18,507)
Corp.	Morgan Stanley & Co. International PLC	158,000	07/25/18	CAD	9.07	CAD	1,155	(5,066)
Newcrest	Morgan Stanley & Co. International The	150,000	01123/10	CIID	2.07	CIID	1,155	(3,000)
Mining Ltd.	UBS AG	25,000	07/25/18	AUD	21.18	AUD	549	(18,860)
Rio Tinto PLC	020110	20,000	0//20/10		21110		0.17	(10,000)
ADR	Citibank N.A.	36,000	07/25/18	USD	61.02	USD	1,997	(4,324)
Smurfit Kappa		.,>					,	× 1- 1
Group PLC	Goldman Sachs International	17,900	07/25/18	EUR	34.31	EUR	619	(18,875)
•		-						

Schedule of Investments (unaudited) (continued) BlackRock Resources & Commodities Strategy Trust (BCX)

June 30, 2018

# **OTC Options Written (continued)**

		Number of	-		Exercise		Notional		<b>X</b> 7 1
Description	<i>Counterparty</i>	Contracts	Date		Price	Атои	ent (000)		Value
Call (continue	d)								
Smurfit Konno Crown									
Kappa Group PLC	UBS AG	40,000	07/25/18	EUR	34.54	EUR	1,383	\$	(37,215)
TOTAL SA	UBS AG	40,000	07/25/18	EUR	53.09	EUR	1,976	φ	(37,213) (22,957)
	Morgan Stanley & Co. International PLC	100,800	07/26/18	EUR	30.11	EUR	2,518		(22,786)
	Morgan Stanley & Co. International PLC	116,000	07/26/18	EUR	29.61	EUR	2,318		(5,046)
BHP Billiton									
PLC	UBS AG	340,200	07/26/18	GBP	17.26	GBP	5,787		(187,686)
CNOOC Ltd.	JPMorgan Chase Bank N.A.	800,000	07/26/18	HKD	14.07	HKD	10,752		(19,916)
Fresnillo	~			~ ~ ~ ~		~~~~			
PLC	Goldman Sachs International	63,800	07/26/18	GBP	12.45	GBP	729		(2,707)
Glencore		704 100	07/06/10	CDD	2.07	CDD	0.505		
PLC	Goldman Sachs International	704,100	07/26/18	GBP	3.97	GBP	2,535		(32,086)
Mondi PLC	Morgan Stanley & Co. International PLC	139,206	07/26/18	GBP	21.47	GBP	2,845		(13,802)
Nufarm Ltd.	Morgan Stanley & Co. International PLC	214,000	07/26/18	AUD	9.04	AUD	1,896		(21,436)
TOTAL SA	Citibank N.A.	70,500	07/26/18	EUR	53.63	EUR	3,666		(28,655)
Yara Internetional									
International ASA	UBS AG	84,700	07/26/18	NOK	360.37	NOK	28,540		(22, 254)
ASA Rio Tinto	UBS AG	84,700	07720/18	NOK	300.37	NOK	26,340		(32,354)
PLC ADR	Citibank N.A.	54,000	07/30/18	USD	58.98	USD	2,996		(25,136)
Hormel	Chibalik N.A.	54,000	07750/10	05D	50.70	05D	2,770		(23,130)
Foods Corp.	Morgan Stanley & Co. International PLC	29,000	07/31/18	USD	36.26	USD	1,079		(39,135)
Lundin		_>,000	01101110	0.52	00120	0.52	1,077		(0),100)
Mining Corp.	Royal Bank of Canada	196,000	07/31/18	CAD	9.03	CAD	1,433		(10,439)
Stelco	5	,					,		
Holdings,									
Inc.	Credit Suisse International	30,000	07/31/18	CAD	26.30	CAD	761		(12,226)
CNOOC Ltd.	Societe Generale	193,000	08/01/18	HKD	12.78	HKD	2,594		(20,674)
FMC Corp.	Morgan Stanley & Co. International PLC	13,700	08/01/18	USD	88.40	USD	1,222		(45,696)
Stelco									
Holdings,									
Inc.	Goldman Sachs International	25,000	08/01/18	CAD	25.85	CAD	634		(13,517)
TOTAL SA	UBS AG	44,000	08/01/18	EUR	53.87	EUR	2,288		(23,770)
BHP Billiton									
PLC	Morgan Stanley & Co. International PLC	179,000	08/02/18	GBP	18.01	GBP	3,045		(48,551)
Rio Tinto									
PLC ADR	Morgan Stanley & Co. International PLC	51,600	08/03/18	USD	58.75	USD	2,863		(31,200)

Royal Dutch Shell PLC								
ADR, Class A Glencore	Citibank N.A.	56,800	08/06/18	USD	70.97	USD	3,932	(65,421)
PLC Lundin	Goldman Sachs International	1,184,511	08/07/18	GBP	3.88	GBP	4,264	(108,761)
Mining Corp.	Citibank N.A.	63,200	08/07/18	CAD	8.31	CAD	462	(4,324)
Nufarm Ltd.	UBS AG	272,000	08/07/18	AUD	9.58	AUD	2,410	(8,852)
Nutrien Ltd.	Barclays Bank PLC	63,000	08/07/18	USD	51.10	USD	3,426	(249,604)
ArcelorMittal	Goldman Sachs International	65,073	08/08/18	EUR	26.10	EUR	1,626	(51,290)
BHP Billiton								
PLC	JPMorgan Chase Bank N.A.	158,700	08/08/18	GBP	16.62	GBP	2,699	(176,037)
Glanbia PLC	Morgan Stanley & Co. International PLC	74,978	08/08/18	EUR	15.91	EUR	1,192	(30,090)
Smurfit								
Kappa Group		(= 0=0	00/00/11 0	FUB	25.40	FUD	2 2 2 2	
PLC	Goldman Sachs International	67,372	08/08/18	EUR	35.40	EUR	2,329	(45,227)
Stelco								
Holdings,	Caldman Saaka International	25.000	00/00/10		25.95		624	(15, 207)
Inc. TOTAL SA	Goldman Sachs International Goldman Sachs International	25,000	08/08/18 08/08/18	CAD EUR	25.85 52.17	CAD	634 3,650	(15,287)
Baker	Goldman Sachs International	70,200	08/08/18	EUK	32.17	EUR	5,050	(94,205)
Hughes a GE								
Co.	Citibank N.A.	31,100	08/13/18	USD	33.93	USD	1,027	(39,092)
Stelco	Chibalik IV.A.	51,100	00/15/10	05D	55.75	05D	1,027	(37,072)
Holdings,								
Inc.	Credit Suisse International	30,000	08/13/18	CAD	26.88	CAD	761	(11,779)
Nutrien Ltd.	JPMorgan Chase Bank N.A.	25,000	08/14/18	USD	53.95	USD	1,360	(53,272)
Bunge Ltd.	Barclays Bank PLC	8,500	08/16/18	USD	70.73	USD	593	(26,455)
Stelco								
Holdings,								
Inc.	Goldman Sachs International	35,500	08/16/18	CAD	27.00	CAD	900	(13,937)
Rio Tinto								
PLC ADR	Morgan Stanley & Co. International PLC	51,600	08/20/18	USD	58.75	USD	2,863	(30,049)
Royal Dutch								
Shell PLC								
ADR,		56.000	00/00/10	LICD	70.07	LICD	2.022	(71.102)
Class A	Citibank N.A.	56,800	08/20/18	USD	70.97	USD	3,932	(71,193)
Stelco								
Holdings,	Coldmon Sooks International	17 200	00/22/10	CAD	26 50	CAD	420	(0.594)
Inc. Stelco	Goldman Sachs International	17,300	08/22/18	CAD	26.50	CAD	439	(9,584)
Holdings,								
Inc.	Goldman Sachs International	18,200	08/22/18	CAD	25.83	CAD	461	(13,530)
Stelco	Goldman Sachs International	10,200	00/22/10	CAD	25.05	CAD	-01	(15,550)
Holdings,								
Inc.	Credit Suisse International	32,200	08/29/18	CAD	26.00	CAD	816	(24,082)
Stelco	··· ··· ·	- ,===		_		_		、 , <i>,,,,</i> ,,
Holdings,								
Inc.	Credit Suisse International	32,200	09/07/18	CAD	26.00	CAD	816	(26,277)
	Goldman Sachs International	22,500	09/12/18	CAD	25.76	CAD	570	(20,930)

Stelco Holdings, Inc.

## (2,844,337)

# Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap			
	Premium	Premium	Unrealized	Unrealized	
	Paid	Received	Appreciation	Depreciation	Value
Options Written	N/A	N/A	\$ 3,795,486	\$ (1,809,764)	\$(7,080,083)

Schedules of Investments

75

Schedule of Investments (unaudited) (continued) BlackRock Resources & Commodities Strategy Trust (BCX)

June 30, 2018

#### Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

			C	Foreigr Currency	y Interest		
	Commodity Contracts(	Credit	EquityE ContractsC	0			Total
Liabilities Derivative Financial Instruments	ContractsC	ontracts	ContractsC	ontract	sContracts	Contracts	Total
Options written Options written, at value	\$	\$	\$ 7,080,083	\$	\$	\$	\$7,080,083

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

				Foreign	<b>T</b>		
	Commodity ContractsC	Credit ontracts	C EquityE ContractsC	xchange	Interest Rate ontractsC	Other ontracts	Total
Net Realized Gain (Log from:	ss)						
Options purchased <sup>(a)</sup> Options written	\$	\$	\$ (5,226) (19,278,563)	\$	\$	\$	\$ (5,226) (19,278,563)
	\$	\$	\$ (19,283,789)	\$	\$	\$	\$ (19,283,789)
<sup>(a)</sup> Includes net capital gain distributions, if applicable.							
<b>Net Change in Unreali</b> <b>Appreciation (Depreci</b> Options written		\$	\$ 10,195,573	\$	\$	\$	\$ 10,195,573

### Average Quarterly Balances of Outstanding Derivative Financial Instruments

Average value of option contracts written

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative asset and liabilities (by type) are as follows:

	Assets	Liabilities
<b>Derivative Financial Instruments</b> Options	\$	\$ 7,080,083
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA	)	(4,235,746)
Total derivative assets and liabilities subject to an MNA	\$	\$ 2,844,337

The following table presents the Trust s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral and pledged by the Trust:

	Derivative				
	Liabilities				Net Amount
	Subject to	Derivatives	Non-cash	Cash	of Derivative
	an MNA by	Available	Collateral	Collateral	Liabilities
Counterparty	Counterparty	for Offset	Pledged <sup>(a)</sup>	Pledged	(b)
Bank of America N.A.	\$ 31,580	\$	\$ (31,580)	\$	\$
Barclays Bank PLC	276,059		(276,059)		
Citibank N.A.	643,090		(643,090)		
Credit Suisse International	189,615		(189,615)		
Goldman Sachs International	684,272		(684,272)		
HSBC Bank PLC	54,073				54,073
JPMorgan Chase Bank N.A.	249,225		(48,722)		200,503
Morgan Stanley & Co. International					
PLC	347,729		(347,729)		
Royal Bank of Canada	10,439				10,439

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

\$6,199,199

Schedule of Investments (unaudited) (continued) BlackRock Resources & Commodities Strategy Trust (BCX)

June 30, 2018

<i>Counterparty</i> Societe Generale UBS AG	Derivative Liabilities Subject to Derivatives an MNA by Available Counterparty for Offset \$ 22,399 \$ 335,856	Non-cash Cash Collateral Collateral Pledged <sup>(a)</sup> Pledged \$ \$ (335,856)	Net Amount of Derivative Liabilities (b) \$ 22,399
	\$ 2,844,337 \$	\$ (2,556,923) \$	\$ 287,414

<sup>(a)</sup> Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

<sup>(b)</sup> Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

#### Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Chemicals	\$ 92,119,637	\$ 25,764,704	\$	\$117,884,341
Containers & Packaging	27,015,307	18,759,400		45,774,707
Electronic Equipment, Instruments &				
Components	6,614,239			6,614,239
Energy Equipment & Services	16,997,861			16,997,861
Food Products	75,456,055			75,456,055
Machinery	12,441,501			12,441,501
Metals & Mining	178,066,063	165,201,409	1,799,820	345,067,292
Oil, Gas & Consumable Fuels	272,550,721	64,371,634		336,922,355
Paper & Forest Products		14,689,980	67	14,690,047
Corporate Bonds		16,176,768		16,176,768
Short-Term Securities	7,893,261			7,893,261
Subtotal	\$689,154,645	\$ 304,963,895	\$ 1,799,887	\$ 995,918,427

Investments Valued at NAV <sup>(a)</sup>			30,673 \$ 995,949,100
Derivative Financial Instruments <sup>(b)</sup> Liabilities: Equity contracts	\$ (4,124,595)	\$ (2,955,488)	\$ \$ (7,080,083)

<sup>(a)</sup> As of June 30, 2018, certain of the Trust s Investments were fair valued using net asset value ( NAV ) per share and have been excluded from the fair value hierarchy.

<sup>(b)</sup> Derivative financial instruments are options written, which are shown at value. Transfers between Level 1 and Level 2 were as follows:

	Transfers into	Transfers out of	Transfers Into Tr	ansfers out of
	Level 1	Level 1 <sup>(a)</sup>	Level 2 <sup>(a)</sup>	Level 2
Assets:				
Long-Term Investments:				
Common Stocks	\$	\$ 5,523,874	\$ 5,523,874	\$

 (a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

See notes to financial statements.

Schedules of Investments

Schedule of Investments (unaudited)	BlackRock Science and Technology Trust (BST)
June 30, 2018	(Percentages shown are based on Net Assets)
Security Common Stocks 97.6%	Shares Value
Automobiles 0.8% Tesla, Inc. <sup>(a)(b)</sup>	16,500 \$ 5,658,675
Consumer Finance 0.2% I3 Verticals, Inc., Class A <sup>(a)</sup>	65,175 991,964
Diversified Consumer Services0.2%Sunlands Online Education GroupADR <sup>()(c)</sup>	177,787 1,584,082
Electronic Equipment, Instruments & Components 1.4%	
Hangzhou Hikvision Digital Technology Co., Ltd.	516,990 2,885,697
Isra Vision AG	42,725 2,611,108
Sunny Optical Technology Group Co. Ltd.	230,800 4,280,730
	9,777,535
Health Care Technology0.5%Pingan Healthcare and Tech Placing (Acquired 04/27/18, Cost \$4)	
Household Durables 0.6%	
Roku, Inc. <sup>(a)(b)</sup>	101,197 4,313,016
Internet & Direct Marketing Retail 7.6%	
Amazon.com, Inc. <sup>(a)(b)</sup>	22,960 39,027,409
Ensogo Ltd. <sup>(a)(e)</sup>	173,282
Netflix, Inc. <sup>(a)(b)</sup>	36,530 14,298,938
	53,326,347
Internet Software & Services 25.9% 58.com, Inc. ADR <sup>(b)</sup>	<b>50</b> 400 - 2 632 416
58.com, Inc. $ADR^{(b)}$ Alibaba Group Holding Ltd. $ADR^{(b)}$	52,400 3,633,416 123,740 22,957,482
Alphabet, Inc., Class A <sup>(a)(b)</sup>	28,186 31,827,349
Baidu, Inc. $ADR^{(b)}$	35,500 8,626,500
Bandwidth, Inc., Class A <sup>(a)</sup>	93,150 3,537,837
Delivery Hero AG <sup>(a)(f)</sup>	93,637 4,963,227
DocuSign, Inc. <sup>(a)(b)</sup>	79,740 4,222,233
Facebook, Inc., Class $A^{(a)(b)}$	71,900 13,971,608
IAC/InterActiveCorp <sup>(a)(b)</sup>	23,100 3,522,519
MercadoLibre, Inc. <sup>(b)</sup> Mercari, Inc. <sup>(a)</sup>	14,700 4,394,271 93,400 3,825,760
MongoDB, Inc. <sup>(a)(b)</sup>	93,400         3,823,700           33,811         1,678,040
Okta, Inc. <sup>(a)(b)</sup>	99,850 5,029,444
SendGrid, Inc. <sup>(a)(b)</sup>	152,159 4,035,257
	· · · · ·

Shopify, Inc., Class A <sup>(a)(b)</sup>	33,800	4,931,082
Spotify Technology SA <sup>(a)(b)</sup>	20,709	3,484,082
Tencent Holdings Ltd.	654,600	32,870,983
Twilio, Inc., Class A <sup>(a)</sup>	83,700	4,688,874
Uxin, Ltd., ADR <sup>(a)</sup>	486,264	4,395,827
Wix.com Ltd. <sup>(a)(b)</sup>	56,100	5,626,830
Yandex NV, Class A <sup>(a)(b)</sup>	250,480	8,992,232
	200,100	0,772,202
		181,214,853
IT Services 12.0%		101,211,055
Adyen NV <sup>(a)(f)</sup>	10,362	5,708,526
GMO Payment Gateway, Inc.	38,300	4,409,488
· · ·	76,600	
InterXion Holding $NV^{(a)(b)}$		4,781,372
Mastercard, Inc., Class $A^{(b)}$	93,300	18,335,316
Pagseguro Digital Ltd., Class A <sup>(a)(b)</sup>	286,408	7,947,822
PayPal Holdings, Inc. <sup>(a)(b)</sup>	97,800	8,143,806
Square, Inc., Class A <sup>(a)(b)</sup>	279,700	17,240,708
Visa, Inc., Class A <sup>(b)</sup>	128,100	16,966,845
		83,533,883
Media 1.2%		
Naspers Ltd., Class N	33,100	8,345,959
Professional Services 0.5%		
UT Group Co., Ltd. <sup>(a)</sup>	90,200	3,368,913
Security	Shares	Value
Security Semiconductor Equipment 13.4%	Shares	Value
•	<i>Shares</i> 294,700 \$	
Semiconductors & Semiconductor Equipment 13.4%		
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. <sup>(a)(b)</sup>	294,700 \$	4,417,553
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> Aixtron SE <sup>(a)</sup> AG	294,700 \$ 210,100 44,830	4,417,553 2,703,808 3,324,598
Semiconductors & Semiconductor Equipment       13.4%         Advanced Micro Devices, Inc. <sup>(a)(b)</sup> 13.4%         Aixtron SE <sup>(a)</sup> 13.4%         ams AG       13.4%         ASML Holding NV       13.4%	294,700 \$ 210,100 44,830 67,100	4,417,553 2,703,808 3,324,598 13,278,066
Semiconductors & Semiconductor Equipment       13.4%         Advanced Micro Devices, Inc. <sup>(a)(b)</sup> 13.4%         Aixtron SE <sup>(a)</sup> 13.4%         ams AG       13.4%         ASML Holding NV       13.4%         Broadcom, Inc. <sup>(b)</sup> 13.4%	294,700 \$ 210,100 44,830 67,100 51,696	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. $^{(a)(b)}$ 13.4%Aixtron SE $^{(a)}$ 13.4%ams AG13.4%ASML Holding NV13.4%Broadcom, Inc. $^{(b)}$ 13.4%Cree, Inc. $^{(a)(b)}$ 13.4%	294,700 \$ 210,100 44,830 67,100 51,696 76,400	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. $^{(a)(b)}$ 13.4%Aixtron SE $^{(a)}$ 13.4%ams AG13.4%ASML Holding NV13.4%Broadcom, Inc. $^{(b)}$ 13.4%Cree, Inc. $^{(a)(b)}$ 13.4%Lam Research Corp. $^{(b)}$ 13.4%	294,700 \$ 210,100 44,830 67,100 51,696 76,400 43,301	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. $^{(a)(b)}$ Aixtron SE $^{(a)}$ Aixtron SE $^{(a)}$ ams AGASML Holding NVBroadcom, Inc. $^{(b)}$ Cree, Inc. $^{(a)(b)}$ Lam Research Corp. $^{(b)}$ NVIDIA Corp. $^{(b)}$	294,700 \$ 210,100 44,830 67,100 51,696 76,400 43,301 37,900	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. $^{(a)(b)}$ Aixtron SE $^{(a)}$ Aixtron SE $^{(a)}$ ams AGASML Holding NVBroadcom, Inc. $^{(b)}$ Cree, Inc. $^{(a)(b)}$ Lam Research Corp. $^{(b)}$ NVIDIA Corp. $^{(b)}$ ON Semiconductor Corp. $^{(a)(b)}$	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> ams AGASML Holding NVBroadcom, Inc. <sup>(b)</sup> Cree, Inc. <sup>(a)(b)</sup> Lam Research Corp. <sup>(b)</sup> NVIDIA Corp. <sup>(b)</sup> ON Semiconductor Corp. <sup>(a)(b)</sup> Qorvo, Inc. <sup>(a)(b)</sup>	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. $^{(a)(b)}$ Aixtron SE $^{(a)}$ ams AGASML Holding NVBroadcom, Inc. $^{(b)}$ Cree, Inc. $^{(a)(b)}$ Lam Research Corp. $^{(b)}$ NVIDIA Corp. $^{(b)}$ ON Semiconductor Corp. $^{(a)(b)}$ Silicon Laboratories, Inc. $^{(a)(b)}$	$\begin{array}{rrrr} 294,700 & \$\\ 210,100 & \\ 44,830 & \\ 67,100 & \\ 51,696 & \\ 76,400 & \\ 43,301 & \\ 37,900 & \\ 200,000 & \\ 54,400 & \\ 34,100 & \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. $^{(a)(b)}$ Aixtron SE $^{(a)}$ ams AGASML Holding NVBroadcom, Inc. $^{(b)}$ Cree, Inc. $^{(a)(b)}$ Lam Research Corp. $^{(b)}$ NVIDIA Corp. $^{(b)}$ ON Semiconductor Corp. $^{(a)(b)}$ Qorvo, Inc. $^{(a)(b)}$ Silicon Laboratories, Inc. $^{(a)(b)}$ Skyworks Solutions, Inc.	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. $^{(a)(b)}$ Aixtron SE $^{(a)}$ ams AGASML Holding NVBroadcom, Inc. $^{(b)}$ Cree, Inc. $^{(a)(b)}$ Lam Research Corp. $^{(b)}$ NVIDIA Corp. $^{(b)}$ ON Semiconductor Corp. $^{(a)(b)}$ Silicon Laboratories, Inc. $^{(a)(b)}$ Skyworks Solutions, Inc.SOITEC $^{(a)}$	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> ams AGASML Holding NVBroadcom, Inc. <sup>(b)</sup> Cree, Inc. <sup>(a)(b)</sup> Lam Research Corp. <sup>(b)</sup> NVIDIA Corp. <sup>(b)</sup> ON Semiconductor Corp. <sup>(a)(b)</sup> Qorvo, Inc. <sup>(a)(b)</sup> Silicon Laboratories, Inc. <sup>(a)(b)</sup> Skyworks Solutions, Inc.SOITEC <sup>(a)</sup> STMicroelectronics NV	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \\ 245,900 \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486 5,459,789
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. $^{(a)(b)}$ Aixtron SE $^{(a)}$ ams AGASML Holding NVBroadcom, Inc. $^{(b)}$ Cree, Inc. $^{(a)(b)}$ Lam Research Corp. $^{(b)}$ NVIDIA Corp. $^{(b)}$ ON Semiconductor Corp. $^{(a)(b)}$ Silicon Laboratories, Inc. $^{(a)(b)}$ Skyworks Solutions, Inc.SOITEC $^{(a)}$	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486
Semiconductors & Semiconductor Equipment13.4%Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> ams AGASML Holding NVBroadcom, Inc. <sup>(b)</sup> Cree, Inc. <sup>(a)(b)</sup> Lam Research Corp. <sup>(b)</sup> NVIDIA Corp. <sup>(b)</sup> ON Semiconductor Corp. <sup>(a)(b)</sup> Qorvo, Inc. <sup>(a)(b)</sup> Silicon Laboratories, Inc. <sup>(a)(b)</sup> Skyworks Solutions, Inc.SOITEC <sup>(a)</sup> STMicroelectronics NV	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \\ 245,900 \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486 5,459,789 8,521,288
Semiconductors & Semiconductor Equipment 13.4% Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> ams AG ASML Holding NV Broadcom, Inc. <sup>(b)</sup> Cree, Inc. <sup>(a)(b)</sup> Lam Research Corp. <sup>(b)</sup> NVIDIA Corp. <sup>(b)</sup> ON Semiconductor Corp. <sup>(a)(b)</sup> Qorvo, Inc. <sup>(a)(b)</sup> Silicon Laboratories, Inc. <sup>(a)(b)</sup> Skyworks Solutions, Inc. SOITEC <sup>(a)</sup> STMicroelectronics NV Taiwan Semiconductor Manufacturing Co. Ltd.	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \\ 245,900 \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486 5,459,789
Semiconductors & Semiconductor Equipment 13.4% Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> ams AG ASML Holding NV Broadcom, Inc. <sup>(b)</sup> Cree, Inc. <sup>(a)(b)</sup> Lam Research Corp. <sup>(b)</sup> NVIDIA Corp. <sup>(b)</sup> ON Semiconductor Corp. <sup>(a)(b)</sup> Qorvo, Inc. <sup>(a)(b)</sup> Silicon Laboratories, Inc. <sup>(a)(b)</sup> Skyworks Solutions, Inc. SOITEC <sup>(a)</sup> STMicroelectronics NV Taiwan Semiconductor Manufacturing Co. Ltd.	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \\ 245,900 \\ 1,200,000 \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486 5,459,789 8,521,288 93,831,354
Semiconductors & Semiconductor Equipment 13.4% Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> ams AG ASML Holding NV Broadcom, Inc. <sup>(b)</sup> Cree, Inc. <sup>(a)(b)</sup> Lam Research Corp. <sup>(b)</sup> NVIDIA Corp. <sup>(b)</sup> ON Semiconductor Corp. <sup>(a)(b)</sup> Qorvo, Inc. <sup>(a)(b)</sup> Silicon Laboratories, Inc. <sup>(a)(b)</sup> Skyworks Solutions, Inc. SOITEC <sup>(a)</sup> STMicroelectronics NV Taiwan Semiconductor Manufacturing Co. Ltd.	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \\ 245,900 \\ 1,200,000 \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486 5,459,789 8,521,288 93,831,354 10,944,288
Semiconductors & Semiconductor Equipment 13.4% Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> ams AG ASML Holding NV Broadcom, Inc. <sup>(b)</sup> Cree, Inc. <sup>(a)(b)</sup> Lam Research Corp. <sup>(b)</sup> NVIDIA Corp. <sup>(b)</sup> ON Semiconductor Corp. <sup>(a)(b)</sup> Qorvo, Inc. <sup>(a)(b)</sup> Silicon Laboratories, Inc. <sup>(a)(b)</sup> Skyworks Solutions, Inc. SOITEC <sup>(a)</sup> STMicroelectronics NV Taiwan Semiconductor Manufacturing Co. Ltd. Software 29.5% Activision Blizzard, Inc. <sup>(b)</sup> Adobe Systems, Inc. <sup>(a)(b)</sup>	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \\ 245,900 \\ 1,200,000 \\ \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486 5,459,789 8,521,288 93,831,354 10,944,288 13,628,979
Semiconductors & Semiconductor Equipment 13.4% Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> ams AG ASML Holding NV Broadcom, Inc. <sup>(b)</sup> Cree, Inc. <sup>(a)(b)</sup> Lam Research Corp. <sup>(b)</sup> NVIDIA Corp. <sup>(b)</sup> ON Semiconductor Corp. <sup>(a)(b)</sup> Qorvo, Inc. <sup>(a)(b)</sup> Silicon Laboratories, Inc. <sup>(a)(b)</sup> Skyworks Solutions, Inc. SOITEC <sup>(a)</sup> STMicroelectronics NV Taiwan Semiconductor Manufacturing Co. Ltd. Software 29.5% Activision Blizzard, Inc. <sup>(b)</sup> Adobe Systems, Inc. <sup>(a)(b)</sup> Altair Engineering, Inc., Class A <sup>(a)</sup>	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \\ 245,900 \\ 1,200,000 \\ \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486 5,459,789 8,521,288 93,831,354 10,944,288 13,628,979 5,277,836
Semiconductors & Semiconductor Equipment 13.4% Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> ams AG ASML Holding NV Broadcom, Inc. <sup>(b)</sup> Cree, Inc. <sup>(a)(b)</sup> Lam Research Corp. <sup>(b)</sup> NVIDIA Corp. <sup>(b)</sup> ON Semiconductor Corp. <sup>(a)(b)</sup> Qorvo, Inc. <sup>(a)(b)</sup> Silicon Laboratories, Inc. <sup>(a)(b)</sup> Skyworks Solutions, Inc. SOITEC <sup>(a)</sup> STMicroelectronics NV Taiwan Semiconductor Manufacturing Co. Ltd. <b>Software 29.5%</b> Activision Blizzard, Inc. <sup>(b)</sup> Adobe Systems, Inc. <sup>(a)(b)</sup> Altair Engineering, Inc., Class A <sup>(a)</sup> Altium Ltd.	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \\ 245,900 \\ 1,200,000 \\ \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486 5,459,789 8,521,288 93,831,354 10,944,288 13,628,979 5,277,836 3,455,363
Semiconductors & Semiconductor Equipment 13.4% Advanced Micro Devices, Inc. <sup>(a)(b)</sup> Aixtron SE <sup>(a)</sup> ams AG ASML Holding NV Broadcom, Inc. <sup>(b)</sup> Cree, Inc. <sup>(a)(b)</sup> Lam Research Corp. <sup>(b)</sup> NVIDIA Corp. <sup>(b)</sup> ON Semiconductor Corp. <sup>(a)(b)</sup> Qorvo, Inc. <sup>(a)(b)</sup> Silicon Laboratories, Inc. <sup>(a)(b)</sup> Skyworks Solutions, Inc. SOITEC <sup>(a)</sup> STMicroelectronics NV Taiwan Semiconductor Manufacturing Co. Ltd. Software 29.5% Activision Blizzard, Inc. <sup>(b)</sup> Adobe Systems, Inc. <sup>(a)(b)</sup> Altair Engineering, Inc., Class A <sup>(a)</sup>	$\begin{array}{r} 294,700 \\ 210,100 \\ 44,830 \\ 67,100 \\ 51,696 \\ 76,400 \\ 43,301 \\ 37,900 \\ 200,000 \\ 54,400 \\ 34,100 \\ 43,700 \\ 89,625 \\ 245,900 \\ 1,200,000 \\ \end{array}$	4,417,553 2,703,808 3,324,598 13,278,066 12,543,517 3,175,948 7,484,578 8,978,510 4,447,000 4,361,248 3,396,360 4,223,605 7,515,486 5,459,789 8,521,288 93,831,354 10,944,288 13,628,979 5,277,836

Avalara, Inc. <sup>(a)</sup>	112,941	6,027,661
Bilibili, Inc. ADR <sup>(b)</sup>	179,800	2,515,402
Carbon Black, Inc. <sup>(a)</sup>	48,040	1,249,040
Electronic Arts, Inc. <sup>(a)(b)</sup>	45,500	6,416,410
FireEye, Inc. <sup>(a)(b)</sup>	207,752	3,197,303
ForeScout Technologies, Inc. <sup>(a)(b)</sup>	88,655	3,037,320
Guidewire Software, Inc. <sup>(a)(b)</sup>	42,500	3,773,150
Kingdee International Software Group Co., Ltd.	3,724,000	3,793,000
Linx SA	636,166	2,905,280
Microsoft Corp. <sup>(b)</sup>	370,380	36,523,172
Pivotal Software, Inc., Class A <sup>(a)(b)</sup>	161,575	3,921,425
Pluralsight, Inc. <sup>(a)</sup>	190,185	4,650,023
Proofpoint, Inc. <sup>(a)(b)</sup>	46,900	5,408,039
PTC, Inc. <sup>(a)(b)</sup>	55,300	5,187,693
RIB Software SE	149,200	3,457,046
SailPoint Technologies Holding, Inc. <sup>(a)(b)</sup>	198,822	4,879,092
salesforce.com, Inc. <sup>(a)(b)</sup>	120,000	16,368,000
ServiceNow, Inc. <sup>(a)(b)</sup>	38,210	6,590,079
Smartsheet, Inc., Class A <sup>(a)</sup>	40,591	1,054,148
Take-Two Interactive Software, Inc. <sup>(a)(b)</sup>	79,700	9,433,292
UbiSoft Entertainment SA <sup>(a)</sup>	77,447	8,465,593
Xero Ltd. <sup>(a)</sup>	120,100	3,994,889
Zendesk, Inc. <sup>(a)(b)</sup>	93,900	5,116,611
Zuora, Inc., 6 mo. (Acquired 04/11/18, Cost \$3,894,522), <sup>(d)</sup>	512,531	13,545,852
Zuora, Inc., Class $A^{(a)(b)}$	88,129	2,397,109
		_,_,_,_,_,_
		206,402,504
Technology Hardware, Storage & Peripherals 3.8%		200,102,001
Apple, Inc. <sup>(b)</sup>	141,896	26,266,369
rippie, me.	111,070	20,200,200
Total Common Stocks 97.6%		
(Cost \$346,208,121)		682,198,468
(0000 40 10,200,222)		002,190,100
Preferred Securities		
Preferred Stocks 2.3%		
Internet & Direct Marketing Retail 0.1%		
Jasper Infotech Private Ltd., Series I, (Acquired 08/08/15, Cost 1,998,435), 0.00% <sup>(d)(e)</sup>	1,054	520,676
Internet Software & Services 2.2%	-,	, 0
Uber Technologies, Inc., Series E, (Acquired 12/04/14, cost \$3,000,048), 0.00% <sup>(d)(e)</sup>	90,044	3,601,760
	20,011	2,001,700

Schedule of Investments (unaudited) (continued)	BlackRock Science and Technology Trust (BST)						
June 30, 2018	(Percentages shown are base	ed on Net Assets)					
Security Internet Software & Services (continued)	Shares	Value					
Xiaoju Kuaizhi, Inc., Series A-17 (Acquired 07/28/15, cost \$3,016 Ant International Co., Ltd., (Acquired 06/06/18, cost \$6,492,863),		\$ 5,602,453 6,492,862					
		15,697,075					
Total Preferred Stocks2.3%(Cost \$14,508,310)		16,217,751					
Total Long-Term Investments99.9%(Cost \$360,716,431)		698,416,219					
<b>Short-Term Securities</b> 0.9% BlackRock Liquidity Funds, T-Fund, Institutional Class,	5 000 000	5 000 000					
1.80% <sup>(g)(i)</sup> SL Liquidity Series, LLC, Money Market Series, 2.16% <sup>(g)(h)(i)</sup>	5,803,333 276,979	5,803,333 277,007					
Total Short-Term Securities 0.9% (Cost \$6,080,330)		6,080,340					
Total Investments Before Options Written100.8%(Cost\$366,796,761)		704,496,559					
Options Written (0.9)% (Premiums Received \$7,916,075)		(6,462,316)					
Total Investments, Net of Options Written 99.9% (Cost \$358,880,686) Other Assets Less Liabilities 0.1%		698,034,243 764,977					
Net Assets 100.0%		\$ 698,799,220					

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

- <sup>(c)</sup> Security, or a portion of the security, is on loan.
- <sup>(d)</sup> Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$33,346,617 and an original cost of \$22,511,279, which was 4.8% of its net assets.
- <sup>(e)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

- <sup>(f)</sup> Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
- <sup>(g)</sup> Annualized 7-day yield as of period end.
- <sup>(h)</sup> Security was purchased with the cash collateral from loaned securities.
- <sup>(i)</sup> During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

								Ch	ange
									in
	Shares		Shares				NetUr	irea	lized
	Held at	Net	Held at	Value at		Rea	aliz <b>A</b> qbpi	reci	ation
Affiliate	12/31/17	Activity	06/30/18	06/30/18	Incom <b>G</b> ain	ı (Lo	s¢Depr	ecia	tion)
BlackRock Liquidity									
Funds, T-Fund,									
Institutional Class	4,696,297	1,107,036	5,803,333	\$ 5,803,333	\$ 32,717	\$		\$	
SL Liquidity Series,									
LLC, Money Market									
Series	3,497,053	(3,220,074)	276,979	277,007	123,932 <sup>(b)</sup>		(464)		179
				\$6,080,340	\$156,649	\$	(464)	\$	179

<sup>(a)</sup> Includes net capital gain distributions, if applicable.

<sup>(b)</sup> Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

For Trust compliance purposes, the Trust s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

#### Derivative Financial Instruments Outstanding as of Period End

#### **Exchange-Traded Options Written**

	Number of	Expiration		Exercise		otional	¥7. 1
Description	Contracts	Date		Price	Amount	t(000)	Value
Call							
Activision Blizzard, Inc.	166	07/06/18	USD	73.00	USD	1,267	\$ (58,930)
Adobe Systems, Inc.	77	07/06/18	USD	257.50	USD	1,877	(808)
Advanced Micro Devices, Inc.	527	07/06/18	USD	13.50	USD	790	(79,577)
Alibaba Group Holding Ltd. AD	R 144	07/06/18	USD	205.00	USD	2,672	(720)
Amazon.com, Inc.	7	07/06/18	USD	1,660.00	USD	1,190	(34,178)

~ 1

SCHEDULES OF INVESTMENTS

# BlackRock Science and Technology Trust (BST)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

Λ	lumber of	Expiration		Exercise	N	otional	
Description	Contracts	Date		Price	Amoun	et (000)	Value
Call (continued)							
Facebook, Inc., Class A	61	07/06/18	USD	202.50	USD	1,185	\$ (1,464)
Microsoft Corp.	195	07/06/18	USD	101.00	USD	1,923	(4,387)
Netflix, Inc.	25	07/06/18	USD	360.00	USD	979	(82,063)
PayPal Holdings, Inc.	70	07/06/18	USD	83.50	USD	583	(6,580)
ServiceNow, Inc.	66	07/06/18	USD	187.50	USD	1,138	(660)
Square, Inc., Class A	362	07/06/18	USD	65.00	USD	2,231	(9,593)
Yandex NV, Class A	27	07/06/18	USD	36.50	USD	97	(945)
salesforce.com, Inc.	86	07/06/18	USD	134.00	USD	1,173	(28,595)
Alibaba Group Holding Ltd. ADF	R 82	07/13/18	USD	205.00	USD	1,521	(2,378)
Alphabet, Inc., Class A	5	07/13/18	USD	1,145.00	USD	565	(5,550)
Amazon.com, Inc.	8	07/13/18	USD	1,657.50	USD	1,360	(47,600)
Apple, Inc.	17	07/13/18	USD	187.50	USD	315	(3,145)
Autodesk, Inc.	62	07/13/18	USD	135.00	USD	813	(8,773)
Broadcom Inc.	40	07/13/18	USD	255.00	USD	971	(3,300)
FireEye, Inc.	100	07/13/18	USD	18.00	USD	154	(250)
Mastercard, Inc., Class A	175	07/13/18	USD	205.00	USD	3,439	(7,175)
Microsoft Corp.	71	07/13/18	USD	103.00	USD	700	(1,704)
Microsoft Corp.	155	07/13/18	USD	102.00	USD	1,528	(6,200)
Netflix, Inc.	25	07/13/18	USD	365.00	USD	979	(75,563)
Spotify Technology SA	16	07/13/18	USD	165.00	USD	269	(11,600)
salesforce.com, Inc.	55	07/13/18	USD	133.00	USD	750	(26,537)
SailPoint Technologies Holding,							
Inc.	360	07/18/18	USD	27.01	USD	883	(9,939)
58.com, Inc. ADR	183	07/20/18	USD	85.00	USD	1,269	(1,830)
Activision Blizzard, Inc.	104	07/20/18	USD	80.00	USD	794	(6,552)
Advanced Micro Devices, Inc.	531	07/20/18	USD	13.00	USD	796	(111,245)
Alphabet, Inc., Class A	8	07/20/18	USD	1,100.00	USD	903	(34,360)
Alphabet, Inc., Class A	9	07/20/18	USD	1,190.00	USD	1,016	(4,095)
Apple, Inc.	164	07/20/18	USD	190.00	USD	3,036	(21,566)
Autodesk, Inc.	21	07/20/18	USD	145.00	USD	275	(630)
Bilibili, Inc. ADR	629	07/20/18	USD	15.00	USD	880	(59,755)
Broadcom, Inc.	38	07/20/18	USD	270.00	USD	922	(760)
DocuSign, Inc.	148	07/20/18	USD	65.00	USD	784	(6,660)
DocuSign, Inc.	148	07/20/18	USD	70.00	USD	784	(2,960)
Electronic Arts, Inc.	58	07/20/18	USD	135.00	USD	818	(44,660)
Facebook, Inc., Class A	24	07/20/18	USD	190.00	USD	466	(17,940)
FireEye, Inc.	92	07/20/18	USD	17.00	USD	142	(1,150)
ForeScout Technologies, Inc.	310	07/20/18	USD	40.00	USD	1,062	(4,650)
-							

Guidewire Software, Inc.	233	07/20/18	USD	95.00	USD	2,069	(8,737)
IAC/InterActiveCorp.	80	07/20/18	USD	165.00	USD	1,220	(6,200)
InterXion Holding NV	92	07/20/18	USD	65.00	USD	574	(3,680)
Lam Research Corp.	65	07/20/18	USD	185.00	USD	1,124	(10,075)
MercadoLibre, Inc.	40	07/20/18	USD	310.00	USD	1,124	(10,075) (29,000)
Microsoft Corp.	324	07/20/18	USD	100.00	USD	3,195	(65,448)
MongoDB, Inc.	118	07/20/18	USD	65.00	USD	586	(885)
NVIDIA Corp.	62	07/20/18	USD	255.00	USD	1,469	(10,230)
Netflix, Inc.	33	07/20/18	USD	255.00 350.00	USD	1,409	(164,835)
-		07/20/18				483	,
ON Semiconductor Corp.	217 275	07/20/18	USD USD	28.00 55.00	USD		(2,170)
Okta, Inc.					USD	1,385	(24,062)
PTC, Inc.	193	07/20/18	USD	95.00	USD	1,811	(57,900)
Pagseguro Digital Ltd., Class A	813	07/20/18	USD	40.00	USD	2,256	(4,065)
PayPal Holdings, Inc.	57	07/20/18	USD	85.25	USD	475	(6,981)
Pivotal Software, Inc., Class A	192	07/20/18	USD	20.00	USD	466	(87,360)
Proofpoint, Inc.	164	07/20/18	USD	130.00	USD	1,891	(2,870)
Roku, Inc.	194	07/20/18	USD	35.00	USD	827	(152,290)
SailPoint Technologies Holding,							
Inc.	168	07/20/18	USD	25.00	USD	412	(15,120)
SendGrid, Inc.	328	07/20/18	USD	30.00	USD	870	(14,760)
Silicon Laboratories, Inc.	187	07/20/18	USD	110.00	USD	1,863	(9,350)
Spotify Technology SA	40	07/20/18	USD	175.00	USD	673	(17,200)
Square, Inc., Class A	362	07/20/18	USD	50.00	USD	2,231	(432,590)
Take-Two Interactive Software, Inc.	95	07/20/18	USD	117.00	USD	1,124	(42,275)
Tesla, Inc.	18	07/20/18	USD	350.00	USD	617	(27,630)
Twilio, Inc., Class A	174	07/20/18	USD	60.00	USD	975	(17,487)

80

2018 BLACKROCK SEMI-ANNUAL REPORT TO SHAREHOLDERS

# BlackRock Science and Technology Trust (BST)

June 30, 2018

# **Exchange-Traded Options Written (continued)**

	Number of	Expiration		Exercise	N	otional	
Description	Contracts	Date		Price	Amoun	et (000)	Value
Call (continued)							
Visa, Inc., Class A	112	07/20/18	USD	135.00	USD	1,483	\$ (15,176)
Yandex NV, Class A	145	07/20/18	USD	36.00	USD	521	(18,125)
Zendesk, Inc.	328	07/20/18	USD	60.00	USD	1,787	(13,120)
Zuora, Inc., Class A	104	07/20/18	USD	22.50	USD	283	(57,720)
Zuora, Inc., Class A	93	07/20/18	USD	35.00	USD	253	(4,650)
Alibaba Group Holding Ltd.	ADR 67	07/27/18	USD	192.50	USD	1,243	(24,790)
Alphabet, Inc., Class A	24	07/27/18	USD	1,160.00	USD	2,710	(57,000)
Amazon.com, Inc.	25	07/27/18	USD	1,725.00	USD	4,250	(138,938)
Apple, Inc.	18	07/27/18	USD	190.00	USD	333	(4,014)
Apple, Inc.	18	07/27/18	USD	187.50	USD	333	(4,995)
Baidu, Inc. ADR	75	07/27/18	USD	270.00	USD	1,823	(16,050)
Cree, Inc.	107	07/27/18	USD	51.00	USD	445	(1,712)
Facebook, Inc., Class A	27	07/27/18	USD	192.50	USD	525	(20,925)
Microsoft Corp.	71	07/27/18	USD	103.00	USD	700	(8,023)
Microsoft Corp.	174	07/27/18	USD	101.00	USD	1,716	(31,755)
PayPal Holdings, Inc.	57	07/27/18	USD	86.00	USD	475	(10,374)
Roku, Inc.	130	07/27/18	USD	48.00	USD	554	(12,025)
ServiceNow, Inc.	67	07/27/18	USD	187.50	USD	1,156	(12,562)
Shopify, Inc., Class A	68	07/27/18	USD	167.50	USD	992	(6,970)
Spotify Technology SA	16	07/27/18	USD	180.00	USD	269	(8,960)
Take-Two Interactive Software	·,						
Inc.	95	07/27/18	USD	118.00	USD	1,124	(45,125)
Tesla, Inc.	39	07/27/18	USD	330.00	USD	1,338	(114,173)
Visa, Inc., Class A	163	07/27/18	USD	137.00	USD	2,159	(26,487)
salesforce.com, Inc.	93	07/27/18	USD	137.00	USD	1,269	(36,270)
Okta, Inc.	275	07/31/18	USD	55.00	USD	1,385	(38,639)
Activision Blizzard, Inc.	119	08/03/18	USD	76.50	USD	908	(38,675)
Adobe Systems, Inc.	50	08/03/18	USD	250.00	USD	1,219	(26,875)
Alibaba Group Holding Ltd.	ADR 82	08/03/18	USD	205.00	USD	1,521	(12,628)
Autodesk, Inc.	57	08/03/18	USD	138.00	USD	747	(12,682)
Baidu, Inc. ADR	49	08/03/18	USD	245.00	USD	1,191	(53,410)
Facebook, Inc., Class A	18	08/03/18	USD	202.50	USD	350	(8,460)
Facebook, Inc., Class A	61	08/03/18	USD	205.00	USD	1,185	(23,942)
Microsoft Corp.	78	08/03/18	USD	102.00	USD	769	(12,987)
NVIDIA Corp.	75	08/03/18	USD	250.00	USD	1,777	(36,000)
Roku, Inc.	130	08/03/18	USD	42.50	USD	554	(39,975)
Take-Two Interactive Software							/
Inc.	91	08/03/18	USD	122.00	USD	1,077	(41,860)

Visa, Inc., Class A	111	08/03/18	USD	135.00	USD	1,470	(29,526)
Yandex NV, Class A	174	08/03/18	USD	36.50	USD	625	(32,625)
Amazon.com, Inc.	15	08/10/18	USD	1,710.00	USD	2,550	(112,838)
Cree, Inc.	80	08/10/18	USD	44.00	USD	333	(8,040)
FireEye, Inc.	50	08/10/18	USD	16.00	USD	77	(4,300)
Microsoft Corp.	174	08/10/18	USD	102.00	USD	1,716	(32,538)
PayPal Holdings, Inc.	79	08/10/18	USD	85.00	USD	658	(23,344)
Square, Inc., Class A	460	08/10/18	USD	62.00	USD	2,835	(192,050)
salesforce.com, Inc.	92	08/10/18	USD	138.00	USD	1,255	(40,710)
Activision Blizzard, Inc.	119	08/17/18	USD	77.50	USD	908	(39,865)
Adobe Systems, Inc.	70	08/17/18	USD	250.00	USD	1,707	(47,250)
Advanced Micro Devices, Inc.	562	08/17/18	USD	16.00	USD	842	(49,456)
Alibaba Group Holding Ltd. ADR	76	08/17/18	USD	210.00	USD	1,410	(16,986)
Alphabet, Inc., Class A	13	08/17/18	USD	1,105.00	USD	1,468	(78,195)
Amazon.com, Inc.	25	08/17/18	USD	1,760.00	USD	4,250	(139,000)
Apple, Inc.	68	08/17/18	USD	190.00	USD	1,259	(28,560)
Broadcom Inc.	106	08/17/18	USD	280.00	USD	2,572	(5,830)
Cree, Inc.	80	08/17/18	USD	49.00	USD	333	(5,200)
Electronic Arts, Inc.	101	08/17/18	USD	145.00	USD	1,424	(54,793)
Facebook, Inc., Class A	60	08/17/18	USD	190.00	USD	1,166	(70,350)
FireEye, Inc.	101	08/17/18	USD	18.00	USD	155	(2,676)
FireEye, Inc.	76	08/17/18	USD	17.00	USD	117	(3,458)
Lam Research Corp.	21	08/17/18	USD	180.00	USD	363	(14,175)
Mastercard, Inc., Class A	151	08/17/18	USD	200.00	USD	2,967	(80,785)
Microsoft Corp.	56	08/17/18	USD	105.00	USD	552	(6,272)
NVIDIA Corp.	73	08/17/18	USD	265.00	USD	1,729	(32,668)

Schedules of Investments

81

# BlackRock Science and Technology Trust (BST)

June 30, 2018

## **Exchange-Traded Options Written (continued)**

	Number of	Expiration	E	Exercise	N	otional	
Description	Contracts	Date		Price	Amoun	et (000)	Value
Call (continued)							
Netflix, Inc.	47	08/17/18	USD	405.00	USD	1,840	\$ (109,275)
ON Semiconductor Corp.	218	08/17/18	USD	23.00	USD	485	(22,345)
Pagseguro Digital Ltd., Class A	815	08/17/18	USD	30.00	USD	2,262	(142,625)
PayPal Holdings, Inc.	79	08/17/18	USD	87.50	USD	658	(17,459)
Pivotal Software, Inc., Class A	192	08/17/18	USD	26.00	USD	466	(33,600)
Qorvo, Inc.	190	08/17/18	USD	82.50	USD	1,523	(74,100)
Roku, Inc.	102	08/17/18	USD	44.00	USD	435	(37,740)
SailPoint Technologies Holding.	,						
Inc.	167	08/17/18	USD	25.00	USD	410	(26,720)
Shopify, Inc., Class A	120	08/17/18	USD	175.00	USD	1,751	(28,800)
Skyworks Solutions, Inc.	154	08/17/18	USD	105.00	USD	1,488	(23,100)
Square, Inc., Class A	361	08/17/18	USD	65.00	USD	2,225	(117,325)
Visa, Inc., Class A	62	08/17/18	USD	135.00	USD	821	(19,840)
Wix.com Ltd.	196	08/17/18	USD	100.00	USD	1,966	(159,740)
Yandex NV, Class A	142	08/17/18	USD	37.00	USD	510	(28,045)
Zuora, Inc., Class A	111	08/17/18	USD	35.00	USD	302	(17,482)
salesforce.com, Inc.	94	08/17/18	USD	140.00	USD	1,282	(37,365)
MercadoLibre, Inc.	40	09/21/18	USD	310.00	USD	1,196	(93,400)
Pivotal Software, Inc., Class A	191	09/21/18	USD	30.00	USD	464	(30,083)

\$ (5,256,833)

## **OTC Options Written**

		Number of	Expiration		Exercise		Notional		
Description	Counterparty	Contracts	Date		Price	Am	ount (000)		Value
Call									
Aixtron SE	Morgan Stanley & Co. International PLC	C 42,000	07/10/18	EUR	14.29	EUR	463	\$	(24)
Delivery Hero AG	Morgan Stanley & Co. International PLC	C 15,100	07/10/18	EUR	41.61	EUR	685		(67,235)
SOITEC	UBS AG	14,200	07/10/18	EUR	81.37	EUR	1,020		(3,595)
STMicroelectronics									
NV	Morgan Stanley & Co. International PLC	25,300	07/10/18	EUR	21.04	EUR	481		(1,222)
SendGrid, Inc.	Barclays Bank PLC	20,400	07/10/18	USD	27.40	USD	541		(16,684)
UbiSoft									
Entertainment SA	Morgan Stanley & Co. International PLC	C 15,700	07/10/18	EUR	87.10	EUR	1,470	(	(127,596)
	Barclays Bank PLC	7,900	07/11/18	USD	37.54	USD	300		(10,424)

Bandwidth, Inc.,								
Class A Bandwidth, Inc.,								
Class A	Citibank N.A.	7,800	07/11/18	USD	35.00	USD	296	(24,656)
Isra Vision AG	Goldman Sachs International	7,800	07/11/18		50.93		408	(23,300)
Linx SA	Morgan Stanley & Co. International PLC	30,600	07/11/18		20.20		542	(37)
Naspers Ltd.,		·						-
Class N	Goldman Sachs International	6,600	07/11/18	ZAR	3,386.25	ZAR	22,828	(53,807)
RIB Software SE Tencent Holdings	Morgan Stanley & Co. International PLC	41,000	07/11/18	EUR	21.22	EUR	813	(10,343)
Ltd. Altair Engineering,	Goldman Sachs International	120,200	07/11/18	HKD	421.00	HKD	47,355	(12,707)
Inc.	Barclays Bank PLC	26,000	07/12/18	USD	38.45	USD	889	(902)
Sunny Optical								
Technology Group Co. Ltd.	UBS AG	90,400	07/12/18	нкр	156.89	чкр	13,155	(14,979)
Co. Ltd. Taiwan	UBS AG	90,400	0//12/10	ΠΛυ	130.02	ΠΚυ	15,155	(14,777)
Semiconductor								
Manufacturing Co.								
Ltd.	Goldman Sachs International	325,000	07/12/18	USD	237.08	USD	70,363	(306)
ASML Holding		)	• • •		-		/	
NV	HSBC Bank PLC	11,500	07/18/18	EUR	184.50	EUR	1,949	(14,304)
Kingdee								
International								
Software Group								
Co., Ltd.	UBS AG	550,000	07/18/18		10.11		4,395	(5,031)
Xero Ltd.	Goldman Sachs International	42,000	07/18/18		44.70		1,888	(41,294)
ams AG	Goldman Sachs International	16,600	07/18/18		101.12		1,219	(179)
Aixtron SE	Morgan Stanley & Co. International PLC	31,500	07/25/18		13.23		347	(2,690)
Delivery Hero AG	Credit Suisse International	17,600	07/25/18		40.87		799	(93,900)
RIB Software SE	Morgan Stanley & Co. International PLC	41,000	07/25/18	EUK	21.22	EUK	813	(22,573)
Taiwan Samiaanduatar								
Semiconductor								
Manufacturing Co. Ltd.	UBS AG	108,000	07/25/18	מפוו	228.60	חפוו	23,382	(3,771)
Altium Ltd.	Morgan Stanley & Co. International PLC	67,300	07/26/18		228.00		25,582 1,512	(3,771) (23,165)
GMO Payment	Worgan Stancy & Co. International I De	07,500	01120110	ΛUΡ	20.00	Πυμ	1,014	(23,105)
Gateway, Inc.	JPMorgan Chase Bank N.A.	13,400	07/26/18	JPY	12,127.50	JPY	170,805	(111,904)
Kingdee								
International								
Software Group Co., Ltd.	JPMorgan Chase Bank N.A.	550,000	07/26/18	חאח	0.45	HKD	4,395	(15,174)
Tencent Holdings	JPMorgan Chase Dank IV.A.	330,000	01120/10	ΠΛυ	ブ.サノ	ПКЛ	4,375	(13,174)
Ltd.	Citibank N.A.	112,400	07/26/18	нкр	408.90	нкр	44,282	(75,939)
InterXion Holding		112,700	01120110		100.20		77,202	(13,737)
NV	Morgan Stanley & Co. International PLC	18,000	07/31/18	USD	66.48	USD	1,124	(6,223)
ON Semiconductor		- )					2	<u>\</u> -, ,
Corp.	UBS AG	26,500	07/31/18	USD	26.22	USD	589	(4,220)
SOITEC	Goldman Sachs International	17,800	08/07/18	EUR	78.93	EUR	1,278	(41,435)
STMicroelectronics								
NV	Goldman Sachs International	23,800	08/07/18	EUR	20.77	EUR	452	(9,819)

UbiSoft								
Entertainment SA	Goldman Sachs International	11,400	08/07/18	EUR	93.55	EUR	1,067	(53,645)
ASML Holding								
NV	UBS AG	12,000	08/08/18	EUR	175.02	EUR	2,033	(62,052)
Altium Ltd.	Deutsche Bank AG	47,000	08/08/18	AUD	24.97	AUD	1,056	(10,293)
Kingdee								
International								
Software Group								
Co., Ltd.	Morgan Stanley & Co. International PLC	154,000	08/08/18	HKD	8.46	HKD	1,230	(12,163)
Smartsheet, Inc.,								
Class A	Barclays Bank PLC	14,200	08/08/18	USD	26.55	USD	369	(32,529)
1								

82

Schedule of Investments (unaudited) (continued)

BlackRock Science and Technology Trust (BST)

June 30, 2018

### **OTC Options Written (continued)**

	Ν	umber of	Expiration		Exercise		Notional		
Description	Counterparty C	Contracts	Date		Price	Amo	unt (000)		Value
Call (continued)									
UT Group Co., Ltd.	Societe Generale	31,500	08/08/18	JPY	4,433.00	JPY	130,257	\$	(38,889)
Carbon Black, Inc.	Deutsche Bank AG	8,400	08/09/18	USD	25.72	USD	218		(22,321)
Bandwidth, Inc.,									
Class A	Barclays Bank PLC	17,000	08/10/18	USD	37.90	USD	646		(35,635)
Isra Vision AG	UBS AG	7,800	08/10/18	EUR	54.88	EUR	408		(28,472)
Carbon Black, Inc.	Deutsche Bank AG	8,400	08/14/18	USD	25.72	USD	218		(23,579)
Altair Engineering,									
Inc., Class A	Barclays Bank PLC	29,400	08/20/18	USD	34.73	USD	1,005		(46,467)
								\$ (1	,205,483)

## Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	Swap	Swap					
	Premium	Premium	Unrealized	Unrealized			
	Paid	Received	Appreciation	Depreciation	Value		
Options Written	N/A	N/A	\$ 2,999,050	\$ (1,545,291)	\$(6,462,316)		
Derivative Financial Instruments Categorized by Risk Exposure							

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

				Foreign	ı		
			(	Currency	y Interest		
	Commodity	Credit	Equity E	Exchange	e Rate	Other	
	Contracts (	Contracts	Contracts C	Total			
Liabilities Derivative Fin	nancial Instr	uments					
Options written							
Options written, at value	\$	\$	\$6,462,316	\$	\$	\$	\$6,462,316

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity	Credit				y Interest	Other		
	ContractsC	ontracts		ContractsCo	ontract	ContractsCo	ontracts		Total
Net Realized Gain (Loss)	from:								
Options purchased <sup>(a)</sup> Options written	\$	\$	\$ (10	(5,100) 0,692,313)	\$	\$	\$	\$ (1	(5,100) (0,692,313)
-	\$	\$	\$(1	0,697,413)	\$	\$	\$	\$(1	0,697,413)
(a) Options purchased are	included in net	realized g	ain (lo	oss) from in	vestme	ents.			
Net Change in Unrealized	d Appreciation	(Depreci	iation	) on:					
Options written	\$	\$	\$	(793,166)	\$	\$	\$	\$	(793,166)
Average Quarterly Balance	s of Outstandi	ng Deriva	ative I	Financial Ir	nstrum	ients			
Options: Average value of option co Average value of option co	•	ed						\$ \$ 6,0	(a) 094,471

<sup>(a)</sup> Derivative not held at quarter-end. The amount shown in the Statements of Operations reflect the results of activity during the period.

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Schedules of Investments

83

Schedule of Investments (unaudited) (continued)

### BlackRock Science and Technology Trust (BST)

June 30, 2018

#### Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative assets and liabilities (by type) are as follows:

Options	Assets \$	<i>Liabilities</i> \$ 6,462,316
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA	<b>A</b> )	(5,256,833)
Total derivative assets and liabilities subject to an MNA	\$	\$ 1,205,483

The following table presents the Trust s derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

		Derivative Liabilities Subject to n MNA by	Derivatives Available for	Non-cash Collateral	Cash Collateral		et Amount Derivative
Counterparty	Coi	unterparty	Offset	Pledged	Pledged <sup>(a)</sup>	Lia	bilities <sup>(b)</sup>
Barclays Bank PLC	\$	142,641	\$	\$	\$ (142,641)	\$	
Citibank N.A.		100,595			(100,595)		
Credit Suisse International		93,900			(30,000)		63,900
Deutsche Bank AG		56,193					56,193
Goldman Sachs International		236,492			(236,492)		
HSBC Bank PLC		14,304					14,304
JPMorgan Chase Bank N.A.		127,078			(90,000)		37,078
Morgan Stanley & Co. International							
PLC		273,271			(273,271)		
Societe Generale		38,889					38,889
UBS AG		122,120			(122,120)		
	\$	1,205,483	\$	\$	\$ (995,119)	\$	210,364

<sup>(a)</sup> Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

<sup>(b)</sup> Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Automobiles	\$ 5,658,675	\$	\$	\$ 5,658,675
Consumer Finance	991,964			991,964
Diversified Consumer Services	1,584,082			1,584,082
Electronic Equipment, Instruments &				
Components		9,777,535		9,777,535
Health Care Technology	3,583,014			3,583,014
Household Durables	4,313,016			4,313,016
Internet & Direct Marketing Retail	53,326,347			53,326,347
Internet Software & Services	143,380,643	37,834,210		181,214,853
IT Services	79,124,395	4,409,488		83,533,883
Media		8,345,959		8,345,959
Professional Services		3,368,913		3,368,913
Semiconductors & Semiconductor				
Equipment	53,028,319	40,803,035		93,831,354
Software	169,690,761	36,711,743		206,402,504
Technology Hardware, Storage &				
Peripherals	26,266,369			26,266,369
Preferred Stocks			16,217,751	16,217,751
Short-Term Securities	5,803,333			5,803,333
Subtotal	\$ 546,750,919	\$141,250,882	\$ 16,217,751	\$704,219,552
Investments valued at NAV <sup>(a)</sup>				277,007

\$704,496,559

Schedule of Investments (unaudited) (continued)	BlackRock Science and Technology Trust				
June 30, 2018					
Derivative Financial Instruments <sup>(b)</sup>	Level 1	Level 2	Level 3	Total	
Liabilities: Equity contracts	\$(5,201,275)	\$(1,261,041)	\$	\$ (6,462,316)	

<sup>(a)</sup> As of June 30, 2018, certain of the Trust s Investments were fair valued using net asset value ( NAV ) per share and have been excluded from the fair value hierarchy.

<sup>(b)</sup> Derivative financial instruments are options written, which are shown at value.

Transfers between Level 1 and Level 2 were as follows:

	Transfers into	Transfers out of	Transfers Into Tra	ansfers out of
	Level 1	Level 1 <sup>(a)</sup>	Level 2 <sup>(a)</sup>	Level 2
Assets:				
Long-Term Investments:				
Common Stocks	\$	\$ 10,286,668	\$ 10,286,668	\$

(a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	Common	Preferred	
	Stocks	Stocks	Total
Assets:			
Opening Balance, as of December 31, 2017	\$ 4,971,557	\$ 9,033,909	\$14,005,466
Transfers into Level 3			
Transfers out of Level 3			
Accrued discounts/premiums			
Net realized gain (loss)			
Net change in unrealized appreciation (depreciation) <sup>(a)(b)</sup>	(1,077,034)	690,979	(386,055)
Purchases		6,492,863	6,492,863

Sales	(3,894,523)		(3,894,523)
Closing Balance, as of June 30, 2018	\$	\$ 16,217,751	\$ 16,217,751
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2018 <sup>(b)</sup>	\$	\$ 690,979	\$ 690,979

<sup>(a)</sup> Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.
 <sup>(b)</sup> Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized

appreciation (depreciation) on derivative financial instruments still held at June 30, 2018 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee ) to determine the value of certain of the Trust s Level 3 investments as of period end.

Assets:	Valu¥aluati	on Approach	Unobservable Inputs	Range of unobservable Inputs Utilized
Preferred Stocks	\$ 16,217,751	Market	Revenue Multiple <sup>(a)</sup> Time to Exit <sup>(b)</sup> Volatility <sup>(b)</sup> Recent Transactions <sup>(a)</sup>	7.50x 2.5 years 35%

#### \$16,217,751

<sup>(a)</sup> Increase in unobservable input may result in a significant increase to value, while a decrease in the unobservable input may result in a significant decrease to value.

<sup>(b)</sup> Decrease in unobservable input may result in a significant increase to value, while an increase in the unobservable input may result in a significant decrease to value.

See notes to financial statements.

Schedules of Investments

Schedule of Investments (unaudited)	BlackRock Utilities, Infrastructure & Power Opportunitie	es Trust (BUI)
June 30, 2018	(Percentages shown are based of	on Net Assets)
Security Common Stocks 99.1%	Shares	Value
Auto Components 1.9%		
Continental AG	14,450	
Valeo SA	58,550	3,192,355
		6,480,853
Building Products 1.1%		0,400,000
Kingspan Group PLC	71,966	3,603,716
Chemicals 4.0%		
Air Liquide SA	53,100	6,655,830
Linde AG	28,950	6,877,907
		13,533,737
Electric Utilities 35.7%		15,555,757
American Electric Power Co., Inc. <sup>(a)</sup>	96,220	6,663,235
Duke Energy Corp. <sup>(a)</sup>	155,468	12,294,410
Edison International	91,290	5,775,918
Enel SpA	3,107,517	17,219,313
Eversource Energy <sup>(a)</sup>	80,420	4,713,416
Exelon Corp. <sup>(a)(b)</sup>	269,310	11,472,606
FirstEnergy Corp. <sup>(a)</sup>	202,980	7,289,012
Fortis, Inc.	144,250	4,598,690
Iberdrola SA	205,992	1,588,559
NextEra Energy, Inc. <sup>(a)(b)</sup>	220,300	36,796,709
PG&E Corp.	80,000	3,404,800
Pinnacle West Capital Corp.	46,720	3,763,763
PPL Corp. <sup>(a)</sup>	114,710	3,274,971
Xcel Energy, Inc.	71,400	3,261,552
		122,116,954
Electrical Equipment 3.9%		122,110,954
OSRAM Licht AG	27,050	1,101,607
Schneider Electric SE	76,750	6,383,047
Vestas Wind Systems A/S	94,150	5,812,475
T 1 1 / R 1 R 1		13,297,129
Independent Power and Renewable El	•	0 000 000
China Longyuan Power Group Corp. Ltd		8,208,229
EDP Renovaveis SA	1,566,700	16,338,259
NRG Yield, Inc., Class C	172,160	2,961,152
		27 507 640

# Multi-Utilities 19.3%

Multi-Utilities 19.3%		
CMS Energy Corp. <sup>(a)</sup>	127,700	6,037,656
Dominion Energy, Inc. <sup>(a)</sup>	180,060	12,276,491
DTE Energy Co. <sup>(a)</sup>	46,620	4,831,231
National Grid PLC	1,241,374	13,718,507
NiSource, Inc. <sup>(a)</sup>	133,100	3,497,868
Public Service Enterprise Group, Inc. <sup>(a)</sup>	239,616	12,972,810
Sempra Energy <sup>(a)</sup>	70,350	8,168,338
WEC Energy Group, Inc. <sup>(a)</sup>	70,180	4,537,137
		66,040,038
Security	Shares	Value
Oil, Gas & Consumable Fuels 12.2%		
Enbridge, Inc. <sup>(a)</sup>	252,040 \$	8,995,308
Energy Transfer Partners LP <sup>(a)</sup>	139,769	2,661,202
Enterprise Products Partners LP <sup>(a)</sup>	94,614	2,617,969
MPLX LP	74,489	2,543,054
ONEOK, $Inc.^{(a)}$	59,551	4,158,446
Targa Resources Corp. <sup>(a)</sup>	33,630	1,664,349
TransCanada Corp.	241,750	10,459,620
Williams Cos., Inc. <sup>(a)</sup>	323,650	8,774,152
		41,874,100
Semiconductors & Semiconductor Equipment 1.0%		
Infineon Technologies AG	133,000	3,378,373
Transportation Infrastructure 11.2%		
Aeroports de Paris	20,170	4,556,206
Atlantia SpA	397,024	11,705,144
Flughafen Zuerich AG	11,710	2,382,576
Fraport AG Frankfurt Airport Services Worldwide	22,880	2,201,159
Getlink SE, Registered Shares	287,850	3,946,383
Sydney Airport	677,826	3,588,371
Transurban Group	1,112,890	9,854,982
1	, ,	, ,
		38,234,821
Water Utilities 0.8%		, ,
American Water Works Co., Inc. <sup>(a)</sup>	32,220	2,750,944
	,	_,, _ ,,
Total Long-Term Investments 99.1%		
(Cost \$270,725,073)		338,818,305
		550,010,505
Short-Term Securities 2.0%		
BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% <sup>(c)(d)</sup>	6,672,678	6,672,678
Total Short-Term Securities 2.0%		
(Cost \$6,672,678)		6,672,678
Total Investments Defense Ontions Written 101 601		
Total Investments Before Options Written 101.6%		245 400 092
(Cost \$277,397,751)		345,490,983

Options Written (1.0)% (Premiums Received \$2,010,942)	(3,592,911)
Total Investments, Net of Options Written 99.6% (Cost \$275,386,809) Other Assets Less Liabilities 0.4%	341,898,072 1,517,159
Net Assets 0.0%	\$ 343,415,231

<sup>(a)</sup> All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

<sup>(b)</sup> All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

<sup>(c)</sup> Annualized 7-day yield as of period end.

<sup>(d)</sup> During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

							Change
							in
	Shares		Shares			Net	Inrealized
	Held at	Net	Held at	Value at		Realiz <b>Aept</b>	preciation
Affiliate	12/31/17	Activity	06/30/18	06/30/18	IncGmin	(LosDep)	reciation)
BlackRock Liquidity Funds,							
T-Fund, Institutional Class	6,376,831	295,847	6,672,678	\$6,672,678	\$31,776	\$	\$

<sup>(a)</sup> Includes net capital gain distributions, if applicable.

Schedule of Investments (unaudited) (continued)

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

June 30, 2018

For Trust compliance purposes, the sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

#### Derivative Financial Instruments Outstanding as of Period End

#### **Exchange-Traded Options Written**

	Number of	Expiration		Exercise	N	otional	
Description	Contracts	Date		Price	Amour	ıt (000)	Value
Call							
Enterprise Products Partners LP	55	07/06/18	USD	29.00	USD	152	\$ (275)
Williams Cos., Inc.	168	07/06/18	USD	27.50	USD	455	(2,100)
FirstEnergy Corp.	110	07/11/18	USD	34.01	USD	395	(21,810)
FirstEnergy Corp.	73	07/13/18	USD	34.50	USD	262	(11,602)
Williams Cos., Inc.	236	07/13/18	USD	27.00	USD	640	(11,918)
Dominion Energy, Inc.	630	07/19/18	USD	66.00	USD	4,295	(167,988)
American Electric Power Co., Ir	nc. 336	07/20/18	USD	65.00	USD	2,327	(152,880)
American Water Works Co., Inc	c. 112	07/20/18	USD	85.00	USD	956	(15,960)
DTE Energy Co.	163	07/20/18	USD	100.00	USD	1,689	(70,090)
Duke Energy Corp.	272	07/20/18	USD	80.00	USD	2,151	(19,040)
Enbridge, Inc.	618	07/20/18	USD	35.00	USD	2,206	(80,340)
Enbridge, Inc.	264	07/20/18	USD	32.50	USD	942	(89,760)
Enterprise Products Partners LP	46	07/20/18	USD	29.00	USD	127	(460)
Eversource Energy	157	07/20/18	USD	60.00	USD	920	(2,748)
Eversource Energy	124	07/20/18	USD	55.00	USD	727	(48,980)
Exelon Corp.	471	07/20/18	USD	41.00	USD	2,006	(84,780)
FirstEnergy Corp.	96	07/20/18	USD	35.00	USD	345	(11,760)
NextEra Energy, Inc.	292	07/20/18	USD	166.25	USD	4,877	(84,028)
NextEra Energy, Inc.	186	07/20/18	USD	165.00	USD	3,107	(66,960)
NiSource, Inc.	370	07/20/18	USD	25.00	USD	972	(51,800)
ONEOK, Inc.	124	07/20/18	USD	60.00	USD	866	(125,240)
Targa Resources Corp.	59	07/20/18	USD	50.00	USD	292	(5,753)
Targa Resources Corp.	58	07/20/18	USD	49.00	USD	287	(8,845)
WEC Energy Group, Inc.	106	07/20/18	USD	60.00	USD	685	(51,410)
WEC Energy Group, Inc.	139	07/20/18	USD	61.90	USD	899	(40,934)
Williams Cos., Inc.	226	07/20/18	USD	28.00	USD	613	(4,859)
FirstEnergy Corp.	74	07/24/18	USD	34.75	USD	266	(11,685)
Public Service Enterprise Group	),						
Inc.	363	07/24/18	USD	52.01	USD	1,965	(84,677)
NextEra Energy, Inc.	293	07/25/18	USD	156.00	USD	4,894	(332,440)
Enterprise Products Partners LP	46	07/27/18	USD	29.00	USD	127	(575)

	1.50	07/07/10	LICD	<b>2</b> 0 <b>5</b> 0	LICD	120	
Williams Cos., Inc.	158	07/27/18	USD	28.50	USD	428	(2,686)
Williams Cos., Inc.	172	07/27/18	USD	28.00	USD	466	(4,988)
FirstEnergy Corp.	111	07/31/18	USD	34.75	USD	399	(18,680)
NiSource, Inc.	95	07/31/18	USD	24.50	USD	250	(16,055)
PPL Corp.	401	07/31/18	USD	27.50	USD	1,145	(55,927)
Duke Energy Corp.	272	08/01/18	USD	73.75	USD	2,151	(151,037)
Enterprise Products Partners LP	138	08/10/18	USD	28.00	USD	382	(6,555)
FirstEnergy Corp.	111	08/10/18	USD	33.75	USD	399	(26,288)
Energy Transfer Partners LP	489	08/17/18	USD	20.00	USD	931	(14,670)
Enterprise Products Partners LP	46	08/17/18	USD	29.00	USD	127	(920)
ONEOK, Inc.	84	08/17/18	USD	70.00	USD	587	(16,590)
TransCanada Corp.	846	08/17/18	CAD	58.00	CAD	4,812	(54,377)
Williams Cos., Inc.	172	08/17/18	USD	28.00	USD	466	(9,116)
Public Service Enterprise Group,							
Inc.	251	08/22/18	USD	54.05	USD	1,359	(38,877)
Sempra Energy	101	08/27/18	USD	116.00	USD	1,173	(40,346)

\$ (2,118,809)

# **OTC Options Written**

<i>Description</i> Call	Counterparty	Number of Contracts	Expiration Date	E.	xercise Price	No Amount	tional (000)	Value
Getlink SE, Registered Shares	Morgan Stanley & Co. International	k						
Valeo SA	PLC UBS AG	53,300 16,600	07/10/18 07/10/18				626 775	\$ (879) (3)

Schedules of Investments

87

Schedule of Investments (unaudited) (continued) BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

June 30, 2018

## **OTC Options Written (continued)**

		e e	Expiration		Exercise		Notional	
Description	Counterparty	Contracts	Date		Price	Атои	nt (000)	Value
Call (continued)								
Xcel Energy, Inc.	Bank of	24.000	0	LICD	10.65	LIGE	1 107	ф ( <b>51</b> .0.66)
	America N.A.	24,900	07/10/18	USD	43.65	USD	1,137	\$ (51,866)
China Longyuan	Morgan							
Power Group Corp.	Stanley & Co.							
Ltd., Class H	International	1 000 000	0	IIIID		IUUD	6.000	
	PLC	1,000,000	07/11/18	HKD	7.53	HKD	6,300	(733)
Pinnacle West Capital	Credit Suisse	16 000	0	LICD		LIGE	1 0 1 0	
Corp.	International	16,300	07/11/18		77.12		1,313	(58,267)
EDP Renovaveis SA	UBS AG	50,000		EUR		EUR	447	(41,078)
Enel SpA	UBS AG	514,600	07/12/18			EUR	2,439	(12,560)
Iberdrola SA	UBS AG	36,000	07/12/18	EUR	6.55	EUR	238	(2,388)
Kingspan Group PLC	Morgan							
	Stanley & Co.							
	International							
	PLC	28,200	07/12/18	EUR	40.11	EUR	1,209	(92,580)
Linde AG	Morgan							
	Stanley & Co.							
	International							
	PLC	10,100	07/12/18	EUR	197.09	EUR	2,055	(95,544)
National Grid PLC	Morgan							
	Stanley & Co.							
	International							
	PLC	97,000	07/12/18	GBP	8.94	GBP	812	(30)
OSRAM Licht AG	Deutsche Bank							
	AG	8,400	07/12/18	EUR	54.41	EUR	293	(4)
Sydney Airport	Morgan							
	Stanley & Co.							
	International							
	PLC	131,900	07/12/18	AUD	7.30	AUD	943	(4,355)
Transurban Group	UBS AG	145,200	07/12/18	AUD	11.90	AUD	1,738	(20,308)
Air Liquide SA	Morgan							
	Stanley & Co.							
	International							
	PLC	3,300	07/13/18	EUR	112.62	EUR	354	(475)
Public Service	Bank of							
Enterprise Group, Inc.	America N.A.	22,400	07/16/18	USD	53.44	USD	1,213	(24,618)
NRG Yield, Inc.,	Bank of							
Class C	America N.A.	16,800	07/17/18	USD	17.78	USD	289	(1,678)

Aeroports de Paris	Goldman Sachs International	7,100	07/18/18	EUR	178.96	EUR	1,373	(121,329)
Atlantia SpA	Bank of America N.A.	17,300	07/18/18	EUR	24.90	EUR	437	(13,425)
China Longyuan		1,,000	01110110	2011	, 0	2011	,	(10,120)
Power Group Corp.	Citibanh N.A	1 267 000	07/10/10	מעוו	7.02		7 092	(7 575)
Ltd., Class H EDP Renovaveis SA	Citibank N.A. Credit Suisse	1,267,000	07/18/18	HKD	7.03	HKD	7,982	(7,575)
	International	50,000	07/18/18	EUR	8.25	EUR	447	(39,985)
Enel SpA	UBS AG	200,000	07/18/18			EUR	948	(15,396)
Iberdrola SA	Goldman Sachs							
	International	36,000	07/18/18	EUR	6.40	EUR	238	(8,912)
Schneider Electric SE	Barclays Bank	15 100	07/10/10	FUD		FUD	1.075	(1.2.42)
Transurban Group	PLC Morgan	15,100	07/18/18	EUK	76.74	EUK	1,075	(1,242)
Transurban Oroup	Stanley & Co.							
	International							
	PLC	98,974	07/18/18	AUD	11.89	AUD	1,185	(16,685)
Vestas Wind Systems	Goldman Sachs							
A/S	International	33,000	07/19/18	DKK	423.68	DKK	12,998	(14,232)
Fraport AG Frankfurt Airport Services	Goldman Sachs							
Worldwide	International	8,100	07/24/18	EUR	81.62	EUR	667	(21,672)
Getlink SE, Registered		0,100	0//2//10	LUK	01.02	LUK	007	(21,072)
Shares	AG	47,500	07/25/18	EUR	11.76	EUR	558	(11,937)
National Grid PLC	Citibank N.A.	9,100	07/25/18	GBP		GBP	76	(1,588)
Air Liquide SA	Citibank N.A.	15,300	07/26/18	EUR	111.75	EUR	1,642	(9,374)
Atlantia SpA	Credit Suisse International	42 200	07/26/18	FUD	25.01	EUD	1.001	(24 477)
China Longyuan	International	43,200	0//20/18	EUK	23.01	EUK	1,091	(34,477)
Power Group Corp.								
Ltd., Class H	Citibank N.A.	1,310,000	07/26/18	HKD	7.13	HKD	8,253	(10,505)
EDP Renovaveis SA	Morgan							
	Stanley & Co.							
	International PLC	50,000	07/26/18	EUD	8.05	EUR	447	(51,357)
Infineon Technologies	Goldman Sachs	50,000	07720/10	LUK	8.05	LUK		(31,337)
AG	International	23,100	07/26/18	EUR	24.08	EUR	502	(4,664)
National Grid PLC	Goldman Sachs							
	International	106,100	07/26/18	GBP	8.83	GBP	888	(2,840)
Transurban Group	Morgan							
	Stanley & Co. International							
	PLC	145,300	07/26/18	AUD	12.00	AUD	1,739	(20,989)
Sempra Energy	Morgan	,					_,, _,	(,,
	Stanley & Co.							
	International							
Atlantic On A	PLC	14,500	07/27/18		116.68		1,684	(33,325)
Atlantia SpA EDP Renovaveis SA	UBS AG UBS AG	78,500 30,000	08/01/18 08/01/18		24.72	EUR EUR	1,982 268	(87,060) (25,656)
EDF Renovavers SA Enel SpA	UDS AU	317,000	08/01/18			EUR	1,503	(11,666)
		217,000	00,01,10	2010		2010	1,000	(11,000)

	Credit Suisse International							
Exelon Corp.	JPMorgan							
	Chase Bank							
	N.A.	47,100	08/01/18		41.18		2,006	(85,020)
Fortis, Inc.	UBS AG	25,400	08/01/18	USD	32.50	USD	810	(22,181)
National Grid PLC	Credit Suisse							
	International	193,900	08/01/18			GBP	1,623	(32,779)
Flughafen Zuerich AG	Citibank N.A.	4,169	08/02/18	CHF	216.75	CHF	840	(2,065)
CMS Energy Corp.	UBS AG	44,600	08/07/18	USD	43.45	USD	2,109	(184,041)
Continental AG	UBS AG	4,500	08/07/18	EUR	227.24		877	(916)
EDP Renovaveis SA	UBS AG	30,000	08/08/18	EUR	8.21	EUR	268	(25,950)
Schneider Electric SE	Morgan							
	Stanley & Co.							
	International							
	PLC	11,800	08/08/18	EUR	71.59	EUR	840	(26,235)
EDP Renovaveis SA	UBS AG	30,000	08/14/18	EUR	8.21	EUR	268	(26,183)
Sydney Airport	JPMorgan							
	Chase Bank							
	N.A.	105,400	08/16/18	AUD	7.60	AUD	754	(3,687)
NRG Yield, Inc.,	Barclays Bank							
Class C	PLC	43,400	08/20/18	USD	17.75	USD	746	(14,794)
EDP Renovaveis SA	Morgan							
	Stanley & Co.							
	International							
	PLC	40,000	08/21/18	EUR	8.49	EUR	357	(24,902)
EDP Renovaveis SA	Goldman Sachs							
	International	40,000	08/29/18	EUR	8.93	EUR	357	(12,875)
FirstEnergy Corp.	JPMorgan							
	Chase Bank							
	N.A.	13,500	08/29/18	USD	36.65	USD	485	(9,574)
Fortis, Inc.	Bank of							
	America N.A.	25,000	09/04/18	USD	31.72	USD	797	(16,050)
EDP Renovaveis SA	Goldman Sachs	-						
	International	40,000	09/05/18	EUR	8.93	EUR	357	(13,593)
								¢ (1 474 102)

\$ (1,474,102)

Schedule of Investments (unaudited) (continued) BlackRock Utilities, Infrastruct

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

June 30, 2018

#### **Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives**

	Swap	Swap								
	Premium	Premium	Unrealized	Unrealized						
	Paid	Received	Depreciation	Appreciation	Value					
Options Written	N/A	N/A	\$ 415,293	\$ (1,997,262)	\$(3,592,911)					
Derivative Financial Instruments Categorized by Risk Exposure										

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

				Foreign	1		
			(	Currency	y Interest		
	Commodity	Credit	Equity E	Exchange	e Rate	Other	
	Contracts (	Contracts	Contracts C	Contract	s Contracts C	Contracts	Total
Liabilities Derivative Fi	nancial Instr	uments					
Options written							
Options written, at value	\$	\$	\$3,592,911	\$	\$	\$	\$3,592,911

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity	Credit	C Equity Ex	0	Interest Rate	Other	<b>T</b> 1
	ContractsC	Contracts Co	ontracts	<i>Contracts</i> C	contracts	Total	
Net Realized Gain (Loss	s) from:						
Options purchased <sup>(a)</sup>	\$	\$	\$ (713)	\$	\$	\$	\$ (713)
Options written			185,899				185,899
	\$	\$	\$ 185,186	\$	\$	\$	\$ 185,186

<sup>(a)</sup> Options purchased are included in net realized gain (loss) from investments.

Net Change in Unrealized Appreciation (Depreciation) on:									
Options purchased <sup>(a)</sup>	\$	\$	\$	(547)	\$	\$	\$	\$	(547)
Options written			(2,	314,197)				(2,	314,197)

	Edgar Filing: B	lackRock	Health Sciences	Trust -	Form N-0	CSRS		
	\$	\$	\$ (2,314,744)	\$	\$	\$	\$ (2,314	4,744)
<sup>(a)</sup> Includes options p		-						
Average Quarterly Ba	lances of Outsta	nding Der	ivative Financial I	Instrun	nents			
Options:								
Average value of opti	ion contracts purc	hased					\$	(a)

Average value of option contracts written

A

\$ 3,257,934

<sup>(a)</sup> Derivative not held at quarter-end. The amount shown in the Statements of Operations reflect the results of activity during the period.

For more information about the Trust s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

## Derivative Financial Instruments Offsetting as of Period End

The Trust s derivative asset and liabilities (by type) are as follows:

	Assets	Liabilities
<b>Derivative Financial Instruments</b> Options	\$	\$ 3,592,911
Derivatives not subject to a Master Netting Agreement or similar agreement ( MNA	.)	(2,118,809)
Total derivative assets and liabilities subject to an MNA	\$	\$ 1,474,102

Schedules of Investments

89

Schedule of Investments (unaudited) (continued)

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

June 30, 2018

The following table presents the Trust s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral and pledged by the Trust:

		Derivative					
		Liabilities					
		Subject to I	Derivatives	Non-cash	Cash	Ne	et Amount
	C	n MNA by	Available	Collateral	Collateral	of L	Derivative
Counterparty	Са	unterparty	for Offset	Pledged <sup>(a)</sup>	Pledged	Lia	ıbilities <sup>(b)</sup>
Bank of America N.A.	\$	107,637	\$	\$	\$	\$	107,637
Barclays Bank PLC		16,036		(2,495)			13,541
Citibank N.A.		31,107		(31,107)			
Credit Suisse International		177,174		(177,174)			
Deutsche Bank AG		11,941		(11,941)			
Goldman Sachs International		200,117			(130,000)		70,117
JPMorgan Chase Bank N.A.		98,281					98,281
Morgan Stanley & Co. International							
PLC		368,089		(368,089)			
UBS AG		463,720		(208,012)			255,708
	\$	1,474,102	\$	\$ (798,818)	\$ (130,000)	\$	545,284

<sup>(a)</sup> Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

<sup>(b)</sup> Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

#### Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust s policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust s investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total	
Assets:					
Investments:					
Common Stocks:					
Auto Components	\$	\$ 6,480,853	\$	\$ 6,480,853	
Building Products	3,603,716			3,603,716	

Chemicals 13,533,737	13,533,737
	15,555,757
Electric Utilities 103,309,082 18,807,872 12	22,116,954
Electrical Equipment 13,297,129	13,297,129
Independent Power and Renewable Electricity	
Producers 19,299,411 8,208,229	27,507,640
Multi-Utilities 52,321,531 13,718,507	66,040,038
Oil, Gas & Consumable Fuels41,874,100	41,874,100
Semiconductors & Semiconductor Equipment 3,378,373	3,378,373
Transportation Infrastructure 38,234,821	38,234,821
Water Utilities 2,750,944	2,750,944
Short-Term Securities6,672,678	6,672,678
\$ 229,831,462 \$ 115,659,521 \$ \$ 34	45,490,983
Derivative Financial Instruments <sup>(a)</sup> Liabilities:	
Equity contracts \$ (1,016,434) \$ (2,576,477) \$ \$	(3,592,911)

<sup>(a)</sup> Derivative financial instruments are options written, which are shown at value. Transfers between Level 1 and Level 2 were as follows:

	Transfers into	Transfers out of	Transfers Into Tr	Transfers out of	
	Level 1	Level 1 <sup>(a)</sup>	Level 2 <sup>(a)</sup>	Level 2	
Assets:					
Long-Term Investments:					
Common Stocks	\$	\$ 3,858,072	\$ 3,858,072	\$	

 (a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

See notes to financial statements.

90

## Statements of Assets and Liabilities (unaudited)

June 30, 2018

	BGR	CII	BDJ	BOE	BGY
ASSETS					
Investments at value					
unaffiliated <sup>(a)(b)</sup>	\$ 475,625,445	\$749,989,101	\$ 1,807,388,599	\$819,443,881	\$689,283,953
Investments at value					
affiliated <sup>(c)</sup>	4,599,459	4,630,300	13,805,466		943,659
Due to broker					1,553,352
Cash pledged:					
Collateral OTC derivatives			16,000		803,000
Collateral options written				3,225,000	5,170,000
Foreign currency at value <sup>(d)</sup>	290,569		1,117	351,455	438,298
Receivables:					
Investments sold	6,732,791	263,300	572,831	1,863,536	3,242,645
Dividends unaffiliated	382,970	864,966	2,431,189	3,752,713	3,771,338
Options written	139,844	601,703	1,378,909	400,215	590,394
Dividends affiliated	6,781	6,269	18,286	7,123	
Securities lending income affiliated			7		
Prepaid expenses	13,098	28,676	65,627	28,615	33,183
r repaid expenses	15,098	28,070	03,027	28,015	55,165
Total assets	487,790,957	756,384,315	1,825,678,031	829,072,538	705,829,822
LIABILITIES					
Cash collateral on securities					
loaned at value			12,294		
Bank overdraft			51,239	380,331	
Options written at value <sup>(e)</sup> Payables:	3,538,539	6,477,238	15,288,978	6,213,872	5,608,380
Investments purchased	6,552,884	372,603	3,065,960	184	5,116,017
Trustees and Officer s fees	485,529	200,707	961,873	711,177	218,602
Investment advisory fees	406,738	529,408	1,198,528	611,512	516,588
Options written	222,218	271,757	498,252	106,610	92,396
Income dividend distributions	159,320	212,598	298,756	191,684	614,474
Other accrued expenses	120,681	196,303	333,681	249,578	227,267
Total liabilities	11,485,909	8,260,614	21,709,561	8,464,948	12,393,724
NET ASSETS	\$ 476,305,048	\$748,123,701	\$ 1,803,968,470	\$ 820,607,590	\$ 693,436,098

## NET ASSETS CONSIST OF:

Paid-in capital Distributions in excess of net	\$	599,545,557	\$6	501,583,666	<b>\$</b> 1	1,320,628,954	\$8	831,421,885	\$6	80,249,058
investment income		(10,562,679)	(	(18,476,686)		(37,685,311)		(19,351,880)	(	(11,950,317)
Accumulated net realized gain (loss) Net unrealized appreciation		(183,729,721)		(2,501,419)		111,709,900		37,262,216		58,068,210
(depreciation)		71,051,891	1	67,518,140		409,314,927		(28,724,631)	(	(32,930,853)
NET ASSETS	\$	476,305,048	\$7	748,123,701	\$ 1	1,803,968,470	\$ 8	820,607,590	\$6	93,436,098
Net asset value <sup>(f)(g)</sup>	\$	15.97	\$	16.96	\$	9.62	\$	11.91	\$	6.36
<sup>(a)</sup> Investments at cost										
unaffiliated	\$	404,613,943	\$5	584,061,337	\$ 1	1,400,290,492	\$ 8	848,155,824	\$7	21,868,971
<sup>(b)</sup> Securities loaned at value	\$		\$		\$	11,215	\$		\$	
(c) Investments at cost affilia	te\$1	4,599,459	\$	4,630,300	\$	13,805,466	\$		\$	943,659
<sup>(d)</sup> Foreign currency at cost	\$	287,746	\$		\$	1,193	\$	357,292	\$	438,364
(e) Premiums received	\$	3,574,813	\$	8,067,614	\$	17,508,135	\$	6,227,625	\$	5,304,238
<sup>(f)</sup> Shares outstanding, unlimi	ted									
number of shares authorized,										
par value \$0.001 per share		29,825,326				187,542,405		68,911,795	1	09,049,017
<sup>(g)</sup> Shares outstanding,										
200 million shares authorized,										
par value \$0.10 per share				44,121,400						
See notes to financial statement	<i>s</i> .									

FINANCIAL STATEMENTS

91

Statements of Assets and Liabilities (unaudited) (continued)

June 30, 2018

	BME	BCX <sup>(a)</sup>	BST	BUI
ASSETS				
Investments at value unaffiliated)(c)	\$337,614,893	\$ 988,025,166	\$698,416,219	\$ 338,818,305
Investments at value affiliated)	7,272,162	7,923,934	6,080,340	6,672,678
Cash	422,843			
Cash pledge as collateral for OTC derivatives			2,310,000	130,000
Foreign currency at value <sup>(e)</sup>	970	533,983	101,678	61
Receivables:				
Investments sold	2,025,642	15,398,531	4,268,837	1,417,520
Capital shares sold	352,211			
Dividends unaffiliated	195,412	1,756,944	290,645	1,267,488
Dividends affiliated	12,385	11,894	6,171	9,342
Options written	236,581	393,259	870,279	12,444
Securities lending income affiliated		102	1,906	
Offering costs	78,142	24.502	14076	16.660
Prepaid expenses	11,170	34,583	14,876	16,662
Total assets	348,222,411	1,014,078,396	712,360,951	348,344,500
LIABILITIES				
Cash collateral on securities loaned at value		27,985	277,000	
Bank overdraft		246,682	,	46,601
Options written at value <sup>(f)</sup>	2,688,836	7,080,083	6,462,316	3,592,911
Payables:				
Investments purchased	2,119,009	16,536,174	5,236,399	710,152
Income dividend distributions		212,092		130,617
Investment advisory fees	281,322	819,901	469,831	271,115
Offering costs	24,000			
Trustees and Officer s fees	27,805	332,218	14,346	7,775
Options written	212,308	396,152	922,674	33,479
Other accrued expenses	139,700	251,680	179,165	136,619
Total liabilities	5,492,980	25,902,967	13,561,731	4,929,269
NET ASSETS	\$ 342,729,431	\$ 988,175,429	\$ 698,799,220	\$ 343,415,231

NET ASSETS CONSIST OF Paid-in capital Distributions in excess of net investment income Accumulated net realized gain (loss) Net unrealized appreciation (depreciation)	(	35,049,601 10,780,214) 7,206,834 11,253,210	\$	1,274,977,072 (22,907,120) (433,014,400) 169,119,877		348,761,569 (20,223,997) 31,109,433 339,152,215	\$2	281,896,948 (4,028,661) (963,829) 66,510,773
NET ASSETS	\$3	42,729,431	\$	988,175,429	\$6	598,799,220	\$3	343,415,231
Net asset value <sup>(g)</sup>	\$	36.54	\$	10.30	\$	31.20	\$	20.26
<sup>(a)</sup> Consolidated Statement of Assets and Liabilities								
<ul> <li>(b) Investments at cost unaffiliated</li> <li>(c) Securities loaned at value</li> <li>(d) Investments at cost affiliated</li> <li>(e) Foreign currency at cost</li> </ul>	\$2 \$ \$ \$	26,572,848 7,272,162 963	\$ \$ \$ \$	820,877,390 20 7,923,928 533,922	\$3 \$ \$ \$	360,716,431 258,390 6,080,330 101,798	\$2 \$ \$ \$	270,725,073 6,672,678 77
<ul> <li>(f) Premiums received</li> <li>(g) Shares outstanding, unlimited number of shares authorized, par value \$0.001 per share</li> </ul>	\$	2,899,524 9,380,449	\$	9,065,805 95,908,874	\$	7,916,075 22,395,449	\$	2,010,942 16,953,526
See notes to financial statements.		<i>J</i> , <i>J</i> 00, <del>11</del> <i>J</i>		<i>JJ</i> , <i>J</i> 00,074		22,373,449		10,755,520

# Statements of Operations (unaudited)

Six Months Ended June 30, 2018

	BGR	CII	BDJ	BOE	BGY
<b>INVESTMENT INCOME</b> Dividends unaffiliated Dividends affiliated Securities lending income	\$ 7,085,380 28,875	\$ 7,035,737 29,997	\$ 24,335,838 67,095	\$ 18,998,651 56,205	\$ 18,760,836 53,789
affiliated net			7		
Foreign taxes withheld	(451,705)	(69,908)	(776,065)	(1,196,883)	(1,636,342)
Total investment income	6,662,550	6,995,826	23,626,875	17,857,973	17,178,283
EXPENSES					
Investment advisory	2,742,268	3,180,371	7,304,337	4,297,630	3,643,847
Professional Transfer exert	44,322	49,685	92,717	73,041	63,257 56,454
Transfer agent Custodian	42,679 25,697	30,428 12,207	96,989 81,925	61,734 56,480	56,454 64,888
Accounting services	17,408	14,923	42,200	24,842	19,900
Trustees and Officer	12,734	34,201	71,898	35,119	34,480
Printing	6,684	4,759	10,349	8,368	8,494
Registration	5,713	8,453	35,926	13,242	20,931
Miscellaneous	55,841	29,844	59,364	88,609	77,829
Total expenses Less fees waived and/or	2,953,346	3,364,871	7,795,705	4,659,065	3,990,080
reimbursed by the Manager	(344,178)	(1,442)	(3,186)	(432,678)	(367,212)
Total expenses after fees					
waived and/or reimbursed	2,609,168	3,363,429	7,792,519	4,226,387	3,622,868
Net investment income (loss)	4,053,382	3,632,397	15,834,356	13,631,586	13,555,415
<b>REALIZED AND UNREALIZ</b> Net realized gain (loss) from:	ED GAIN (LOS	S)			
Investments Payments by affiliates <sup>(b)</sup>	3,787,294	28,001,029	75,000,639	3,550,649	93,880,466 <sup>(a)</sup> 243,859
Foreign currency transactions	11,596	95,365	38,465	140,397	(174,449)
Options written	(14,337,904)	(4,323,450)	(9,659,803)	2,305,969	3,505,781
	(10,539,014)	23,772,944	65,379,301	5,997,015	97,455,657
Net change in unrealized					

appreciation (depreciation) on:

Investments Foreign currency translations Options written	21,231,224 (1,996) 4,386,198	(19,378,866) 3,616,469	(99,473,803) (2,412) 6,323,305	(77,873,927) (60,005) (63,217)	(160,402,903) (98,503) (1,888,476)
	25,615,426	(15,762,397)	(93,152,910)	(77,997,149)	(162,389,882)
Net realized and unrealized gain (loss)	15,076,412	8,010,547	(27,773,609)	(72,000,134)	(64,934,225)
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS	\$ 19,129,794	\$ 11,642,944	\$ (11,939,253)	\$ (58,368,548)	\$ (51,378,810)

<sup>(a)</sup> Including \$(211,516) realized foreign capital gain tax.

<sup>(b)</sup> See Note 6 of the Notes to Financial Statements.

See notes to financial statements.

FINANCIAL STATEMENTS

93

Statements of Operations (unaudited) (continued)

Six Months Ended June 30, 2018

	BME	BCX <sup>(a)</sup>	BST	BUI
INVESTMENT INCOME				
Dividends unaffiliated	\$ 2,295,732	\$ 16,735,533	\$ 2,046,613	\$ 7,403,454
Dividends affiliated	83,489	73,740	32,717	31,776
Securities lending income affiliated net	1,241	2,510	123,932	
Foreign taxes withheld	(65,244)	(975,872)	(140,143)	(388,091)
Total investment income	2,315,218	15,835,911	2,063,119	7,047,139
EXPENSES				
Investment advisory	1,667,258	4,933,186	3,351,219	1,710,322
Professional	74,999	73,683	58,648	49,543
Transfer agent	24,563	61,372	32,913	30,272
Custodian	49,895	53,159	89,536	26,227
Accounting services	9,975	24,842	19,900	19,900
Trustees and Officer	14,631	40,980	30,227	15,626
Printing	7,418	8,492	8,105	6,832
Registration	5,838	18,509	4,672	5,980
Miscellaneous	20,545	121,010	55,317	49,422
Total expenses	1,875,122	5,335,233	3,650,537	1,914,124
Less fees waived and/or reimbursed by the Manager	(4,091)	(3,732)	(671,816)	(44,315)
Total expenses after fees waived and/or reimbursed	1,871,031	5,331,501	2,978,721	1,869,809
Net investment income (loss)	444,187	10,504,410	(915,602)	5,177,330
REALIZED AND UNREALIZED GAIN (LOSS)				
Net realized gain (loss) from:				
Investments unaffiliated	12,777,732	45,478,107	47,251,198	1,260,532
Investments affiliated	13	2	(464)	
Foreign currency transactions	5,323	371,864	(48,482)	(17,034)
Options written	(2,080,545)	(19,278,563)	(10,692,313)	185,899
	10,702,523	26,571,410	36,509,939	1,429,397

Net change in unrealized appreciation (depreciation) on:

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS									
Investments unaffiliated Investments affiliated	7,749,006 7	(50,501,437) 45	60,415,871 179	(6,608,666)					
Foreign currency translations	(1,049)	(21,802)	(1,953)	(5,287)					
Options written	6,401	10,195,573	(793,166)	(2,314,197)					
	7,754,365	(40,327,621)	59,620,931	(8,928,150)					
Net realized and unrealized gain (loss)	18,456,888	(13,756,211)	96,130,870	(7,498,753)					
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS	\$ 18,901,075	\$ (3,251,801)	\$ 95,215,268	\$ (2,321,423)					

<sup>(a)</sup> Consolidated Statement of Operations. See notes to financial statements.

94

Statements of Changes in Net Assets

	BG	R	CII			
S	ix Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17		
INCREASE (DECREASE) IN NET ASSETS						
<b>OPERATIONS</b> Net investment income Net realized gain (loss) Net change in unrealized appreciatio		\$ 12,016,029 240,009	\$ 3,632,397 23,772,944	\$ 6,643,909 10,582,824		
(depreciation)	25,615,426	(484,738)	(15,762,397)	119,853,112		
Net increase in net assets resulting from operations	19,129,794	11,771,300	11,642,944	137,079,845		
DISTRIBUTIONS TO SHAREHOLDERS						
From net investment income From return of capital	(13,886,672) <sup>(a)</sup>	$(12,093,542)^{(b)}$ $(15,679,802)^{(b)}$		(6,682,172) <sup>(b)</sup> (37,156,851) <sup>(b)</sup>		
Decrease in net assets resulting from distributions to shareholders	(13,886,672)	(27,773,344)	(21,919,512)	(43,839,023)		
<i>NET ASSETS</i> Total increase (decrease) in net asset Beginning of period	s 5,243,122 471,061,926	(16,002,044) 487,063,970	(10,276,568) 758,400,269	93,240,822 665,159,447		
End of period	\$476,305,048	\$471,061,926	\$748,123,701	\$758,400,269		
Distributions in excess of net investment income, end of period	\$ (10,562,679)	\$ (729,389)	\$ (18,476,686)	\$ (189,571)		

<sup>(a)</sup> A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

<sup>(b)</sup> Distributions for annual periods determined in accordance with U.S. federal income tax regulations. *See notes to financial statements.* 

FINANCIAL STATEMENTS

Statements of Changes in Net Assets (continued)

	BD		BOE			
	Six Months Ended 06/30/18 (unaudited)	S Year Ended 12/31/17	ix Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17		
INCREASE (DECREASE) IN NET ASSETS						
<b>OPERATIONS</b> Net investment income Net realized gain Net change in unrealized appreciation (depreciation)	\$ 15,834,356 65,379,301 (93,152,910)	\$ 30,942,206 191,391,199 22,107,356	\$ 13,631,586 5,997,015 (77,997,149)	\$ 11,728,245 188,939,188 (54,178,546)		
Net increase (decrease) in net assets resulting from operations		244,440,761	(58,368,548)	146,488,887		
<b>DISTRIBUTIONS TO</b> <b>SHAREHOLDERS</b> From net investment income From net realized gain	(52,549,382) <sup>(a)</sup>	(31,328,211) <sup>(b)</sup> (74,032,175) <sup>(b)</sup>	(32,250,719) <sup>(a)</sup>	(12,416,010) <sup>(b)</sup> (145,314,426) <sup>(b)</sup>		
Decrease in net assets resulting from distributions to shareholders	(52,549,382)	(105,360,386)	(32,250,719)	(157,730,436)		
<b>CAPITAL SHARE TRANSA</b> Redemption of shares resulting from share repurchase program (including transaction costs)		(12,272,105)		(7,428,758)		
<i>NET ASSETS APPLICABLE TO</i> <i>COMMON SHAREHOLDERS</i> Total increase (decrease) in net assets Beginning of period		126,808,270 1,741,648,835	(90,619,267) 911,226,857	(18,670,307) 929,897,164		
End of period	\$ 1,803,968,470	\$ 1,868,457,105	\$ 820,607,590	\$ 911,226,857		

Distributions in excess of net				
investment income, end of period \$	(37,685,311)	\$ (970,285)	\$ (19,351,880)	\$ (732,747)

<sup>(a)</sup> A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

<sup>(b)</sup> Distributions for annual periods determined in accordance with U.S. federal income tax regulations. *See notes to financial statements.* 

96

# Statements of Changes in Net Assets (continued)

	BG	Y	BM	E
	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17
INCREASE (DECREASE) IN NET ASSETS				
OPERATIONS				
Net investment income Net realized gain Net change in unrealized	\$ 13,555,415 97,455,657	\$ 9,657,720 20,853,143	\$ 444,187 10,702,523	\$ 184,052 16,290,255
appreciation (depreciation)	(162,389,882)	104,149,768	7,754,365	43,865,227
Net increase (decrease) in net asset resulting from operations	s (51,378,810)	134,660,631	18,901,075	60,339,534
<b>DISTRIBUTIONS</b> From net investment income From net realized gain	(24,863,178) <sup>(a)</sup>	(9,780,974) <sup>(b)</sup>	(11,163,071) <sup>(a)</sup>	(355,707) <sup>(b)</sup> (19,026,099) <sup>(b)</sup>
From return of capital		(40,102,438) <sup>(b)</sup>		$(19,020,099)^{(6)}$ $(2,234,310)^{(b)}$
Decrease in net assets resulting fro distributions to shareholders	m (24,863,178)	(49,883,412)	(11,163,071)	(21,616,116)
<b>CAPITAL SHARE TRANSACT</b> Proceeds from the issuance of shar (including deferred offering costs) Reinvestment of distributions			2,867,059 265,971	20,787,792 1,653,765
Redemption of shares resulting from share repurchase program (including transaction costs)		(5,726,813)		
Net increase in net assets derived from capital share transactions		(5,726,813)	3,133,030	22,441,557
<i>NET ASSETS</i> Total increase (decrease) in net				
assets Beginning of period	(76,241,988) 769,678,086	79,050,406 690,627,680	10,871,034 331,858,397	61,164,975 270,693,422

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS									
End of period	\$ 693,436,098	\$ 769,678,086	\$ 342,729,431	\$331,858,397					
Distributions in excess of net investment income, end of period	\$ (11,950,317)	\$ (642,554)	\$ (10,780,214)	\$ (61,330)					

<sup>(a)</sup> A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

<sup>(b)</sup> Distributions for annual periods determined in accordance with U.S. federal income tax regulations. *See notes to financial statements.* 

FINANCIAL STATEMENTS

Statements of Changes in Net Assets (continued)

	Six N	BCX Months Ended 06/30/18 (unaudited)	(a)	Year Ended 12/31/17	Six N	BS Ionths Ended 06/30/18 (unaudited)	Г Year Ended 12/31/17
INCREASE (DECREASE) IN NET ASSETS							
<b>OPERATIONS</b> Net investment income (loss) Net realized gain	\$	10,504,410 26,571,410	\$	19,831,605 40,599,529	9	6 (915,602) 36,509,939	\$ (1,073,646) 18,280,612
Net change in unrealized appreciation (depreciation)		(40,327,621)		71,294,123		59,620,931	182,129,520
Net increase (decrease) in net assets resulting from operations	5	(3,251,801)		131,725,257		95,215,268	199,336,486
<b>DISTRIBUTIONS</b> From net investment income From net realized gain From return of capital		(29,737,204) <sup>(b)</sup>		(23,004,937) <sup>(c)</sup> (36,309,489) <sup>(c)</sup>		(17,456,110) <sup>(b)</sup>	$(1,173,241)^{(c)}$ $(4,969,225)^{(c)}$ $(22,536,962)^{(c)}$
Decrease in net assets resulting from distributions to shareholde	ers	(29,737,204)		(59,314,426)		(17,456,110)	(28,679,428)
CAPITAL SHARE TRANSA Reinvestment of common distributions Redemption of shares resulting from share repurchase program (including transaction costs)		<b>NS</b> (6,307,631)		(21,837,878)		739,593	(2,799,570)
Net increase (decrease) in net assets derived from capital shar transactions	e	(6,307,631)		(21,837,878)		739,593	(2,799,570)
<i>NET ASSETS</i> Total increase (decrease) in net assets		(39,296,636)		50,572,953		78,498,751	167,857,488

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS										
Beginning of period	1,027,472,065	976,899,112	620,300,469	452,442,981						
End of period	\$ 988,175,429	\$ 1,027,472,065	\$698,799,220	\$620,300,469						
Distributions in excess of net investment income, end of period	\$ (22,907,120)	\$ (3,674,326)	\$ (20,223,997)	\$ (1,852,285)						

<sup>(a)</sup> Consolidated Statement of Changes in Net Assets.

<sup>(b)</sup> A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

<sup>(c)</sup> Distributions for annual periods determined in accordance with U.S. federal income tax regulations. See notes to financial statements.

## Statements of Changes in Net Assets (continued)

	BU Six Months Ended 06/30/18 (unaudited)	II Year Ended 12/31/17
INCREASE (DECREASE) IN NET ASSETS		
OPERATIONS Net investment income Net realized gain Net change in unrealized appreciation (depreciation) Net increase (decrease) in net assets resulting from operations	\$ 5,177,330 1,429,397 (8,928,150) (2,321,423)	\$ 9,484,921 20,594,890 23,259,316 53,339,127
<b>DISTRIBUTIONS</b> From net investment income From net realized gain Decrease in net assets resulting from distributions to shareholders	$(12,303,649)^{(a)}$ (12,303,649)	$(7,954,054)^{(b)}$ $(16,614,050)^{(b)}$ (24,568,104)
CAPITAL SHARE TRANSACTIONS Reinvestment of common distributions	263,846	708,672
<i>NET ASSETS</i> Total increase (decrease) in net assets Beginning of period	(14,361,226) 357,776,457	29,479,695 328,296,762
End of period Undistributed (distributions in excess of) net investment income, end of period	\$ 343,415,231 \$ (4,028,661)	\$ 357,776,457 \$ 3,097,658

<sup>(a)</sup> A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

<sup>(b)</sup> Distributions for annual periods determined in accordance with U.S. federal income tax regulations. *See notes to financial statements.* 

FINANCIAL STATEMENTS

99

Statements of Cash Flows (unaudited)

Six Months Ended June 30, 2018

	BGR	CII	BDJ	BOE	BGY						
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES											
Net increase in net assets resulting from operations	\$ 19,129,794	\$ 11,642,944	\$ (11,939,253)	\$ (58,368,548)	\$ (51,378,810)						
Adjustments to reconcile net increase in net assets resulting											
from operations to net cash											
provided by operating											
activities: Proceeds from sales of											
long-term investments and											
principal paydowns	114,571,364	116,237,176	363,606,803	155,101,865	350,498,589						
Purchases of long-term											
investments	(89,564,193)	(92,071,676)	(305,526,879)	(147,814,279)	(338,849,992)						
Net (purchases) sales of short-term securities	(728,615)	(1,487,326)	(8,838,277)	13,118,524	4,130,041						
Premiums received from	(720,015)	(1,407,520)	(0,050,277)	15,110,524	4,150,041						
options written	14,800,983	33,060,594	75,228,716	25,885,437	20,158,527						
Premiums paid on closing											
options written	(28,920,943)	(37,339,445)	(87,400,772)	(24,781,616)	(17,978,422)						
Net realized (gain) loss on investments and options											
written	10,517,637	(23,677,336)	(65,340,836)	(5,551,856)	(97,967,425)						
Net unrealized gain (loss) on	- , ,	( - ) )	(	(-))							
investments, options written											
and foreign currency	(05 (15 400)	15 702 007			160 700 100						
translations (Increase) Decrease in Assets	(25,617,422)	15,792,997	93,086,688	77,937,145	160,708,193						
Receivables:	•										
Dividends affiliated	(2,717)	(2,066)	(13,080)	29,896	(2,971)						
Dividends unaffiliated	4,877	(245,091)	(257,382)	(570,075)	(1,392,057)						
Securities lending income											
affiliated Prepaid expenses	1,031	3,618	(7) (8,530)	2,221	(9,385)						
Increase (Decrease) in Liabili		5,018	(8,550)	2,221	(9,565)						
Collateral on securities loaned											
at value			12,294								
Payables:											
Investment advisory fees Trustees and Officers fees	(1,717)	(17,256)	(68,866)	(112,801)	(65,830)						
musices and Officers fees	(30,381)	1,302	(33,146)	(36,293) (12,332)	(30,803) (116,814)						
				(12,332)	(110,014)						

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS											
Deferred foreign capital gain tax Other affiliates				(76,934)							
Other accrued expenses		18,245		43,045		22,293		6,455		2,534	
Net cash provided by (used for) operating activities	14	4,177,943		21,864,546		52,529,766		34,833,743		26,200,375	
CASH PROVIDED BY (USE	D FO	R) FINAN	CI	NG ACTIVIT	ſIE	2S					
Cash dividends paid to Shareholders Increase (decrease) in bank	(1.	3,892,273)		(21,939,546)		(52,582,273)		(35,324,522)		(24,873,009)	
overdraft		(11,776)				51,239		380,331			
Net cash used for financing activities	(1.	3,904,049)		(21,939,546)		(52,531,034)		(34,944,191)		(24,873,009)	
CASH IMPACT FROM FOR Cash impact from foreign	REIG	N EXCHA	NG	<b>SE FLUCTUA</b>	TI	ONS					
exchange fluctuations	\$	2,822	\$		\$	(56)	\$	(4,478)	\$	(2,199)	
<b>CASH</b> Net increase (decrease) in restricted and unrestricted cash and foreign currency Restricted and unrestricted cash and foreign currency at		276,716		(75,000)		(1,324)		(114,926)		2,830,167	
beginning of period		13,853		75,000		18,441		3,691,381		5,134,483	
Restricted and unrestricted cash and foreign currency at end of period	\$	290,569	\$		\$	17,117	\$	3,576,455	\$	7,964,650	
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AT VALUE AT THE END OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES:											
Due from Broker Cash pledged:	\$		\$		\$		\$		\$	1,553,352	
Collateral for OTC derivatives Collateral for options written						16,000		3,225,000		803,000 5,170,000	
Foreign currency at value		290,569				1,117		35,455		438,298	
	\$	290,569	\$		\$	17,117	\$	3,576,455	\$	7,964,650	

RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AT VALUE AT THE BEGINNING OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES:					
Cash	\$	\$	\$	\$	\$ 20,583
Cash pledged:					
Collateral for OTC derivatives		75,000	16,000	20,000	2,118,000
Collateral for options written				2,970,000	2,350,000
Foreign currency at value	13,853		2,441	701,381	645,900
	\$ 13,853	\$ 75,000	\$ 18,441	\$ 3,691,381	\$ 5,134,483

See notes to financial statements.

100

Statements of Cash Flows (unaudited) (continued)

Six Months Ended June 30, 2018

	BME	BCX	BST	BUI							
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES Net increase in net assets resulting from											
operations	\$ 18,901,075	\$ (3,251,801)	\$ 95,215,268	\$ (2,321,423)							
Adjustments to reconcile net increase in net											
assets resulting from operations to net cash											
provided by (used for) operating activities:											
Proceeds from sales of long-term investments	63,002,792	403,155,155	192,064,386	63,993,278							
Purchases of long-term investments	(60,570,975)	(367,331,390)	(164,526,263)	(56,800,800)							
Net (purchases) sales of short-term securities	7,150,150	8,720,851	2,112,661	(295,847)							
Premiums received from options written	11,409,301	34,674,571	31,496,701	7,793,703							
Premiums paid on closing options written	(12,917,161)	(52,771,784)	(40,088,866)	(7,472,059)							
Net realized (gain) on investments and options											
written	(10,665,080)	(26,199,546)	(36,580,903)	(1,406,572)							
Net unrealized gain (loss) on investments,											
options written and foreign currency translations	(7,451,568)	40,242,904	(59,622,884)	8,922,863							
(Increase) Decrease in Assets:											
Receivables:											
Dividends affiliated	1,015	3,618	(1,361)	(4,149)							
Dividends unaffiliated	46,482	186,767	(180,125)	(392,511)							
Securities lending income affiliated	617	183	35,687								
Prepaid expenses	(993)	(3,799)	4,390	1,982							
Other assets											
Increase (Decrease) in Liabilities:	(120,000)										
Collateral on securities loaned at value	(120,900)	(457,358)	(3,220,229)								
Payables:	262	( <b>0</b> ( <b>7</b> ))	40.010	$(0 \in \mathbf{F}(0))$							
Investment advisory fees	362	(26,708)	49,010	(26,560)							
Trustees and Officer s fees	(405)	(26,231)	970	(398)							
Other accrued expenses	(15,169)	16,817	(5,388)	1,182							
Net cash provided by (used for) operating											
activities	8,769,543	36,932,249	16,753,054	11,992,689							
activities	8,709,545	30,932,249	10,755,054	11,992,089							
CASH PROVIDED BY (USED FOR)											
FINANCING ACTIVITIES											
Cash dividends paid to Shareholders	(10,897,100)	(29,732,298)	(16,861,897)	(11,909,186)							
Proceeds from issuance of Shares	2,560,422										
Payments on redemption of Shares		(7,018,860)									
Increase (decrease) in bank overdraft	(10,013)	246,682		46,497							
Net cash provided by (used for) financing											
activities	(8,346,691)	(36,504,476)	(16,861,897)	(11,862,689)							

<b>CASH IMPACT FROM FOREIGN EXCHAN</b> Cash impact from foreign exchange fluctuations	FLUCTUA 2	TIO \$	<b>NS</b> 61	\$ (130)	\$ 1
<b>CASH</b> Net increase (decrease) in restricted and unrestricted cash and foreign currency Restricted and unrestricted cash and foreign	422,854		427,834	(108,973)	130,001
currency at beginning of period	959		106,149	2,520,651	60
Restricted and unrestricted cash and foreign currency at end of period	\$ 423,813	\$	533,983	\$ 2,411,678	\$ 130,061
<b>NON-CASH FINANCING ACTIVITIES</b> Capital shares issued in reinvestment of distributions paid to Shareholders	\$ 265,971	\$		\$ 739,593	\$ 263,846
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AT VALUE AT THE END OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES:					
Cash pledged: Collateral for OTC derivatives Foreign currency at value	\$ 422,843 970	\$	533,983	\$ 2,310,000 101,678	\$ 130,000 61
	\$ 423,813	\$	533,983	\$ 2,411,678	\$ 130,061
RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AT VALUE AT THE BEGINNING OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES: Cash Cash pledged: Collateral for OTC derivatives	\$	\$	94,925	\$	\$